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ABSTRACT 
Pulsed Short Wave Therapy (PSWT): its clinical use and physiological effects in 
healthy subjects and osteoarthritic (OA) patients 
PSWT is a commonly used electrotherapy modality and surveys have shown it to be one 
of the most widely used modalities among physiotherapists in the UK. Nevertheless, the 
literature supporting its therapeutic effects and explaining its mechanism of actions 
remain scant, of poor methodological quality and of minimal clinical value. 
This research program was set to examine both the nature of use and the efficacy of 
PSWT. The nature of PSWT use was examined in outpatient clinics using an audit and a 
nationwide survey. The efficacy of PSWT was examined in two randomised placebo 
controlled trials; one conducted in a laboratory setting on healthy subjects and the other 
was a clinical trial on patients with osteoarthritis. Following the same methodology and 
protocol, the effects of low and high dose of PSWT on skin temperature (SkT), blood 
volume (BVo1), and nerve conduction velocity (NCV) were evaluated against a placebo 
and a control condition. 
The findings have revealed the poor documentary skills of physiotherapists, and a state 
of confusion in the clinical decision-making with regard to PSWT dosage. Based on 
experimentation, it was established that patients react differently from healthy subjects 
when similar levels of energies are applied. Whilst low dose resulted in non-significant 
changes in SkT and NCV in healthy subjects, the same dose significantly altered BVol, 
SkT, and NCV in patients. Placebo effects were found to account for 39% of the 
patients' response to PSWT treatments. 
The findings have revealed a discrepancy between evidence and practice that 
necessitates a reconsideration of the treatment approaches adopted by physiotherapists 
when using PSWT. The study has also demonstrated the physiological and therapeutic 
efficacy of PSWT on patients with osteoarthritis, and showed that treatment outcomes 
are dependent on the amount of exogenous energy applied and the type of tissue treated. 
The thesis also highlights areas for future research based on the literature reviewed and 
the experimentation conducted. 
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CHAPTER I 
INTRODUCTION AND CURRENT 
RESEARCH ISSUES WITH PULSED SHORT 
WAVE THERAPY (PSWT) 
1.0 DEVELOPMENT OF PSWT GENERATORS 
Early experiences with high frequency current started around the 1880's when a 
French physiologist named d'Arsonval passed a current of 1 ampere (despite the belief 
that a current of such strength could be deadly) through his body and the body of his 
assistant and they only experienced gentle warmth (Scott, 2002). 
Based on that work, the first attempts at PSWT production started in 1930 by an 
American physicist Arthur Milinowski and his colleague Dr Ebraham Ginsberg. Their 
experimentation had focused on eliminating the heating effect associated with the 
application of continuous short wave diathermy (CSWD) and reducing the adverse 
outcomes associated with the application of CSWD for sprains (Low and Reed, 2000; 
Lightwood, 1989). They introduced pauses in the electromagnetic field (EMF) output of 
the CSWD, which was thought at the time to allow for dissipation of heat and the 
prevention of thermal build up (Arghiropol et al, 1992). Their attempts culminated in 
the production of an ultra short wave apparatus in 1936. They followed their efforts by 
experimenting on animals; however their task was terminated by World War H. In 1953 
experiments were resumed and the first Diapulse apparatus was produced and marketed. 
The revolution of Diapulse was followed by the production of Curapuls in 1970, 
a machine that was capable of providing both continuous and pulsed EMF, and this was 
followed by the production of Megapulse in 1981, which was also capable of producing 
continuous and pulsed output (Hayne, 1984). 
Introduction of PSWT to the UK however, was not until 1968 when Miss Parclay 
observed its therapeutic effects on the speed of recovery with the American team in 
Mexico Olympics. She later co-operated with a local physician to look into its efficacy 
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with different conditions. Since then PSWT has been increasingly employed in various 
UK hospitals (Foley-Nolan, 1990). 
1.1 TERMINOLOGY WITH PSWT 
PSWT can be operated in both thermal and athermal modes, as such it has been 
classified as being one of the diathermy family. Diathermy machines are those devices 
that emit high frequency EMF and are capable of producing heat in the tissues (Prentice 
and Draper, 2001). This group includes pulsed ultrasound (PUS), continuous ultra 
sound (CUS), CSWD, and microwave (MW) (Figure 1.1). 
Unlike other electrotherapy modalities, PSWT has fallen victim to numerous 
diverse interpretations resulting in the use of several terminologies (Prentice and 
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Draper, 2001). It has been referred to as pulsed electromagnet energy treatment 
(PEMET), pulsed electromagnetic therapy (PEMT), and magnetotherapy. Adding to this 
confusion is the reporting in some of the electrotherapy literature referring to PSWT by 
its make or manufacturer's name as such it has been a common practice to refer to 
PSWT as Megapulse or Diapulse. 
Two more terms that have been used repeatedly in the literature are pulsed short 
wave diathermy (PSWD), and pulsed electromagnetic energy (PEME). Using the term 
PEME or the terms mentioned above to describe the pulsed mode of SW is confusing. 
The electromagnetic (EM) spectrum encompasses frequencies ranging from zero to 
1020Hz (Foley-Nolan, 1990; Delpizzo and Joyner, 1987). The spectrum starts with 
direct current, which has zero frequency and ends with Gamma rays, which has the 
highest frequency range. Further explanation is found in Table (1.1) 
Frequency range 
(Hz) 
Use Classification Biological effect 
0 Direct current (D. C. ) Non ionising 
0-300 Domestic EMF 
equipments 
Bone healing devices 
Extremely low 
frequency (ELF) 
Non ionising 
300-10 Low frequency (U) Non ionising 
104_ 10 SW, Ultrasound Radio Frequency (RF) Non ionising 
109_1012 Microwave and Radar 
bands 
Non ionising 
- 14 1012-4x10 Infra-red (IF) band Non ionising 
_ 1014 -7x 10 Visible light Weakly ionising 
1014 - 10 Ultraviolet band Weakly ionising 
10 -10 X-ras Stron 1 ionisin 
Over 10 Gamma rays Strongly ionising 
Table (1.1) Classification of EM spectrum according to the frequencies and their biological effects 
(adapted from Rubik et al, 1992) 
Another classification by Markov and Colbert (2000) divide EMF frequencies 
according to their therapeutic use. The classification includes magnetic (H) field, Low 
frequency sine wave (mostly 50 or 60 Hz), pulsed EM (Low frequency fields with 
4 
Chapter 1 Introduction and current research issues with PSWT 
specific shapes and amplitude), pulsed RF (13.56 MHz, 27.12 MHz, 40.68 MHz), 
transcranial magnetic stimulation (uses short and intense magnetic fields) and 
millimetre waves (those with high frequency ranging from 30-100 GHz) and each of 
these categories can be taken to mean PEME if delivered in a pulsed mode. With both 
classifications the term PEME does not necessarily describe PSWT as PEME could 
employ a wide range of frequencies other than the 27.12 MHz RF assigned for the 
therapeutic SW. Additionally, the wide range of equipment utilising EMF employs 
currents with different amplitude, shapes, engineering, physical and biological effects 
(Markov and Colbert, 2000) making them even more different than the frequency of 
27.12 MHz. Other classifications can be found in the literature, but the above two 
classifications are used as an example. 
In the term PSWD, the confusion comes from assigning the word diathermy 
(heat through) to the name implying a heating modality. Although several reports have 
demonstrated the thermal effects associated with its use (Murray and Kitcken, 2000; 
Bricknell and Watson, 1995), the word diathermy negates the possibility of using this 
modality in the non-thermal mode as such could be confusing. Although the term 
PSWD represents the best terminology among the others discussed above, throughout 
this work the pulsed mode of SW will be referred to as PSWT (pulsed short wave 
Therapy) as this term was seen to better cover the thermal and the non-thermal modes of 
pulsed short wave. The term SW however, will be used wherever the reported literature 
does not make the distinction of whether SW was on a pulsed or a continuous mode. 
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1.2 THE NEED FOR RESEARCH IN PSWT EFFICACY 
PSWT is one of the electro-physical modalities that have been used for many 
years to treat a variety of soft tissue lesions (Kahn, 2000). It is used to alleviate pain, 
aid the resolution of haematoma, bruising, inflammation, and oedema, and increase the 
rate of healing in soft tissue lesions (Kitchen and Partridge, 1996). It is argued that 
PSWT has undergone a fluctuating pattern of use throughout the years and is 
experiencing a decline in its use (Prentice and Draper, 2001). Several reasons have been 
proposed in the literature as being responsible for the move away from PSWT use. For 
example, the presence of a considerable number of portable modalities that are capable 
of tackling pain with minimal difficulty to both therapist and patient, and the long list of 
precautions and contraindications associated with PSWT use (Behrens and Michlovitz, 
1996; Nieda et al, 1996). Other reasons that could be responsible for PSWT being 
superseded by other electrotherapy modalities or other physiotherapy interventions 
could be the unresolved issues on its harmful effects on the operator (Shields, 2003; 
Kitchen, 2002), its cost and its interference with other electro-physical modalities found 
in the vicinity (Wadsworth and Chanmugam, 1983). 
Kitchen (1995b) debates this view, stating that PSWT is a widely used modality 
and is being employed clinically more than CSWD. Kitchen adds that therapists are 
increasingly moving towards applying lower levels of energy and preferring athermal 
on thermal modes of treatments. This move is caused by the belief that lower levels of 
energy are safer to use and are expected to achieve the desired physiological responses 
with minimal side effects (Low and Reed, 2000). 
Further validation to the wide clinical use of PSWT was reflected by the surveys 
conducted throughout the years in England. 
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A survey undertaken by Pope et al in 1995 confirmed PSWT to be one of the top three 
modalities used in physiotherapy after ultrasound (US) and interferential current (IFC), 
with the majority of their sample opting to use it twice daily. Kitchen and Partridge in 
1996, also showed PSWT to be a very common treatment modality in England being 
accessible to 98% of the respondents (response rate 89%, 98 therapists from 14 
outpatient departments) and that 72% of those respondents used it more than once a 
week. 
In agreement with the above findings were the results of the survey conducted 
by Foster et al (1999). They demonstrated on a sample of 813 physiotherapists across 
England and Ireland (response rate of 58.3%) that PSWT is one of the top three 
modalities being used by 64.3% of their sample. The survey has also demonstrated that 
PSWT is more popular than CSWD, with 11.2% of the sample choosing it as their first 
option among other electrotherapy modalities compared to 5.2% choosing CSWD as a 
first treatment option. Similar findings were reported by Shields (2003) in a survey 
conducted in Ireland. PSWT was owned and used by 53.8% of the hospital-based 
therapist surveyed and again PSWT was more popular among therapists than CSWD 
(Shields, 2003). 
Despite this wide use, the majority of therapists whether privately-based or 
NHS-based were reluctant to buy new SW machines due to its unproven therapeutic 
effects (Pope et al, 1995), lack of space, cost and safety issues related to its use 
(Shields, 2003). 
Moreover, a lot of discrepancy surrounds PSWT as still little is known with 
regards to why or how to best use it (Robertson and Spurritt, 1998), specific information 
on dosage parameters, and defined biophysical mechanisms (Markov and Colbert, 
2000). All of these factors may indicate a possible under-explored therapeutic effect 
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(Pope et al, 1995). Moreover, with the increasing attention paid to electro-physical 
agents, PSWT remains to be the one with the least attention (Kitchen, 1995a). 
The claims that this modality can operate in the athermal mode and still result in 
therapeutic effects was and still is an area for debate (Cleary, 1996; Martin et al, 1990; 
Foster and Palastanga, 1985). Failure to provide evidence for such claims have lead 
some to attribute the effects of PSWT to placebo (Wall, 1992). With the literature being 
nowhere conclusive (Ide, 1990) a lot of therapists have relied on their personal 
experience, anecdotal evidence and repeated observations to guide them through their 
practice (Bork, 1993). Such behaviour was validated by the work of Turner & Whitfield 
(1999) where they demonstrated that 90% of the sample surveyed in both UK and 
Australia listed their prior experience as the main source for the choice of a treatment 
technique in many areas of practice including electrotherapy. 
With the pressure mounting on policy makers to best utilise the financial 
resources, hit and miss policies of treatment, and treatment based on opinions and 
preferences can be considered a waste of time and money (Hicks, 1999). Therapists 
need to have a clear understanding of the molecular, and cellular mechanism 
underpinning the electro-physical agents they employ in their practice (Dyson, 1990) in 
order to obtain the most of their equipment, and to better market their practice for users, 
purchasers of service and policy makers. 
A major problem that faces therapists trying to extrapolate research findings to 
the clinical setting is the absence of full reporting of dosage. Specifying dosimetry 
becomes even more difficult with the response being dose-specific. Rubik et al (1992) 
concurs that the relation between biological response and the energy applied is not 
linear. As such higher amounts of energy are not necessarily associated with better 
outcomes. It is only the proper frequency at the proper site that could result in clinically 
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useful outcomes (Rubik et al, 1992). In order to plan an optimal treatment regime, the 
practitioner has to choose the appropriate setting among a variety of parameters, which 
include pulse duration (PD), pulse repetition rate (PRR), and power output. However, 
literature offers little direction for clinicians in terms of dose-response relationship. To 
further complicate the situation there has been a paucity of studies looking into the 
effectiveness of certain dosage parameters on particular dysfunctions (Green, 1991). All 
of this creates a state of uncertainty when it comes to a clinical decision-making 
process. This confusion was reflected in the work by Kitchen (1995b), when in an 
interview, therapists were asked to specify their dosage parameters with given 
conditions. They were able to do so with regard to Laser and US but not PSWT or 
CSWD, conveying the lack of knowledge in that area. Respondents also expressed their 
lack of confidence with these two modalities. 
The literature is confusing in terms of the information given. Wadsworth and 
Chanmugam (1983) argue that best results with PSWT are obtained when the power is 
set to the highest level possible, this is excluding acute conditions when the power 
needs to be reduced. Cameron et al (1999) recommended the combination of high peak 
power (PP) with the highest PRR. Low and Reed (2000) on the other hand, consider 
PRR the determining factor for best treatment outcomes and recommend using high 
PRR to obtain the best results. All these recommendations are merely suggestions and 
have no experimental support. 
Given the above, the need for more trials that explore PSWT mechanism of 
action, and the area of dosimetry are urgently needed (Kitchen and Partridge, 1996; 
Beckermann et al, 1992; Holmes and Rudland, 1991). Both laboratory and clinical trials 
are needed to provide evidence on PSWT efficacy, and to justify its continued clinical 
use. Such demand highlights the importance of the current work. 
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Interestingly, reviewing the literature that has discussed PSWT use and 
mechanism of action, it could be found that most of it was laboratory based employing 
normal subjects, and there has been very little work directed to studying a physiological 
response in a patient population. Experimentation needs to be directed to uncover 
mechanisms of action and reactions to EMF with both healthy subjects and patient 
population. It is suggested that injured tissues may be more sensitive to the energy 
delivered hence unlike healthy tissues they may react to lower doses of energy 
(Bricknell and Watson, 1995). As a result, experimental findings from healthy subjects 
should not be directly extrapolated to the patient population (Kitchen and Partridge, 
1996). 
All the above justify and highlight the importance of both clinical and laboratory 
studies. It is anticipated that the findings of this study when incorporated with other 
work done in the field will help develop theoretical basis that may support (or not) the 
use of some modes of PSWT and explain part of its mechanism of action. 
Compared with other electrotherapy modalities, PSWT requires minimal attention once 
set up, and as such has the advantage of leaving therapists with time to concurrently 
attend to other clients (Comorosan et al, 1993). PSWT is also capable of stimulating 
tissues up to a depth of 3 cm (Prentice and Draper, 2001), or as claimed by some up to 
5 cm (Behrens and Michlovitz, 1996). PSWT can deliver heat more effectively than 
many modalities such as IF or hot pack (Draper et al, 2002; Draper et al, 1999) and has 
achieved better results with pain compared with CSWD (Wagstaff et al, 1986, Wilson, 
1974). This is because at similar power outputs, the pulsed field has higher amplitude 
and a greater probability of overcoming the intensity threshold of the tissues, thus 
eliciting a biological response (Tenforde, 1996). Additionally, unlike other 
electrotherapy modalities, PSWT has been shown to have remote effects; that is by 
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applying it to the abdomen a desirable change in the circulatory system can be observed 
at the extremities and as such can be used in cases where direct application of an 
electrotherapy modality to a painful area is not possible (Wessman and Kottke, 1967; 
Morrissey, 1966; Erdmann, 1960). It could be added that PSWT can retain therapeutic 
effects more than other modalities such as US. In a study by Draper et al (1995) that 
was later validated by Garret et al (2000) it was shown that after 20 minutes of 
treatment, PSWT recoded the highest temperature increase compared to US, and while 
US took 14.88±4.7 minutes to revert to baseline temperature PSWT took 38.50±6.61 
minutes. This means that PSWT could provide longer time for physiotherapists to 
exercise or manipulate the treated area (Rose et al, 1996; Draper et al, 1995). All of this 
makes PSWT a versatile modality to work with and being able to provide evidence on 
its efficacy could be of significant clinical benefit. 
The early chapters of this thesis review the literature and experimentation 
conducted to-date on PSWT in order to summarise the experimental work, highlight 
areas for future research and provide justification for undertaking the current work. No 
attempts however, were made to include CSWD in the review, the reasons are three 
fold. Firstly: although these two modalities are expected to function on the same 
principle it is not agreed that both affect various tissues similarly unless both were set 
on the thermal mode, and as such they should be treated as two distinct modalities. 
Secondly: there exists a considerable amount of literature on CSWD, its use and 
mechanism of action unlike PSWT, which has received minimal attention throughout 
the years (Kitchen, 1995a). Thirdly: separating the two modalities could be of more 
benefit clinically as this will reduce the state of confusion in the literature and allow 
clinicians to better judge the efficacy of these modalities based on individualised body 
of knowledge. 
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1.3 THE SCOPE OF THE CURRENT STUDY 
The current study was based on incorporating both the qualitative and the 
quantitative approaches to research in order to enrich the study findings. Phase 1 which 
was the qualitative work was accomplished in two stages. The initial stage was an audit 
in eight randomly chosen hospitals (Chapter 5). The work was undertaken to evaluate 
the documentary skills of physiotherapists in the area of electrotherapy with particular 
reference to PSWT, and to gather preliminary data on the current clinical use of PSWT 
in outpatient clinics in England. This information was used in construction of a 
questionnaire, which was utilised in the second stage of the project (Chapter 6). Stage 2 
was a nationwide postal survey, which was conducted across England on a sample of 
360 physiotherapists. The survey covered physiotherapists from all clinical grades 
working in outpatient clinics and using PSWT in their routine treatment of patients. 
Phase two of the project was a quantitative laboratory based study. The experimental 
work was undertaken in three stages; stage 1 (Chapter 8) was the pilot experimental 
work, which aimed to validate the acquisition system and establish the feasibility of the 
experimental protocol. This was followed by a small pilot laboratory work on 10 
healthy subjects to test the experimental protocol and to examine its practicality, 
reliability and validity. Essential alterations were made to the methodology of the 
experiment before the laboratory trial on healthy subjects was undertaken. Normative 
data were derived from a single blinded placebo controlled laboratory-based trial (stage 
2-Chapter 9). In this trial, 31 healthy students and staff were recruited. Comparison was 
made to the physiological effects of applying two modes of treatments dose (high dose 
of 24W and a low dose of 3W) to the knee joint and measuring its effects on skin 
temperature (SkT), blood volume (BVol), and nerve conduction velocity (NCV). 
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Response to the treatment was compared with those of a placebo group and a control 
group. 
In order to bridge the gap between laboratory experimentation and the real world and in 
order to identify a clearer and wider perspective on the physiological changes 
accompanying the administration of PSWT, a clinical trial was conducted (stage 3- 
Chapter 10). Based on the same methodology and using the same outcome measures as 
the laboratory trial, a single blinded placebo controlled trial that compared twenty six 
osteoarthritic (OA) patients reactions to the same doses of treatment was undertaken. 
This section aimed to compare the changes seen in a healthy tissue and a diseased tissue 
to the administration of PSWT. 
The last chapter (Chapter 11) of this thesis is a general discussion that summarises the 
experimentations conducted in this research programme and discusses the main findings 
in terms of the overall research question. The chapter also identifies the strengths and 
limitations of this work and discusses areas for future research. 
1.4 OVERALL STUDY AIMS 
9 To evaluate the quality of therapists' documentation in the field of 
electrotherapy with specific reference to PSWT treatments. 
" To explore the nature of clinical practice with PSWT in outpatient clinics in 
England. 
9 To subject clinical practice to validation for efficacy via laboratory and clinical 
experimentation. 
These aims cover the general concept underpinning the implementation of the 
current research, more specific aims and hypothesis will be discussed in each 
experimental chapter relative to the work conducted. 
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CHAPTER 2 
PSWT BACKGROUND, MECHANISM OF 
ACTION AND SAFETY 
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2.0 EM SPECTRUM 
The EM spectrum encompasses a range of radiation waves with frequencies 
ranging between 3.105 - 3.1023 Hz with wavelengths ranging between 103 m to several 
Km. These EM waves are electric fields (E) and magnetic fields (H) fields travelling in 
space at a speed of 3x108 ms-1. The E field can be found wherever electric charges are in 
motion. Charges exert forces on one another in a direction along the lines of force 
between them. Charges with the same sign repel and charges with opposite signs attract. 
The magnitude of the force exerted on one charge by another charge is proportional to 
the square distance between the two charges (Durney and Christensen, 2000). The H 
field on the other hand, is produced by the moving electrical current. Both fields travel 
in straight lines with the E component perpendicular to the H component (Rubik et al, 
1992). The EM spectrum includes waves such as radio waves (RF), microwaves, X-rays 
and more. Further clarification is found in Figure (2.1). 
Nm ionising iadi*ion 
F (Hz) 3x10,3x10' 3x100 3x104 3x10'' 
h (m) 10' 10' 10' Ion loll Ion 
SW (short, mcdiunL lone 
ELF RF IF visible UV 
light 
X-ray 
Figure (2.1) EM spectrum (from Durney and Christensen, 2000) 
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These frequencies can be classified according to their biological effects into 
ionising or non-ionising frequencies. The term non-ionising radiation refers to all forms 
of radiation that have energies less than 30 electron-volt and contrary to ionising 
radiation have insufficient energy to alter the basic constitutions (atoms & molecules) of 
matter and break down chemical bonds (Rubik et al, 1992), and as such are expected to 
cause less health hazards. 
The frequency range of 10-100 MHz named RF contains short, medium, and long 
waves. The short wave range of this band has been employed medically in the 
production of the physiotherapy modalities PSWT and CSWD. 
2.1 SW GENERATORS 
Therapeutic SW equipment is one of the many medical devices that utilises high 
frequency EMF. In an attempt to regulate the use of high frequency currents in different 
disciplines, the Federal Communication Commission in 1947 assigned three frequencies 
at the short end of the RF band for the medical use of SW (Foley-Nolan, 1990). They 
are the frequency of 40.68 MHz (±20 KHz) and a wave length of 7.5 m, the frequency 
of 13.56 MHz (±6.25 KHz) and a wave length of 22m, and the frequency of 27.12 MHz 
(±160 KHz) and a wave length of 1 im (Prentice and Draper, 2001). It is believed that 
these frequencies could resonate better with the human body resulting in maximum 
energy transfer and absorption (Martin et al, 1991). The frequency of 27.12 MHz is the 
most commonly used among the above mentioned frequencies as it has the largest error 
margin and the biggest band amplitude allowing the frequency to drift with minimal 
interference to other equipments (Low and Reed, 2000). 
SW can be applied to the tissues in either a continuous or a pulsed mode. The 
alternating high frequency current in both modes is produced in a similar manner. Two 
16 
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circuits are incorporated to produce high frequency EMT (Figure 2.2), the machine and 
the patient circuits. The machine (or the oscillator) circuit is composed of a high 
frequency generator, amplifier (to raise the output to therapeutic levels), and a power 
supply. The second circuit is the patient (or the resonator circuit) composed of a 
variable capacitor (to account for the changing capacity of the resonator circuit due to 
the type of tissue treated), and a method of transferring energy to the tissues and this is 
achieved by either capacitive or inductive electrodes (Figure 2.2). 
High- 
frequency 
Mains power generator 
supply 
Machine 
Ampler circuit 
Oscillator 
coil 
Resonator 
coil 
Resonator 
ill, 
Variable 
or capacitor 
patient for tuning 
circuit 
Electrodes 
plus tissues 
Qb forming a 
4ý capacitor 
Figure (2.2) Electrical circuits with SW generators, with capacitive electrodes coupled to patient tissues 
(adapted from Kitchen, 2002). 
As identified previously, the output of a SW machine can be delivered to the 
tissues in either a continuous or a pulsed mode. The difference between the two is that 
with CSWD the energy is delivered to the patient the whole time of the treatment as 
such it is always associated with thermal effects. With PSWT, the output is delivered to 
the tissues in a train of pulses of varying durations and repetition rate as such allowing 
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high amplitude of energy to be delivered to the tissues with either thermal or non- 
thermal effects (Wadsworth and Chanmugam, 1983). These pulses vary in frequency 
between 15-800 Hz, though the range of pulses may be different between various 
PSWT units. The duration of these pulses is controlled by the operator and may range 
between 20-400 µs (Prentice and Draper, 2001). Most PSWT machines have peak 
power (PP) output ranging from 50W (Medilink-EMS) - up to 1000 W (Curapuls- 
Enraf-Nonius). 
Pulsing the output of PSWT means that the therapist can control the mean power 
(MP) delivered to the tissues. This is achieved by altering variables such pulse 
repetition rate (PRR), pulse duration (PD) and PP. Changing these variables however is 
dependent on the manufacturing properties of the PSWT machines as some equipment 
has fixed PP output (such as Megapulse), while others may have fixed PD (such as 
Diapulse). 
Although a PSWT unit produces both E and H fields in the tissue, this ratio 
could differ according to the type of electrode in use, the carrying frequency, and 
manufacturing characteristics. Equipment with a carrying frequency of 13.56 MHz for 
example, tends to have a higher ratio of H fields when compared to the machines using 
a frequency of 27.12 MHz (Markov and Colbert, 2000; Hand, 1990). 
2.2 METHODS OF COUPLING SW TO THE TISSUES 
There are two methods of transferring energy to the tissues when using PSWT: 
the capacitance and the inductance methods. Each application affects different target 
structures and each has its own mechanism of producing heat in the tissues. The 
interaction between the tissues and the field produced by SW generators is governed by 
the dielectric constant of the tissues, which is dependent on the depolarisation 
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characteristics and the amount of water content. The interaction is also affected by the 
specific absorption rate (SAR), which is a function of a tissue's electrical properties, 
and the ease by which energy is absorbed by the tissues (Scott, 2002; Hand, 1990). This 
interaction is explained further in Section (2.4). 
2.2.1 Capacitive method 
Capacitor electrodes produce a higher proportion of E than H field in the tissues 
with the field being stronger in the centre of the treated area (Prentice and Draper, 
2001). The strength of the field is governed by the electrode placement in relation to the 
tissue (stronger field when the electrodes are situated closer to the skin), the size of the 
electrodes (small, medium and large; small electrodes have less penetration than large 
electrodes. Uniform field in the tissues is achieved by using electrodes that are slightly 
larger than the treated area) and spacing (Hand, 1990). 
The heat produced using the capacitive method is the resultant of the movement 
of three components: charged molecules, dipolar molecules and non-polar molecule. 
Heat can be produced as a result of the oscillation of charged molecules such as protein 
and ions about a mean position along the lines of the E forces that are created by the 
EMF. The oscillation and friction converts the molecule kinetic energy to heat. 
Molecules such as water, some proteins, and hormones possess permanent electric 
dipoles. Normally, these dipoles are randomly arranged. Under the influence of an E 
field, these dipolar molecules undergo polarisation and align themselves to the opposite 
charged pole of the E field. The alternating nature of the field causes the dipoles to 
rotate and collide, and the friction between these dipoles generates heat. The extent of 
this alignment is determined by the strength of the field (Hand, 1990). Additionally, 
each of these polar molecules possess a weak field of its own, extending from the 
19 
Chapter 2 PSWT background. mechanism of action and safety 
positive to the negative pole, and when the substance is under the influence of E field, 
the net result of these fields governs the electric properties of the matter. Dipolar 
molecules produce a mixture of real and displacement currents. Real current refers to 
the current that develops in the tissues and determines the electrical properties and heat 
production in a matter (Ward, 1980) unlike the displacement current which does not 
play a great role in the electrical properties of a matter (Scott, 2002). 
The third type of molecules is the non-charged molecules. E field affects non-charged 
molecules by polarising and distorting their electron cloud fields. Movement of the non- 
charged molecules in response to the E field results in displacement currents and as 
such contributes the least to heat production in the tissues, unlike the movement of 
charged molecules, which could result in real current. This is because the induced 
dipoles are not as strong as natural dipoles and tends to lose their properties as soon as 
the E field is removed (Ward, 1980). 
As mentioned earlier the heat produced using the capacitive method is governed 
by the strength of the E field and conductivity of the tissues (more heat is produced in 
tissues with high conductivity). Capacitive application is expected to concentrate the 
field in the superficial tissues such as the skin and fat layers rather the deep tissues such 
as muscles (Van der Esch and Hoogland, 1991). This is mainly caused by the reduction 
of field intensity as it propagates in the tissues. The refraction of the lines of force as 
they cross the muscle fat layer causes the loss of part of the applied field strength and 
termination of some field lines (Ward, 1980). 
As the heating pattern with these electrode is mostly in the skin, and 
subcutaneous fat layer, this method is best suited for treating ribs, spine, and areas of 
low subcutaneous fat such as hands and feet (Prentice and Draper, 2001). 
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Two types of electrodes are used with the capacitive method: air space plates 
and pad electrodes (Wadsworth and Chanmugam, 1983). 
2.2.1.1 Air space plates 
Air space plates are composed of two metal plates (ranging in diameter from 7.5 
to 17.5 cm) enclosed in plastic or sometimes a glass plate guard. Two electrodes are 
needed for this application and the patient is part of the electrical circuit acting as a 
dielectric. The distance between the skin and the electrodes can be adjusted not only by 
changing the skin/electrode distance but also by adjusting the metal plates within the 
electrode housing. No consensus exists in the literature on the ideal skin electrode 
distance, with some suggesting 2.5 cm (Wadsworth and Chanmugam, 1983) and others 
recommending 2-4 cm (Scott, 2002; Low and Reed, 2000). However, no justification 
was given to the choice of these values. 
2.2.1.2 Pad (rubber) electrodes 
These types of electrodes are composed of a metal plate encased in rubber. They 
are placed on the treated part with the electrode in uniform and even contact with the 
skin. Two electrodes are used and the area treated is part of the circuit. Spacing between 
the skin and the electrodes is ensured by layers of towelling or felt spacers. The amount 
of heating generated in the tissue is dependent on the spacing between skin and 
electrodes (more distance between the pads is thought to provide deeper penetration) 
(Prentice and Draper, 2001). 
2.2.2 Electrode arrangement 
With conductive techniques, electrodes can be positioned in a contra-planar, 
coplanar, longitudinal, or crossfire arrangement. In contra-planar the electrodes are 
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placed opposite to each other on either side of the treated area. The distance between the 
skin and the electrodes (Figure 2.3) can either be symmetrical if an even field is 
desirable or they can be positioned with uneven distances if the aim is to concentrate the 
field on one side of the treated area (Wadsworth and Chanmugam, 1983). 
........ ... ........................................ 
Uneven spacing concentrates the field on the 
side where the electrode is the closet to the 
part treated 
-0 
......... ............................ 
Using different sized electrodes 
concentrates the field on the side closet to 
the small electrode, and alters the 
uniformity of the field 
Using even spacing and equal sized electrodes lead 
to a uniform field in the tissues 
Figure (2.3) Spacing of electrodes, and its effect on field distribution 
Electrodes can also be positioned in a co-planar arrangement where both 
electrodes are placed on the same aspect of the treated area. For safety reasons the 
distance between the two electrodes needs to be more than the sum of skin electrode 
distance in order to result in better field distribution. Although this technique produces 
superficial field, the depth of the field can be increased by increasing the distance 
between the two electrodes (Martin et al, 1991). 
Other electrode arrangements include the longitudinal application where the electrodes 
are placed at either ends of a limb parallel to the alignment of the tissues. In the 
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crossfire technique, the electrodes are placed diagonally over the treated tissue for half 
the time and are then changed to the other diagonal for the rest of the time. This 
technique is best used with cavities containing air such as the sinus and the uterus 
(Forster and Palastanga, 1985). 
2.2.3 Electrodes size 
The size of the applicators is another important factor in determining the 
strength of the field in the tissues (Figure 2.3). Using two electrodes of similar size 
results in uniform distribution of the field in the tissues. Using electrodes of different 
sizes however, leads to the accumulation of the field on the side of the smaller electrode 
(Tzima and Martin, 1994). Hand (1990) adds that applicators act as antennas for 
coupling the power to the tissues. When small applicators are used (small in relation to 
the other electrode or in relation to the size of the treated area) they act as poor radiators 
decreasing the intensity of the field as the distance increases. This is believed to cause 
excessive heating at the superficial layers and reduction in the depth of penetration 
(Hand, 1990). 
2.2.4 Inductive method 
The inductive method produces mainly H field via a cable that is either wrapped 
around the extremity or coiled inside an electrode housing. Unlike the conductive 
technique, the patient is not part of the circuit, and the electrodes are placed 
perpendicular to the part treated (circuplode) or wrapped around it (cable) (Hand, 1990). 
When the alternating high frequency current is generated in the cable, the E field is 
passed in the tissues, generating an H field that is set up at right angles to the direction 
of current flow (Scott, 2002). The amount of E field emitted by the electrodes can be 
decreased with some electrodes like the monode by using Faradic screen. The 
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magnitude of the H field is proportional to the strength of the E field. The strength of 
the H field is determined by the rate at which the current alternates, and the number of 
coils of the conducting wire contained within a conductor (Hand, 1990). 
The generated H field induces a secondary current in the tissues known as the 
eddy current (which is small circular E fields). Heat is generated as a result of the 
friction between eddy currents and intermolecular vibration of the tissue contents. It is 
believed that the effect of the H field produced by the inductive technique acts as a 
carrier for the eddy current which acts as the main element responsible for the 
physiological effect gained during the application (Scott, 2002). This form of heating is 
not associated with strong sensory stimulation and as such, the heat may not be as 
obvious to the patient as in the capacitive application (Prentice and Draper, 2001). 
The inductive application is believed to result in selective heating with tissues 
having high electrolyte content and low impedance such as muscle and blood. The most 
superficial layers such as skin and fat are minimally affected (Lehmann and DeLateur, 
1990). Ward (1980) argues that with an inductive application, there will be both 
superficial and deep heating. Structures such as blood and muscles will be heated as 
they have high dielectric content, however the superficial fat layer will also be heated 
because fat is an inhomogeneous structure and usually incorporates areas of high 
conductivity found in the tiny blood and lymphatic vessels. These tissues lack an 
efficient way of dissipating heat, and as such tend to absorb heat and concentrate it in 
the tiny blood vessels. Hand (1990) adds that when the separation between the 
electrode and tissue is less than 3 cm, high intensities of the power are absorbed by the 
fat layer. However, by increasing this distance the field is expected to penetrate up to a 
depth of 4 cm. Although this reference is one of the few that discussed the exact 
distance between inductive electrode and the tissues it was not clearly mentioned 
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whether these findings were based on experimentation or were based on a theoretical 
model. Draper et al (1999) were able to demonstrate up to 4°C increase in intramuscular 
temperature using inductive electrodes (skin temp was not measured). Although the 
distance between the electrode and the treated area was not mentioned, it could be 
deduced from the pictures that it was less than 1 cm. 
Inductive PSWT can be applied to the tissues by means of either a drum or a cable 
electrode (Prentice and Draper, 2001). 
2.2.4.1 Drum electrode 
The drum is composed of one or more monoplanar coils encased inside a plastic 
housing Figure (2.4). A main disadvantage with this technique is not being able to fit 
the skin contour, and its size means if a large area is to be treated more than one 
electrode may be needed (Wadsworth and Chanmugam, 1983). Maximum penetration 
with this technique is believed to be 3-4 cm given that the subcutaneous fat layer does 
not exceed 2 cm. This is believed to be caused by the distortion of the field when it 
passes the fat layer and crosses the fat/muscle interface which is expected to lead to 
unwanted increase in temperature in the fat layer (Prentice and Draper, 2001; Low and 
Reed, 2000; Ward, 1980). Examining seven types of applicators Lehmann et al (1983) 
demonstrated using human tissue substitute substances that the SAR ratio of muscle to 
fat heating with inductive electrodes could vary between 0.39-2.67: 1 times. 
Measurements were taken using thermographic scanning with power 420 W (it was not 
mentioned whether this was the mean or the peak output). However, heating pattern 
vary between applicators due to differences in electrostatic shielding (Lehmann et al, 
1983). 
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(2.4) Drum electrode 
2.2.4.2 Cable electrode 
The cable is a thick insulated wire with plugs on either end. The cable can be 
wrapped in a pancake arrangement and placed over the treated area or it can be wrapped 
around the extremity. It has the advantage of fitting the contour of the body unlike air 
space or drum electrodes. A distance of at least 1 cm should be kept between the skin 
and the electrode, and a distance of about 5 cm should be kept between the turns of the 
cable to prevent overheating (Prentice and Draper, 2001). 
It is of interest to mention that most of the theories explaining the field distribution 
under the various types of electrodes, their depth of penetration, and the possible 
approaches for arrangements remain to be theoretical with little supportive research 
evidence. Whilst these beliefs are widely accepted, further research is warranted. 
2.3 HEAT PRODUCTION WITH PSWT 
It is believed that PSWT can work in either thermal or non-thermal modes. 
Considerable understanding exists about the interaction between EMF and biological 
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systems in the thermal modes as tissue responses to the field can be measured in terms 
of the heat generated and the resulting physiological reactions (Tenforde, 1996). 
The thermal mode with PSWT can be achieved by using long PD and high PRR. 
It is accepted that tissues with high dielectric content such as muscle and blood are good 
conductors of the current as they have the ability to absorb more energy and dissipate 
the resulting heat more efficiently (Scott, 2002). Fatty tissues on the other hand have 
low dielectric constant and low conductivity (Ward, 1980) and as such tend to heat up. 
Some have explained this by poor vascularity and the lack of thermoregulatory 
mechanism in the fatty layer (Wadsworth and Chanmugam, 1983) whilst others 
suggested that it is the tiny blood vessels spread throughout the fatty layer, which are 
responsible for retaining heat and the build up of temperatures (Ward, 1980). These 
views remain to be theories with little supportive evidence. 
The athermal effects of PSWT have been an area of dispute (Cleary, 1996; 
Adey, 1988). It is accepted that athermal mode results when short pulses are interposed 
by long inter pulse periods. Such application is believed to cause no net increase in 
temperature (AT) as all the heat gained during the "on phase" is dissipated by the 
circulating blood during the inter pulse period (Scott, 2002). However, this could be 
taken to be true when the duration of the treatment is short. It is expected that long 
treatment durations are able to facilitate the accumulation of heat and a change of the 
application from being athermal to thermal. Heat generated in the tissues is the product 
of tissue resistance and current density as explained in Equation (2.1). 
Equation (2.1) Heating= Current density2 x Resistance (Prentice and Draper, 2001) 
Hitherto, it is anticipated that longer treatment durations are expected to result in more 
energy delivered to the tissues; higher current densities and a possibility of heat build up 
compared to applications with short durations. 
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Wadsworth and Chanmugam (1983) argue that the determining factor in the 
production of heat is the PRR and that reducing it will reduce the amount of heat 
experienced by the patient however, no rationale or experimental evidence was given 
for such claims. Other work on the thermal sensation and heat production with PSWT 
(Murray and Kitchen, 2000) has confirmed Wadsworth and Chanmugam views. The 
authors have shown that definite thermal sensation can be experienced by the subjects if 
the MP was increased to 21.19 ± 8.27W using PRR. However, it could be debated that 
other variables such as PD, PP can also contribute to the net amount of energy delivered 
during a treatment, which were not comprehensively investigated in the literature. Two 
other unpublished studies have examined the relation between detectable and definite 
thermal sensation (www. electrotherapy. or2). McMahon and Watson examined the 
effect of applying 400 tsec, 400 pps, MP of 10.82W on the time it takes subjects to 
report thermal sensation. In a sample of 40 subjects, they found that it took 104±65 sec 
to reach possible thermal sensation and a 179±107 sec to reach definite perception. 
Another unpublished study by Watson and Evans, examined the time it takes 20 non- 
injured subjects to report possible and definite thermal sensation using two parameter 
combination and same MP. The dose used was 400 µsec, 800 pps, MP 12W, and 100 
µsec, 800 pps, MP 12W. Only eight out of 20 subjects reported thermal heat. SkT 
results with the two modes were not significant. These findings are in agreement with 
the above studies as a MP of 12 W is not enough to lead to thermal sensation. The 
studies also imply that it is the MP rather than the combination of the parameters such 
as PD and PRR that are responsible for the thermal sensation with PSWT. Further 
validation to this notion was provided by the laboratory work conducted by Hill et al 
(2001) where they were able to demonstrate that changing parameters (PD, PRR) while 
keeping MP the same did not alter the outcome. 
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Controversies arise as to whether PSWT can really be considered an athermal 
modality (Cleary, 1996; Barker et al, 1985; Ward, 1980). It was postulated that the 
amount of energy delivered to the tissues is one of the determining factors governing 
whether the application is associated with a thermal effect or not (Murray and Kitchen, 
2000; Bricknell and Watson, 1995; Oliver, 1984). With PSWT, the term athermal could 
be taken to have two meanings, external and internal athermal effects. External athermal 
effects refer to the thermal sensation experienced by the patients. That is to say, 
athermal mode is where the patient reports no perceptible thermal sensation (Scott, 
2002). This thermal sensation experienced by the patient could vary depending on the 
subject sensory threshold and sensitivity of skin thermoreceptors (Kingsley, 1996). 
Internal athermal effects denote the change in the state of the cell in response to PSWT 
when AT is zero and no measurable change in the state of the cell is detected. 
As such, athermal could be viewed to have different meanings, and several thresholds, 
which necessitate clear definition in the literature. Nevertheless, this aspect is rarely 
explained and usually both athermal types are confused. 
Adey (1988) argues that EMF absorbed by the tissues will always result in internal 
thermal energy regardless of the mode of application. The energy delivered to the 
tissues increases the kinetic energy of the molecules resulting in random ionic 
movement. Atoms become excited, and move into higher levels of energy, releasing 
photons of EMF, which may be transferred to other atoms or changed into heat (Scott, 
2002; Low and Reed, 2000). Tissues contain ions, polar molecules and non-charged 
molecules. The energy delivered to the tissues has the effect of orienting dipoles 
according the applied current, polarizing atoms and molecules and displacing the 
electric cloud of non-charged molecules. The friction and the collision resulting from 
dipoles when orienting to the applied field or molecules vibrating in their place, and 
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polarisation of non-charged molecules is transferred into heat (Durney and Christensen, 
2000; Delpizzo and Joyner, 1987). The resultant current flow in the tissues is given by 
the sum of drift, friction, and oscillation for each component in the treated tissues. 
Although no AT is detected externally, non-uniform heating occurs and microthermal 
effects are still occurring at the cellular level. These effects however are believed to be 
caused by E rather than H fields (Durney and Christensen, 2000). 
Contrary to the work of Cleary, Ward (1980) argues that energy could still be 
applied to the tissues and result in no heat internally as this is dependent on the nature of 
tissues treated. Tissues could be irradiated with PSWT, collision and friction of 
molecules could still be occurring, however, the proportion of E current converted into 
heat could be very slight, and no real current is initiated in the tissues. In this case, the 
molecule movement results in thermal agitation (Foster, 1996) and their movement 
could be no more than random movement or electrical noise (Stenger, 1999), which 
lasts for the time of the pulse on period (Michaelson and Elson, 1996; Tenforde, 1996). 
It could be added that even with tissues containing high dielectric molecules, under the 
influence of E field it is the extent of dipolar alignment to E field that determines the 
amount of heat produced and this is dependant on the strength of the applied current, 
and amount of E field absorbed by these molecules (Hand, 1990). Ward (1980) adds 
that it is the proportion of displacement to real current that determines whether a given 
application is thermal or not. Hence it could be argued that since almost all thermal 
effects are related to E field, and since the E field is reduced to the minimum with the 
monode (drum electrode) when using a faradic screen, it could be speculated that other 
mechanisms, probably non-thermal, could be responsible for the therapeutic effects 
obtained especially if the low dose levels PSWT is used (Ward, 1980). 
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Given the above, PSWT application can be thermal and athenmal, internal and external 
depending on the conductivity of the tissues stimulated (Behrens and Michlovitz, 1996; 
Delpizzo and Joyner, 1987), the method of application, the dosage used (Lehmann et al, 
1983) and the time of exposure (Behrens and Michlovitz, 1996). 
2.4 MECHANISMS OF ACTION OF PSWT 
The effects of irradiating tissues with PSWT will be divided for ease of 
explanations into two levels, the micro level and the macro level. The micro level deals 
with changes that occur in and around the cell in terms of ion transport, membrane 
permeability and others. In the macro effects section, body reactions to the applied EMF 
are discussed and the way in which the changes at the cell level influence the overall 
response to reduce symptoms are explained. 
2.4.1 Micro effects of EMF 
It is believed that the response of biological systems to EMF could be the result 
of either thermal or athenmal effects. In the thermal mode, it has been hypothesised that 
a temperature increase of more than 1°C is useful for mild inflammation, and an 
increase between 2-3°C is helpful in reducing pain and muscle spasm whereas an 
increase of 3-4°C is necessary to cause tissue extensibility (Prentice and Draper, 2001). 
With thermal application that produces temperature increase above 1°C in the 
tissues, the body temperature increases and then stabilises. This is accompanied by an 
increase in BVol, increase in heart rate, increase in blood pressure, and changes in the 
neuroendocrine functions in an attempt to regulate the rate of heat dissipation and 
prevent heat from building up and the possibility of irreversible damage occurring in the 
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tissues. For applications that result in less than 1°C temperature rise, the changes in cell 
behaviour was found to be reversible on termination of application (Michaelson and 
Elson, 1996; Tenforde, 1996). 
The effects of athermal or microthermal exposures on human tissues remain 
uncertain (Tenforde, 1996). The work conducted on EMF at both ELF and the high 
frequency of 27.12 MHz has shed some light on this area. However, despite the actual 
underpinning mechanism not being fully understood (Rubik et al, 1992), several 
theories have been postulated. 
Inside the cell, it is theorised that the nucleus and the microtubules are some of the 
structures that may respond to exogenous EMF. The nucleus is postulated to be one of 
the sites for interaction. It is not known how this interaction occurs, but it is expected to 
be mediated by the presence of ions such as Cam (Low and Reed, 2000). Another site 
that is thought to change cell function under the influence of EMF is the mitochondria, 
which could alter the rate of cell metabolism (Cleary, 1996). 
The work conducted by Pope et al (1989) on rats have shown that the interior of 
the cell reacts to the applied current by decreasing mitochondria size and increasing 
plasmic reticulum size. There was a decrease in cell lipid size, a migration of these lipid 
cells to cell poles and an increase in activity of ATP-ase. The size of the response was 
seen to correlate with the amount of energy delivered to the cell. Reaction was higher 
with PD 400 µs, PRR 400 pps intensity 1, for 10 minutes, compared to PD 400 µsec, 
PRR 80 pps intensity 4,10 minutes (treatments were delivered using Diapulse). 
Microtubules are another structure found within the cell, and because they are 
dipoles (Charman, 1990) they are expected to respond to the alternating E field by 
rotating and colliding producing heat (Low and Reed, 2000), which may alter cell 
function. There may be other structures inside the cell that could react to the exogenous 
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EMF but the above identified are the most frequently discussed. However, issues 
discussed above are assumptions that need to be clarified and further researched. 
One of the main sites for interaction between EMF and the biological tissues 
outside the cell is thought to be the cell membrane. It is at this site that amplification to 
the exogenous signals is occurring (Cleary, 1996; Adey, 1988). 
It is believed that the E field could change membrane selectivity to ions hence 
altering ion transport across the membrane (Hand, 1990). EMF is suggested to change 
the rate of opening, formation of ion channels across the protein bilayer found in cell 
membrane (Cleary, 1996). This changes the charged ion build up at the surface and the 
way new molecules are bound to the surface (Polk and Postow, 1996). Cations such as 
Na' and K+ were found to leak from inside the cell to extra cellular fluids under the 
influence of EMF (Cleary, 1996) altering the intracellular and the extracellular 
environment (Adey, 1988). It is also expected that such changes may restore ions, 
oxygen and nutrients concentrations to a more balanced state (Markov and Colbert, 
2000). By doing that the function of the bioelectric closed circuit normally found in 
lymphatic and micro vascular systems is restored to normal (Rubik et al, 1992; Herbst et 
al, 1988; Nordenstrom, 1983). 
EMF absorption was found to be non-uniform with maximum absorption 
occurring at the poles of the cell where the E component of the field is perpendicular to 
the cell. This absorption was found to be related to the carrying frequency of the current 
and the angle of EMF incident. Optimal absorption was found to be when angle of 
incident is either 0° or 180° (Cleary, 1996). Mcleod et al (1992) have argued that the 
efficacy of a treatment is dependant on providing selective pathways through the 
channels across the cell membrane and this is a frequency dependant process. They 
proposed that the helical radius of various ions in the field is modulated differently 
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under the influence of EMF to facilitate the passage of the ions through the channels 
easily. The cross sectional area of the channels found in the cell membrane plays a big 
role in the ionic transport across the membrane. Moreover, both the ionic pathway and 
the channel need to be in resonance and the sharpness of this resonance is determined 
by the parameters of the applied field. Interestingly, the above authors only found one 
intensity window for biological effects and there was a cut point beyond which there 
were no interaction between the field and the cell. They also reported that best results 
were obtained when there was maximum disturbance to the cell environment whether 
this was its internal environment (wound healing situation) or external environment 
(applied current, or change in temperature). These factors are considered to activate 
selective transient ion channels in an attempt to establish equilibrium (McLeod et al, 
1992). Although such an explanation is plausible, it was based on a computerised 
model that was not substantiated with in vivo or in vitro experimentation. 
Homeostatic equilibrium and communication between cells and their 
environment is normally maintained through a series of signal biochemical processes 
which include neural messages, growth regulatory factors, internal currents of muscle 
and nerve. These signals are responsible for regulating all cell activities such as cell 
differentiation, gene expression, and enzyme activity. These signals however, are 
thought to alter in response to exogenous EMF consequently altering cell function 
(Luben, 1996). 
All the above changes are expected to revert the diseased cell potential to normal 
status, correct the endogenous abnormalities and restore cell polarity (Nordenstorm, 
1983). However, it is argued that the exogenous field needs to be of sufficient strength 
to couple with and overcome the internal electrical noise found in the targeted tissue 
(Barnes, 1996) and it needs to be applied at sufficient durations for the biological 
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system to respond before it could be of any use therapeutically (Foster, 1996). For 
example, cell enzymes are structures that contain protein and are heat sensitive. Enzyme 
activity may cease and structural damage may occur at temperatures above 45° C 
(Kiang et al, 1990; Vidair et al, 1990). As such appropriate levels of energy need to 
delivered to the tissues to avoid unwanted adverse reactions. 
Cell response was found to be temperature specific with some of the reactions 
occurring at certain temperature ranges (17.7-25°C) and with SAR above 100W/kg, 
other work has showed the cell to be even more sensitive responding to SAR as low as 
4W/Kg (Luben, 1996). 
There is no consensus however, on the latent effect of EMF application. Cleary 
(1996) argues that the alteration in cell state could last up to 4 days with SAR of 5- 25 
W/Kg, suggesting accumulative effects of EMF. Tenforde (1996) disagrees stating that 
with athermal exposure or when the increase in tissue temperature does not exceed 1°C, 
the effects were found to be reversible upon termination of the exposure. However, 
Tenforde did not specify the dosage, or the SAR for the exposure that lead to such 
findings, as such these results should be viewed with caution. 
Experimental work has shown that different carrying frequencies affect different 
target tissues (windows of frequency) (Trock, 2000). For example, Ca++ binding to cells 
was observed to occur with low carrying frequencies in cardiac cells, and cat brain but 
the same applications were not found to have any effect with skeletal muscle and rat 
brain cells (Postow and Swicord, 1996). Hill et al (2001) have demonstrated that human 
fibroblasts were selective in that they showed the highest level of proliferation when 
MP was 12W, the proliferation was found to be less with values outside this range. 
Human chondrocytes were found to proliferate at constant dosages of 6W when 
treatment time was 5 minutes and to decline when the treatment time was changed to 10 
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minutes (Hill et al, 2001). Although a lot of work needs to be done in this area, the 
above-mentioned observations must be taken into consideration when extrapolating 
research findings between different frequencies of EMF and among different species. It 
also suggests the existence of MP and time window that need to be explored further due 
to its influential effects on treatment outcome. 
2.4.2 Macro effects of EMF 
EMF coupling to endogenous fields is believed to alter physiological processes 
(Ward, 1980). Though not experimentally supported, it is thought that such reactions 
could promote endothelial cell proliferation (O'Connor et al, 1990), and repair the 
vascular network in the injured area (Markov and Colbert, 2000; Rubik et al, 1992; 
Herbst et al, 1988). Moreover, by increasing nutrients and oxygen supply to the tissue, 
growth and healing are expected to occur. It is not clear though which of these changes 
is purely the result of thermal effect and which is expected to be mediated by the 
microthermal effects, thus they will be discussed in conjunction. 
The macro effects of EMF are (Scott, 2002; Low and Reed, 2000; Wadsworth and 
Chanmugam, 1983): 
" Speeding the recovery of soft tissue injuries by increasing the activity of 
fibroblast and the stimulation of ATP and protein synthesis (Cameron et al, 
1999), which may increase in the rate of collagen deposition (Low and Reed, 
2000). Interestingly, EMF can work in two directions. It could accelerate cell 
growth as in tissue healing and it could inhibit abnormal high cell proliferation 
like in neoplastic growth (Markov and Colbert, 2000). For example, by exposing 
human lymphocytes for 2 hours to a 27 MHz field and a SAR ranging between 
0.5 to 200W/Kg, it was found that cell proliferation increased when SAR was up 
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to 25W/Kg, however, it was suppressed when the exposure exceeded 50W/Kg 
(Cleary, 1996). The latter observations were further supported by the 
suppression of melatonin levels in the body as a result of EMF irradiation, a 
process that is known to be involved in strengthening body defence against 
caner growth. 
" Tendon extensibility: using PSWT in the thermal mode could lead to elongation 
of collegneous structures and mobilise scars provided that the application of heat 
is associated with stretching (Kitchen, 2002). 
" Muscle performance: muscle performance can be enhanced by using the thermal 
mode of PSWT. Heat can improve flexibility, isometric strength and increase 
range of motion (ROM) if the application was accompanied by stretching 
(Draper et al, 2002; Peres, 2002). 
" In cases of oedema and haematomas: PSWT is expected to aid the resolution of 
haematomas and oedema by increasing the rate of interstitial fluid drainage 
(Goat, 1989), and increasing venous return (Wadsworth and Chanmugam, 1983; 
Golden et al, 1981). As such helping to reduce the removal of the excess fluid 
from the injured tissues back to the circulation. Heat however, is contraindicated 
in the early stages of oedema or haematoma as it may increase capillary 
hydrostatic pressure and lead to the production of bradykinin or histamine which 
are chemical mediators that could aid in increasing vessels permeability 
consequently increasing oedema (Kitchen, 2002). 
" In cases of inflammation, PSWT is believed to aid the resolution of 
inflammation by increasing phagocytosis (Cameron et al, 1999), increasing the 
number of white blood cells and antibodies that help reinforce body defence 
mechanism, removal of noxious toxins and improve oxygenation (Wadsworth 
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and Chanmugam, 1983). Evidence to the above claims was provided by Hill et 
al (2001) who demonstrated that there was a significant increase in fibroblast 
number after 10 minutes PSWT with MP of 48W applied twice daily. Hill et al 
have also demonstrated that cell proliferation is time and energy dependent. This 
means that research findings on certain parameters cannot be simply 
extrapolated to other settings. All of which warrants further investigations in 
order to establish the appropriate treatment parameters to use clinically. 
" PSWT is expected to reduce joint stiffness by reducing synovial fluid viscosity 
(Scott, 2002; Yung et al, 1986). 
" The vasodilatation observed with PSWT is thought to occur as a result of several 
mechanisms. It is theorised that the accumulation of waste products, or the direct 
stimulation of smooth muscles of the vessels in response to heat are ways by 
which blood vessel dilatation is triggered (Ward, 1980). Blood vessels are 
thought to dilate in response to the stimulation of sensory nerve endings at the 
skin surface, which in turn are stimulated by the heat, initiating an axon reflex 
(Kitchen, 2002). With vasodilatation, there may be a decrease in blood viscosity 
to ease the flow of blood (Low and Reed, 2000). 
" The increase in temperature associated with PSWT use is claimed to increase 
metabolism and speed up chemical reactions (Ward, 1980). It is expected that 
for each 1°C increase in tissue temperature, there will be 13% increase in the 
rate of metabolic reaction (Kitchen, 2002). These claims were only validated in 
animal studies (Vanharanta et al, 1982) and no human studies are available. 
" Though still anecdotal, it has been accepted widely that PSWT can cause pain 
reduction as a result of the inhibition to the sensory impulses transmission, 
which may lead to a sedative effect in the treated area. Inflammatory pain is 
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expected to reduce as a result of the vasodilatation and absorption of the 
exudates accumulating in the tissues (Ward, 1980). The pain resulting from 
muscle spasm could decrease as a consequence of vasodilatation and the 
removal of excess lactic acid and other metabolic products in the muscle that 
cause muscle soreness (Kitchen, 2002). 
" PSWT is expected to aid nerve regeneration particularly small diameter fibres 
(Wilson and Jagadeesh, 1976). The effect of PSWT on nerves is an under 
researched area and the increase in the rate of nerve regeneration was only 
demonstrated in animal studies (Zienowicz et al, 1991; Raji and Bowden 1983; 
Wilson and Jagadeesh, 1976) and human studies are still lacking. 
The majority if not all of the above-mentioned physiological responses are proposed 
and lack experimental evidence however, as theories they can be expected to be 
reactions that are dependent on the rate of temperature increase, the electrical 
characteristics and SAR of the targeted tissue. The lack of a clear understanding of 
PSWT mechanism of action makes it very hard to reach a clinical decision about the 
actual therapeutic effect of PSWT. 
2.5 GENERAL CONTRA-INDICATIONS AND PRECAUTIONS 
WITH PSWT 
For years, the use of PSWT was associated with few contra-indications 
compared to CSWD. This was due to the belief that PSWT is a completely athermal 
modality and as such there was no need to warn the patient during the treatment or 
perform a sensory test (Forster and Palastanga, 1985). However, the increasing amount 
of evidence suggesting the ability of PSWT to heat the tissues when enough energy has 
been applied (Murray and Kitchen, 2000; Bricknell and Watson, 1995) necessitate a 
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change in the way PSWT is perceived being athermal modality and indeed a change to 
its list of contra-indications. It is worth noting that the list of contra-indications 
discussed below is drawn mainly from electrotherapy textbooks. Most of these contra- 
indications are speculation and deduction lacking experimental evidence. 
2.5.1 Metal implanted in the treated area 
Despite the lack of studies examining the effect of PSWT on a metal implant, it 
has been widely accepted that metal is a highly conductive substance, and its presence 
near a treated area creates an alternative pathway of low resistance, disturbing the EMF 
field and concentrating the line of force in the metal away from the treated area 
(Wadsworth and Chanmugam, 1983). The high field density created in the tissues could 
cause high thermal load and consequently a bum (Scott, 2002). These findings however, 
have only been validated with CSWD (Stott and Wallbank, 1993; Heick et al, 1991) and 
the support with regard to PSWT use is still lacking. 
The dispute on using PSWT with metal implants (Scott, 2002; Low and Reed, 
2000) is due to its mixed mode of action (thermal and athermal). The application of 
PSWT at low doses is expected to result in no perceivable thermal sensation hence it 
was thought to be safe practice. The literature however, lacks a definition of what is 
meant by low dose and when would the athermal mode becomes a thermal mode 
especially with the experimental evidence giving different power levels 10.8W 
(Bricknell and Watson, 1995), 21.5W (Murray and Kitchen, 2000), and 25W 
(Wadsworth and Chanmugam, 1983). Such conflicts suggest that PSWT use with 
patients bearing any metal implant in any part of their body should be avoided until 
further decisive evidence have been presented. 
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2.5.2 Cardiac pacemaker and hearing aid 
It has been accepted that PSWT treatment to patients wearing pacemakers is an 
absolute contra-indication. This is because of the possibility that EMF emitted from 
PSWT machines could interfere with the function of some of these pacemakers 
resulting in a change in their rhythm. The use of PSWT on the extremities however, was 
suggested by some to be safe (Prentice and Draper, 2001; Delpizzo and Joyner, 1987). 
The use of low energy pulsed SWD (equipment was manufactured by the authors and 
was worn as a collar for 8 hours) was associated with arm parasthesia (Foley-Nolan et 
al, 1990). Although recent advances in technology are expected to improve the shielding 
of the new generations of pacemakers, making them more immune to interference from 
PSWT, safe practice however, necessitates that even the application of low dose of 
PSWT to any part of the body should be avoided due to the possibility of the 
pacemakers having metal part in them and the devastating risk it may have on patient 
health when it malfunction as a result of being in EMF. 
PSWT is also expected to interfere with the function of some hearing aids (Low 
and Reed, 2000). Experimentation has shown that absorption of pulsed RF in the brain 
causes a rise in the temperature leading to air expansion which eventually launches 
pressure waves inside the skull. These waves can turn into acoustic waves, which reach 
the cochlea and disturb the function of the hearing aid aside from causing patient pain 
and discomfort (Bassen, 1998; Roschmann, 1991). 
2.5.3 Circularity disorder 
The thermal application of PSWT is associated with an increase in blood flow to 
the treated area (Draper et al, 1999). It is speculated that patients with venous 
thrombosis or phlebitis may be in danger of dislodging the blood clot as a result of the 
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dilation of the blood vessels. Some however, have argued the safe application of PSWT 
with these conditions once the vessel has fibrosed (Low and Reed, 2000). 
Patients with arterial diseases may also experience tissue destruction due to the 
inability of the blood vessels to function effectively in dissipating the heat resulting 
from the treatment. In all the above conditions, it is expected that the impaired 
circulation could be responsible for a decrease in the amount of oxygen supplied to the 
treated area and a possibility of a gangrene developing (Low and Reed, 2000). 
PSWT should also be avoided on areas of recent injury or tissues that have the 
tendency to bleed as with vasodilatation the blood is expected to decrease in viscosity 
(Scott, 2002) inducing more haemorrhage (Forster and Palastanga, 1985) 
It is likely that patients with diseased heart muscle may lack the ability to 
respond to the increased demands in the blood that are needed as a result of the 
vasodilatation occurring in the treated area. It is deduced that the heart may not be able 
to increase its output endangering the patient of undue physical stress (Wadsworth and 
Chanmugam, 1983). It is not clear whether these changes are proportional to the 
severity of the condition, that is the more serious the condition the worse the outcomes 
of using PSWT. Findings are mainly deductive due to the obvious ethical issues 
associated with conducting such studies. 
2.5.4 Inflammation 
Applying PSWT in a thermal mode could exacerbate the inflammatory process 
and as such need to be avoided. The use of this modality in the athenmal mode is 
considered appropriate and is expected to aid its resolution (Low and Reed, 2000). 
The use of PSWT should be avoided at the "flare up" stage of OA and rheumatoid 
arthritis (RA). Heat is believed to increase the activity of collagenase (a cartilage 
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destroying enzyme), leading to more destruction in the joint (Van Den Bouwhuijsen et 
al, 1990). 
The application of PSWT to tuberculosis should also be avoided as the increase in 
circulation may spread the infection to other parts of the body (Low and Reed, 2000; 
Van Den Bouwhuijsen et al, 1990). 
2.5.5 Diabetes 
Diabetic patients are predisposed to peripheral neuropathy (Mendell et al, 2001). 
This could result in the loss of sensation and as such, high field intensities may 
endanger patients of being burned (Kahn, 2000). 
2.5.6 Pelvic area 
It is contra-indicated to irradiate the pelvis during pregnancy as this may induce 
haemorrhage or miscarriage. 
Applying PSWT to female pelvis during menstruation is expected to increase 
haemorrhage (Wadsworth and Chanmugam, 1983) and possibly disturb the menstrual 
cycle (Van Der Esch and Hoogland, 1991). 
Evidence with regard to male gonads has demonstrated adverse reactions in both animal 
and human studies. Male fertility was shown to decrease when the heat is applied on 
their reproductive organs (Dada et al, 2003; Hjollund et al, 2002; Lue et al, 2002), as 
such the use of PSWT should be avoided. 
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2.5.7 Malignancy 
Applying PSWT in a thermal mode could promote the growth of metastasis 
(Scott, 2002; Prentice and Draper, 2001). Tumours are known to respond adversely to a 
mild increase in temperature meaning that malignant cells undergo a more rapid 
increase in temperature than normal cells especially if the area has been previously 
treated with radiotherapy (Delpizzo and Joyner, 1987). 
Outside the realm of physiotherapy, heat is used widely in treating cancer and 
limiting its growth (Vargas et al, 2003; Bachar et al, 2003). This practice cannot be 
applied to the heat produced from PSWT generators because despite the attempts to 
calculate PSWT dosimetry it remains difficult to quantify (Behrens and Michlovitz, 
1996). PSWT incorporate power meters that only indicate the amount of power emitted 
by the machine and not that delivered to the patient and as such, it becomes very hard to 
measure the amount of energy delivered to the tissues (Delpizzo and Joyner, 1987). 
Hand (1990) discusses that the frequency of 27.12 MHz has been used to treat 
tumours and states that two electrodes of different sizes should be placed within a 
distance of 3-5 cm from the tumour. However, this was the only reference located that 
discussed the use of SW for tumour management. Nevertheless, for safe practice, it is 
considered best to avoid using PSWT with malignant conditions. 
2.6 ELECTRO-POLLUTION 
Electro-pollution is a term that refers to the health hazards associated with the 
exposure to exogenous EMT (Rubik et al, 1992). EMF pollution could be caused by 
either residential (e. g. electric blankets, home heating, heated waterbeds, mobile phones, 
television, and radio), occupational (e. g. power lines, radio transmitters, medical 
devices, video display units, electric power transmitters, and long range military 
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communication systems) or exposure to natural fields from the atmosphere (e. g. solar 
activity, thunderstorms, lighting) (Markov and Colbert, 2001). 
The work on low and extremely low frequencies of EMF has associated 
exposure with detrimental effects on health (Shaw and Croen, 1993; Hand, 1990). 
Animal studies have shown an association between a decrease in foetus weight, increase 
in anomalies, increase in mortality (Martin et al, 1991; Peterson, 1983), and reduced 
fertility (Brown-Woodman et al, 1989) with increased EMF exposure. Structural 
damage to the cell was found to be greatest 4 hours after exposure to LF compared to 
immediately after exposure (Lai and Singh, 1995). 
Observations on humans have also shown an association between the risk of 
spontaneous abortion (Ouellet-Hellstrom and Stewart, 1993; Taskinen et al, 1990; 
Goldhaber et al, 1988), foetus malformation (Nordstrom et al, 1983), low birth babies 
(Wertheimer and Leeper, 1989), birth defect (Kallen et al, 1992), headache (Dowson et 
al, 1988), adult cancer (Pollan et al, 1999; Wartenberg, 1996), childhood cancer 
(Feychting and Ahlbom, 1993; Savitz et al, 1990), Alzheimer disease (Sobel et al, 1996) 
and the exposure to low frequencies of EMF. 
Although the mechanism underpinning these observations is not completely 
known (Berman, 1990), some theories have been put forward to explain these incidents. 
It is plausible that weak EMF could disturb cell to cell communication, a crucial process 
for good health. The process of cell communication is maintained via a series of 
chemical reactions and ionic transport system. Exposure to EMF could disturb this 
system leading to unregulated cell proliferation, activation of tumour promoting agents 
such as Ornithine decarboxylase (Luben, 1996) resulting in cell damage. Body 
immunity to tumours may also be suppressed as a consequence of the depressed 
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production of some hormones such as thyroxin, thyrotropin, steroid, plasma 
corticosterone (Michaelson and Lin, 1978; Yang et al, 1983). 
Another type of cell damage could also occur from the disturbance of Ca" 
binding to cell membrane and enhanced DNA synthesis (Adey, 1990; Blackman et al, 
1985; Liboff et al, 1984), increase in the intracellular level of growth enzyme (Litovitz 
et al, 1993) the breakdown of neuro-endocrine-immune system interaction (Tendorde, 
1996), and chromosomal stickiness and breakdown (Hand, 1990) all of which could 
disturb the environment around the foetus resulting in the adverse reactions. 
Conversely, it has been argued that hyperthermia is the mechanism by which all 
these adverse effects occur (Taskinen et al, 1990). Animal studies have shown that 
increase of maternal temperature by 4°C is enough to disturb the environment around 
the foetus and lead to malformations and increased mortality (Lary et al, 1986). 
Excessive heat could cause enzyme breakdown, change the cell membrane to a more 
fluid state, stimulate mediators such as histamine and brakykinin to alter capillary 
hydrostatic pressure and increase capillary permeability resulting in oedema (Kitchen, 
2002). 
Though it may be plausible that hyperthermia may lead to malformations and 
increased fatalities in animals, it is hard to accept it as a cause for foetus malformations 
and deaths in human. In the absence of experimental evidence, it is unlikely that the 
temperature of the human uterus will increase 4°C just from being in the vicinity of LF 
or ELF. 
Human studies have failed to present sufficient evidence on these adverse 
reactions due to the difficulty in replicating study findings (Adair, 1999), the lack of 
definition and measurements to RF exposure and the possibility that participants were 
subjected to other sources of RF, which were not monitored during the study. All of 
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these are confounding factors that could lead to misclassifying the real size of exposure 
and the risk associated with it (Swerdlow, 1996). 
2.7 ADVERSE EFFECTS OF PSWT 
Therapeutic diathermy machines can be a source of occupational hazard 
(Coppell, 1988; Delpizzo and Joyner, 1987). These observations were underpinned by 
the fact that EM waves emitted from SW machines can propagate freely in air (Scott, 
2002) without a need for a medium, making it difficult to concentrate the energy in the 
area treated (Docker et al, 1994; Martin et al, 1991). This risk of electro-pollution is 
increased by the small treatment cubicles and the cramped conditions in some hospitals 
(Coppell, 1988), which could subject other patients present within the vicinity of 
operating equipment to increased risk of unintentional EM strays. 
Kallen et al (1992) examined the incidence of congenital malformations among 
physiotherapists over a five year period. Using a mailed questionnaire, they studied 33 
physiotherapists with offspring of congenital malformation compared to 63 therapists 
who were used as controls. They reported that the 33 physiotherapists who had babies 
with congenital malformation used SW daily compared to the controls. However, the 
authors failed to measure the duration of exposure. Furthermore, although malformation 
was associated with increased use of SW by the therapist while they were pregnant, 
closer examination to the data reveals the contrary. Among the 33 with severe reported 
infant malformation, nine physiotherapists reported the use of SW daily and 2 used it 
often, this is in comparison to 15 who never used it and 7 who seldom used SW and still 
they had malformed infants. All these findings mean that there were other factors that 
were not accounted for by the authors and might have been responsible for the reported 
findings. 
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Hamburger et al (1983) have reported incidents of heart pain among male 
physiotherapists using SW. The study used a postal survey and unfortunately, had a low 
response rate and no other record in the literature has further examined such claims. 
Taskinen et al (1990) found that pregnant physiotherapists using SW for more than 5 
hours a week are at more risk of spontaneous abortion than those using it for shorter 
durations. The incidence of abortions could be escalated if the therapist is beyond 10 
weeks gestation period and is a frequent user of higher doses with her patients 
(Taskinen et al, 1990). Discordant conclusions were obtained by Lerman et al (2001). 
They found that for therapists to have abnormal infants, SW exposure must exceed 10 
hours a week and not 5 hours (p=0.002). However, both studies failed to report and 
measure the complete EMF exposure profile (occupational versus residential) making it 
hard to accept one finding as opposed to the other. It could also be argued that Lerman 
et al may have missed some of the adverse effects of exposure as a result of their 
classification system which divided exposure to either less than 10 and more than 10 
hours which makes it less sensitive than Taskinen et al (1990) (who divided exposure to 
less than 5 hours and more than 5 hours), this is besides the absence of a rationale for 
their classification. 
In disagreement with the above studies, Larsen et al (1991) found no statistical 
difference between therapists exposed to SW compared to those who were not in terms 
of congenital malformation. Their findings however, have related congenital anomalies 
with longer EMF exposures (p<0.05). A small difference, though not significant, was 
found between prematurity of male infants exposed to longer durations of SW 
compared to those with shorter exposures. No association was found between reduced 
fertility and exposure or between length of gestation and SW exposure. Their findings 
were not supported by genetic causes for differences in outcome between male/female 
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infants. This study was a retrospective case report which collected data through 
telephone interviews and such method is more likely to be subjected to recall bias (Polit 
et al, 2001; Bowling, 1997) 
Guberan et al (1994) examined the gender ratio of offspring in Swiss 
physiotherapists. A questionnaire was sent to all the physiotherapists who were 
members of the Swiss Federation of Physiotherapy. In a sample of 1030 (response rate 
79.5%) it was found that there was no difference between the exposed and non-exposed 
physiotherapists in offspring gender ratio or in the prevalence of low birth weight 
infants. They also found that the electrode type (air space plates, circuplode), duration 
of exposure per week, and the distance from the SW machine did not play a significant 
role in the findings. Although these findings were in disagreement with Larsen et al 
(1991), it could be speculated that the large size employed in Guberan et al study might 
have accounted for this difference. Similar to the previous study Guberan et al, used a 
retrospective approach, with the questionnaire being the tool to collect the data. In the 
questionnaire they asked therapists to recall detailed information such as the number of 
times they have been exposed to SW in the first month of their pregnancies, how many 
times per week they worked within a distance of less than or more than one meter. 
These questions demand a remarkable memory and lot of recall, which could bias the 
findings. 
Although the majority of studies have associated SW exposure to adverse 
reproductive outcomes, these studies have failed to account for other confounding 
factors for abortions (Taskin et al, 1990) such as heavy lifting, bad posture (West and 
Gardner, 2001; Hollis, 1992) and workload. Moreover, some studies employed a 
retrospective design where they have used medical records to trace incidents of 
abortions. Nevertheless, data obtained in this manner could be endangered by the loss of 
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some files (Polft et al, 2001), hence the files may not give a true representation to the 
actual status. Furthermore, almost all studies have mainly used self- reporting 
questionnaires as a tool to obtain information on EMF exposure. Self-reporting is 
considered a source of potential recall bias if substantial amount of time has elapsed 
(Heiman, 1995). The reliability of the reporting could also be further endangered by the 
heightened public awareness on a sensitive issue such as EM exposure (Shaw and 
Croen, 1993; Taskin et al, 1990). 
Additionally, although the above studies have shown association between EMF 
exposure, abortions and foetus malformation (Ouellet-Hellstrom and Stewart, 1993; 
Larsen et al, 1991; Hamburger et al, 1983; Kallen et al, 1992; Taskin et al, 1990; 
Stellman and Stellman, 1980), no causal relationship can be established from those 
studies due to the nature and methodology of these studies and the absence of 
quantitative measurements. 
2.8 ELECTROMAGNETIC RADIATION (EMR) AROUND PSWT 
MACHINES 
Studies on the strength of EMF around SW machines found differences 
according to the PSWT make, mode of application (continuous or pulsed), and 
treatment setting (Shields, 2003; Coppell, 1988; Skotte, 1986). 
The type of electrode used could affect the stray irradiation around PSWT unit. 
Capacitive electrodes recorded higher E field than drum electrodes and inductive coil 
(Lau and Dunscombe, 1984). In agreement with these findings are the findings of Skotte 
(1986) who reported that air space electrodes were associated with higher stray emission 
followed by circuplode. Interestingly, although both monode and circuplode are 
inductive applicators, the level of unwanted radiation associated with their use is 
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different, the authors however, did not specify the make of these electrodes, as such it 
could be speculated that the alignment and configuration of the coil within the treatment 
head was responsible for this difference. Coppell (1988) measured EMR from a distance 
of lm around a PSWT machine. Findings confirmed that air space electrodes were 
associated with 10 times higher values of stray emission when compared with pad 
electrodes and 100 times higher radiation levels than inductive electrodes. These 
findings on air-space electrodes were further supported by Martin et al (1991). 
Tzima and Martin (1994) have evaluated the stray of E and H fields of several 
SW machines in pulsed and continuous mode and with different electrode 
configuration. Air spaced electrodes were found to emit more EMR when used on 
continuous mode compared to pulsed, with field extending above National Radiation 
Protection Board (NRPB) (1993) levels to 0.8-1.1 m in continuous and 0.4-0.8 m in 
pulsed. The strength of the field was also found to decrease with increasing distance 
from the unit. Although the authors have described the positions from where 
measurements were taken, description to dose on which they set the SW machines was 
not complete, information such as PRR, and MP were lacking. 
The E field was found to be higher near the electrodes while the H field was 
highest near the cables (Shields, 2003; Martin et al, 1991). As such it is expected by 
standing at the end of a diathermy console opposite to the applicator instead of the front 
of the unit the amount of unwanted EMR exposure is expected to decrease (Li and 
Feng, 1999; Skotte, 1986). 
Li and Feng (1999) measured EMR intensities from a distance of 30,100,150 
cm from a SW machine. They measured the strength of both E, H fields at the level of 
the knee, waist and hand of the operator. Although the authors found that the operator 
exposure to be below the recommended levels, the strength of the measured field was 
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found to be variable in different directions around SW machine. The highest recorded 
value was in front of the diathermy at a distance of 30 cm at the level of the knee. 
Li and Feng (1999) and Skotte (1986) found that both E and H were higher at the front 
of the unit rather than at the back. Fields were found to be 55A/m and 0.19V/m in the 
former study, 19.2A/m, and 0.22V/m in the latter. In conflict with the above findings, 
Coppell reported values that E field strength were between -0.011 to 0.32 times higher 
and the H field was 0.015-1.6 times higher than the recommended values at the back of 
SW unit and recommended that the design of the unit console be changed to avoid over 
exposure to physiotherapists. Though it is hard to accept one study over the other due to 
differences in methodology and nature of measurements, all those studies confirm that 
there is a potential safety issue with SW that demands care from operators. Studies have 
presented different values for the strength of E and H fields possibly because of the 
difference in SW makes or SW dose employed during testing (which is not reported in 
those studies). 
The size and placement of the electrodes on patient body also plays a role in the 
strength of the field distribution. Field strength was found to be proportional to the size 
of the electrode. A 20-30% increase in field strength was demonstrated when the 
electrode diameter was increased from 6 to 14 cm (Tzima and Martin, 1994). Contrary 
to these findings were the results of Shields (2003) who found on 8 SW machines and 
two different sized electrodes (4 medium electrodes were compared to 4 small 
electrodes from different PSWT makes) that the medium electrodes did not always emit 
higher field strength compared to drum electrodes and commented that electrode size 
and effects on the field strength is only important when measuring from single unit. 
However, such differences disappear when multiple units are compared as other factors 
come into play such as the make and the power output of each unit. Moreover, given 
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that SW units have different power outputs, when units with higher output were 
compared with units having lower power outputs for EMR, contrary to the common 
belief, units with higher power outputs did not always emit higher stray radiation and 
similar units did not always emit the same level of radiation. Such findings imply that 
findings from studies should not be extrapolated to all makes of SW units and should 
not be taken as gold standards but as guidelines and modification should made as seen 
necessary depending on the working circumstances. 
The arrangement of the electrodes is another factor that could affect the strength 
of the field around SW machines. Co-planer arrangement was found to emit lesser stray 
field compared to contra-planer (Tzima and Martin, 1994). The distance between the 
electrodes and the area treated seems to play a role in the size of EMR emitted. The 
extent of the field was found to be proportional to the distance between the treated area 
and the electrodes, with less stray emission with closer applications (Lau and 
Dunscombe, 1984). These findings were in agreement with Tofani and Agnesod (1984) 
who also reported a proportional relationship. Martin et al (1991) supported Tofani and 
Agnesod and commented that with an increase from 10 to 30 mm the field is expected 
to increase 10-30%, and this is expected to cause uneven heating and concentrate the 
EMF field under the treatment head (Section 2.2.2). 
Shields (2003) argues that even with similar treatment settings, the field strength around 
the electrodes could vary according to the type of unit used (Shields, 2003). However, a 
downfall of many of the previous studies is that they failed to give sufficient details on 
the type of electrodes used, their arrangement, and the SW make to allow for 
comprehensive comparisons. 
General practice recommendations state that conductive PSWT units emit the 
lowest stray radiation as such a distance of 0.5m is sufficient. Although CSP guidelines 
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recommend that a1 meter distance is the safe working distance, recent work by Shields 
(2003) has shown that increasing the distance to lm is essential in order to ensure that 
physiotherapists exposure to EMR is below NRPB (1993) recommendations. Such 
findings were reached following the measurement to EMR emitted from inductive 
CSWD and inductive PSWT in eight units of different makes. 
These findings are not definitive as field strength could be altered in the clinical 
setting due to the use or the presence of metallic furniture around the treatment area, 
another SW machine operating within a distance of 2 m, and the therapist standing in 
close proximity to SW cables (Coppell, 1988; Delpizzo and Joyner, 1987). Each of 
these factors could play a role in creating alternative conduction path, distorting the 
EMF (Docker et al, 1994). 
It could be argued that the majority of these studies were undertaken in 
laboratory setting with units that have been serviced and calibrated for that purpose. 
Shields (2003) has demonstrated that many of SW units used in hospitals are not 
monitored regularly for output and performance. Examining 20 machines from different 
hospitals in Ireland, it was found that they were not functioning to their required 
specifications. For example, it was found that some of these units have unreliable 
timers, the output was at times 45% higher than the selected dose and in other instances, 
it was 26% lower than was expected. 
Additionally, the majority of those studies used a phantom of saline, which is more 
homogenous than human tissues. This makes direct extrapolation from research findings 
to the clinical setting difficult due to the difference in real and the displayed power 
outputs of those machines. 
Studies have shown that therapists average exposure time during a treatment is 
around 3 minutes (Stuchly et al, 1982), which may lead to the speculation that with such 
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short exposures EMR exposures are unlikely to exceed the recommended levels by 
NRPB (which state that over a6 minute period, maximum E field exposure should not 
exceed 61 A/m, and maximum H field exposure should not exceed 0.16 V/m, SAR of 
10 W/cm2). However, no quantitative measurement to physiotherapists EMR exposure 
were undertaken, and all studies have reported findings from questionnaires with no 
actual measurements, such safety issues warrants further research. 
2.9 CONCLUSION 
This chapter has presented background knowledge on the mechanism of PSWT, 
its indications and contra-indications. Many of the issues raised are not founded by 
experimental research and are mostly anecdotal. Despite that, these theories have been 
largely accepted as a foundation for PSWT actions. Effective and safe use of PSWT 
necessitate that more research is conducted. 
This chapter has also summarised the occupational hazards associated with the use of 
PSWT. Epidemiological studies have not presented a definite correlation between the 
use of PSWT and congenital malformation or PSWT and abortion. Studies on the 
strength of the field have shown that physiotherapists are safe provided that they work 
in a distance that is at least 1 meter from PSWT units. Literature, however, lacks studies 
that quantitatively measure the durations and the extent of therapists EMR exposure and 
hence quantify the actual risk. 
The next two chapters will discuss the physiological effects of PSWT and the clinical 
trials conducted on various pathological conditions in order to examine the evidence 
behind PSWT clinical use. 
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CHAPTER 3 
LITERATURE REVIEW ON THE 
PHYSIOLOGICAL EFFECTS OF PSWT 
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3.0 INTRODUCTION 
The application of PSWT is believed to be associated with dilation of blood 
vessels, increase in blood flow, reduction in blood viscosity, and increase in skin and 
muscle temperature (Low and Reed, 2000). A considerable number of studies have 
examined the application of PSWT on the maximum settings when PSWT is thermal 
(Garret et al, 2000; Draper et al, 1999, Bricknell and Watson, 1995); as such, a 
reasonable understanding exists with regard to the physiological effects of PSWT in the 
thermal mode. However, its mechanism of action and interaction with biological 
systems when it is set on lower doses and is believed to generate little or no sensory 
thermal effect is still unclear. 
This chapter is a critical evaluation of the studies conducted to-date on the physiological 
effects of PSWT, the review will focus on the studies that have examined blood flow, 
and nerve conduction velocity, skin, and muscular temperature, as these variables will 
be used in succeeding experimental sections. The search strategy for the literature 
review is explained in Appendix G. 
3.1 LITERATURE REVIEW 
3.1.1 PSWT and skin/muscle temperature 
Six research papers were located discussing the effect of PSWT on skin 
temperature (Wessman and Kottke, 1967; Valtonen et at, 1973; Heick et al, 1991; 
Oosterveld et at, 1992; Draper et at, 1999; Garret et at, 2000). 
Using the indirect reflex method of heating, Wessman and Kottke (1967) 
investigated the effect of the abdominal heating on the temperature of both the leg and 
the foot. On 10 normal women (age 21 and 22 years) blood flow, blood pressure, SkT, 
and oral temperature were measured following abdominal heating for 80 minutes. Blood 
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flow was measured using a boot shaped plethysmograph, SkT was measured using iron 
constantan thermocouples taped to the right foot, the pads of big toe and little toe, the 
sole, the dorsum of the foot, right calf, pad of thumb and little finger and the dorsum of 
the hand, and another thermocouple was attached to the forehead. Temperature was 
recorded every 2.5 minutes. Oral temperature was recorded using a mercury 
thermometer, pulse rate (PulsR) was taken from the wrist and blood pressure was 
estimated by auscultatory method. Although no significant relation was found between 
SkT and blood flow, a measurable increase in calf and foot temperature was evident, 
accompanied by an increase in oral temperature and PulsR measurements. The authors 
however failed to mention the dose of PSWT, and did not explain the rationale for using 
a small sample (n = 10) of only women aged 21 and 22. Moreover, no rationale was 
given for the choice of long treatment duration especially that 80 minutes of PSWT is a 
regime that is difficult to transfer to a hospital setting. 
Valtonen et al (1973) compared the effect of irradiating the abdomen with 
PSWT and CSWD on lower limb SkT in a sample of ten healthy females. Three 
treatment protocols were employed. CSWD was applied using a pad electrode placed 
under the sacrum and a condenser electrode placed over the abdomen. The second 
CSWD protocol was achieved using the hinged type drum (Diplode) over the abdomen. 
With both protocols the CSWD was set to deliver gentle mild heat. The third protocol 
was the PSWT (Diapulse machine, circuplode electrode, 65 µsec, 600 pps, MP 38 W). 
All treatments were administered for 15 minutes on three consecutive days. 
Temperature was measured from the lower limb every 5 minutes using thermocouples. 
Findings have shown that the increase in SkT peaked at 15 minutes after application. 
There was no statistical difference between the three modes of application despite 
PSWT recording the greatest increase compared to continuous. Despite the small 
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sample size the findings suggests the importance of selecting the proper treatment 
duration if beneficial effects are to be gained from the treatment. The authors however, 
failed to mention the site of temperature thermocouples on the lower limb and there was 
no reporting of statistical analysis. 
In 1991, Heick et al studied the safety of applying PSWT and US on eight 
women with a copper intrauterine device. The women were complaining from 
perimenopausal bleeding and were hospitalised in order to do curettage. The treatment 
was given to the lower abdominal skin while the patients were in the operating theatre 
and are under general anaesthesia. Temperature was measured from both the uterus and 
the rectum using two types of glass/ethanol thermometer one with copper and the other 
without. PSWT was delivered using Ultratherm at intensity 3, PP 400W for 20 min, US 
was given at 1.5W/cm2 for 5 minutes. They concluded that both modalities were safe to 
apply as no temperature above 38.1°C was recorded with both modalities, and as they 
expected the thermometer with metal content recorded higher temperature than the one 
without. Despite the small number employed in the study, the sample had been further 
divided into 2 treatment groups. According to the authors no control group was used 
because the increase in uterine temperature was minute, a reason that was not clearly 
justified because the need to include a control group should come at the planning stage 
and not after collecting the data. The dosage for both the US and PSWT were not 
comprehensively mentioned. No rationale was given for using two types of 
thermometers especially as the one with metal component would always record higher 
temperature than the one without due to the heating effect. Additionally, with all 
patients unconscious during the application of PSWT, this study carries an ethical issue. 
Oosterveld et al (1992) conducted a study to examine the effects of topical heat 
and cold on intra-articular and skin temperature. Forty two healthy students were 
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recruited for the study. Subjects were randomly assigned to one of four groups: group 1 
was treated with ice chips placed in plastic bag over the anterior knee for 30 minutes. 
The knee of group 2 was cooled with nitrogen-cold air for 6.4 minutes. Group 3 was 
treated with PSWT for 15 minutes. The treatment was delivered using a Curapuls 419 
unit with MP of 180W, electrodes (condenser field method) were placed on the medial 
and lateral sides of the knee. In the fourth group the knee was treated with lingo-paraffin 
for 10 minutes. Intra-articular temperature was measured using intraflon infusion needle 
inserted into the joint and its position was confirmed by radiography. SkT was 
measured using a medical thermometer attached to medial surface of the knee. Skin fold 
measurements (SFM) were taken from the biceps, triceps, subscapular muscles, and 
iliac crest. 
There was a recorded decrease in SkT with both ice chips and nitrogen cold air, this 
reduction however, did not reach statistical significance. Joint temperature also 
decreased with the two modalities however it was only statistically significant with ice 
chips (p<0.001). Heat generated from the application of lingo paraffin was higher than 
the heat produced with PSWT (p<0.001) both in skin and joint temperature. The latent 
effect of heat and cold modalities has shown different results. The recorded drop in 
intra-articular temperature with ice chips and nitrogen cold air was evident even after 3 
hours post treatment unlike the heat produced by lingo-paraffin and PSWT, which 
returned to baseline reading before 3 hours. Although the exact time the heat modalities 
took to revert to baseline readings was not mentioned, the findings suggest that cold 
treatment offered a larger window for interventions such as stretching and exercise post 
treatment. No significant association was noted between SFM and AT or intraarticular 
temperature. Furthermore, no baseline temperature recording was available for the 
PSWT group and this was due to the difficulty in administering PSWT with metal in the 
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joint cavity as such the mean readings from other groups was used for analysis, doing 
this the authors failed to mention whether the groups were comparable at baseline or 
not. 
Draper et al (1999) studied the nature of temperature increase and decay in the 
gastrocnemius muscle in 20 healthy college students following the administration of 
PSWT. The temperature was measured intramuscularly (by the insertion of a thermistor 
which was pulled out when PSWT was turned on) at 5,10,15 and 20 minutes during 
the application of PSWT and 5 and 10 minutes post treatment. PSWT was applied for 
20 minutes at 800pps, 400µsec, and MP of 48W. An increase in temperature of about 
4°C was detected at a depth of 3 cm. The heat peaked at 15 minutes after which it 
levelled for 5 minutes and started to decline slowly with around 1 degree per 5 minutes. 
In the study the output of PSWT was interrupted every 5 minutes to take temperature 
measurements as such it could be speculated that the reported temperature increase is 
not the true cumulative effect. Moreover, it was argued that the heating pattern with 
inductive applications is not selective, meaning that with heating of deep tissues there 
will be excessive thermal build up in superficial tissues (Ward, 1980) as such it would 
have been interesting if the authors had compared the temperature of skin and 
superficial adipose tissue to the muscle temperature recorded. 
Another study was conducted by Garret et al (2000) to compare the amount of 
temperature rise and decay of both PSWT and US in the triceps surae muscle of 16 
healthy students. The temperature was measured intramuscularly by using three 
thermistors placed at 3 cm depth and 5 cm apart. Half the sample received PSWT 
followed by US and the rest received the opposite. PSWT was delivered using 
Megapulse given for 20 minutes at 48W MP, PRR 800 Hz, 850 µsec interburst interval, 
PD 400 µsec, PP 150W, while US was given in the continuous mode at 1MHz, intensity 
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of 1.5W/cm2 for 20 minutes. With both modalities the middle point in the muscle 
demonstrated the highest increase (4.58±0.87°C for PSWT and 0.09±0.56°C for US) in 
temperature (p<0.05). The tissues treated with US took 14.88±4.7 minutes to return to 
baseline reading while it took PSWT 38.50±6.61 minutes to return to baseline reading. 
The authors concluded that PSWT is more effective in heating and retaining heat when 
large areas are the target. The conclusion reported in this study cannot be taken as a real 
difference between US and PSWT, for two main reasons. Firstly: during the experiment 
the authors left the thermistor needle in the muscle to record minute by minute change 
in temperature during US application. This leads to the speculation that the increase in 
temperature reported could be the joint increase of needle and muscle temperature. 
Secondly: the baseline temperature reading for the US was always higher with all the 
subjects who received US as the second modality in their randomisation, this could 
mean that not enough time was given to the muscle to recover after PSWT and this may 
have affected the overall findings of this study. 
The latter two studies described above have utilised MP of 48W. This setting 
represents the maximum output of Megapulse units. No other attempts were made to 
examine other power settings despite the wide range of parameters available. 
3.1.2 PSWT and blood perfusion 
Two research papers (Morrissey, 1966; Erdmann, 1960) and one conference 
abstract (Burden and Mitchell, 2000) were located discussing the relation between 
PSWT and blood flow. Erdmann (1960) examined the effect of radiating the 
epigastrium on the blood flow in the feet of 20 adults. In a controlled temperature room, 
20 fasting healthy subjects ranging in age between 25 to 38 years were recruited. Blood 
flow was measured from the second toe of each foot using plethysmography. 
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Temperature was recorded every two minutes from the dorsum of the foot, rectum and 
the skin under the treatment head using thermocouples. The treatment head was applied 
to the epigastrium (with power outputs being increased gradually from PP 410W to PP 
1025W). The authors recorded a noticeable increase in blood flow that was proportional 
to the gradual increase of intensity. Blood flow started to increase in the first 8 minutes 
with a plateau reached within 35 minutes of application. The blood flow reading went 
back to baseline after 30 minutes post treatment. The increase in temperature was 2°C in 
the foot and ranged between 0.5°C to 1.5°C under the treatment head. There was no 
change in rectal temperature. 
These findings unfortunately can not be related to the amount of energy delivered to the 
subjects because the treatment parameters reported by the authors (intensity 4 or 5) are 
not transferable to other PSWT devices, especially as some of the parameters and the 
make of the PSWT are not reported. The authors also failed to analyse their findings 
statistically, and the results reported were merely descriptive. 
On 28 normal subjects (aged between 20-39 years) Morrissey (1966) studied 
the effects of three PSWT protocols (irradiation of the leg for 15 minutes, irradiation of 
the eqigastrium for 15 minutes, irradiation of the calf followed by irradiation of the 
epigastrum for 15 minutes) on BVo1 using MP of 40W (600 Hz) and 80W (2000 Hz). 
Changes in BVol were measured before and after the treatment from calf and foot pre 
treatment, every 2 minutes during the treatment and post treatment using venous 
occlusion plethysmography. SkT was recorded using iron copper thermocouples from 
the foot and calf. Results showed that significant increase in BVol was noted with 80W 
MP and not with 40W. The report however lacks comprehensive statistical description, 
with unclear reporting of the significance level. Furthermore, one of the applications 
included applying PSWT to the calf followed by irradiating the epigastrium for 15 
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minutes, it was not mentioned whether the 15 minutes was divided into 2, which means 
that each part was treated for 7.5 minutes (this could mean that both areas received 
lower power outputs compared to other groups). The description could also mean that 
both the calf and the epigastrium were treated with 15 minutes each, which may have 
resulted in more energy outputs being delivered to the mentioned area. All of which 
would makes it difficult to compare the findings of the 3 applications directly to each 
other. Furthermore, the part of the experiment which examined the effects of 80W was 
done on only 4 subjects which raises the question of the validity of the conclusions. 
Nineteen healthy subjects were employed in a single blind experimental design 
to investigate the effects of PSWT on blood flow in the quadriceps muscle (Burden and 
Mitchell, 2000). The sample was divided into a treatment and a placebo group. The 
treatment group received 15 minutes of PSWT (Megapulse II, 65 Nsec, 400pps, MP 
3.25W) and the other group received the same time of treatment with the equipment not 
turned on. The blood flow using volumetric plethysmograph was measured 3 times: 
after 15 minutes baseline, after 15 minutes treatment, after 15 minutes recovery. 
Findings suggest that PSWT administered at these parameters significantly increases 
blood flow in the treated area. Unfortunately, no other findings were available as this 
was a poster abstract from a conference and the study was not published (the co-author 
was contacted and the study was an undergraduate project). 
3.1.3 PSWT and peripheral nerves 
The effect of applying PSWT on peripheral nerves was examined by Currier and Nelson 
(1969) and Abramson et al (1966). 
Abramson et al (1966) examined the effect of experimentally changing local 
circulation and temperature on ulnar and median nerve conduction velocities on 29 
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healthy adults. Blood flow was measured using venous occlusion plethysmograph, 
muscle temperature was measured at a depth of 3.5 cm using copper thermocouples. 
In first part of the experiment the plethysmograph was filled with histamine and a 
current strength of 10 to 15 mA was applied for 25 minutes to aid ion transfer to the 
body. Skin and muscle temperature were measured before, during and after treatment. 
In the second part of the experiment SW was administered for 25 minutes while the arm 
was exposed to either a temperature bath of 93.2°F or of 39.2°F. Two air spaced 
electrodes were used, one placed on the shoulder and another one on the wrist. 
Temperature, and motor nerve conduction was measured before and after treatment. The 
water in the plethysmograph was heated using a heating coil while water cooling was 
maintained using a refrigeration unit incorporated into the plethysmograph. Findings 
revealed that there was a significant (p<0.05) increase in motor conduction in the 93.2°F 
bath. There was also a measured increase in blood flow and temperature (no 
significance level was mentioned). In the 39.2°F bath there was a significant (p<0.05) 
decrease in median and ulnar nerve conduction velocity, skin, subcutaneous and muscle 
temperature with no significant difference noted on the blood flow (no significance 
level is reported). Histamine by ion transfer caused no increase in motor nerve 
conduction of ulnar or median nerves and tissue temperature but a significant increase 
in blood flow in the forearm. Given this, the authors concluded that the changes in 
blood flow do not play a significant role in changing motor nerve conduction unlike the 
small change in tissue temperature, which may alter the nerve velocity considerably. 
Although both nerves shown similar trend of increase and decrease in velocity there was 
a difference in the magnitude of the response to the environment around the nerve 
whether it was hot and cold. Results revealed a greater increase with the ulnar nerve, 
though no explanation was proposed for that. Unfortunately, the work above has used a 
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technique that is not utilised in hospitals and one that might have some safety issues, 
with no rationale given for the reason of enclosing the arm with water at certain 
temperature and no justification for the choice of temperatures for water baths. 
Currier and Nelson (1969) conducted a study on 10 healthy subjects (22-37 
years). They examined the effects of active exercise (riding bicycle ergometer for 5 
minutes with 60 repetition per minute) and passive heating (SW; irradiating the 
lumbosacral area for 20 minutes, PRR 13.56 Hz) on motor nerve conduction velocity. 
Delivering supramaximal stimuli of 100 µsec repeated every 1 second, they measured 
motor nerve conduction in the peroneal nerve. The recording electrodes were positioned 
4 cm apart with the proximal electrode placed over the belly of the muscle (extensor 
digitorum brevis) and the distal electrode over the tendon of the muscle. SkT was 
monitored along the course of the nerve at the site of the electrodes using a 
thermocouple. Rectal and oral temperature was measured using standard clinical 
thermometers. Although both treatment programmes resulted in an increase in nerve 
conduction velocity, exercise resulted in a greater increase (3.36m/sec) compared with 
the increase with PSWT, which was not significant (p>0.05). Despite the findings not 
being significant (p>0.05) diathermy has shown a greater CorT increase (0.33°C) 
compared to Exercise (0.09°C). The authors of this work did not report the dosage they 
used for the PSWT and whether it was used on the pulsed or the continuous mode. Their 
non-significant results reported could be attributed to the small number of subjects 
employed in their study. 
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3.1.3.1 Animal studies 
Wilson and Jagadeesh (1976) have examined the effects of PSWT on the rate of 
nerve regeneration. In 132 rats they divided the median and ulnar nerve in the rats 
forefoot and removed a segment that measured 2 mm, they reapposed the nerve ends 
and closed the skin. Half the sample was treated with PSWT for 15 minutes a day, the 
rest acted as controls. The rate of regeneration was monitored using nerve conduction 
studies and histology. It was found that nerve conduction in some of the treated rats 
returned after 12 days, though it required that the stimulus strength be ten times higher 
than it was before surgery. After 30 days all rats had normal NCV compared to the 
controls, which after 60 days only showed a flicker in the response. Histology 
examination showed fibrosis around the nerve in the controls. There was less fibrosis 
and scarring in the treated group. It was found that large diameter fibres were slower 
than small fibres in reappearing. 
The same authors conducted another study on cats, which underwent hemicordotomies. 
The cats were treated with half an hour daily for a month with Diapulse (field strength 
of 50 milliwatt per square cm and 400 PRR). After 3 months the animals were 
sacrificed and dissected. As with the previous experiment, the scarring in the treated 
group was less with an abundance of regenerating neurons showing in histology. 
With both experiments insufficient details were mentioned on treatment equipment and 
parameters, electrode type, and statistical analysis. The second experiment on cats the 
sample size was not mentioned. 
Raji and Bowden (1983) conducted a study to investigate the effects of PSWT 
on the regeneration of the common peroneal nerve in rats. The left common peroneal 
nerve was exposed and crushed above the knee in half the sample (n=12) while it was 
cut with a razor in the other half (n=12). In both groups, a3 cm section was removed 
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from the nerve. The right side acted as a control. PSWT (Diapulse) was delivered on 
400 pps, PD 65 µsec, PP 15.2W, for 15 minutes a day. Animals were paired and one 
was treated with active PSWT and the other was treated with sham PSWT. Temperature 
was measured every 5 minutes before intervention, immediately after PSWT, and for an 
hour after PSWT. It was measured from the skin, rectum, and deep tissues using 
thermocouples and an electrical resistance thermometer, the depth of the measured 
tissues was not mentioned. Animals were sacrificed at 31/z days, one week, two weeks, 
three weeks, and four weeks and at eight weeks post operation for dissection. Response 
to treatment was accomplished using microscopy, photographs and functional activity 
level (playing, gait, grooming, absence of foot dorsiflexion, presence or absence of toe 
spreading). There was a significant increase in temperature recorded with all three 
recordings (p<0.05) during treatment. SkT declined gradually after treatment reaching 
baseline reading within 35 minutes. There was rapid functional recovery both after 
crushed and sectioned nerves with a difference in times. Whether the nerve was crushed 
or sutured there was less swelling and adhesion in the treatment group compared to 
sham treated group. However, insufficient information was provided on the difference 
in time scale of recovery in crushed and sectioned nerves. The ambient temperature 
fluctuation was around 5°C, which means that its effects on the outcome cannot be 
discarded. The animals were placed on the PSWT treatment head during irradiation 
which means whole body irradiation not leg treatment has been administered. This 
means the amount of energy delivered to the animal in relation to its size is large as 
such direct extrapolation of findings to human should be done with caution. 
Another study was conducted by Raji (1984) to investigate the effects of PSWT 
on nerve repair. The peroneal nerve in 24 rats was cut with a razor and the skin above 
the nerve was sutured after ensuring that the ends of the nerve were in apposition. The 
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other leg in each rat served as control. PSWT (Diapulse) was set on peak power 4,400 
PRR for 15 minutes in half the sample while the other half received sham PSWT. A 
calibrated thermograph was used to measure skin, rectal and deep tissue temperature 
every 5 minutes before treatment, during the treatment and post treatment for an hour. 
Functional rat activities was monitored in terms of playing, gait, grooming, absence of 
foot dorsiflexion, presence or absence of toe spreading. Paired animals were sacrificed 
3'h days, one week, two weeks, three weeks, four weeks and at eight weeks for 
dissection. Outcome was compared in terms of myelinated nerve fibre counts, and axon 
diameter measurement. There was a recorded temperature increase of 3.6°C in skin, 
4.4°C rectal, and 3.6°C in the deep tissue post treatment, though the depth of 
measurement was not mentioned. There was a significant difference between the treated 
and non treated group in the size and magnitude of adhesions and fibrosis at the site of 
surgery (p< 0.01). The untreated group showed more adhesions and fibrosis which made 
dissection more difficult compared to the treated group. A progressive improvement in 
function and regeneration with newly formed collagen fibrils, less swelling of stumps, 
evidence of axonal sprouting, accelerated phagocytosis and fibroblastic activity. There 
was an increase in the number of vessels within the endoneurium at and above the site 
of trans-section in the treated group. The outcome of this study however is promising in 
terms of the effects of therapeutic SW on nerve regeneration, and the fact that less 
adhesion existed around the nerve post sectioning is promising and could have its 
clinical implications, however, more investigations on humans are a prerequisite to 
validate the outcome on human. 
A study conducted by Zienowicz et al (1991) examined the effect of pulsing SW 
on nerve regeneration. In the first part of the study, they looked at the interaction 
between the timing of the nerve surgery, and the process of healing in n=48 rats divided 
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into eight groups. In a complex procedure, the rats either underwent an immediate repair 
or delayed nerve repair (after 5 days). At each stage, the rats were either assigned 
standard care or PSWT (coil electrode, PRR 2 Hz, PD 20 µs, amplitude 3G) for 4 hours 
per day for 5 days. Rats were assessed at day 45,75,105 and 140 for walking ability 
and functional level. The results of this phase demonstrated that the timing of pulsing 
PSWT was a crucial factor in the rate of recovery. Immediate pulsing of PSWT delayed 
the healing compared to delayed treatment (after 5 days). 
The second phase was undertaken to determine the effect of exposure time on the rate of 
healing. Ninety rats were divided into 6 groups each containing 15 rats. Group 1 had no 
PSWT, group 2 had PSWT only before surgery, group 3 had PSWT before surgery and 
post surgery for 5 days, group 4 had PSWT before surgery and after surgery till day 
165, group 5 had PSWT only after surgery for 5 days and group 6 had PSWT post 
surgery till day 165. PSWT parameters were set the same as phase 1. Rats were 
evaluated on day 1,21,45,75,105, and 165. The results showed no difference between 
groups. Unfortunately the authors fail to mention the carrying frequency of their 
equipment, only mentioned the parameters of their treatment, as such difficult to 
speculate whether it was of 27.12 MHz or not. In addition, in the second phase of the 
study details were not provided on the time of exposure, which was varied with 
different groups and a major factor in judging the study outcome. 
Despite the very limited number of experimental studies undertaken to examine 
the effects of PSWT and nerve conduction, the findings of the above mentioned studies 
point to a direction of interaction between PSWT and the process of regeneration of 
peripheral nerves. Such mechanism warrants further exploration. 
A Summary of the studies discussed above is presented in Table (3.1) 
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Chapter 3 Literature review on the physiological effects of PSWT 
3.2 DISCUSSION 
The previous sections have reviewed the literature on the experimental studies 
conducted to-date with PSWT. The review covered areas such as the interaction 
between PSWT and blood flow, nerve conduction, skin and muscular temperature and 
nerve regeneration. 
Although some studies have demonstrated that PSWT may have some effect on 
changing body temperature or blood perfusion, absence of the treatment dosage used 
makes these reports of limited value. The paucity in the number of studies conducted 
highlights the importance of conducting more studies that examine wider ranges of 
treatment parameters and subject PSWT for further extensive experimentation in order 
to be able to state with certainty that the effects observed with treatment are a genuine 
response not just a possible placebo effect. Additionally, researchers in the field need to 
pay more attention to the quality and the amount of reporting for their work in order for 
it to be informative. 
To illustrate the point discussed above on the quality of the published reports, the 
studies discussed above were further classified according to their quality of reporting in 
the Table (3.2). 
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Study Author & Topic MP of Random Blindness Control Power 
Year PSWT Allocation group calculation 
Erdman, 1960 Blood flow 16 NM NM NM NM 
Abramson et al, Motor nerve N114 NM NM NM NM 
1966 conduction 
Morrissey, 1966 Blood flow 40,80 NM NM NM NM 
Wessman & Blood flow, NM NM NM NM NM 
kottke, 1967 temperature, 
pulse 
Currier and Motor nerve NM N AI NM N VI NM 
Nelson, 1968 conduction 
Voltonen et al, Blood flow 38 NM NM NM NM 
1973 
Oosterveld et al, Core & intra- 180 Yes NP NM NM 
1992 articular 
temperature 
Draper et al, 1999 Intramuscular 48 NM NM NM NM 
tem 
Garrett et al, 2000 Intramuscular 48 Yes NM NM NM 
temperature 
fBurdcn and Blood flow 3.25 Yes Yes Yes NM 
Mitchell, 2000 
Table (3.2) Quality of the studies conducted on the physiological effects of PSWT 
f Abstract from conference proceedings 
NP: not possible, due to the nature of the modalities involved 
It can be seen from Table (3.2) that the studies conducted to date on the 
physiological effects of PSWT were scarce in number and the majority were not 
controlled and a lot of the information crucial for making informed clinical decision is 
lacking. Such issues justify the importance of conducting studies that utilise carefully 
controlled methodology and cover wider ranges of setting of PSWT. 
3.3 CONCLUSION 
Given the amount of time that PSWT has been employed clinically, it is 
surprising that only a very small number of studies have examined its efficacy in terms 
of changes in physiological parameters. At present there is very little evidence to 
support the athermal physiological effects. The work conducted however was only on 
healthy subjects with no attempts to explore the physiological reactions of a patient 
population, with the majority of the studies examining the maximum setting of PSWT 
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machine. More experimentation is still needed to elucidate PSWT mechanism of action 
especially on the lower power settings. 
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CHAPTER 4 
LITERATURE REVIEW ON PSWT 
EFFICACY 
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4.0 INTRODUCTION 
PSWT has been used by physiotherapists for decades to manage a wide range of 
pathologies. It has been the source of interest for many researchers in the last few years, 
especially with surveys in the UK showing it to be one of the top three modalities 
employed by therapists in the clinical setting (Pope et al, 1995). PSWT has been used 
clinically to reduce pain, enhance the rate of healing, encourage the resolution of 
haematoma and oedema and reduce the symptoms associated with OA and RA (Scott 
2002; Low and Reed, 2000). Nevertheless, a lot of uncertainty exists regarding the 
efficacy of PSWT and how to best set its parameters. 
This chapter reviews the literature published to date discussing the use of PSWT with 
various conditions. Following the reporting of the studies, a compilation of the dosage 
was made and examination of their impact on the outcome was undertaken in attempt to 
explore further the concept of windows of effectiveness with PSWT. The studies 
discussed cover areas such as rheumatology, musculoskeletal conditions, wound healing 
and pain. Search strategy is explained in Appendix G. 
The term SW will be used when no parameters are mentioned that could identify 
whether the application was on pulsed or continuous mode. 
4.1 RHEUMATOLOGY 
Several research papers were located examining the effect of PSWT on 
"arthritic" symptoms in the knee (Ganguly et al 1996; Klaper-Moffett et al 1996; Jan 
and Lai 1991; Leclaire and Bourgouin 1991; Svarcova et al 1988; Quirk et al, 1985). In 
general the findings of the studies were in favour of positive outcomes with the majority 
reporting improvement in function and reduction in pain (Ganguly et al 1996; Klaper- 
Moffett et al 1996; Jan and Lai 1991; Leclaire and Bourgouin 1991; Quirk et al, 1985). 
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In studies where PSWT was compared to other treatments or other interventions it was 
found to be more effective than placebo (Klaper-Moffett et al 1996; Quirk et al, 1985) 
and no better than US, IFC, Exercise (Ex), and stretching (Ganguly et al 1996; Jan and 
Lai 1991; Leclaire and Bourgouin 1991; Svarcova et al 1988; Quirk et al, 1985). 
Early work was conducted by Quirk et al (1985) who randomly allocated 38 
patients complaining from OA knees, into three experimental groups: group 1 had Ex 
and IFC, group 2 had Ex and SW and group 3 had Ex alone. IFC was given for 10 
minutes, 0-100 Hz rhythmical frequency followed by 5 minutes at 130 Hz. SW was 
delivered for 20 minutes using capacitive electrodes, and no other parameters were 
reported. All groups performed exercises twice daily: straight leg raise repeated twice 
for 30 times with a 10 minutes hold, and free knee flexion repeated 10 times twice a 
day. Patients were encouraged to continue taking their medication. All treatments were 
given 3 times a week for a period of 4 weeks except the exercise group who had to 
attend less frequently. Outcome measures were ROM, Ex endurance (which included 
the distance walked and the number of stairs the patient can manage), maximum knee 
girth, subjective pain measurements (using visual analogue scale (VAS) and a verbal 
scoring technique), and functional capacity, which included gait, method of climbing 
the stairs and the use of a walking aid. The outcome was measured by an impartial 
physiotherapist before the start of the trial, on completion of the trial, 3 and 6 months 
post trial. All three groups showed improvement in the level of pain (IFC p<0.002, SW 
p<0.05, Ex p<0.03) and an overall improvement in their clinical condition (IFC 
p<0.004, SW p<0.02, Ex p<0.03), however no protocol was better than the other. 
Although electrotherapy had a significant effect on increasing knee ROM (p<0.05), 
none of the protocols had any effect on knee girth. There was a general deterioration in 
all groups in 3 month follow up, however the overall condition remained to be better 
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than the pre-treatment status. Unfortunately, the authors failed to mention SW 
parameters, and whether the application was on pulsed or continuous mode. They also 
failed to provide enough information on the 4th follow up which was 6 months post trial. 
No information was mentioned regarding the method by which patients were 
randomised into groups or what factors were used to match patients. 
Another study conducted by Svarcova et al (1988) compared the effects of 
treating OA with US, galvanic current, and PSWT. The study employed 180 patients 
complaining from either unilateral or bilateral hip and knee OA. Patients were divided 
into 3 groups of 60 patients each. There was no mention of whether the patients were 
randomised or just divided into experimental groups. Half the patients in each group 
were given Ibuprofen 400mg twice daily and the other half was given placebo tablets to 
further assess the analgesic effects of physiotherapy modalities with and without 
medication. US was administered for 5 minutes to the knee medially, posteriorly and 
laterally with the US treatment head moved at a velocity of 5 cm/sec, no other dose 
parameters were given. Galvanic current was applied for 20 minutes at a current density 
of 0.1 mA /cm2. PSWT was given for 2 minutes medially and another 2 minutes 
laterally with a PP 700W and PRR of 46 pps using either Curapuls or Diapulse. All 
patients received 10 treatments at 2 day intervals over a total of 3 weeks. Pain level was 
assessed after 5 and 10`h session using VAS, and was also assessed on completion of 
the trial by both the patient and physician using excellent, good, no benefit and worse 
criteria. No statistical difference was noticed between all three types of physiotherapy, 
however a better outcome was obtained when active treatment (electrotherapy) and drug 
were combined. The study however, did not use a control group and the time of 
exposure for PSWT was very short and unlikely to achieve therapeutic effects. The 
authors also failed to discuss the reliability and the reproducibility of the scale used to 
79 
Chapter 4 Literature review on PSWT efficacy 
rate treatment outcome. As such it is speculated that the outcome measures used were 
not stringent or reliable enough to detect differences between groups. Furthermore, the 
authors used 3 different machines to deliver galvanic current (Eltron D, Dinapuls 424 or 
Diadynamics) and the same was done with SW treatments (Curapuls and Diapulse). The 
output of that equipment is not necessarily the same, as such it was expected that the 
amount of energy delivered to the tissues was not identical which reveals a flaw in the 
methodology and a lack of consistency, which may have affected the findings. 
The work above was followed by another study conducted by Jan and Lai 
(1991). They examined the effect of applying PSWT to 61 female patients complaining 
of either unilateral or bilateral OA knees. The patients were either assigned to 
electrotherapy or electrotherapy with Ex (straight leg raise for 200 repetition a day) for 
4 times a week. The sample was divided into four groups US, SW, US and Ex, SW and 
Ex. Treatment was randomised but it was not mentioned how this was achieved. The 
treatments were continued until significant or total relief was detected. Electrotherapy 
was either US for 10 minutes or PSWT for 20 minutes, no other description of the US 
or PSWT dose was given. Pre and post trial assessment was done using functional 
incapacity score (FIS), peak torque flexion and extension using Cybex II isokinetic 
dynamometer. The outcome was rated according to X-ray findings using a Standard 
Radiographs of Arthritis Scale, Body Mass Index, Peak Torque for knee flexors and 
extensors and FIS. Patients responded positively to the treatments with no significant 
difference among the four groups (p<0.05). The findings however, point towards better 
outcomes when electrotherapy was combined with Ex. The findings of this study were 
of limited clinical value as the study was not controlled, the authors failed to mention 
electrotherapy parameters whether it was for US or SW and also the mode of the SW 
application (continuous or pulsed). Additionally, the authors failed to mention whether 
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patients were randomly assigned to groups or whether they were divided into groups 
according to convenience and how were the experimental groups matched at baseline. 
In contrast with those findings, Leclaire and Bourgouin (1991) have reported 
PSWT to have no benefit over placebo treatment. In a triple blinded trial (where 
patients, therapist, and investigators were blinded from the purposes of the trial), and 
according to a comprehensive inclusion criteria, 47 patients with periarthritis of the 
shoulder were randomised and matched to either a treatment (SW, hot pack, Ex) or a 
placebo group (hot pack and Ex). PSWT was given using Magnetopulse for 30 minutes 
at PRR of 10 Hz for the first 6 sessions, and at PRR 15 Hz onward till session 16 and 
then at 30 Hz PRR from session 17 to the last session. Treatment was administered 3 
times a week for 12 weeks or until complete remission of symptoms. All patients were 
also given hot packs for 20 minutes, 5 minutes passive glenohumeral stretching, 10 
minutes pulley exercise, and 20 minutes active non-assisted wooden stick Ex. Changes 
in movement was recorded at baseline and monthly thereafter however there was no 
reporting on how movement was evaluated. Changes in pain level were recorded at 
baseline and weekly thereafter using VAS. A similar scale was used to assess activity. 
Authors concluded that PSWT was no better than control although no control was 
employed as all patients in both experimental groups received a hot pack, and Ex. The 
authors however, failed to mention the rationale for the choice of the treatment 
parameters or the reason for giving a certain dose for the first 6 sessions then changing 
it in the next 9 sessions then again changing it for the last few sessions. Furthermore, 
outcome whether it was pain or level activity was only assessed subjectively using 
VAS. 
In a clinical trial by Ganguly et al (1996) 35 patients with rheumatoid 
polyarthritis were randomly assigned to either active or placebo PSWT treatment. They 
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used a specially designed PSWT unit by the authors. The unit delivers a train of pulses 
with duration of 0.2 ms and inter-pulse period of 0.7 ms, no parameters were given for 
the PRR, PP or MP. Treatments were given to every affected joint 3 times a week for 
15 minutes. Outcomes measures were pain, tenderness, swelling, joint functional 
disability. Patients were evaluated weekly, and at 3,12,18 months post trial. Both the 
seropositive and the seronegative groups demonstrated improvement with the latter 
demonstrating better results. This study however did not use a control group, neither did 
the authors mention clearly the treatment parameters such issues detracts from the value 
of findings. Moreover, the methodology was not standardised as 11 of the 35 were 
having medical, surgical, gynaecological problems for which they were taking 
treatment. The eleven patients were later withdrawn from the study because of their 
absenteeism and irregularity of treatment. It was not mentioned clearly though at what 
stage this was done and whether their initial data were entered into the statistical 
analysis. The authors chose the most affected joint for analysis as such there was no 
uniformity in the analysis. 
Klaber-Moffett et al (1996) conducted a double blind study on 30 patients 
complaining from hip and knee OA. Following an inclusion and exclusion criteria 
patients were randomly assigned to dummy PSWT, control group, or active PSWT 
group. All patients underwent all experimental conditions. PSWT was delivered using 
Ultratherm IIS 601, circuplode for 15 minutes on 23W MP, and PF 82 Hz for 3 weeks. 
Therapists were blinded from treatment and placebo. PSWT was achieved using 
equipment modified by manufacturer where half the numbers on the dial are inactive 
and the other half were active. PSWT was used following a pilot study on 45 subjects. 
Three PSWT protocols were employed to deliver 23W MP a mode that was considered 
athermal by the authors (200 pps, 110 pps, 82 pps). Outcome measures were a battery of 
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Chapter 4 Literature review on PSWT efficacy 
subjective tests (pain diaries, VAS for local and referred pain, nature of pain, general 
health questionnaire, activities of daily living (ADL). All patients were taught simple 
hip and knee Ex. Assessment was carried out pre/ post trial and a follow up was done 
after 3 weeks. Summary of all studies can be found in Table (4.1). 
Findings have showed no significant difference between placebo and active treatment 
groups. The placebo group reported more reduction in pain though this did not reach 
statistical significance. 
Interestingly, patients who were on the waiting list for surgery have reported 
better outcomes than those who were not awaiting surgery denoting a possibility of 
placebo effect. The authors have used MP of 23W as an athermal mode of treatment 
however, this mode has been shown repeatedly in the literature to be thermal (Murray 
and Kitcken, 2000; Bricknell and Watson, 1995). Moreover, the study has only 
employed subjective outcome measures, which may be less sensitive in picking up 
differences between groups eventually ending in insignificant results. 
In summary, the studies above had their flaws however, their limited 
contribution to the literature cannot be ignored. The studies have presented equivocal 
evidence on PSWT effectiveness with rheumatology, though the trend is towards 
positive outcomes. This limited evidence highlights the need for conducting more 
randomised trials to clarify the role of PSWT in rheumatology. 
4.2 MUSCULOSKELETAL 
4.2.1 Subdeltoid bursitis 
Early reports on the use of PSWT for soft tissue injury were published in 1961 
by Ginsberg (Ginsberg, 1961). The reported cases were on sub-deltoid bursitis. The 
outcome of conditions treated over a period of 15 years were collated and analysed. The 
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PSWT machine employed for the study was built by the author and operated on a 
frequency of 27.12 MHz. Ninety four subjects were treated with PRR 600 Hz, intensity 
6 for 10 minutes at the affected site and another 10 minutes at PRR 400 Hz intensity 4 
directed at the liver and the adrenals. Findings were encouraging in that 86 of those 
subjects had partial to complete recovery with X-ray signs of Ca' re-absorption. 
Unfortunately, the author failed to mention the number of sessions given to patients to 
reach these findings. There was inadequate reporting of the treatment parameters (power 
setting whether it was PP or MP). The study was also lacking a control group and 
statistical analysis, which makes it hard to exclude the effect of chance on the findings. 
4.2.2 Ankle sprain 
Several research papers were located examining the effect of PSWT on ankle sprain 
(McGill, 1988; Barker et al, 1985; Pasila et al, 1978; Wilson, 1974; Wilson, 1972). The 
use of PSWT with ankle sprain was found to be better than CSWD (Pasila et al, 1987; 
Wilson et al, 1974), and placebo (McGill, 1988; Santiesteban and Grant, 1985; Barker 
et al, 1985; Wilson, 1972). 
Wilson (1972) conducted a study employing 40 patients complaining of ankle 
sprain (36 hours) to either a placebo PSWT or active PSWT (n=20 in each group, it was 
not clear whether they were randomised or not). Patients were matched for age, weight, 
sex and degree of trauma. The PSWT group was treated with Diapulse (65 µsec) for an 
hour daily for a period of three days (no other parameters were mentioned). The ankle in 
both groups was bandaged and all patients were given same standard care (Ex, and 
instruction). Assessment was done pre and post trial for swelling, pain and disability 
according to a grading system that was developed by the authors. Findings were in 
favour of PSWT treatment with improvement in pain, disability, and swelling (p<0.05). 
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The same author (Wilson , 1974) conducted another trial to examine the effect of 
PSWT on ankle sprain, however, instead of using placebo, active PSWT was compared 
to CSWD. CSWD was applied via an inductothermy cable wrapped around the foot and 
ankle, intensity 2, no other parameters were mentioned. Two fifteen minute treatments 
were given in one hour for 3 days. PSWT was delivered as in Wilson (1972). Using 
same number of patients and same outcome measures, improvement was noticed after 3 
days and results were in favour of PSWT with 82.8% improvement with PSWT 
compared to 44.2% with CSWD. However, this kind of improvement is expected as the 
energy delivered differed with the two modalities (complete hour in PSWT compared to 
two 15 minutes with CSWD). Despite the difference in application time, the findings 
suggest that a better outcome is associated with longer treatment duration. The authors 
failed to report full parameters such as the frequency and the power setting of PSWT 
machine. 
Pasila et al (1978) conducted a study to examine the effects of both Diapulse and 
Curapuls on ankle and foot sprain. Three hundred patients were randomised into three 
groups: Diapulse, Curapuls and placebo PSWT, with n =100 in each group. Diapulse 
was given on MP 38 W, Curapuls was given on MP 40 W and no other parameters were 
mentioned. Treatment was delivered for 20 minutes. Outcome measures were muscle 
strength measurements using dynamometer, ROM, gait impairment. Weight bearing on 
toe and heel was also measured but it was not clearly described how it was done. 
Swelling was measured by tape and by fluid displacement. Treatment did not change 
muscle strength, or affect weight bearing. There was a small change but not statistically 
significant on ROM. There was a significant decrease in swelling in the Curapuls group 
(p<0.01), significant improvement in gait has been found with the Diapulse group 
(p<0.01). Although the groups were matched at baseline the difference in findings with 
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the two PSWT machines was interesting, the authors did not propose any explanation 
for it. The authors also failed to mention full treatment parameters. 
In a double blind, non-controlled clinical trial Barker et al (1985) investigated 
the therapeutic effects of PSWT on lateral ligament sprain of the ankle. Seventy three 
subjects were randomly assigned to active or placebo PSWT (Therafield Beta, PRR 640 
pps, low intensity). Treatment lasted for 45 minutes on three consecutive days. Outcome 
measures were ROM using goniometer, gait analysis using a purpose designed 
walkway, pain levels using VAS, and swelling using water displacement techniques. 
Assessment was done pre and post treatment. All patients received elbow crutches, 
advice to elevate the leg, analgesics (paracetamol) and the ankle was bandaged. The 
authors concluded that there was no statistical difference between the two groups 
however the active PSWT was superior to placebo treatment. Findings were reported in 
terms of active and control group while the authors have used active and placebo group. 
No rationale was given for the choice of treatment duration and the PSWT parameters 
were not comprehensively mentioned. 
In a double blind trial McGill (1988) explored the effect of PSWT on 37 patients 
between the ages of 16-60 who had sustained a lateral ligament injury to the ankle 48 
hours previously. The subjects were randomly allocated to a placebo PSWT or a PSWT 
group (Bosch Ultramed, PRR 82 Hz, intensity 6, MP 16.9W, 15 minutes for 3 
consecutive days). Treatment was decided according to a number that was pulled out in 
the randomisation stage. Both groups were given tubigrip, advice, axillary crutches, 
analgesics and a diary to record drug consumption and the number of hours the leg was 
kept elevated. Patients were assessed by a blinded therapist prior to and after the 
treatment using water displacement for ankle oedema, VAS for pain levels, and the 
amount of medication consumed. The blinded therapist also analysed gait, colour of the 
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ankle, ankle mobility and static muscle strength. No significant difference was noted 
between the groups in the variables monitored. However, because the study was not 
controlled and traditional treatment (which included advice, analgesics, crutches and 
tubigrip) was continued with both experimental groups it was difficult to exclude the 
effect of natural course of healing. 
4.2.3 Hand injuries 
In a large trial Barclay et al (1983) conducted a study on 230 patients 
complaining from hand and thumb injury. Subjects were paired and assigned to either a 
control group (n=116) or a treatment group (n=114). PSWT was delivered using a 
monode with PP 975W for two 1/2 hours daily. Patients in both the control and the 
active group received conventional treatment, which was not described. Patients were 
assessed before and after the trial and on day 3,5,7 post treatment for swelling using 
water displacement, disability and pain following categorical criteria developed by the 
author. The non-injured hand was used as a control for the same patient. Findings were 
in favour of PSWT as the results have shown it to relieve pain, reduce swelling, and 
improve function in patients who have sustained a hand injury in the last 36 hours. 
However, the authors failed to mention the duration of the treatment course when using 
PSWT for the findings to be of value clinically. It was not clear whether they treated 
patients using the PP of the PSWT or they were only reporting the PP of the machine 
they used. Moreover, if the maximum PP was used to treat recent injuries this means 
that the patients were in danger of exacerbation of their symptoms because of the 
possibility of heat developing in the tissues. 
Summary of the studies can be found in Table (4.2). 
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4.3 WOUND HEALING 
4.3.1 Laboratory studies 
4.3.1.1 Experimental wound healing 
Only two laboratory research papers were located examining the effect of PSWT on the 
rate of wound healing (Hill et al, 2001; Badea et at, 1993). Both studies have presented 
evidence on PSWT effectiveness. 
In 1993, Badea et al investigated the effect of PSWT irradiation on the rate of 
microbial growth in a sample of cells prepared in the laboratory, a setting that was 
designed to replicate the open wound situation. Their experiment was divided into 
several parts. 
In the first part of the study, the specimens were irradiated with PSWT at maximum 
setting for 30 minutes. The aim of this phase was to discover if the application of PSWT 
at maximum setting would result in adverse reactions. The specimen was then irradiated 
with PSWT at 8 hours and 12 hours of growth, and an increase in cell number was 
demonstrated. They concluded from this part of the experiment that it was safe to apply 
PSWT for open wounds, as its application was not associated with any increase in 
bacterial growth. It was not clear though how did they reach this conclusion and how 
they extrapolate their conclusion to human wound healing. 
They then repeated the same protocol but with the specimens at 30,60,90 minutes of 
growth (to represent different stages of the healing process). They found that PSWT 
interaction with the cell culture was most intensive at a narrow window between 60-90 
minutes but not at 30 minutes. The authors have linked their findings to the active 
potentials and transport processes across the membrane that accompanies different 
phases of wound healing. Although the findings suggest a time window for 
effectiveness with PSWT it is hard to accept the findings due to lack of reporting of 
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comprehensive methodology and failure of the authors to explain in what way was the 
laboratory specimen seen as a wound. 
In a similar laboratory setting, Hill et al (2001) investigated the effect of PSWT 
on human fibroblast. Using four single blind trials, adult fibroblast and chondrocytes 
were incubated for 5 days. The fibroblasts were irradiated with PSWT at MP of 48W 
for 10 minutes in order to explore if there was any kind of interaction between fibroblast 
and exposure to PSWT. It was found that the cell division increased significantly 
(p<0.001) with this application. 
In the second part of the study the relation between the amount of energy and the rate of 
fibroblast proliferation was studied. On a sample of 16 cultures 7 exposure dosages 
were used (MP of 1,3,4,8,12,48W). It was found that the best results were obtained 
with MP 12W (improvement was judged based on cell count). However, the PRR, PD 
was not reported for the above mentioned MP(s). 
This was followed by another phase of the study, which was planned to investigate the 
effect of different patterns of energy on fibroblast proliferation. For this part of the 
study MP of 6W was delivered in three combinations (100 µsec/ 400 Hz-200 µsec/ 200 
Hz- 400 µsec/ 100 Hz). This was done in order to examine the effect of different 
combinations PRR and PD with the same MP on cell number. On 11 samples, no 
statistical difference was found between different combinations. However, the 
investigators have demonstrated in the previous section that 12W has resulted in the 
highest fibroblast count, nevertheless they used 6W just because it was possible to 
reproduce 3 different pulse patterns using Megapulse H. 
In the final part of the study, the effect of applying PSWT with different exposure 
durations was examined in relation to the rate of chondrocyte proliferation. A constant 
MP of 6W was used with four exposure times of 5,10,15, and 20 minutes. On 91 
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samples, it was found that cell proliferation varied considerably with different exposure 
times. The highest level of proliferation was seen with a5 minute application compared 
to longer treatments. The work on low output of 6W has clearly provided evidence for 
the window of effectiveness with specimens demonstrating response at a narrow time 
and energy window. Moreover, it was not mentioned the set up for irradiation and how 
many samples were irradiated at one time. The importance of that lies in the difference 
in field strength between the centre and the periphery, which may affect the field 
density if more than one sample was irradiated at the same time. 
The above work suggests a positive outcome and favourable findings when the 
effect of PSWT was examined on the rate of cell proliferation. Although laboratory 
studies lack the thermodynamic mechanism found in human and may be considered not 
representative to human reactions (Luben, 1996), they still remain very crucial to the 
development of a clear understanding on PSWT interaction with biological systems. 
Studies conducted in laboratories enable researchers to have precise control on the 
experimental setting, and provide more possibilities for manipulating variables (Cleary, 
1996). As such they remain the core of many advances in understanding cellular 
biology (Luben, 1996), by providing possible molecular mechanism for the effects of 
PSWT, and shedding some light on time/energy window suggested by previous work on 
EMF (Watson, 2000; Cleary, 1996; Luben, 1996). 
4.3.2 Postoperative wound healing 
Several research papers were found examining the effect of PSWT on postoperative 
wound healing (Arghiropol et al, 1992; Grant et al, 1989; Santiesteban and Grant; 1985; 
Nicolle et al, 1982; Bentall and Eckstein, 1975; Aronofsky, 1971). All studies reported 
reduction in pain, swelling, oedema and enhanced rate of healing. 
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Aronofsky (1971) examined the effect of PSWT on dental wounds. The 
treatment was delivered in two parts using a Diapulse (15 minutes, 600 pps, intensity 6), 
administered 24 hours prior to surgery and for another 15 minutes immediately before 
surgery. The operated site was then irradiated with PSWT for 10 minutes post surgery 
on the same dose and then again, at 24,48, and 72 hours post surgery. Ninety patients 
were divided into 3 groups. Group 1 (n=30) had PSWT pre and post surgery, group 2 
(n=30) had PSWT only post operative, and group 3 (n=30) had no PSWT. It was not 
mentioned if the sample was randomised or just divided into groups and whether there 
was a blinding of the patients or assessors. Outcome measures were size of oedema, 
pain, inflammation and swelling, which were recorded using a scale (none, moderate, 
good, fair, and poor). Despite all outcome measures being subjective, the author has 
reported substantial improvement for group 1 (pre-and post treatment) followed by 
group 2 when compared to control. Inflammation was present in 6.7% in group 1, and 
53.3% in group 2 and in 76.7% in the control. The authors did not mention how soon 
postoperatively PSWT was given as this could have its clinical implications. No 
rationale was given for the choice of treatment duration or treatment dose. 
In a double blind trial by Bentall and Eckstein (1975) the efficacy of PSWT was 
examined in relation to children undergoing orchidopexy. Fifty paired children were 
included in the study to undergo either active or sham PSWT treatment. PSWT was 
applied using Diapulse locally (550 pps, intensity 5,20 minutes), followed by 
epigastrium application (500 pps, intensity 4,10 minutes). The treatment was repeated 3 
times a day for 4 days. Outcome measures were a series of photographs taken at 
different intervals, pre and postoperative circumferential measurements of oedema, 
bruises, and discolouration of the scrotum. All these variables were followed and 
compared from both subjective (photographs and amount of operative correction 
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needed) and objective (circumference measurement) data. Findings revealed that both 
direct measurement of circumference and other subjective findings demonstrated an 
increase in the speed of healing along with a quick return to normal appearance. 
However, no control group was used, as it would be interesting to gauge the level of 
recovery to the natural process of recovery. Additionally, detailed analysis of the rate of 
recovery of both treated and placebo group was lacking. No rationale was given 
regarding the choice of the parameters, or the reason for the epigastrum application, and 
the dose level reported is not transferable between equipment especially with the brand 
of PSWT not reported. 
An interesting study was conducted by Nicolle et al (1982) to investigate the 
postoperative reaction to blepharoplasty. Authors used a small rechargeable, portable 
device that operated on 27.12 MHz. The device had a square pulse of 100 sec and a 
coil of 6 cm in diameter. The coil was adjusted with a loop in the shape of a spectacle 
that could be held in place by bandages. Twenty one patients were recruited. Although 
outcome measures were subjective based on photographs taken on several occasions 
after the operation, the authors reported that six cases showed complete recovery and 11 
showed remarkable improvements. Unfortunately, neither the PP nor the MP for the 
PSWT was mentioned and the same for the duration of exposure. Moreover, it is 
speculated that the function of portable PSWT might have been different from a 
therapeutic machine employed clinically despite operating on the same carrying 
frequency. It was not mentioned whether the investigators were blinded or not as this 
may have biased the outcome. 
Santiesteban and Grant (1985) have conducted a study to examine the effects of 
active and placebo PSWT on wound healing. Fifty patients with foot surgery were 
recruited for the study (n=25 in each group). PSWT was delivered twice (immediately 
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after surgery, and 4 hours post first application) for 30 minutes, 95 µsec, power 12 (120 
PP), 700 pps. Outcome measures were length of hospital stay, and analgesic 
consumption. Results showed that the PSWT group consumed less drugs and their 
length of stay was shorter than the placebo group. However, examining the data it could 
be seen that the difference in hospital stay between the two groups was 8 hours, which 
did not constitute a big difference. It could be added that because traditional treatment 
was continued, the limited reporting of statistics and the subjective outcome measures 
taken, it is hard to relate improvement to the effect of PSWT alone. 
In accordance with the above findings was Grant et al (1989) who investigated 
the effect of PSWT on soft tissue injury by comparing the rate of recovery of perineal 
trauma after childbirth using either PSWT or US. Four hundred and fourteen subjects 
were randomly assigned to active US, active PSWT, or placebo modalities. US was 
given at a frequency of 3 MHz, pulse 1: 4, intensity 0.5 W/cm2 for 2 min, PSWT was 
given with Megapulse on 100 pps, 65 µsec for 10 minutes. Therapy was started 12 
hours after delivery for 3 days. Outcome measures were extent of oedema, bruising, 
haemorrhoids, and analgesia taken. Over 90% of all women in all groups felt better with 
the treatment given. However, there was no significant difference between the groups 
immediately, 10 days, or at three months post treatment. It could be argued that the non- 
significant results could be due to the outcome measures employed, which were 
subjective and may not be sensitive in detecting the change. 
Arghiropol et al (1992) studied the effect of using PSWT on the rate of healing 
of surgical wounds in 25 patients. Ten patients were randomly assigned to a control 
group and the other 15 constituted the PSWT group. PSWT (Diapulse) was started on 
the second day post operative, and was applied daily for one week for a period of 15 
minutes on 400 pps, intensity 4 followed by hepatic application (600 pps, intensity 6,30 
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minutes). Only the hepatic application was continued for the second week. They 
included the hepatic application in order to investigate the relation between the 
production of plasma fibronectin (which is a glycoprotein synthesized by the liver and 
was associated with wound healing) and healing process initiated by PSWT. Objective 
measures included laboratory tests, fibronectin count, blood tests, appearance of 
oedema, bruise, and haematoma. Laboratory findings were also correlated with other 
objective outcomes measures such as level of haematoma and oedema. Increase in 
fibronectin concentration was observed as an indication of the increase in the rate of 
wound healing, which is a subjective outcome measure. However, the authors failed to 
mention the sites of the wounds. It is expected that different body parts may react 
differently to the applied current (Odia and Aligogun, 1988) and this may have effect on 
the rate and the speed of their recovery. It was not mentioned why the PSWT 
application on the operated area was stopped and only the hepatic application was 
continued. 
4.3.3 Skin graft 
Goldin et al (1981) examined the effect of PSWT on the rate of skin graft 
healing. They employed patients aged between 15-65, with a medium thickness split 
skin graft. Patients were randomised to either a placebo PSWT or an active treatment 
(Diapulse, 30 minutes, 400 pps, 65µs, PP 975W). They had 29 patients in PSWT group 
and 38 patients in the placebo group. Treatment was given preoperatively, and 6 hours 
post operative on the donor site for seven days. Outcome measures were pain severity, 
analgesic consumed, and percentage of wound healing. Patients were assessed by a 
blinded physician. Healing rates were 59% for active group and 29% for placebo group. 
Although the rationale for using the above mentioned parameters was not reported, and 
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despite the limited statistical analysis of the findings, the study demonstrated that PSWT 
does have a potential role in aiding the healing of wounds. Unfortunately, the wound 
healing was expressed in percentages, and no definition was given to the scale used to 
assess the different stages of healing. 
4.3.4 Skin ulcers 
A limited number of research papers were located discussing the interaction 
between PSWT and pressure sores (Salzberg et al, 1995; Comorosan et al, 1993; Itoh et 
al, 1991; Todd et al 1991). PSWT was effective in reducing skin ulcers (Itoh et al, 1991) 
though the improvement was governed by the method of application (Salzberg et al, 
1995). Active treatment was also better than placebo (Comorosan et al, 1993). 
Itoh et al (1991) conducted a study to evaluate the effects of PSWT on the rate 
of healing of stage II and stage III skin ulcers. Seven patients with stage II and thirteen 
with stage III ulcer were recruited. All patients selected for the study had received 
conventional treatment for at least 8 weeks with no benefit. Subjects had ulcers at 
varying sites (sacrum, buttock, heel, leg, foot, right malleolus and knee), the subjects 
also varied in the duration and the size of the ulcer. All patients continued to receive 
conventional treatment (cleansing of the wound, and dressing). PSWT was delivered 
using Diapulse drum electrode, 600 Hz, power 6, for 30 min twice daily with 
approximately 8 hours in between applications. The wound was evaluated in terms of 
visual observations, measurement of size, coloured photographs. Results shown that 
stage II ulcers took 1-6 weeks for full recovery while stage III ulcers took between 1-22 
weeks. The number of subjects in each group was small with no control group, which 
makes it difficult to rule out the effect of natural recovery on the improvement levels 
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obtained. No definition was given to nature of ulcer in stage II or III. Moreover, no 
statistical analysis was employed. 
Todd et al (1991) investigated in a double blind study the effects of PSWT on 19 
patients with resistant varicose ulcers. Subjects were either entered into an active group 
(dressing, PSWT) or inactive group (dressing, dummy PSWT). Treatment was given 
twice weekly for five weeks, using Megnetopulse 1500 (coil electrodes). The reporting 
of the dose was vague and incomplete (field strength was "60" and the intensity was 5 
Hz, treatment was given for 15 minutes). Outcome measures were ulcer size, lower leg 
girth, pain severity, and presence of infection. Both groups showed overall reduction in 
ulcer size; however the results were in favour of the active group (though not 
statistically significant, the mean decrease in ulcer size was 2.77% compared to controls 
1.16%). There was no significant difference between active and placebo PSWT in girth 
measurement, pain level and the presence of infection. The study has employed a small 
sample size which was divided into 2 groups. The small sample size might have 
contributed to the non-significant results. There was incomplete reporting of treatment 
parameters such as power setting and the pulsing mode. The study lacks enough 
information on how the outcome measures were assessed. Examining the data it could 
be seen that the patients in the two groups were matched for gender and age but not 
ulcer size. There was a difference in the mean ulcer size between the groups (the active 
group had larger mean ulcer size). This difference at baseline may have been 
responsible for the non-significant results. 
In a later report by Comorosan et al (1993), 30 elderly patients were employed 
in a double blind study to examine the effects of PSWT on decubitus ulcer of buttock, 
sacrum, knee, back, heel and leg area. The patients were randomly assigned into control 
(conventional treatment i. e. dressing), placebo (conventional treatment with sham 
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were not compatible at baseline as all patients with large ulcers were in the placebo 
group and only one big ulcer was in the control group. With grade III ulcer best results 
were demonstrated in the active group (70.6% for active and 20.7% for placebo). In 
both groups the site of the ulcer was not mentioned, the treatment parameters were 
lacking, grade III ulcer had only 10 patients, which were further divided into placebo 
and active group. The authors repeatedly report that they employed a control group 
where in fact they used a placebo and an active treatment group. 
4.3.5 Pressure sores 
Seaborne et al (1996) examined the effects of non-thermal application of PSWT 
on pressure sores. They employed 20 non-ambulatory patients between 60 and 101 
years, who had a pressure sore on trochantric or sacral region in an ABAB repeated 
measures design. Treatment was delivered in weeks 2 and 4 while weeks 1,3,5 were 
taken as baseline measurements. Subjects were randomly allocated into four groups. 
PSWT was delivered using Curapuls 419 with PD fixed at 400 µsec, and PP 700W. 
Two groups were given PRR 20 pps, MP 5.6W using either capacitive or inductive 
electrodes as such patients were treated with the above parameters with either E or H 
field; the same was done with the remaining two groups but the treatment combinations 
were changed to PRR 110 pps, MP 30.8W. E field was delivered via a coplanar 
technique using air space electrodes while H field was delivered using a circuplode. 
Routine nursing dressing was maintained throughout the study. All treatments were for 
20 minutes twice a day for 2 weeks. An independent assessor took measurements of the 
size of the wound weekly over a 5-week period by tracing the wound using a paper and 
a pen (reliability of the method was reported by the authors). All four protocols showed 
reduction in the size of the ulcer, with significant difference between the groups 
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showing in week 4 (p<0.007) and week 5 (p<0.001). Findings were better with H field 
(5.6W) followed by E (5.6W) followed by H (30.8W) and least effective was E 
(30.8W). The study however, used the ABAB design where subjects act as their own 
controls. This design is not preferable where the treatment applied has a latent reaction 
(Kazdin, 1982). Therefore, it was difficult to conclude that the improvement was only 
related to PSWT treatment especially that nursing care was continued. Interestingly, the 
positive significant outcome obtained with PSWT on week 4,5 is an indication of the 
cumulative effect of PSWT with wound healing which is in accordance with the 
literature discussed earlier (Gray et al, 1995). 
However, there was an ethical issue with this study, as the majority of participants were 
confused and some were asleep for the entire treatment. The authors perceived that there 
was no need for consent. However, despite all the flaws in this study it is of interest to 
mention that it is one of the very few studies that reported full description of treatment 
protocol and dose. 
It is expected that PSWT may assist healing by changing the local nervous 
system rather than the cell activity alone. It is plausible that changes in nerve supply to 
the vessels in the damaged area have a direct effect on the redistribution of blood to the 
tissues. Moreover, PSWT is believed to activate the sodium pump resulting in the 
repolarising of the depolarised cells in the injured area which may restore the ionic level 
of the cell membrane to pre injured state (Scott, 2002). Such theorises need be validated 
before being accepted as a confirmed mechanism of PSWT action. Moreover, despite 
the many downfalls of the above-mentioned studies, the literature is in favour of using 
PSWT on pressure sores with the studies generally demonstrating positive outcomes. 
Summary of the studies discussed above can be found in Table (4.3). 
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4.3.6 OTHERS 
An interesting report was published by Lightwood (1989) on the positive 
outcomes of PSWT with post surgical soft tissue conditions, RA, OA, pain, back pain, 
delayed bone healing and even spina bifida and stroke. The application was not 
according to the usual textbooks or manufacturer's instructions (15 to 20 minutes and 
maximum of 30 minutes) but instead treatment durations lasted for a minimum of 1 
hour and were usually repeated several times a day. Unfortunately, no treatment 
parameters were mentioned in this report. All conditions demonstrated remarkable 
improvements in enhancing the rate of tissue healing. The author failed to report the 
outcome measures employed in the study and how recovery was judged and as such it 
was hard to judge the reliability and validity of these measures and to accept the 
findings without caution. 
Barker et al (1985) examined in a double blind study the effect of applying 
PSWT to the abdomen post surgery to stimulate peristalsis. A portable PSWT that 
utilised 27.12 MHz, MP 12 W, pulses of 0.1 millisecond were delivered for an hour 
twice daily. Fifty patients were randomised to either a treatment (n= 26) or a control (n= 
24) group. Outcome measures were fluid balance, abdominal girth, and bowel sounds 
recorded by stethoscope taped to the abdomen for 15 minutes. Results showed that the 
return of bowel sounds was quicker with the active group, however findings were not 
statistically significant and were not associated with passage of flatus or restoration of 
fluid balance. There was no mention to the type of surgery the patient underwent or the 
type of electrodes used. 
Although the authors have reported that they have used athermal mode of PSWT, the 
long duration of application may have been responsible for developing heat in the 
tissues, which may have been responsible for lack of significant results. 
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PSWT) and a treatment group (Diapulse, local application on site of ulcer: 600 pps-30 
minutes- intensity 6 twice a day; hepatic application: 400 pps- intensity 4- 20 minutes- 
1/day). Patients were monitored daily by observation and weekly by colour photography 
following categorical scale (excellent, very good, good, fair, poor, no improvement). 
Poor to no improvement was noted in control and placebo group. PSWT group showed 
good to excellent results with the complete healing achieved between 1-4 weeks for 
stage II and between 2-8 weeks for stage III ulcer for all patients. These results were 
accompanied with disappearance of wound exudates after 48-72 hours. Findings have 
demonstrated beneficial effects of PSWT on pressure sores at stages II and III. Although 
the authors have reported the intensity they used with their patients (4, and 6) the 
numbers are meaningless unless the brand of the PSWT machine is reported and so is 
PP and MP. The outcome measures they used were subjective and no reliability 
information was mentioned on the scale they used for assessing the rate of ulcer 
improvement. 
In agreement with the studies reported above are the findings of Salzberg et al 
(1995). They examined the effect of PSWT on 30 spinal cord injured patients with 
ulcer. Patients were stratified according to the stage of the ulcer (20 had stage H, and 10 
had stage III). All patients continued to receive moist saline dressing. Patients were 
randomised to receive a treatment or a placebo treatment, though there was no 
description of how this was achieved. Treatment was delivered using Diapulse but no 
treatment dose was mentioned. Patients, and therapists were blinded from the treatment. 
The ulcer was measured and photographed weekly, full recovery was taken as the end 
point for analysis. The active group of stage II ulcer demonstrated better results 
compared with placebo (recovery of active group 84%, recovery of placebo group 40%, 
p=0.01), with shorter duration to achieve recovery. However, patients in stage II ulcer 
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Livesley et al (1992) have studied the effect of applying PSWT on displaced 
fracture of the neck of humerus. Forty eight patients were randomised to receive either 
active PSWT (Curapulse) or placebo PSWT. Treatment was administered for 30 
minutes, intensity 3, PRR 35 pps, 300 maximum pulse power. Outcome measures were 
pain using VAS, analgesics consumption, muscle strength, ROM using goniometer, and 
function using European Shoulder Association Assessment Charts. Patients were also 
evaluated 1,2, and 6 month later. Findings showed no significant difference between the 
two groups. 
Although muscle wasting and strength were assessed it was not mentioned how this was 
accomplished. Additionally, the scales used for assessing the outcome were mostly 
subjective. 
Buzzard et al (2003) examined the effects of PSWT on oedema following 
calcaneal fractures in 39 patients with unilateral and bilateral fractures. Patients were 
allocated to either PSWT (Curapuls 403,26 Hz, 200 psec, twice daily for 15 minutes 
using circuplode) or ice therapy (Cryocuff adjusted to 30 mm Hg six times a day for 20 
minutes). Outcome measures were circumference measurement using tape measure and 
ROM. Although both modalities have shown improvement, no modality was reported to 
be superior. 
However, it could be argued that no control group was used as such the role of natural 
improvement cannot be ruled out. The sample was randomised to groups but the 
procedure followed was not described. Furthermore, although the study involved 
repeated measurements over the course of the experiment no reliability studies for 
investigators were mentioned nor how consistency was ensured when swelling and 
ROM were measured between days. Additionally, the study employed patients with 
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bilateral fractures however, it was not mentioned whether they were treated as one case 
or 2 cases in the analysis. Summary of the studies can be found in Table (4.4). 
4.4 PAIN 
Several studies have investigated the therapeutic effects of PSWT on pain. 
Studies have looked at pelvic pain (Varcaccio-Garofalo et al; 1995; Jorgensen et al, 
1994), temporomandibular pain (Gray et al, 1994), back pain (Wagstaff et al, 1986) and 
pain of trigger points (McCray and Patton, 1984). Studies have related PSWT 
application to positive outcomes (Varcaccio-Garofalo et al; 1995; Jorgensen et al, 1994; 
McCray and Patton, 1984) others have found no significant difference between PSWT 
and laser or CSWD, but findings were better than placebo (Gray et al, 1994). 
McCray and Patton (1984) randomly assigned 19 patients to two experimental 
groups. The groups were either treated with superficial heat (hot pack) or PSWT. Using 
the algometer to measure threshold to pressure, both modalities were compared for 
efficacy. It was found that PSWT increased the pain threshold by 56% compared to 
47% with hot pack. Results were superior with very sensitive pressure points compared 
to the moderately sensitive. However, care need to be taken when accepting these 
findings as the total number of subjects (n=19) was further divided into 2 subgroup 
leaving 9 in one group and 10 in the other, making it difficult to conduct meaningful 
statistical analysis. This is besides absence of a control group, insufficient reported 
information on blinding or the randomisation process, and lack of enough explanation 
on how trigger points were divided into slightly, moderately, and severely sensitive. 
In 1986, Wagstaff et al compared the effect of pulsed versus continuous short 
wave on low back pain. Twenty three patients were randomly divided into 3 groups. 
The modes of treatments were: continuous (n=8, no parameters were reported), pulsed 
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(n=8,82 Hz, MP 23.2W, PP 700W), pulsed (n=12,200 Hz, MP 23.4W, PP 300W). 
Patients were treated twice for 15 minutes in a3 week period. Findings were evaluated 
in terms of pain pre and post treatments. All groups demonstrated significant relief of 
pain (continuous p<0.01,82 Hz p<0.0005,200 Hz p< 0.005). Both pulsed modalities 
demonstrated superior outcome (with no significant difference between the 82 Hz and 
200 Hz) compared to continuous (p<0.05). However, there was no reporting on the 
chronicity of the back pain and whether acute pain has responded the same as the 
chronic pain. Additionally the number of patients in each group was small and the 
treatment parameters were not mentioned in full. 
In a double blind randomised controlled trial Reed et al (1987) examined the 
effect of PSWT on inguinal herniorrhaphy. Forty three patients were randomised to two 
groups (active and placebo PSWT). Treatment was given twice daily for 15 minutes, 
PRR 320 pps, PD 60 µsec, maximum output 1W. Post analgesic drugs were 
standardised and given when required to control the pain. Outcome measures were pain 
(using VAS, immediately, 24 and 48 hours post operation), drug consumption. There 
was no significant difference between the two groups in pain and analgesic consumed. 
There was no difference between the two groups one week after discharge in pain level 
and in swelling at the wound site. However, the study did not use a control group. 
Additionally, the investigators used portable PSWT which may be different from 
commercial PSWT employed in clinics and which may have different carrying 
frequency than 27.12 MHz. It could be added that the outcome employed were 
subjective and may have been responsible for the insignificant results. 
In a double blind placebo controlled trial Foley-Nolan et al (1990) have 
examined the effect of PSWT on persistent neck pain. Twenty patients were recruited 
complaining of neck pain for more than 8 weeks, all patients had pain that was 
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irresponsive to other conservative treatments. They were randomly assigned to either 
active (n=10) or placebo collar (n=10). The placebo group was given sham treatment for 
the first 3 weeks and replaced by the active treatment group for another 3 weeks. PSWT 
was delivered via a soft cervical collar (utilised 27.12 MHz, MP 1.5 mW/cm2, weighed 
100 gram, that operated on battery) 8 hours a day. At entry patients were assessed for 
blood count, ESR, biochemical profile, and they were also assessed for neck movement 
(following a criteria full, one third, two third of the range), pain (using VAS) each 
session. Half way in the trial (3 weeks) subjects were asked to rate their improvement 
on a categorical scale. By the end of trial (6 weeks) there was no difference in pain level 
or ROM between the two groups although both have displayed reduction in pain level 
and improvement in ROM. However, the authors failed to mention why the placebo 
group changed regime half way to the active collar. Additionally the process of 
randomisation to experimental groups was not explained. It could be added that because 
drug consumption was not standardised between groups, it was difficult to judge its 
influence on the outcome especially with the absence of a control group. 
Foley-Nolan et al (1992) conducted a study to examine the effects of PSWT on 
acute whiplash injury. In a double blind study, 40 subjects were randomised to either 
active (collar with PSWT generator, weight 100 gram, MP 1.5 milliwatt / cm2, PD 60 
psec, PRR 450 pps, 8 hours a day for 12 weeks) or dummy PSWT. Patients were 
instructed to exercise their neck five times a day. Initial examination consisted of 
history taking, X-ray and physical examination. Patients were assessed at week 2,4, and 
12 in terms of analgesics consumption, pain level (using VAS), ROM (using full range, 
two third or one third criteria) and subjective reporting of progress. Results showed 
decrease in pain and analgesics consumption, with an increase in ROM. The study 
however was not controlled and the criteria for assessing ROM was subjective. 
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Additionally throughout the course of the study a lot of patients were lost to traditional 
treatment as the treatment given in the experiment did not have any effect on their 
symptoms, however, it was not clear whether they were entered into the analysis or 
were excluded. 
Jorgensen et al (1994) conducted a study on seventeen females complaining of 
pelvic pain (ranging from acute, sub acute and chronic). They were treated with PSWT 
for a period of 15-30 minutes. Although the treatment dosage was not reported, no 
control group was employed, and it was not mentioned whether the pulsed or the 
continuous mode was used, no information on the dosage, the authors reported 90% 
improvement in all but two cases, which makes it hard to accept the conclusion without 
questioning its validity. 
Gray et al (1994) have evaluated the effect of four electrotherapy modalities on 
patients with temporomandibular pain. One hundred and thirty nine subjects were 
allocated randomly to one of five groups: CSWD (mild heat, 10 min), PSWT (60 µsec, 
100 pps, 20 minutes), US (pulsed 2: 1,2 minutes, 3 MHz, 0.25W/cm2), laser (4 joules, 
904 nm, 3 minutes) or placebo treatments. Outcome measures were the rate of 
improvement immediately after treatment and 1,2, and 3 months later. Objective 
measurements included the ROM of jaw opening, joint tenderness, and presence of joint 
sounds. Assessments were performed by both the oral surgeon and the physiotherapist. 
Patients showed improvement in the level of pain, tenderness, ROM. All modalities led 
to similar degrees of improvement. Although both the treatment and the placebo groups 
demonstrated similar findings post treatment, follow up has shown the symptomatic 
improvement of the placebo group to decline from 53.9% to 19.2% unlike treatment 
groups, which maintained the improvement (70.9% post treatment and 74.3% post 
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follow up). The placebo group did not demonstrate a correlation between reported 
improvement and objective measurements unlike other treatment groups. 
There was a little variation in the time scale of improvement (patients treated with SW 
or PSWT reported their peak improvement in 2°d week while Laser and US reported 
maximum improvement in week 3 of treatment). No statistical difference was noticed 
between the four electrotherapy modalities although all four were better than placebo 
(the difference between treatment groups and placebo was only statistically significant 
at follow up). Unfortunately, the authors failed to mention the power setting of the 
PSWT treatment and although some parameters were mentioned it was hard to calculate 
the MP due to absence of reporting of the type of Megapulse used (senior or Megapulse 
II as each has different PP). The same study was published again as Gray et al (1995) 
reporting the same findings and same interpretations. 
Findings were contradicting with regard to effectiveness of PSWT with pain, while 
Gray et al (1994) presented positive outcomes, Wagstaff et al (1986) have presented 
negative outcomes. Differences in outcome could be due to the site of the condition 
treated, which was TMJ in the former study and the back area in the latter, the severity 
of the symptoms, the difference in sample size or it could be related to the dose, 
employed by both investigators. 
In 1995, Varcaccio-Garofalo et al used equipment called the thelf system; this 
equipment emits EMF and utilises a frequency of 27.23 MHz. Employing 64 patients 
complaining of chronic pelvic pain, the treatment was administered daily for 2 hours, 
PRR was 64 pps in first hour and 320 pps in the second hour. The whole treatment 
lasted between 20-40 days. Outcome measures were pain severity, disability, and 
psychosocial adjustments. Pain had completely disappeared in 61% of patients, while 
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23% experienced relief during the treatments but started to complain when the treatment 
was terminated. Patient depression, marital adjustments, and inappropriate health care 
utilisation all were decreased. This study, although it reported positive outcome did not 
employ a control group. 
Additionally, the protocol employed for the study was hard to replicate (daily treatment, 
2 hours PSWT for a period between 20-40 days) in the clinical setting due to time 
constraints. The number of sessions delivered to patients was variable and the end point 
for analysis was not identified. The scales used for evaluating the effect of treatment on 
psychological, disability, health, depression and anxiety were not mentioned nor is the 
reliability of these scales. 
Despite the methodological flaws in reporting some of the above studies (absence of 
control, limited reporting of dosage and the lack of statistical information), all findings 
were in favour of a positive interaction between PSWT and the relief of pain. The 
quality of the studies urges for the conduction of more rigorous studies and better 
reporting of methodology and outcome. Summary of the studies can be found in Table 
(4.5). 
4.5 ANIMAL STUDIES 
4.5.1 Surgical wounds 
A study was conducted by Brown and Baker in 1987 on 32 rabbits to examine 
the effect of PSWT on the rate of healing of surgical wounds. The rabbits were either 
assigned to an experimental group 1 (n=8, treatment for 8 days) or experimental group 2 
(n=8, treatment for 16 days). The other half of the sample was assigned to either control 
group 1 (n=8, observation for 8 days) or control group 2 (n=8, observation for 16 days). 
Xylocaine was injected into the lateral head of the gastrocnemius to induce tissue 
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damage. PSWT was introduced 24 hours after injury using Magnatherm (MP 12W, 
1600 pps, this was increased to 4000 pps at a later stage of the treatment, treatment was 
administered twice daily for 20 minutes). Results showed that PSWT did not alter the 
rate of healing. These are two major drawbacks with this study. Firstly: the investigators 
used one machine to deliver the treatment to two animals at a time and this may have 
resulted in distortion of the EMF applied. Secondly: with animals it is always hard to 
concentrate the field in the area treated given the size of the animal body, as such it is 
expected that other body parts may have been under the influence of EMF and may 
have affected the overall findings. The authors have changed the parameters of 
treatment throughout the course of the experiment however, no rationale was given and 
there were instances when the reporting was not clear. All these factors beside failure to 
control possible confounding variables could have resulted in insignificant findings. 
Despite the very limited scientific values of these studies, extrapolating findings 
from animal to human should be done with extreme care due to differences in size, in 
shape and in physiology. Animals react differently to the same amount of EM when 
applied to human tissue due to the difference in ratio in the size of the tissue to 
wavelength, which will result in different internal fields (Durney and Christensen, 2000; 
Markov and Colbert, 2000). 
4.6 DISCUSSION 
There is a growing emphasis on basing clinical decisions on best available 
evidence. Randomised clinical trials (RCT) have been viewed as the highest level of 
evidence in terms of their ability to answer clinical questions (Gray, 1997). However, 
the challenge for physiotherapists in the field of electrotherapy is the paucity of RCTs. 
While acknowledging the insights into electrotherapy practice offered by the 
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aforementioned studies, they nevertheless provide a limited perspective being not 
controlled or lacking important reporting such as the mode of application (whether 
PSWD or CSWT) or treatment protocols, absence of dose reporting, and power setting 
(Gray et al, 1994; Sweetman et al, 1993; Quirk et al, 1985) and explanation on the 
validity and reliability of their outcome measures. 
Moreover, in many cases the investigators recruited a large enough sample at the 
initial phase of the study but this number is usually divided into 2 or more sub groups 
that are rarely matched at baseline for certain characteristics. As a result, the study ends 
with small number of subjects in each experimental subgroup. This limits the 
generalisation of the findings with the results being obtained from a very small sample 
and also reduces the confidence in the nature of the analysis. 
Additionally, very limited number of papers have mentioned the subject's 
compliance and the dropout rate and very rarely a power calculation is undertaken. An 
added area of weakness was the failure to describe sufficient statistical details. All of 
the above detracts from the clinical value of any given study and limits its implication. 
It is crucial that all information related to the treatment dosage is reported in the 
published papers for the findings to be of relevance clinically (Markov and Colbert, 
2000). In the clinical setting, if therapists were to plan optimal treatment regime, they 
would have to choose the appropriate dosage by combing a variety of parameters, which 
include the PD, PRR, and the power output. Scott (2002) argues that MP is the critical 
parameter hence it must be reported unlike PD or PRR. The work by Hill et al (2001) 
have shown that changing parameters such as PD and PRR while keeping MP the same 
did not alter the outcome. Wagstaff et al (1986) have demonstrated that by keeping the 
MP at 23W and changing the treatment combination, the outcome of the two modes of 
treatments was not statistically significant on back pain. Despite that, it is not sufficient 
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to report only MP as PP differs between various PSWT machines and too few 
investigations have been conducted to compare the same MP from different machines 
on treatment outcomes. As such, until such assertion is validated, it is safer to report all 
treatment parameters including PRR, PD, MP, PP and duration of exposure. 
As discussed earlier, due to the scarcity of the information reported on the 
dosage, the literature offers little direction for clinicians in terms of a dose-response 
relationship. The biological effects of EM application are dose-specific (Watson, 2000; 
Rubik et al, 1992) and the relation is not linear, which means that increasing the applied 
energy does not necessarily culminate in better results. This was seen with studies such 
as Hill et al (2001), Leclaire and Bourgouin (1991), Wagstaff et al (1986) where varying 
the combination of the treatment parameters and keeping MP constant or increasing MP 
outputs does not always mean improvement in outcomes. As such, it is only the proper 
frequency at the proper duration that may result in a clinically useful result (Rubik et al, 
1992). All of this creates a state of uncertainty and confusion when it comes to the 
clinical decision-making process. 
The work on low frequency of EMF has revealed the concept of therapeutic 
windows. That is to say, certain reactions are likely to occur at certain frequencies, or at 
given durations of exposures (Cleary, 1994). Despite both frequency and amplitude 
windows being evident with ELF from experiments conducted on human and animals 
(Binhi and Goldman, 2000), it is not clear whether these findings are transferable to the 
frequency of 27.12 MHz due to the very limited amount of work that has been 
conducted to-date on this frequency. In addition, although those findings have been 
used to explain the reaction of different tissues to PSWT, there is little evidence to 
suggest that humans will react similarly to different frequencies. Previous experimental 
work has associated some frequencies with certain biological behaviours. An example 
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would be the frequency of 15 Hz and 72 Hz were found to increase bone density and 
improve the rate of delayed and non-union bone healing (Buch et al, 1993; Tabrah et al, 
1990; Aaron et al, 1989). The work on the frequency of 50-60Hz have been associated 
with permanent changes to enzyme activity, suppression of mitotic activity, and an 
increase in the incidence of chromosomal aberrations as such they were linked with 
cancer (Moses and Martin, 1993; Khalil and Qassem, 1991). ELF on the other hand, 
was found to improve performance of multiple sclerosis patients (Richards et al, 1998). 
Unfortunately, no similar work has been conducted on frequencies used in 
physiotherapy treatments such as the frequency of 27.12 MHz used in PSWT or 1 and 3 
Hz used in US or other therapeutic modalities however, it would be wise not extrapolate 
findings directly from frequency to the other based on the reporting above. 
Regardless of the considerable number of studies reported, it is hard to reach a dose- 
response conclusion regarding which doses better suit which condition due to the lack 
of information reported. Table (4.6) summarises the studies above in terms of the 
reported dose. The table was constructed with the objective of relating outcomes and 
exploring the concept of a window effect with PSWT. Unfortunately, it was hard to 
reach a conclusion as a consequence of the amount of information missing, all of which 
demonstrates the poor quality of studies in the field of PSWT. 
Study PSWT make PP MP PD PF Intensity Time Type of 
electrode 
Pain 
McCray and Patton, 1984 Magnotherm Inductor coil 
Wagstaff et al, 1986 Curapuls 700 
300 
23.2 
23.4 
82 
200 
15 Circuplode 
Aron , 1971 Diapulse 975 65 600 6 15 
Gray et al, 1994 Megapulse 60 100 20 
Jorgenscn et al, 1994 15-30 
Varcaccio-Garofalo et al, 
1995 
Thelft 
Stiffness 
Yung et al, 1986 Erbotherm 
110 
20 Condencer 
Rheumatolo 
Quirk et al, 1985 20 Condeser 
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Study PSWT make pp MP PD PF Intensity Time Type of 
electrode 
Svarcova et al, 1988 Curapuls or 
Diapulse 
700 46 4 
! an and Lai 1991 20 
Leclaire and Bourgouin 
1991 
Magnetopulse 10 
15 
30 
30G 
40G 
60G 
30 
Ganguly et al, 1996 02 15 
Moffett et al 1996 I Ultratherm 
IIS601 
23 82 15 Circuplode 
Wound healing 
Ginsberg, 1961 600 
400 
6 
4 
10 
_Aronfsky 
1971 Diapulse 975 65 600 6 10,15 
Wilson, 1974 Diapulse 65 2 60 Inductothermy 
cable 
Bentall and Eckstein 
1975 
Diapulse 550 
550 
5 
4 
20 
10 
Goldin et al 1981 Diapulse 975 65 400 30 
Nicolle et al 1982 100 
Barclay et al 1983 975 30x2 Monode 
Barker et al, 1985 Therafield 
Beta 
640 45 
McGill 1988 Bosch 
ultramed 
16.9 82 6 15 Circuplode 
Grant et al 1989 M Ise 65 100 10 
Arghiropol et al 1992 Diapulse 975 400 
600 
4 
6 
15 
30 
Itoh et al 1991 Di lse 975 600 6 30x2 C' lode 
Todd et al 1991 Magnetoplus 
1500 
5 15 Coil 
Comorosan et al 1993 Diapulse 975 600 
400 
6 
4 
30x2 
20 
Circuplode 
et al 1995 
_Salzberg 
Diapulse 975 Circuplode 
Seaborne et al 1996 Curapuls 419 700 5.6 
30.8 
400 20 
110 
20 
Laboratory studies 
Badea et al 1993 30 
Hill et al (2001) Megapulse II 150 48 10 
1,3, 
4,8, 
12,4 
8,6 
100, 
200, 
400 
400, 
400 
100 
10 
6 
i I i 
1 5,10,1 
5: 20 
Table (4.6) Summary of the quality of report ing treatment d ose. shaded area resembles mi ssing treAt ment nnrnnwPc 
It is of interest to mention that PSWT appears to be a safe therapeutic modality as none 
of the studies have reported deleterious outcomes. The findings also relate higher levels 
of energy to good outcomes. This approach seem to have its support in the literature 
with Low (1995) arguing that whilst superior results were reported with dose above 
I OOJ/ 24 hours, lesser success rates were obtained with a dose of 40J/ 24 hours and no 
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effect was obtained with lower doses. The work of Low however did not include all the 
studies conducted on PSWT and as such the reported findings may have been biased. 
The majority of the work conducted to-date on PSWT examined its effects on 
musculoskeletal and wound healing and this may have been responsible for the size of 
the evidence in favour of its use on soft tissue injury compared to other conditions. 
Findings also suggests that best results were obtainable when PSWT was applied more 
than once a day and if it was applied directly after injury (within 36 hours). 
Another area of interest is the combination of local and hepatic application 
especially that the findings of the reported studies have showed promising results. The 
theory underpinning this practice was that the application of PSWT to the liver could 
increase the synthesis levels of plasma fibronectin (which is a type of glycoprotien) 
associated with the formation of clot, which is a necessary process for, wound healing 
(Arghiropol et al, 1992). With the majority of the studies that examined this technique 
being outdated, further research into the effectiveness of this approach should be 
undertaken to explore its implications clinically. 
Attention should be paid to the reporting of carrying versus the modulated 
frequency. When interpreting research findings on frequencies within the radio- 
frequency band, a clear distinction needs to be made between the carrying frequency 
and the modulated frequency. PSWT operates at a carrying frequency of 27.12 MHz, 
while the output of this frequency is modulated and delivered to the tissues in bursts 
with various repetition rates (1-7000 Hz). The published reports on other frequencies 
rarely make this distinction between the two types of frequencies. For example, a 
frequency of 15 Hz could be taken to mean a carrying frequency or a repetition rate, 
which constitute different treatment outputs and would have different implications on 
the outcome. The reason for this confusion could be caused by the fact that the majority 
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of the physiotherapy literature that examines the physiological effects of PSWT on the 
tissues originated in different disciplines and most of the experiments were conducted 
by physiologists, biochemists or mechanical engineers who have different 
categorisations and interests in the EMF. 
As mentioned earlier the aim of this chapter was to summarize research work 
conducted to-date and to compile evidence on PSWT with different conditions, compare 
and identify areas of homogeneity in results and in windows of effectiveness. However, 
there was no consensus in the work discussed above on a common window effect but 
instead there were results that indicated an incidence of isolated windows. The reason 
being that a great diversity of treatment parameters was employed in the trial protocols. 
Treatment durations ranged between 10 minutes to 6 hours with all showing positive 
results. The mode of applying PSWT was also controversial with the application 
ranging from daily to two or 3 times a week with no method apparently being superior 
to the other. The findings also suggest that PSWT may have multiple rather than one 
intensity window of effectiveness. However, until further work is conducted to 
overcome these limitations, the available evidence on PSWT remains to be of little 
direct value in directing the clinical decision. 
The literature review has covered and analysed studies, both clinically based and 
laboratory based, to evaluate the nature of the evidence and the amount of support it 
holds for many conditions. Unfortunately, many reports did not quote the dose applied, 
a lot of information regarding the frequency, the type of equipment was not mentioned. 
With the finding of many studies pointing towards a positive outcome, it could be 
argued that the reported outcome is not merely a coincident or a placebo effect, there 
must be a mechanism underpinning these observations. However, this mechanism is yet 
to be elucidated. 
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Additionally, numerous of studies appear to have failed to demonstrate a difference 
between placebo and active treatment groups possibly because of methodological flaws 
or lack of genuine effect between the dose examined and placebo. Moreover, a lot of the 
studies have resulted in no significant statistical difference between the experimental 
groups. This however, does not mean that PSWT is ineffective, but could rather mean a 
small sample size and the possibility of using tests that were not powerful enough to 
detect a difference (Eng, 2003; Karlsson et al, 2003). 
4.7 CONCLUSION 
Many modes of PSWT treatments have not been subjected to scientific scrutiny 
or controlled clinical trials, though as such, absence of evidence on effectiveness does 
not necessarily mean the treatment is worthless. Furthermore, lack of statistical 
significance does not mean the treatment examined is futile clinically. Research in the 
area of PSWT efficacy is fragmented and of a mixed quality warranting more quality 
experimentation. 
While many of the claims on PSWT remain unproven, replication of some of the key 
experiments is crucial to establish the finding's credibility. Studies should not be 
dismissed as lacking real effects when they identify inconclusive findings, instead they 
need to be replicated with more robust methodologies and larger sample sizes. The fact 
that a lot of work failed to reach statistical significance might be related to the number 
of subjects employed or the low sensitivity of the methodology or the outcome 
measures utilised, especially if the effect one is looking for is small or the possibility 
that the treatment is actually ineffective. 
Despite the insufficient quality of the evidence reported in the majority of the studies, 
the literature points towards positive outcomes with pressure sore, wound healing and 
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pain relief. However, the evidence in favour of the relief of arthritic symptoms is still 
inconclusive. 
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124 
Chapter 5 An audit of the contemporary clinical use of PSWT 
5.0 INTRODUCTION 
PSWT is one of the electrotherapy modalities used by physiotherapists since the 
1880's. It was used as a focus for the current study being one of the popular and 
frequently used modalities among therapists in UK (Robertson and Spurritt, 1998; 
Kitchen and Partridge, 1996; Pope et al, 1995). Surprisingly, the growing clinical use of 
PSWT, was not associated with a growing body of evidence. There exists a dearth in the 
data available on the frequency, mode and use of PSWT in outpatient clinics in 
England. Given that very limited number of investigations has examined the nature of 
clinical use of PSWT, an exploratory audit was undertaken to examine and extract 
evidence of use from therapists' documentations. Reports have invariably described 
evidence that physiotherapists are not integrating their documentation skills into their 
daily record keeping (Hill et al, 1997; Turner and Whitfield, 1996). However, no reports 
have been identified that examined the quality of therapist's documentation with regard 
to electrotherapy. 
Documentation is an essential and integral part of physiotherapy practice. It is a 
tool for communication between caregivers, and as a result needs to be of high quality. 
Given that the success of any medical intervention is judged from its outcome, record- 
keeping becomes a crucial method of monitoring the quality of service delivered to 
patients (Sumner et al, 2000). The importance of keeping efficient records has always 
been emphasized by the Chartered Society of Physiotherapy (CSP) due to its great 
impact on the safety, continuity and quality of patient care (CSP, 1996). Maintaining 
high quality records is vital for the profession in a climate where demonstrable clinical 
effectiveness and measurement of outcomes are of central importance (Hicks, 1999). 
Given the above it was determined that a study that aimed to appraise the practice 
through documentation would be valuable. 
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5.1 AIMS OF THE STUDY 
" To evaluate the standards of the written content, the amount of information 
documented, and its significance on patient care in a sample of eight randomly 
selected outpatient clinics across England. 
" To compare the current practice with CSP guidelines and the existing evidence. 
9 To extract documented evidence on the use and efficacy of PSWT from these 
files. 
a To generate clinically relevant questions, derived from practice to be used in the 
development of a questionnaire (second phase of the study). 
5.2 METHODOLOGY 
5.2.1 Sample selection 
The total population of the study was defined as UK physiotherapists who use 
PSWT routinely in their daily practice. To identify the sample there was a need to limit 
the number of the hospitals within each health region. This process started by including 
all health authorities that contained four or more hospitals within them in a table (health 
authorities and hospitals' names were obtained from the IHSM - Health and Social 
Services Year Book, 1999-2000). There was a need to define the health authorities that 
will be entered to the draw because some of the authorities only contained two or three 
hospitals. Limiting the authorities to those containing four or more allows the researcher 
the flexibility of the choice between hospitals if the request for conducting the audit was 
rejected by the selected hospital. 
All the health authorities that were entered in the draw were assigned a number 
and these numbers were used to construct a table (Table 5.1). The researcher picked up 
a number randomly out of a hat and the health authority that corresponded to that 
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number was chosen. The draw was repeated eight times each time for a different health 
region. 
Strata 1 Trent 1 2 3 4 5 6 7 8 9 10 1 
Strata 2 West Midlands 1 2 3 4 5 6 7 8 9 10 11 IT 
Strata 3 Northern Yorkshire 1 2 3 4 5 6 7 8 9 10 11 12 
Strata 4 South East 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Strata 5 South West 1 2 3 4 5 6 7 8 
Strata 6 Eastern 1 2 3 4 5 6 7 8 
Strata 7 London 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Strata 8 North West 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Table (5.1) The table used tor stratitying the health authorities within each region 
The health authorities were chosen following stratified random sampling (SRS). 
This approach was used as it overcomes the problem of simple random sampling in 
obtaining unrepresentative sample by chance, hence has the advantage of reducing the 
sampling error (Rice and Ezzy, 2000). Moreover, the population lends itself to this 
approach being already divided into eight groups or strata. Randomisation has the 
advantage of ensuring that all characteristics of interest were equally distributed 
between the groups and all authorities have an equal and known probability of being 
chosen (Rice and Ezzy, 2000; Jenkins et al, 1998). 
After limiting the number of health authorities and following inclusion/exclusion 
criteria the hospitals within the chosen authorities were arranged in lists according to 
their size (using the bed number as a reference). Starting at the top of the list the 
hospital with the highest number of beds was selected. 
The manager of the physiotherapy department in that hospital was then contacted by 
phone to enquire about their willingness to participate and to negotiate access. In cases 
where approval was obtained a letter, explaining the purpose of the project followed 
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(Appendix A. 1). However, if access was denied by the manager, the next hospital down 
the list was contacted and the same procedure was repeated. 
5.2.2 Inclusion criteria 
9 The hospital should have an outpatient practice that uses PSWT as a routine 
treatment in patient care. 
5.2.3 Exclusion criteria 
" Mental hospitals 
" Children hospitals 
" Ambulance services 
These hospitals were excluded, as it is unlikely that these facilities will be using PSWT 
in their treatment to patients and even if they do it would not be in sufficient numbers to 
meet the objectives of this work. 
5.3 THE PROCEDURE 
With the intention of exploring the nature of PSWT use in outpatient clinics, a data 
collection form (Appendix A. 2) was devised. It was divided into six sections as 
follows: 
" Number of patients treated with PSWT compared to the number of patients seen 
in the department at the time of the audit 
9 Number of sessions given until discharge (i. e. until PSWT was stopped) 
9 The most common conditions treated with PSWT 
9 The dose of clinical treatment parameters 
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" The frequency of use of PSWT for each patient (number of sessions per week) 
" Treatment outcome (whether the patient has improved, deteriorated, or remained 
the same) 
All the files found in the physiotherapy departments at the time of the study were 
audited looking for records that had information on PSWT treatments. When these files 
were located, they were analysed in the light of the auditing tool. The information 
collected contained details on numbers of patients, frequencies of attendance and the 
nature of PSWT use. 
5.4 ETHICAL ISSUES 
The proposed plan of action for the audit was endorsed by the ethical committee of 
Radiology and Physiotherapy in University of Hertfordshire (Appendix A. 3). 
A consent form (Appendix A. 4) was signed by either the manager or someone on their 
behalf in all the hospitals chosen consenting to the study and approving its purpose and 
access to patient notes. 
All the written reports and the data gathered were coded to ensure anonymity and 
confidentiality to patients, their therapists, and the hospital visited. No file number, 
patient names, or therapist's name were included in the reported results. For further 
security all documents and printouts were stored in a locked place where only the 
researcher had access to them. 
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5.5 RESULTS 
Eight hospitals one from each of the eight health regions were chosen randomly to 
represent the practice with PSWT across England. Results are presented below under 
the following headings: 
" Treatment time 
" Mode of delivering PSWT 
9 Treatment outcomes 
" Conditions treated. 
One thousand seven hundred and fifty files were examined among which one hundred 
ninety two files had useful information relevant to this investigation. From Table (5.2) it 
can be seen that the percentage of PSWT use among therapists in the hospitals visited 
ranged between 8-13%. 
Code of hospital No of files examined No of patients treated with 
PSWT 
Percent of use 
1 280 36 12.9 
2 178 19 10.7 
3 293 35 12.0 
4 195 17 8.7 
5 316 34 10.8 
6 141 16 11.3 
7 156 13 8.3 
8 191 22 11.5 
Total 1750 192 
Table (5.2) Proportion of PS W'1' use 
These files were judged in terms of quality of documentation and the results are 
presented in Table (5.3). The files were judged against the requirements of CSP (1996) 
for quality of documentation which stated that files should include information on 
power (mean, peak), time of irradiation, method of coupling, pulsing regime, patient 
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position, PSWT make, and when applicable the consent form. According to this list 
none of the files in any of the hospitals visited met the requirement. 
File description No of files 
_ _Percentage 
Files without full description to the treatment delivered 192 100 
Files with incomplete reported Dosage 169 88 
Files without treatment time reported 0 0 
Files without frequency of sessions reported 36 18.8 
Files without outcome reported 73 38 
Files without progression updates reported 133 69.2 
Table (5.3) The nature of documentations in the eight hospitals 
Total number of observations is 192 
Eighty eight percent of the files were lacking a complete description on dosage 
parameters. Around 70% had hardly any information about treatment progression and 
were lacking continuous updating. In around 20% of files there was nothing to indicate 
the plan of treatment in terms of frequency of sessions per week or the total number of 
sessions for which the therapist intends to see the patient. Interestingly, all the files had 
details on treatment duration. All of the above reflects low practice standards and poor 
quality of documentation. 
5.5.1 Treatment time 
In all the hospitals visited, the time of applying PSWT varied between 5-20 minutes 
(Table 5.4). The most common duration for using PSWT was 10 minutes and this was 
reported by 41% of the therapists. In second rank was 15 minutes (31.8%) followed by 
20 minutes (9.9%). 
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Treatment time Frequency of occurrence Percent 
5 9 4.7 
10 79 41.1 
11 2 1.0 
12 12 6.3 
13 10 5.2 
15 61 31.8 
20 19 9.9 
Total 192 
Table (5.4) Treatment times as reported in the files 
5.5.2 Mode of delivering PSWT 
Over half the sample (56.8%) administered PSWT once a week (Figure 5.1). 19.7% of 
the therapists applied it twice a week and only 4.7% applied it 3 times a week. 
Although 18.8% of therapists did not specify the frequency of use, it could be inferred 
that since information on PSWT was only mentioned once in patient's notes, the 
treatments was only administered once (single session). This gives a majority of 75.6% 
of therapists using PSWT once a week with the majority of conditions. 
4.7% 
18.8% 
19.7% 
©1 /wk   2/wk Q 3/wk ® not reported 
Figure (5.1) Frequency of PSWT use as reported by therapists in patient's notes 
5.5.3 Treatment progression 
In files where the use of PSWT was mentioned more than once, the treatment 
progression was further investigated. Three major approaches appear to have been 
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adopted by therapists to progress a treatment plan: to increase the dose, decrease it or 
leave it the same. The majority opted for increasing the dosimetry (either by increasing 
the time or any other parameter on the machine console). 
Examining Table (5.5), best results were obtained by either increasing the dose or by 
leaving it the same; the worst results however, were obtained when the dose was 
decreased. 
T Dosage Dosage Leave dosage the same 
Better Worse NR STHS Better Worse NR STHS Better Worse NR STNS 
19 3 14 3 3 5 3 2 5 - 2 - 
48.7% 7.7% 35.9% 7.7% 23 % 38.5% 23% 15.4% 71.4% - 28.6% - 
Total 39 Total 13 Total 7 
Table (5.5) Treatment progression 
NR: not reported, STHS: stayed the same 
* The percentage is calculated from the number files with pertinent information on dose progression divided by the total number of 
files 
5.5.4 Treatment outcome 
From the values presented in Table (5.6), it can be seen that the majority of therapists 
report good treatment outcomes when using PSWT. These results however, should be 
viewed with caution, as in 38% of the files therapists did not report the treatment 
outcome. 
Treatment outcome Frequency of occurrence Percent 
Not reported 73 38.0 
Better 69 35.9 
Worse 34 17.7 
Same 16 8.4 
Total 192 
Table (5.6) 'T'he outcome of treatment as reportea in the mies 
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5.5.5 Classification of treated conditions 
The conditions treated with PSWT were diverse. Therefore there was a need to 
construct a unified language or a framework for classifying them. At first it was 
decided to use the International Classification of Impairment, Disabilities, and 
Handicap (1980) (ICIDH), the widely used classification system by physiotherapists. 
However, this classification system was found to cover problems of social and physical 
dimension besides being non-diagnostic. Several other preliminary categorising 
schemes were attempted by the researcher and their suitability were examined, 
unfortunately non fulfilled the intended aim. 
The International Classification of Disease (1994) (ICD) was identified as the best 
option. The ICD is a statistical classification of disease. It allows users to transform 
diagnosis and diseases into alphanumeric codes. This system is mainly used to record, 
analyse, interpret, and compare mortality and morbidity data from different countries. 
The classification criterion is based on dividing disorders to families with alphanumeric 
coding scheme (one letter followed by three numbers). The system was determined to 
be sufficiently comprehensive, with the scheme of families of disease adding more 
breadth and flexibility. The classification allows for coding of a wide range of 
information using a standardised methodology that permits communication across 
members of the disciplines and across different disciplines and facilitate comparison of 
data from different sources. 
It is of interest to mention that there was more conditions under each category than the 
ones used for this study, however, only the ones that related to the findings were 
utilized. 
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5.5.6 Conditions treated 
All the conditions accumulated were grouped and classified using ICD (Figure 5.2). The 
categories relevant to the study were as follows: 
" Arthropathies: RA, OA, joint pain 
" Dorsopathies: spondylosis 
" Osteopathies: fractures 
" Soft tissue disorders: muscle tear, muscle strain, epicondylitis, rotator cuff 
syndrome, tendon impingement, dislocation, subluxation, bursitis, ligaments 
and meniscus problems 
" Other musculoskeletal and connective tissue disorder: positional vertigo, 
post operative conditions 
" Diseases of oral cavity: temporomandibular disorders (TMJ) 
Table (5.7) presents the classification of conditions with the number of cases in each 
group. 
Condition No of cases % of occurrence 
Diseases of oral cavity & Jaws 7 3.6 
Dorsopathies 13 6.8 
Other musculoskeletal and connective tissue disorder 16 8.4 
Osteopathies 21 10.9 
Arthropathies 62 32.3 
Soft tissue disorders 73 38 
Total 192 
Table (5.7) Classification of disorders according to ICD 
In order to rank the conditions in terms of the most prevalent, further sub-classification 
to the three top categories in Table (5.7) is needed. Table (5.8) includes the sub- 
classification of arthropathies, soft tissue disorder and osteopathies which represent the 
highest occurrence among other conditions. 
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Sub classification of Arthropathies 
Condition Frequency 
N=62 
OA knee 22 
Low back pain 10 
RA 9 
Shoulder pain 8 
Hip pain 4 
OA hip 3 
Hand pain 2 
Elbow pain 2 
OA shoulder 1 
Sacroiliac pain 1 
Sub classification of soft tissue disorder 
Condition Frequency 
N=73 
Muscle disorder 16 
Disorders of synovium 11 
Tendon impingement 7 
Tendon inflammation 7 
Dislocation 6 
Tendon rupture 5 
Subluxation 4 
Bursa disorder 3 
Meniscus disorder 2 
Sub classification of Osteopathies 
Condition Frequency 
N=21 
Fractures 21 
Table (5.8) Sub-classification of disorders 
From Table (5.8) it can be seen that OA knee (n=22) was the most common condition 
treated with PSWT followed by the fractures (n=21). 
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5.6 DISCUSSION 
The study was based on an audit, which was undertaken to examine therapists' 
documentation skills relative to the standards of practice, compare the written standards 
with the current CSP guidelines and explore the nature of use of PSWT in the clinics so 
that relevant questions are developed in the questionnaire (second phase of the study). 
The audit was undertaken in eight randomly selected outpatient clinics representing the 
eight health regions in England. Although the study was conducted on a small sample, 
this sample was randomly chosen from wide geographical locations to allow for 
practice variation. 
Unfortunately, the structure of some of the records examined did not allow for 
evaluating neither the full process nor the comprehensive quality of care delivered to 
patients. One of the most interesting findings of this study was the amount of 
information lacking from the files. The documented rationale explaining therapists' 
actions was absent in many files. The problem list was not always identified, and the 
time for achieving treatment goals was not always mentioned. Feedback on patient 
improvement was lacking and progress notes were not always updated with changes in 
treatment parameters. In the majority of files examined, only the pre-treatment status of 
the patient is mentioned in full and little if any is reported on the patients after cessation 
of the treatment with PSWT. Furthermore, in many cases the therapist altered the 
treatment plan without specifying the reasons underpinning this change or whether the 
patient got better, worse or did not respond to that alternation. Generally, the files 
examined did not meet the CSP (1996) objectives of facilitating communication and 
ensuring continuity of care. 
Safety guidelines recommended that records should include notes on power, 
time of irradiation, method of coupling, pulsing regime, and any special feature of the 
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treatment (Docker et al, 1994). Furthermore, the CSP has always encouraged its 
members to record sufficient details for the notes to be understood and easily replicated 
by another physiotherapist (CSP, 1996). The guidelines have also urged therapists to 
draw a problem list with the time needed to achieve the treatment goals. Both the plan 
and the progress notes need to be recorded and updated. All of this is underpinned by 
the fact that documentation is a method of communication between members of the 
profession and the rest of the multi-disciplinary team and is a mean of protecting 
therapists in cases of litigation. 
Regrettably, the aim of the treatment, which is crucial information, was not 
mentioned in the majority of the files, consequently, it was difficult to judge the reason 
for using PSWT with certain conditions such as positional vertigo. 
The data gathered did not facilitate the production of common trends in 
treatment dosimetry, as the majority of records did not include enough information 
regarding treatment parameters (PD, PRR, PP and MP). Therapists did not seem to 
follow a specified way of selecting treatment parameters. It was therefore impossible to 
link the nature of dosimetry to the condition treated. Although the author attempted to 
calculate the MP from the parameters documented, the scarcity of the information 
provided did not facilitate this. 
Additionally, a wide range of PSWT equipment were seen in the sampled 
departments. Given that different PSWT machines deliver different outputs even if they 
were set on the same parameters (Forster & Palastanga, 1985) it is crucial that this 
information is documented in patient's files. As such the author saw that it would not be 
meaningful to compare and extrapolate parameters of one machine to the other. It was 
interesting to note that the parameters for other modalities such as IFC or TENS were 
mentioned in full which suggest that absence of this crucial information is not due to 
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lack of time to document full treatment plan but possibly therapists' understanding and 
knowledge about this modality. 
Progression in the treatment plan however, was achieved by changing one of the 
dosage parameters (time, PD or PRR), which is an acceptable practice. There was little 
agreement on the approach adopted, as some therapists progress by increasing the dose 
and others by reducing it. However, it was evident that increasing the dosage seems to 
result in better outcomes. This may be related to the accumulative effect of the dosage 
in the tissue that may override tissues threshold hence produce improvement (Cleary, 
1996). 
The current audit has revealed that only time, PRR, and PD were mentioned 
regularly in the files. A point of concern is that therapists rarely report parameters units 
(µsec, Hz), and because there is no evidence that the numbers used for PD, and PRR are 
interchangeable, reporting them in this manner could be of limited value for those who 
will replicate the treatment or for those researching the files. Examples of the way 
therapist document treatment parameters in the files (100,200,20') or (200,800,8 min). 
A surprising finding was that most treatments were administered once only for 
duration of 10 minutes, nevertheless the outcome was good improvement. This practice is 
not in accordance with the available evidence as there was nothing in the literature nor in 
the manufacturer's recommendation that supports such a practice. Manufacturers 
recommend a minimum of 15 minutes for most conditions. Moreover, measuring intra- 
muscular temperature Draper et al (1999) demonstrated that the peak of physiological 
response could be reached in 15 minutes when the MP was set to 48W. These findings 
were based on the maximum increase in muscle temperature. Therefore, it could be 
speculated that treatment times of 5,8 or even 10 minutes are less likely to result in 
therapeutic effects as lower settings are expected to take longer periods to affect 
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pathology if the effects are to be reached through temperature increase. Although a non- 
thermal mechanism could be taking place, no evidence exists that treatment periods of 5 
or 8 minutes could have a detrimental effect on the patient's condition. 
Despite the work being conducted on small sample, the frequency of use of 
PSWT among various outpatient clinics was ranging between 11-13% which was in 
agreement with Foster et al (1999) who conducted a bigger survey across England and 
Ireland with a sample of 2654 (response rate 58.3%). This verifies that the findings of 
this work carry a great promise of being representative of the actual clinical practice 
despite the size limitation. 
The results of this investigation have reflected a plethora of diverse ranges of 
practice styles adopted by physiotherapists in various clinics. It also revealed a lack of 
uniformity and consensus, an issue that could be attributed to the effect of experience 
and clinical expertise developing throughout the years. 
5.7 CONCLUSION 
Patient's notes are a source of evidence and a method of evaluating the process 
and the outcome of interventions. Findings of this study have demonstrated that 
physiotherapists fail to adopt a systematic method of documentation. Such practice is in 
direct conflict with what is urged by the CSP. If therapists are to evaluate their practice 
against evidence, files need to be well documented and updated; otherwise, it is almost 
impossible to assess effectiveness. 
The result of this audit was surprising in that none of the files examined fulfilled the CSP 
standards of documentation, 88% of those files did not have reproducible treatment plan 
in terms of dosimetry. This deficit in the quality of documentation is a source of concern 
from a professional and a legal standpoint. 
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While the findings of this work are sample-specific, they were nonetheless informative 
and have provided a wealth of information on the nature of the current practice with 
PSWT. 
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CHAPTER 6 
A SURVEY OF PSWT USAGE IN ENGLAND 
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6.0 INTRODUCTION 
Non-thermal agents are gaining an increased popularity, as therapists expand 
their use of low levels of energy to induce tissue healing (Watson, 2000; Kitchen and 
Partridge, 1996). PSWT is one of the electro-physical agents that is claimed to operate 
in the non-thermal mode and still result in therapeutic effects (Martin et al, 1990; 
Forster and Palastanga, 1985). It is a modality that is widely employed by 
physiotherapists across UK (Pope et al, 1995), yet, despite that, a lot of speculation 
surrounds its use, little is known on why or how to best apply it (Robertson and Spurritt, 
1998). PSWT is therefore an under-explored modality (Pope et al, 1995), given the lack 
of researched literature in the field. 
With the lack of published work on the nature of PSWT use in the clinical settings, it is 
assumed that physiotherapists are working according to practice standards and the best 
available evidence. This notion is not entirely true as physiotherapists are largely 
accused of basing their practice on observations and anecdotal evidence (Harris, 1996; 
Riddoch & Lennon, 1990). However, the survival of the profession in a climate of 
evidence based practice and budget driven care (Bury, 1996), demands that therapists 
demonstrate the efficacy of their services to policy-makers, consumers, and professional 
colleagues (Hick, 1999). 
Given the above, it is imperative to conduct studies that validate clinical 
practice, and explore the criterion of patient care, especially given that a limited amount 
of information exists on therapist's beliefs, and factors affecting their choices to electro- 
physical modalities (Kitchen, 1995a). The objectives of conducting this nationwide 
survey were two fold: Firstly: to address and follow further the issues that have evolved 
from the audit on a wider sample. Secondly: to disclose the contemporary standards of 
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clinical practice and the impact of the interaction with evidence, and experience on the 
nature of the clinical practice in outpatient clinics. 
6.1 AIMS OF THE STUDY 
" To explore the nature of the current use of PSWT in outpatient clinics in 
England 
" To explore practice standards with PSWT in outpatient clinics 
9 To explore the factors governing clinical decisions with PSWT 
" To develop dosage protocols based on clinical practice using theoretical case 
studies (to be used in the next experimental phase) 
6.2 METHODOLOGY 
6.2.1 The development of the study tool 
A questionnaire was developed based on the literature reviewed and the 
exploratory study (audit) undertaken in phase one. A mixture of both open-ended and 
close-ended questions were employed. Close-ended questions were used in areas where 
enough understanding exists about the topic, while the free text questions were used 
elsewhere. 
The close-ended questions used in this questionnaire required respondents to tick a box. 
By using close-ended questions the number of the subjects unwilling to answer or 
compose lengthy written responses are expected to decrease (Polft et al, 2001). 
However, close-ended questions are criticised of being superficial (Polft et al, 2001; 
Bowling, 1997), and restricting in that they force respondents to choose an answer from 
a list, which may not meet their needs. Moreover the questions may be irrelevant or 
uninteresting to the respondent, and there is always the possibility that the researcher 
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may have overlooked some areas that could have influenced the study validity (Polft et 
al, 2001; Rees, 1997). However, it is anticipated that by basing the work on the findings 
of the exploratory study, such obstacles have been largely overcome. 
Open ended questions on the other hand, although time consuming to analyse 
are rich in valuable information (Polft et al, 2001; Oppenheim, 2000). The questionnaire 
at hand utilized an equal distribution of both modes of questioning. 
The sequence of the questions is another critical area in planning a 
questionnaire. The intention was that the questions (in this phase of the questionnaire) 
asked earlier do not influence or give direction to the questions that follow. As a result, 
some questions that belong to the same section did not follow each other in sequence to 
avoid giving hints to respondents about the answers. This was done to reduce biased 
responses (Monette et al, 1998). 
Cormack (1996) highlighted that a main disadvantage linked with the use of 
questionnaires is that the sample may be altered if the questionnaires were 
inappropriately answered by a person who is not from the intended sample (in this case 
the questionnaires being answered by a therapist who is not using PSWT in practice). 
Such an issue was not seen as a threat to this study as dealing with professionals is 
different from conducting public surveys where such problems may be encountered. 
The length of the questionnaire is a decisive factor as it may boost or lower the 
response rate (Heiman, 1995). There is no hard and fast rule governing the length of the 
questionnaire, but a general rule is to keep it less than 5 pages long and filling it 
however, should not take more than 30 minutes (Monette et al, 1998). This 
questionnaire is 3 pages long and is anticipated to take less than 15 minutes to fill. 
Moreover, to improve the response rate and to stimulate respondent's interest and 
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encourage them to complete the questionnaire, a light green paper was used (Ballinger 
and Davey, 1998). 
The questionnaire consisted of 17 items divided into several sections, each 
conveying an issue of practice. The first section was concerned with the demographic 
information of the respondents such as year of graduation, years of experience, and 
current post. Although it is preferred to avoid starting questionnaires with personal 
information as some respondents may lose interest (Heiman, 1995), the approach 
adopted in this study was known as the funnel approach (Lydeard, 1991) where the 
questions gradually increase in difficulty, smoothly leading the respondent to the harder 
questions. 
Both the year of qualification and years spent working with electrotherapy 
were collected as they were thought to reveal different angles of practice. It was 
anticipated that the age and years of qualification might not indicate the actual number 
of years the therapist spent working with electrotherapy. This is because of the time 
spent working in different departments (e. g. inpatient or outpatient) or the time taken 
out of work or the possibilities of part time hours. 
The second part of the questionnaire, comprised questions that were designed to 
elicit therapists' existing experience, and general knowledge on PSWT. The third part of 
the questionnaire covered the standards of practice and tackled issues such as 
documentation in patient's notes, general use of PSWT (time of application, frequency 
of use, progression and termination of treatment), and satisfaction with the literature. 
The fourth section of the questionnaire introduced hypothetical case studies to 
therapists on OA. This section was added to the questionnaire to provide the researcher 
with guidelines to plan a treatment protocol for the subsequent phases of the project 
Definition, classification and clinical picture of OA can be found in Appendix B. 6 
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(examination of the physiological effects associated with the application of PSWT on 
healthy subjects and OA patients). The main plan of the questionnaire is further 
explained in the Table (6.1). 
Domain Content Question 
Number 
Demographic information Clinical grade 1-2-3 
Year of qualification- 
Years of experience in electrotherapy 
Therapists' general knowledge on Conditions treated 7-9-10-11- 
PSWT Aims of treatment 16 
Factors affecting therapists choice 
Knowledge about the literature 
Standards of practice Documentation 8 
Application/ general use 4-6 
(Time of administration, frequency of 14-15 
use) 12-12a-12b 
Progression/ 13 
Termination of treatment 
Satisfaction with outcome 
Theoretical case studies 16a-16b 
16c 
Table (6.1) The basic plan of the questionnaire 
6.2.2 Pilot study 
The pilot study was carried out in one of the local general hospitals. Polit et al 
(2001) define a pilot study as a trial run of the major study. It helps in identifying the 
unanticipated problems, checking the accuracy of the instrument, assessing its reliability 
and refining the data collection method hence allowing the study to progress smoothly 
enhancing optimal results. 
The questionnaire was piloted with 8 physiotherapists. The respondents also 
completed an extra form for comments on the questionnaire clarity and ease of 
comprehension (Appendix B. 1). According to the pilot sample it took them between 10- 
15 minutes to complete it. Their comments however, did not raise major concerns, 
although minor modifications were subsequently made to the terminology and the lists 
of choices provided for some questions before distribution of the final version 
(Appendix B. 2). 
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Answers obtained from the pilot group did not differ significantly from what was 
anticipated based on the audit work. 
6.2.3 Sample selection 
The first intention was to select a random sample of therapists identified by 
contacting the CSP. However, the primary reason for rejecting this sampling procedure 
was the possibility of ending with a sample which although random and representative 
fails to fulfil the inclusion criteria (therapist must be working in outpatient clinic and is 
using PSWT on regular basis). Instead, the forms were sent to the managers of 
randomly chosen hospitals. 
All the general hospitals of the eight health regions were entered the 
randomising process. The hospitals were stratified, given a code and entered into a table 
in the proper strata that corresponded to their health authority. 
The questionnaire was approved by the ethical Committee of Radiology and 
Physiotherapy (Appendix 3) The sample was randomly drawn by the researcher who 
picked a number out of a hat. The manager of the physiotherapy department in that 
hospital was then sent an introductory letter (Appendix B. 4) explaining the aims of the 
study and seeking co-operation. The covering letter also explained who was conducting 
the research, how the sample was chosen, the potential benefits to participants and to the 
profession as a whole. 
Enclosed with the letter were four forms to be distributed by the manager to members of 
staff whom they see eligible (therapists working in outpatient clinic and is a frequent 
user to PSWT). Three hundred and sixty questionnaires were sent to 90 outpatient 
clinics. The hospitals covered the eight health regions across England. This large 
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number of hospitals was included to convey the diversity found in the preliminary work 
(audit) and to reflect regional variations. 
On completion of the questionnaire therapists were asked to place the form in 
the stamped self addressed (SAE) envelope provided and send it to the researcher. As 
the questionnaires were coded according to the name of the hospital, it was possible to 
calculate how many forms came from each hospital. 
Each therapist was asked in the covering letter (Appendix B. 5) to complete the 
questionnaire and was assured that their responses were voluntary, and would remain 
confidential. To further ensure anonymity, physiotherapists were contacted through 
their managers and were not asked to write down their names. By asking the manager to 
distribute the forms and by asking the therapists to fill them in and return them in the 
provided envelope neither the manager nor the researcher are able to identify those who 
participated in the questionnaire, hence ensuring respondent confidentiality. 
Follow up letters were sent when the forms stopped coming in. According to 
James and Bolstein (1990) follow up could boost the response rate by up to 20%. Given 
this, all those who did not respond or return the questionnaires, were sent a follow up 
letter through their managers, who was asked to remind their staff to fill the forms and 
send back the remaining questionnaires. All the forms received after the designated date 
mentioned in the follow up letter were ignored. 
Responses were then entered into a file, and data were analysed descriptively using 
SPSS package (version 11). 
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6.3 DATA ANALYSIS 
Data were analysed descriptively using the statistical package for the Social 
Sciences Software Program (SPSS-11). The replies for the open-ended questions (free text 
comments) were analysed using content analysis (Oppenheim, 2000), where answers were 
grouped into themes, collapsed, summarised into simple statements, and coded. Close- 
ended questions were analysed using frequencies. 
6.4 RESULTS 
Three hundred and sixty questionnaires were sent to 90 hospitals in the eight health 
regions across England. 
Out of 360 forms sent out, 210 were returned giving a response rate of 58.3%. After the 
follow up letter 59 more forms were received raising the response rate to 68.8%. Total 
received was 269 forms, the valid forms were 247 (Table 6.2). 
Before follow up After Follow up 
No. No. No. No. In Total 
Returned 210 Completed 198 Returned 59 Completed 49 247 
Not 
completed 
12 Not 
completed 
9 22 
Not 
returned 
150 Total not 
returned 
91 
Table (6.2) Response rate before and after touow up 
The number of hospitals that were included in the survey from each region is shown in 
Table (6.3). 
Region Eastern London South 
East 
South 
West 
Trent West 
Midlands 
North 
West 
Northern & 
Yorkshire 
No 8 15 15 7 10 11 13 11 
Table (6.3) The number of hospitals selected from each health region 
151 
Chapter 6A survey of PSWT usage in England 
Although the number of the hospitals in each region is not identical, this reflects the size 
of the health authority. 
6.4.1 Demographic information 
The data revealed that the majority of therapists were senior II (49%) and senior I 
(32%). Further explanation of the characteristics of the sample is presented in Table 
(6.4). 
Clinical grade Frequency % 
Basic grade 18 7.3 
Senior II 121 49.0 
Senior I 79 32.0 
Clinical specialist 7 2.8 
Superintendent IV 4 1.6 
Superintendent III 18 7.3 
Table (6.4) Characteristics of the sample according to the clinical grade 
The years of experience in the field of electrotherapy for the sample are presented in 
Table (6.5). The table shows that 50% of the sample had between 1 and 5 years of 
experience in the field of electrotherapy. The overall years of experience as 
physiotherapists however, ranged between few months to 44 years with a mean of 11 ± 
0.8 years. 
Years of experience Frequency % 
1-5 years 125 50.6 
6-10 years 65 26.3 
11-15 years 21 8.5 
16-20 years 26 10.5 
21-25 years 5 2.0 
More than 25 years 5 2.0 
Table (6.5) Years of experience in the Held of electrotherapy 
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6.4.2 Standards of practice 
The length of the treatment session with PSWT ranged between 5 minutes to 30 minutes. 
However, the 10 minutes treatment time was the model response and was the mostly 
preferred by therapists as shown in Table (6.6). 
Treatment durations Frequency % 
5 nun 6 2.4 
8 min 53 21.5 
10 min 99 40 
12 min 31 12.6 
15 min 38 15.4 
20 min 9 3.6 
25 min 7 2.8 
30 min 4 1.6 
Table (6.6) 'treatment durations 
As for the frequency of use, therapists were asked to report the number of times they 
use PSWT for each patient. The frequency ranged between daily use to less than once a 
week, with the twice weekly being the most common answer (48.2%). More 
information is presented in Table (6.7). 
Treatment frequency Frequency % 
Daily 15 6.1 
3/week 46 18.6 
2/week 119 48.2 
1/week 26 10.5 
Less than 1/week 41 16.6 
Table (6.7) Frequency of administering treatment 
As for the satisfaction with treatment outcomes, the majority of therapists (72.4%) 
reported a good outcome with PSWT compared to 26.3% who thought that PSWT has no 
effect on the outcome (Table 6.8). 
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Treatment outcome Frequency % 
Excellent 8 3.2 
Good 171 69.2 
Poor 23 9.3 
Indifference 42 17.0 
Missing values 3 1.2 
Table (6.8) Treatment Outcome 
6.4.3 Therapist's general knowledge on PSWT 
The sample reported several aims for using PSWT. These aims are mentioned below 
according to their priority with most frequent reported first: 
1. To reduce pain (43.7%) 
2. To reduce swelling (27.1) 
3. To reduce inflammation (17%) 
4. To promote wound healing, and increase cell activity in the area surrounding the 
affected site (8.5%) 
5. To improve circulation (2.4%) 
6. To increase ROM, and improve mobility (0.8%) 
7. To achieve placebo (0.4 %), to increase tissue extensibility (0.4%), to decrease 
nerve irritability (0.4%) 
The survey results revealed that PSWT was used to treat a wide range of conditions. 
These conditions were classified using the ICD and are displayed in Table (6.9). 
Arthropathies OA, RA 
Spondylopathies Spondylosis, ankylosing spondyliti 
Osteopathies Fractures, Osteoprosis 
Diseases of musculoskeletal 
System 
Soft tissue disorders Muscle tear, muscle sprain, 
epicondylitis, capsulitis, 
subluxation, 
dislocation, bursitis, ligament 
and meniscus problems 
Other musculoskeletal disorders Post operative conditions 
Diseases of digestive system Oral cavity disorders TMJ 
Diseases of nervous system Nerve, nerve root & plexus disorder Nerve injuries, facial palsy 
Table (6.9) Classification of conditions according to ILL). Londltions snown in italics are addition to the 
conditions reported in the audit 
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Conditions mentioned above further confirm the audit findings and add a few categories 
(shown in italics). 
The majority of the sample 222 (89.9%) surveyed preferred to use PSWT as a sole 
modality. It was not clear though if the choice to use PSWT as a sole modality was due 
to time constraints, departmental guidelines or the outcome obtained. A small number 
22 (8.9%), combined their treatment with other modalities (responses arranged 
according to their frequency of occurrence) 
1. US (5.3%), laser (5.3%) 
2. Hot pack (1.2%), or IFC (1.2%) 
3. Ice (0.4) 
The reasons given for combining modalities were as follows: 
" Therapists combine US with PSWT believing that the patient may benefit further 
from the local effects of the micromassage attributed to US. 
9A small number of therapists believed that superior effects could be gained from 
administering two modalities in comparison to one due to the possible placebo 
effects it may have on patients. 
" Therapists who reported using PSWT with IFC believed that IFC has more 
immediate and better results with pain, and if combined with PSWT additional 
improvement to the blood supply could be obtained in and around the affected 
area. 
9 PSWT is thought to be the last resort by some therapists who thinks that the use of 
PSWT may trigger a healing process that was not achieved by other modalities 
" No reasons were given for combing PSWT with a hot pack and cold pack. 
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Combining modalities did not have a profound effect on the outcome. Findings 
demonstrate that the most reported outcome was good regardless of whether the therapist 
combined the treatment with another modality or not (Table 6.10). 
Outcome Combing PSWT with other modalities 
Combine treatment % Do not combine 
treatment 
% 
Excellent 1 4.5 9 3.2 
Good 14 63.6 156 70.6 
Poor 3 13.6 22 9 
Indifference 4 18.2 38 17.2 
Total 22 225 
Table (6.10) Effects of combing modalities on the outcome 
When writing in patient's notes therapists explain their treatment plan by reporting 
treatment time, PD, PRR and the part treated. Other parameters are mentioned though not 
so frequently. Table (6.11) shows the elements mentioned in patient's notes to describe a 
treatment plan with PSWT. 
Parameters mentioned % 
Pulse width 96.8 
Pulse repetition rate 96.4 
Part treated 96 
Treatment time 96 
Power output 23.9 
Patient position 13 
Type of equipment used 10.5 
Patient consent 7.3 
Type of electrode 6.9 
Treatment frequency 5.7 
Outcome 5.7 
Table (6.11) Parameters recorded in patient rile 
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The decision to terminate the treatment if the patient was not responding was usually 
made after 3 sessions have been given to the patient. Further information is revealed in 
Table (6.12). 
Termination of treatment Frequency % 
1 session 8 3.2 
2 sessions 73 29.6 
3 sessions 113 45.7 
4 sessions 33 13.4 
More than 4 sessions 19 7.7 
Missing values 1 0.4 
Table (6.12) Number of session netore terminating me treatmem 
However, if the patient was responding and the therapists decided to progress the 
treatment, it is usually done by changing more than one parameter simultaneously. 
The results also demonstrate that 21.2% prefer to change nothing, and 15.2% preferred 
to change the treatment time. Further description can be seen in Table (6.13). 
Treatment progression Frequency % 
Change modality 2 0.8 
Pulse width 7 2.8 
Pulse rate 8 3.2 
Treatment time 38 15.3 
Nothing 56 22.6 
More than 1 settings a time 136 55.0 
Table (6.13) Ditterent approaches uses Dy tnerapists to progress tneir ueatmem 
The choice of treatment dosage is usually determined by several factors. The survey 
results are ranked according to their importance: 
1) Stage of the disease (acute, sub-acute or chronic) (59.2%) 
2) General symptoms of the patient (17%) 
3) Site of lesion (13.2%) 
4) Personal experience (5.3%) 
5) Published literature (3.6%) 
6) Equipment manual (1.2%) 
7) Discussion with colleges (0.5%) 
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When respondents were asked about the factors that could determine their preference to 
PSWT among other electrotherapy modalities they ranked their answer as follows: 
1) Patient signs and symptoms (80.6%) 
2) Previous experience (16.2%) 
3) Recommendation from senior therapists or physicians (2%) 
4) Familiarity with the machine (0.8%) 
5) Availability of equipment (0.4%) 
The interaction between experience as a whole in the field of physiotherapy and in the 
field of electrotherapy was further analysed using Chi square test (X2) test to examine its 
effect on the therapist's decisions. Results are shown in Table (6.14). 
Variable X2 Df Correlation 
Experience Vs treatment outcome 0.311 15 NS 
Years since qualification Vs outcome 0.068 15 NS 
Experience Vs satisfaction with literature 0.283 5 NS 
Years since qualification Vs satisfaction with literature 0.858 5 NS 
Experience Vs treatment time 0.000 35 S 
Years since qualification Vs treatment time 0.000 35 S 
Experience Vs uenc of use 0.108 20 NS 
Years since qualification Vs frequency of use 0.019 20 S 
Years since qualification Vs combining treatment 0.627 5 NS 
Experience Vs combining treatment 0.047 5 S 
Experience Vs treatment progression 0.675 25 NS 
Years since qualification Vs treatment progression 0.022 25 S 
Years since qualification Vs treatment termination 0.022 20 S 
Experience Vs treatment termination 0.066 20 NS 
Table (6.14) Interaction between experience and the nature of practice 
S: significant relationship, NS: not significant 
Interesting findings have emerged from further analysis of the results. The years of 
experience in electrotherapy field seems to affect the choice to combine PSWT with other 
modalities significantly. While the years since qualification seems to have more effect on 
determining physiotherapist' choices with regard to the frequency of applying a treatment, 
treatment progression and termination. Deciding on the length of the session with PSWT 
appears to be affected by the years of experience as a physiotherapist in total and in 
electrotherapy field in particular. 
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Experience was always second as the most important factor in decision after the nature of 
the condition. This may be caused by the lack of clear evidence on PSWT effectiveness, 
especially given that more than half the sample (58%) were not satisfied with the quality 
and the amount of the existing literature as could be seen in Figure (6.1). 
Satisfied 
39% 
Not 
Figure (6.1) Therapists' satisfaction with the literature on PSWT 
The therapists advocated the following solutions to improve their satisfaction with the 
literature. 
1- Up to date and recent well conducted controlled trials are needed, as most of 
the studies are outdated. 
2- Specific trials on treatment parameters, and the effectiveness of a given 
treatment on a single condition. 
3- Research results should be made more available. Clinicians do not have the 
time, the resources nor the knowdge to search various databases for such 
information. 
4- More credible studies are needed. Some studies have used treatment protocols 
that are unrealistic to apply in NHS setting. As a result studies are seen to be 
ailented from the clinical setting. Therapists prefer that the studies are 
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conducted in a clinical setting instead of a laboratory to allow for extrapolating 
the findings to clinical practice. 
5- The use of clear and less vague terminology is paramount in order to increase 
the readership. 
6- A number of therapists proposed that the CSP should play more active role in 
organising courses or conducting systemic reviews hence pooling study results 
making it easy for therapists to access evidence. Further explanation to the 
frequencies of these suggestions is explained in Figure (6.2). 
0.9 
0.8 
0.7 
0.6 
O 0.5 
0 
>+0.4 
C 
0.3 
0.2 
LL. 
0.1 
0 
gukkkvs dear c ed le findrigs trials on updated 
by CSP termi ology practice made treatment wel 
W- accessiMe parameters conducted 
studies trials 
Figure (6.2) Suggestions to improve satisfaction with the literature 
6.4.4 Theoretical case studies 
The case studies presented in the last section of the questionnaire were intended to guide 
the experimental work at later stages of the project by providing guidance to the 
researcher to plan the treatment dosage. The cases were to describe acute, sub-acute and 
chronic knee OA. Although it was not expected that therapists would come up with 
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identical choices, it was anticipated that their replies would identify trends that could 
direct planning the next experimental phase. Results for the 3 conditions are shown in 
Table (6.15). 
Disease stage Time 
(min) 
Frequency per 
week 
PRR 
(Hz) 
PD 
( ec 
MP 
(W) 
Acute 15 2 200 100 3W 
Sub-acute 10 2 200 100 3W 
Chronic 20 2 800 200 24W 
Table (6.15) Therapist's proposed plans for the theoretical case studies (the values reported in the table 
represent the most frequent answers) 
As this questionnaire aimed at identifying trends in practice and to understand how 
PSWT was being employed clinically, the questionnaire findings were further divided 
into two subgroups in terms of how the therapists reported PSWT outcomes (either 
excellent/good or poor/indifference). Their proposed treatment plans were analysed 
accordingly. 
Two dosage tables were formulated, one for the Excellent/good outcomes and another 
for the poor/indifference outcomes. The table contained the PD, PRR, frequency of 
administering the treatment per week, and time of application. The tables also 
contained all the probable ranges of dosage that the therapists have written down, and 
their first choice (highest occurrence) is highlighted in each section for ease of 
comparison. 
Dividing the findings according to the outcome was undertaken in an attempt to find out 
whether therapists who obtain good outcomes with their patients have a certain trend in 
choosing the dosage in relation to those who were not satisfied with the outcome. 
Results are displayed in Table (6.16) and Table (6.17). 
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Case 1 Case 2 Caw 3 
Acute OA Chronic OA with acute Chronic OA 
exacerbation 
Range of PD reported (psec) 20 20 20 65 40 65 
100 1" choice 65 100 
200 100 I" choice 200 I" choice 
400 200 400 
400 
Range of PRR reported (Hz) 50 50 100 65 100 200 
100 2II() I" choice 400 
200 I" choice 400 800 I" choice 
400 800 
900 
Range of treatment duration 8 8 10 
reported (min) 
10 10 1" choice 12 
12 12 15 
I5 I" choice 15 20 I" choice 
20 20 
30 
Range of treatment frequency 1 1 1 
reported 
2 I choice 2 I" choice 2 I" choice 
3 3 3 
5 5 4 
Table (6.16) Table of suggested treatments for those reporting good/excellent outcomes for the 3 cases 
Case I Case 2 Case 3 
Acute OA Chronic OA Chronic OA 
with acute exacerbation 
Range of PD reported (µsec) 65 20 65 100 40 100 
200 65 200 
400 I" choice 100 400 I" choice 
200 
101) 1" choice 
Range of PRR reported (Hz) 50 50 50 100 100 100 
200 200 I choice 200 
400 I" choice 400 400 1" choice 
800 800 800 
Range of treatment time 10 8 10 
reported (min) 
12 10 15 
" 15 Is 20 choice 1 
20 I' choice 20 I choice 30 
30 
Range of treatment frequency 1 I " 
reported 
I~ choice I choice I choice 
3 3 3 
Table (6.17) The suggested treatment plans for those who reporting poor/indifference outcome (first 
choice according to most common reporting 
A clear pattern was seen in the choice of PD and PRR for the three proposed conditions. 
Those who reported good outcome opted to use low dosage with less time for acute and 
sub-acute conditions. Therapists also tend to increase the dosage and the time for 
chronic conditions. The treatment parameters identified by therapists who report poor 
outcomes were almost the same suggesting that they were not selective in their dosage, 
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a practice that therapists are known to use when not sure on the dosage to apply 
(Kitchen, 1995b). 
Observations have showed that the use of 15 minutes as an initial treatment time with a 
PD of 100 A sec and PRR of 200 pps for acute conditions resulted in best outcome. The 
same dosage was proposed for sub-acute knee OA but with shorter treatment duration 
(10 minutes). With chronic conditions, a time of 20 minutes, a PD of 200 sec and PRR 
of 800 pps seem to produce the desired effects. 
These parameters will be examined later in both the laboratory and clinical trials for 
validation of effectiveness or lack of effectiveness. 
6.5 DISCUSSION 
This nationwide survey was conducted to explore the nature of PSWT use in 
outpatient clinics, and further explore the issues that emerged from the audit. 
Employing a questionnaire as a tool for the study was because of the advantage of 
covering a large sample of people (Hicks, 1999; Burns and Grove, 1993). By using 
questionnaires, the possibility of the researcher influencing respondents' answers 
intentionally or unintentionally is considerably reduced (Hicks, 1999). Moreover, by 
maintaining confidentiality and anonymity, respondents are more likely to provide 
honest accounts of their experience and current knowledge (Cormack, 1996). 
6.5.1 Response rate 
According to Babbie (1995) a response rate of 50% is adequate for analysis. 
However, Oppenheim (2000) and Barker (1991) emphasised that a response rate of 
above 60% shows a well-conducted research tool. Monette et al (1998) supported the 
above view stressing that high response rate allows for generalisation to a wider 
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population. A low response rate on the other hand, lowers the researchers confidence in 
extrapolating findings as the characteristics of those who refused to participate may 
have been different from those who returned the questionnaire (Monette et al, 1998). 
In this study 360 questionnaires were mailed to ninety hospitals in the eight 
health regions in England. This has the advantage of collating data from a wide 
geographical area. 
In order to have a good response rate the subjects in this study were provided with SAE 
to return the questionnaire. They were not rushed in answering back, thus conveying to 
therapists that the researcher appreciated their busy schedule. The questionnaire did not 
require respondents to provide their names. This feature maintained confidentiality and 
as such may have increased the likelihood that the respondents were objective (Babbie, 
1995). Subjects were not asked to fill in a consent form and their participation was 
accepted as consent to the study. The SAE were not coded according to participants 
instead it was coded according to hospitals to assure therapists that there was no way of 
identifying any individual respondents and hence may have reduced biased responses, 
and might have had the added advantage of increasing the response rate. 
The initial response rate for this questionnaire was 58.3%, this was boosted to 
68.8% after follow up. The number of forms received back from each hospital varied 
between one to four forms according to the size of PSWT use in that facility. However, 
all the hospitals made the effort to participate either by filling the forms in and sending 
them back to the researcher or by the manager sending a note to the researcher with the 
unfilled questionnaires stating that the eligible physiotherapists have been contacted, 
and the unfilled forms were being sent back. 
Monette et at (1998) argued that respondents usually react better to surveys that 
are directly related to them. The high response rate in this study may support this notion 
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and suggests that therapists are in need of studies that may provide some practice 
directions, an issue that was previously raised in the literature by Ide (1990). The 
response rate may further indicate that physiotherapists were aware of their role in the 
contribution to research and the evidence base of their profession. 
6.5.2 The sample 
The response rate (n=247,68.8%) was considered sufficiently high to be 
representative of the intended population in the eight health regions across England, 
especially with the replies being received from all regions and including all the clinical 
grades. Although fifty percent of the sample had between 1 and 5 years of experience, 
this did not mean that half the sample were junior physiotherapists. The 1-5 years 
referred to the years of experience in the field of electrotherapy, the overall years of 
experience however, ranged between a few months to 44 years with a mean of 11 t 0.8 
years of experience in the field of physiotherapy. 
In an attempt to determine the extent to which respondents differ from non- 
respondents, the author contacted the CSP to obtain the percentage of therapists in 
different posts hence examining any bias that may have resulted from non response or 
the randomisation process. However, these attempts failed, as there was no response 
from the CSP. 
Unlike previous surveys conducted in England where the sample was limited to 
either a sample of convenience or some of the local health authorities, this survey has 
covered large sample from all health regions around England. As such the results have 
an added advantage of being representative of the current practice. 
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6.5.3 Frequency of use 
The majority of the findings are in agreement with the audit data in phase 1 of the 
research. Curiously, in the audit the most common mode of applying PSWT was once per 
week compared to twice in this phase of the study, this may be caused by the broader 
range and the large sample surveyed. 
Pope et al (1995); and Kitchen and Partridge (1996) have reported PSWT to be a 
widely used modality with the latter study reporting that more than half their respondents 
using PSWT more than once a week. The findings of the current study are in agreement 
with these results. Almost three quarters (72.9%) of the sample in this study use PSWT 
more than once a week and out of those, 48.2% were using it twice weekly. Such results 
refute the speculation that PSWT is losing its popularity (Prentice and Draper, 2001) and 
confirm the regional differences identified previously in the literature (Baxter et al, 1991; 
Lehmann and DeLateur, 1990; Ziskin et al, 1990). 
The duration of the treatment with PSWT varied between 5-30 minutes, with 10 
minutes being the most commonly used. These results are in agreement with the first part 
of the study (audit). It is interesting that both sections of the work have shown that 10 
minutes is the most common practice with regard to PSWT durations. This could reveal 
an area of mismatch between practice and research. Studies conducted on PSWT efficacy 
usually administer the treatment for 15-30 minutes. This means that the research findings 
are not in accordance with practice and may not inform the clinical decision, which could 
explain why therapists are relying on their experience when it comes to deciding the best 
treatment. 
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6.5.4 Mode of use 
As for the strategy of applying PSWT, therapists were asked about the number of 
sessions given to patients before deciding that PSWT is of limited value. The majority 
(45.7%) preferred to wait for 3 sessions before they judged that the treatment was not 
working and there was a need to terminate it. These findings are in agreement with 
Kitchen (1995b) who reported that therapists believe that 2-4 session is the maximum that 
should be given because if no improvement was seen by then it is unlikely that any 
improvement would be seen at all. The findings are in accordance with the available 
evidence (Hayne, 1984) and are further suggesting that therapists are looking for the 
cumulative effect of applied treatment. 
Examining the approach adopted by therapists to progress treatments revealed a 
degree of confusion as changing two or three parameters at one session reveals 
uncertainty of the effect that each element may have on the output and hence on the 
patient response. However, adopting this approach leaves therapists unclear on which 
factor has brought patient improvement or deterioration. Results were in disagreement 
with Kitchen (1995b) who found from a sample of 5 therapists, that treatment is 
progressed in terms of time or intensity and therapists tend to change one or the other. 
Differences in outcome could be caused by the small sample employed in that study or the 
fact that Kitchen used interviews and subjects tend not to tell what they feel when they are 
in a one to one situation (Cormack, 1996). 
Findings have also revealed that there was a belief among therapists (9%) that combining 
modalities will have superior outcomes compared to single modality. Although these 
notions have not been validated by clinical trials, it has been referred to in the literature in 
several occasions (Kitchen, 1995b; Gray et al, 1994). 
167 
Chapter 6A survey of PSWT usage in England 
According to the literature, PSWT may have several therapeutic effects. The 
sample was asked to report the aims they were trying to achieve when choosing PSWT as 
a treatment modality. The lists of aims reported by the sample revealed a state of 
confusion between the short and long term aims. Although it was not part of the question 
to specify short and long term goals, it was expected that therapists could differentiate 
between direct and indirect effects of the treatment. For example, improving ROM and 
mobility will not result from PSWT application alone but from incorporating an exercise 
program as an adjunct to treatment. 
In agreement with some of the work conducted on treatment goals, pain relief 
was highlighted being the top of the list (Kitchen, 1995b). The mechanism by which 
PSWT can relieve pain is not understood but several theories have been proposed. 
Though still anecdotal, it has been widely accepted that PSWT can reduce pain by 
inhibiting the sensory impulses transmission, this in turn may lead to a sedative effect in 
the treated area. However, if the cause of pain is inflammatory, the pain is expected to 
reduce as a result of the vasodilatation and absorption of the exudates accumulating in 
the tissues (Ward, 1980). The pain resulting from muscle spasm could reduce as a 
consequence of vasodilatation and the removal of access lactic acid and other metabolic 
products in the muscle that cause muscle soreness (Kitchen, 2002). 
Interestingly, the number of therapists who believe in the placebo effect of PSWT 
was greater than those who believed in its effects on tissue extensibility or nerve growth. 
The placebo effect of PSWT has been demonstrated repeatedly in the literature (Klaber- 
Moffett et al, 1996; Foley-Nolan et al, 1992; Foley-Nolan et al, 1990; Reed et al, 1987) 
and its effect on patients cannot be denied. 
Despite the fact that therapists use PSWT to promote bone growth, not enough evidence 
exists to support that, and the majority of the experimental work was conducted on ELF 
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especially the carrying frequency of 15 Hz, and 75 Hz (Fredericks et al, 2000; Landorf, 
1998; Rubin et al, 1993). 
Muscle spasm is one of the aims that appeared in the list as a reason for using 
PSWT. There is no evidence to suggest that PSWT may work directly on the muscle to 
relive spasm however, by improving the circulation and clearing waste products resulting 
from muscle contraction, certain degree of muscle relaxation may occur, though there is 
no experimental evidence to support these claims. 
The majority (89.9%) of those surveyed preferred to use PSWT as a sole modality 
and not to combine it with other electrotherapy modalities. These results are in 
disagreement with Kitchen and Partridge (1996) that electro-physical agents are rarely 
used in isolation, though their survey was looking at combining four modalities (US, 
SWD, PSWT and Laser) with each other and with any other physiotherapy interventions. 
Thirty eight percent of their sample opted for combining modalities. Over half of those 
38% combined PSWT with US, and 2.6% combined PSWT with laser. The reason given 
for these combinations was the same as the one of respondents in this study that is to 
augment the effect of the treatment and to treat more than one type of tissue at a time. 
Although no direct evidence could be obtained from the literature to support 
combining electro-physical modalities, three possible reasons could be speculated. Since 
the depth of penetration and the nature of the anatomical structure each modality may 
stimulate is different, targeting more than one level of tissue could have superior 
therapeutic effect. Secondly: the net energy resulting in the tissues as a result of 
combining modalities may have better effect in augmenting and triggering the healing 
process. Thirdly: switching between modalities may overcome the plateau response 
patients may show as a result of using a single modality (Kitchen, 1995b). 
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The fact that the majority of therapists prefer to use PSWT as a sole modality should 
direct future research, so that experimentation serves to inform clinical needs and the 
research findings becomes of more use to therapists. 
The continuous development in the field of electrotherapy (Pope et al, 1995; 
Wadsworth and Chanmugam, 1983) requires that physiotherapists constantly update 
their knowledge of research, techniques and machines (Roberstson and Spurritt, 1998). 
However, therapists in this study commented that literature is not filtering through to 
them, aside from the other issues of difficult language that drives therapists away. 
Additionally, with much of the electrotherapy literature being published in non- 
physiotherapy journals (Turner and Whitfield, 1996; Mitchell, 1993), it would be 
expected that a wealth of information goes by unnoticed by the busy therapists 
(Sahrmann, 1998). Therapists in the study however have suggested that compiling 
studies in databases by the CSP is needed. This intiative has already started by forming 
the electrotherapy interest group which was formed by a group of individuals with 
interest in the field of electrotherapy. 
6.5.5 Conditions treated 
Previous studies have used several different methods to classify conditions, but 
none have attempted to use ICD classification employed in this study, possibly because 
this classification was originally meant for physicians and epidemiologists. The ability of 
this classification system to embrace large number of categories highlighting its wide 
flexibility as a classification system and its potential benefit to physiotherapists. 
The conditions reported by the sample confirmed those reported in the audit. Other 
conditions were added to the list such as ankylosing spondylitis, osteoprosis, nerve 
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injuries, and facial palsy. The addition of new cases could be attributed to the large 
sample size included in the survey compared to the audit. 
6.5.6 Documentation 
The issue of documentation was raised in the first section of the study (audit) 
and was also detected in the questionnaire. The majority of therapists opted for 
describing their treatment plan with only PD, PRR, and the duration of application. 
Given that PSWT machines have different PP, different outputs will be delivered by 
different units even if they were set on the same parameters (Forster & Palastanga, 
1985). As a result it becomes imperative that all relevant information such as type of 
equipment, and MP are mentioned. Factors such as patient position, site of application, 
electrode placement and type are crucial for treatment repeatability hence need to be 
mentioned. The CSP has always encouraged its members to record adequate details for 
the notes to be understood and easily replicated by another physiotherapist (CSP, 1996). 
The guidelines have also urged therapists to draw a problem list with the time needed to 
achieve the treatment goals. Both the plan and the progress notes need to be recorded 
and updated. All of this is underpinned by the fact that documentation is a method of 
communication between members of the profession and the rest of the multi- 
disciplinary team and is a mean of protecting therapists in cases of litigation. 
Interestingly, a small number of therapists mentioned the patient consent. 
Consent is defined by the Department of Health as the voluntary and continuing 
permission of the patient to receive a particular treatment based on adequate knowledge 
of the purpose, nature, likely effects and risks of that treatment (DOH, 2001). Consent is 
about treating patients as co-partners in the decision making process. This right may 
only be overridden if harm to the patient may occur (Wear, 1993). However, patients 
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appearing in the department should not be viewed as consent to the treatment. 
Physiotherapists have a duty to clearly inform their patients about the proposed 
treatment. Patients must be informed about risks, benefits and alternative treatment 
using simple language (CSP, 1996). However, the reason for not mentioning it could be 
due the notion that PSWT is thought to be athermal modality, hence there is no need to 
warn the patient (Forster & Palastanga, 1985). It is a legal requirement for therapists to 
document it in the patients' notes (Wear, 1993) to protect themselves from legal action 
(Armstrong et al, 1997). The CSP rules states that oral and implied consent are accepted 
in physiotherapy practice (CSP, 1996) as such it is assumed that possibly because 
consent is obtained once at the initial visit of any patient and is not repeated in every 
session, it was not reported in the questionnaire. 
The findings of this work is in agreement with Turner and Whitfield (1999) who 
in a survey of 320 therapists reported experience to be the second most important source 
for decision making after intial eduction. The current study has examined the effect of 
overall years of experience and the years of experience in the field of electrotherapy on 
the clinical decision making. The years of experience in the electrotherapy field seems 
to have a significant relationship with the choice of treatment time and whether to 
combine the PSWT treatment with other modalities or not, while the years since 
qualification seems to have more effect on determining the physiotherapists' choices 
with regard to the treatment, frequency of use, treatment progression and termination. It 
could be speculated from these results that the overall years as a physiotherapist seem to 
define therapist choices more than the years spent in electrotherapy and may be because 
of the lack of available evidence therapists tend to extrapolate work experience from 
different fields of physiotherapy to electrotherapy. 
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Results demonstrate that even with the increasing pressure on therapists to base 
their practice on evidence, therapists still follow their intuition to guide them through 
their practice. The survey conducted by Sheilds (2003) has shown that the use of PSWT 
was not influenced by evidence as the choice to use the modality was mainly influenced 
by space, availability, and cost and that evidence ranked 6th in the list. These findings 
were consistant with the current findings as the available literature and equipment 
manual were ranked at the bottom of the list denoting their minimal role in influencing 
therapists' decisions. 
6.5.7 The nature of the clinical decision with PSWT 
The findings of this study along with those of the audit have raised issues about 
the interaction between both the evidence, and the nature of the clinical decision with 
regard to PSWT. 
According to Hunink et al (2001) and March (1984), rational decisions are made 
following the knowledge of the available choices, the alternatives to consider and 
choose from, and the consequences stemming from these available choices. This means 
that for a clinician to make a rational decision, a clear understanding of two basic 
factors should proceed: 
1- The reason for choosing PSWT when a range of electro-physical 
modalities is available. 
2- How to best tailor the dosage (MP, PP, frequency of application, time of 
application) according to patient needs. 
However, a lot of dispute still embraces those issues. In order to know why a given 
modality is chosen there needs to exist enough knowledge on its proven effects. The 
amount of experimental work conducted on PSWT remains limited and the outcome of 
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these studies is not conclusive. A general rule is to use low dose for acute conditions 
and slightly higher dose for sub-acute and even higher for chronic with no definitions to 
what is meant by low and high dose and what is the boundary between them. With some 
suggesting a combination of high PP and high PRR (Cameron et al, 1999) and others 
emphasising the role of a single parameter such as short PD (Low and Reed, 2000) or 
high pulse power (Wadsworth and Chanmugam, 1983). However, all of these 
suggestions resemble attempts to provide a method of categorising treatment 
parameters, these attempts remain to be anecdotal and lack experimental validation. 
New technological advances have led to the production of new generations of 
PSWT machines with user friendly screens and pre-programmed advice offering the 
"best" treatment parameters based on the "best" available scientific evidence. Although 
such devices are thought of as being in accordance with the move towards evidence- 
based practice, the quality of the evidence provided is questionable as it is governed by 
the quality of the trials conducted and marketing needs. Moreover, according to many, 
the evidence in the field of electrotherapy especially with PSWT is fragmented and 
provides little direction to clinicians (Markov and Colbert, 2000). 
Additionally, deciding on the right dosage is a complex issue that is not easily 
resolved. The area of dosage is complex due to the lack of a tool that quantitatively 
measures the amount of power absorbed by different tissues in the treated area 
especially with the power meter on the PSWT console showing the amount of output 
delivered by the equipment with no indication to how much is being absorbed by the 
tissues (Delpizzo and Joyner, 1987). The application of PSWT is associated with no or 
minimal skin sensation, and this could vary between subjects depending on the 
sensitivity of skin thermoreceptors. As such it is hard to depend on patient thermal 
sensation to judge the intensity of the field. 
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Moreover, given the number of combinations that PSWT machine can be set in (Table 
6.18) and the number of these combinations that have not been subjected to 
investigation for effectiveness, it becomes evident that the literature has little to offer 
clinicians (Dyson, 1994). Consequently, therapists are left to rely on their personal 
experience, trial and error, and intuition to guide them through their practice (Turner 
and Whitfield, 1999; Green, 1991). Clinicians are forced to integrate their theoretical 
knowledge, and clinical expertise in what is called the empirical reasoning (Wulff and 
Gotzsche, 2000). One major disadvantage in adopting empiricism as a philosophy for 
practice is that it fosters the techni- physiotherapist and supports the move away from 
professionalism as it could retard the personal and possibly the professional growth and 
denies the active pursuit for new information as individuals lose interest in searching for 
new information and only utilise their reservoir of knowledge (Wolf, 1986). 
PD PRR PP Pulse modes Possible 
combinations 
6 5 3 
20-40-65-100- 50-100-200-400- Fixed (150 W) 1: 3 - 2: 3 - 3: 3 90 
200-400 ( ec) 800 (Hz) 
Table (6.18) Example of the possible combinations when setting YSWT machine. Parameters resemble 
Megapulse Senior 
Basing decisions on experience alone could also obscure the thoroughness of the 
subjective and objective assessment obtained at the assessment stage into routine 
approaches (those that have been tried and was seen to be working). In doing so 
therapists are dismissing other available options and basing their practice on habit and 
convenience rather than rationale (Watt, 1985). 
All of the above results in fragile decisions that are easily overturned and 
dismissed (March, 1984). Such behaviour may manifest itself in the frequent alterations 
to a treatment plan without a clear underpinning rational, a behaviour that was widely 
detected when patient's files were audited. 
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The state of the current practice could be a representation of the poor quality of 
the evidence and the lack of clear clinical guidance. Such issues justify the importance 
of conducting further trials that explores PSWT effectiveness. Trials should be directed 
to investigate the interaction between EMF and biological tissues on both healthy and 
patient population. Trials conducted on healthy subjects allow for understanding the 
PSWT mechanism of action and obtaining normative data, while trials on patients allow 
for the understanding of diseased tissue reactions to the applied energy. 
6.5.8 Theoretical case studies 
Three case studies were presented in the last section of the questionnaire in order 
to provide a basis for deciding on the dose to test when examining the physiological 
effects of PSWT. This was done to overcome the pitfalls of the majority of the 
published reports when they examine arbitrary doses with no rationale presented. By 
basing experimentation on clinical practice, the findings of this work will be of more 
value to clinicians. 
The three cases presented were intended to represent acute, sub-acute and 
chronic states. Two of those cases will be subjected to experimentation which are the 
acute and the chronic. Findings in Table (6.16) reveal that both acute and sub-acute 
conditions appear to be treated similarly by therapists with the same MP. 
There appears to be no selectivity in treating the 3 conditions as therapists 
preferred to treat patients twice a week regardless of the chronicity of the disease. This 
may have been caused by the therapists' load rather than the condition treated because it 
is expected that acute cases be treated more than sub-acute more than chronic (Low and 
Reed, 2000). 
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An interesting trend has emerged from the data suggesting that selec 
treatment parameters is associated with better treatment outcome. This selecti 
to be explored further and studied in future research as it may throw some ligh 
nature of the clinical decision with PSWT and possibly in the area of selecting o 
the field of electrotherapy. 
Based on the reporting of therapists summarised in Table (6.17) and (6.18) 
was decided that 100 psec-200 pps -10 minutes and 200 µsec -800 pps -10 minutes 
would be used for the laboratory and clinical trials. It was decided to standardise the 
time for the two conditions to prevent time from becoming a confounding factor and 
altering the results by delivering more energy to the tissue making it hard to compare 
the results of the two conditions. 
6.6 CONCLUSION 
The findings suggest that PSWT is a modality that is used to reduce pain, swelling 
and inflammation. It was demonstrated that the years of experience in the field of 
electrotherapy seems to shape therapists' decisions on whether to combine PSWT with 
other modalities, choice of treatment time while experience as a whole in the field of 
physiotherapy seems to affect therapists' choices to frequency of treatment, and treatment 
progression. As little is known on the process of decision making in the field of 
electrotherapy, further research is warranted in order to understand the underpinning 
reasons for this behaviour. 
ocumentation is an area that needs further attention, as it was evident from this survey 
ig with the previous audit section that the quality of documentation is poor and needs 
improved for the information to facilitate treatment plan replication and to protect 
its against legal litigation. 
177 
Chapter 7 Physiological, anatomical and measurement principles 
CHAPTER 7 
PHYSIOLOGICAL, ANATOMICAL AND 
MEASUREMENT PRINCIPLES 
178 
Chapter 7 Physiological. anatomical and measurement principles 
7.0 INTRODUCTION 
This chapter will provide a physiological and anatomical background to the 
outcome measures, and description of the range of instruments available for measuring 
them. The chapter will be dealing with blood perfusion, skin and core temperature, and 
nerve conduction velocity (NCV). They were chosen as primary outcome measures due 
to their close reflection to changes in the thermoregulatory system besides being widely 
used non-invasive parameters that reflect the body reaction to exogenous EMF (Rivner 
et al, 2001; Buschbacher, 1998). 
In the trial that will be conducted on a patient population, along with the primary 
outcome measures mentioned above, there will be measurement of secondary outcome 
factors which include pain, muscle strength, and ROM. These outcome measures were 
included in an attempt to reflect both subjectively and objectively the observations 
reported by the patients and correlate that with changes in primary variables measured 
during the treatment. 
7.1 PRIMARY OUTCOME MEASURES 
7.1.1 Body Temperature 
Skin and core temperature are two physiological parameters that are often 
monitored for therapeutic and research purposes in order to track the thermal effects of 
external exposure to either hypothermia or hyperthermia. 
SkT can be measured using various SkT probes that can be affixed to any area of 
the body. With the skin being superficial it is subjected to different variations in the 
environment. Therefore, both air temperature and humidity have a direct effect on SkT 
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as they control the amount of evaporation, conduction, convection, and radiation and 
hence the thermoregulatory mechanism (Houdas and Ring, 1982). 
Core temperature (CorT) is a reflection of the heat in the blood perfusing the 
thermoregulatory receptors in the hypothalamus (Betta et al, 1997). CorT undergoes a 
process of rhythmical variation with the lowest recorded in the early hours of the 
morning (between 2-5 am), the temperature then starts to increase during the day, 
reaching its maximum at about 5 pm, then starts to fall down gradually. This cyclic 
variation is known as the circadian cycle and is known to affect the overall temperature 
variation by a range of 0.5-1.5°C (Houdas and Ring, 1982). A variation of up to ±0.6°C 
in CorT temperature is considered normal when taking repeated measurements (Guyton, 
and Hall, 2000). 
The hypothalamus is the ideal place for measuring CorT. However, since it is 
hard to measure the temperature at the hypothalamic region, a variety of alternative 
body sites have been sought to monitor body temperature. CorT can be measured from 
either natural or artificial cavities. These cavities provide a place for measuring the 
temperature with minimal environmental disturbances. They include the rectum, the 
mouth, the ear, bladder, and sometimes the vagina. There is also what is called artificial 
cavities and these include the axilla, the groin, area between the thighs when the legs are 
crossed, and in the space between the two palms if they were kept together (Erickson 
and Kirklin, 1993; Houdas and Ring, 1982). 
The tympanic site, offers a close reflection of the thalamic temperature because 
of the anatomic proximity and shared vascularization as such is considered one of the 
best sites to measure CorT (Betta et al, 1997; Houdas and Ring, 1982). 
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Various devices can be used to measure CorT such as liquid in glass thermometers, 
electric thermometers, digital thermometers, infra-red thermometers and the tympanic 
thermometers. 
The tympanic thermometer is a hand held probe that detects thermal radiation 
from the ear canal (Dowding et al, 2002; Erickson, 1983). The tip of the probe is 
inserted into the auditory canal and the wave guide within the probe directs the infra-red 
radiation from the tympanic membrane to infra-red sensor. Inside the probe is a sensor 
unit that contains the detector which converts the infra-red radiation to an electrical 
signal and an electronic unit that processes the electrical signal and displays it as a 
reading (Betta et al, 1997). 
Tympanic thermometers have the ability to measure core temperature in seconds 
(Beckstrand et al, 1996, Erickson, 1983) with minimal distress to the subject (Johnson 
et al, 1991) making them more practical. Although tympanic thermometers have been 
shown to record underestimated values for CorT, this deviation in the recorded 
temperature was found to be consistent within the same make and not affected by the 
distance between the probe tip and the targeted tissues (Betta et al, 1997; Pontious et al, 
1994). 
7.1.2 Blood perfusion 
Blood can be measured and monitored in terms of flow, volume, and 
movement. Although there may be other ways of measuring blood, in this review the 
above three are grouped under blood perfusion. 
Blood perfusion can be monitored using a range of either invasive or non-invasive 
techniques. These techniques are based on measuring the physical movement of blood. 
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The invasive techniques include radioisotope clearance, flourescein injection, venous 
occlusion plethysmography (VOP), thermal clearance. Non-invasive techniques include 
Laser Doppler Flowmetry (LDF), and photoplethysmography (PPG). Both LDF and 
PPG, allow monitoring of blood perfusion with minimal discomfort to the subject being 
non-invasive. 
PPG is an instrument that provides qualitative (Nitzan et al, 1998) measure of 
tissue BVo1 (Figure 7.1). It can be applied virtually to any blood bearing tissue (Swain 
and Grant, 1989). Using the electro-optic technique either with a tungsten lamp or an 
infrared light, the PPG provides a qualitative measure of the cardiovascular pulse wave 
found throughout the human body (Nitzan et al, 1998) in tissues up to 3.3 mm deep 
(Schultz-Ehrenburg and Blazek, 2001). PPG utilises an infrared light, as it is relatively 
well absorbed in the blood and weakly absorbed in other tissues; thus allowing for 
observations to changes in blood volumes with reasonable contrast (Schultz-Ehrenburg 
and Blazek, 2001). 
When the skin is illuminated with the infrared light, the light is absorbed, reflected, or 
scattered in the tissues and in the blood. The part of light reflected is picked up by a 
photo-detector and the size and the shape of the pulse waves is analysed as a function 
of BVo1 changes. Depending on the volume of blood in the tissues the light detected 
would either increase or decrease. The amount of light absorbed by the probe is 
inversely related to the volume of blood (Babchenko et al, 2001; Nitzan et al, 1998). 
The amount of light reflected depends on the attenuation of the tissues, the amount of 
blood in the vessels of the skin, and the variation in the BVo1 by time (Swain and 
Grant, 1989). 
During systole, blood is ejected from the left ventricle into the peripheral vascular 
system, increasing arterial blood content and decreasing the amount of light emitted. 
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The maximal value of PPG corresponds with end of diastole when the blood volume is 
minimal (Babchenko et al, 2001). 
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Figure (7.1) Distribution of blood vessels in the skin (from Swain and Grant, 1989) 
However, because PPG is normally affixed to the skin, it carries the 
disadvantage of recording signals that are not related to the actual changes in blood 
perfusion. Motion artefacts can be seen when the subject moves or the probe moves in 
relation to the skin. The recorded signal could also depend on the degree of 
pigmentation in the tissues, and the initial blood volume in the area (Schultz-Ehrenburg 
and Blazek, 2001). 
PPG is known to produce comparable results with VOP (De Trafford and 
Lafferty, 1984) and LDF (Almond et al, 1988). It has considerable degrees of sensitivity 
even in cases of temperature alternation (Lindberg, 1991; Almond et al, 1988). 
rz 
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7.1.3 Nerve conduction velocity 
NCV studies refer to the study of the speed of impulse conduction along a 
motor, a sensory or a mixed nerve. It is a diagnostic measure of the patho- 
physiology of the nerve. 
When a nerve is stimulated, the impulse has the ability to travel in two 
directions both distally and proximally away from the point of stimulation this allows 
for two methods of measurements to the evoked response either orthodromically or 
antidromically (Delisa, 1994). Orthodromic measurements are done by stimulating 
distally and recording the action potential (AP)* proximally, while antidromic 
measurement is accomplished by reversing the orthodromic procedure (stimulating 
proximally and recording distally). 
Several devices exist that can be used to measure nerve conduction, though they 
may differ in shape, almost all have the same components. The recording unit, a 
stimulator to deliver the impulse, an amplifier to magnify the recorded signal and keep 
unnecessary interference signals (noise) as low as possible using either high or low 
filters. Some units may also have audio amplifier and a speaker to allow the acoustic 
examination of the potential. The recorded signal is either displayed on an oscilloscope 
or directly on the monitor depending on the measuring unit used. The amplitude of the 
potential is determined by the sensitivity control which typically ranges between 5 to 
10000µV. The potentials can be displayed using oscilloscope, and recorded using 
Polaroid photography, paper or tape recording (Oh, 1996). 
Nerves are usually stimulated using a square-wave stimulus. The stimulating 
signal can vary between 0.05 to 1 msec, however the longer the duration of the impulse, 
the more painful the stimulus to the subject. The response is usually obtained by 
increasing the intensity gradually from zero to the supramaximal level. It is 
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recommended that the stimulus is delivered with a rate of 1 stimulus per second as it is 
desirable for both the patient (less painful) and the investigator (to allow for better 
examination to the function of the neuromuscular transmission) (Oh, 1996). 
Three sets of electrodes are needed for NCV studies; ground electrodes to reduce 
stimulation artefacts, lowers interference and noise and a set of stimulating and 
recording electrodes to deliver the stimulus, and pick up the AP. While some equipment 
may use one set of recording and one set of stimulating electrodes others may use two 
sets of recording electrodes and two sets of stimulating electrodes (Oh, 1996). 
Additionally, although some may refer to the ground electrode as a reference electrode 
(Oh, 1996; Dong and Livesone, 1983) negating its effects on the measured signal, it 
actually contributes to the AP waveform shape by distorting the initial deflection at 
baseline and elongating the onset latency if misplaced. As such, the signal recorded can 
be distorted by the site of the ground electrode. It was found that by altering the 
reference or indifferent electrode placement, NCV could change by up to 1.5m/sec 
(Phongsmart et al, 2002). 
NCV can be measured using either needle or surface electrodes. Surface 
electrodes are usually attached to the body while needle electrodes are inserted directly 
into the muscle. Both techniques have their advantages and disadvantages. Surface 
electrodes are easy to apply however, are not capable of recording a single AP nor can 
they record AP of short duration. An inherent difficulty with surface electrodes is 
controlling the number of fibres, and the size of the fibres that react to the external 
stimulus delivered. Different nerves have different electrical thresholds this in turn 
results in impulses travelling at various speeds along the nerve fibres. Small nerves need 
*Definition and basis of AP can be found in Appendix C. 1 
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stronger stimulation in order to be excited and impulses usually travel more slowly 
compared to larger sized fibres. Additionally, large diameter fibres tend to respond 
quicker than small diameter non-myelinated ones (Oh, 1996). Consequently, the evoked 
response picked up by the recording electrodes is the summation of impulses of 
different nerves with the fastest nerve composing the first parts of the AP recorded. To 
overcome this problem stimulation should be performed at supra-maximal level to 
ensure the stimulation of all nerve fibres and a consistent response. 
NCV is the product of dividing distance by time (onset latency). Distance is taken 
as the distance between the centre of the stimulating electrode to the centre of the 
recording electrode if one set of electrodes is used or the distance between two 
stimulating sites divided by the conduction time between the two stimulating electrodes if 
two sets are used (Oh, 1996; Dong and Livesone, 1983). 
Sensory and motor responses can be measured quantitatively using the distinct 
components of the signal. These components are the onset latency, which is measured in 
milliseconds and is defined as the time between the introduction of a stimulus and the 
initial deflection of the evoked response. The amplitude of a response, which is measured 
in micro or millivolts, and is defined as the vertical displacement from the baseline and 
the peak of the negative peak in motor recording or peak to peak distance in sensory 
recording. Other components include the duration of the response (Dong and Livesone, 
1983). 
NCV recordings vary with age, temperature, segment of the nerve (distal or proximal), 
between different nerve types (Rivner et al, 2001; Buschbacher, 1998) and obesity 
(Rutkove, 2001). 
Temperature plays a significant role in the conduction velocity, and the shape of 
the signal recorded. However, in cases where the temperature can not be controlled, 
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correction can be made by either heating the part or recalculating the conduction 
velocity at lower temperatures using special equations (Rutkove, 2001; Delisa, 1994). 
7.2 SECONDARY OUTCOME MEASURES 
7.2.1 Body fat 
There are several methods of measuring body fat. These methods include SFM 
using callipers, hydrostatic weighing, anthropometrics variables, height-weight ratio 
(BMI), bioelectric impedance (BEI), dual energy X-ray absorptiometry, magnetic 
resonance imaging (MRI) and air displacement plethysmography. 
SFM were found to provide similar estimates of body density than methods such 
as hydrostatic weighing (Young et al, 1998), ultrasound (Weits et al, 1986), 
anthropometrics variables (Jackson and Pollock, 1985) and near infrared 
spectrophotometry (Eaton et at, 1993). Results from SFM were also found to be 
comparable with BEI, dual energy X-ray absorptiometry, and MRI (Kwok et al, 2001; 
Nicholson et al, 2001; Wattanapenpaiboon et al, 1998). 
SFM is a method of calculating body fat from body density using specific or 
general equations (Cyrino et al, 2003). It is a measure of the thickness of two layers of 
skin and the underlying subcutaneous fat (Heyward and Stolarczyk, 1996). Given that a 
third of body fat is located subcutaneously (Jackson and Pollock, 1985) and that the fat 
layer is not evenly distributed throughout the body, different equations use different 
combination of anatomical sites (ranging from 2 sites to 10 sites) in order to have an 
overall estimate of fat distribution (Cyrino et al, 2003; Riegerova and Pridalova, 2002). 
Several predictive equations have been developed to calculate body density, Durnin and 
Womersley (1974), Jackson and Pollock (1987), Jackson et al (1980) are the mostly 
used. 
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Scherf et al (1986) compared equations used by Jackson and Pollock with 
Durnin and Womersley and hydrostatic weighing and found that although the findings 
were comparable the error margin with Durnin and Womersley equations was within 
6.6% while it was within 0.7% of body fat with Jackson and Pollock. 
A lot of disagreement exist on the proper method of measuring Skinfold. While 
some discusses the importance of taking the measurement over the fold (He et al, 
1999; Clasey et al, 1997). Jackson and Pollock (1985) argue that it can be taken 
horizontally, obliquely or vertically depending on the site. Other factors such as the 
technician skill, type of calliper and equations employed (Lehman et al, 1984), all 
could play a role in the accuracy of the reading. Controversies also exist on the side of 
measurement. There is no Conesus on the side of the body, the measurements need to 
be taken from (Heyward and Stolarczyk, 1996). While Lehmann et al (1988) 
recommended that all measurements need to be taken on the right side, Harrison et al 
(1988) compared measurements taken from both sides and found no significant 
difference. As such for consistency the side measured needs to be standardised. All of 
the above necessitate that investigator reliability be established prior to data collection. 
7.2.2 Muscle strength 
Muscle strength can be measured either manually or mechanically. Manual 
muscle testing (MMT) is based on grading the strength of the muscle against the 
examiner or the gravity resistance using a 5-point grading scale that ranges from poor 
to normal. Mechanically, muscle strength can be measured using many methods, most 
popular is the myometer, Cybex, and grip meters. 
The hand held myometer is a method of quantitatively measuring muscle 
strength and providing a direct recording of force output. Its construct validity with the 
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Cybex was shown to be high (r = 0.8). Being less expensive, portable and consuming 
less time to record a measurement, it becomes a practical alternative to Cybex II 
(Andrew et al, 1996). Hayes et al (2002) tested 3 methods for assessing the shoulder 
strength in patients with shoulder pathology (MMT, myometer, and spring scale 
myometer). Hand held myometer has shown the highest reliability with all shoulder 
movements (ICC value ranging between 0.79-0.92) except internal rotation (ICC value 
between 0.7-0.72). The investigators suggested that higher levels of reliability are 
expected with normal subjects. Reliability of hand held myometer was also 
demonstrated with elderly (Wang et al; 2002). 
Myometer could be challenging with strong and athletic individuals especially 
if the examiner is physically weak. This problem is mostly seen with testing the hip 
musculature as such the use of anchoring station (Nadler et al, 2000) or a belt resisted 
method where the subject body weight adds more stability is advisable (Kramer et al, 
1991) however, both devices are still under examination for reliability. 
Although the myometer is associated with high level of intra-examiner (95- 
96%) and inter-examiner (91-95 %) reliability (Schreuders et al, 2000), its reading 
could be affected by the position of the joint due to the change in lever arm which may 
show as a change in the force exerted without an actual change in strength (McMahon 
et al, 1992). It also depends on the examiners strength and ability to hold against the 
resistance of the patient as such may exhibit variability that is not related to isometric 
muscle strength (Ford-Smith et al, 2001). This variability was found to be between 9- 
24% intra-assessor and 37-52% inter-assessor reliability (Schreuders et al, 2000). 
In testing muscle strength, the movement can be done using either make or 
break technique, that is to either break or make the movement. Although both make and 
break methods measure maximal voluntary muscle strength, the force produced by the 
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break test is greater than the force produced by the make test (Stratford and Balsor, 
1994; Bohannon, 1986). The break testing has been shown to provide more reliable and 
accurate measurements (Phillips, 2000). It can be performed by asking the subject to 
exert maximal force against the examiner or the testing device while the examiner 
opposes the movement to overcome the patient effort until the joint gives away. While 
in the make testing the examiners asks the subject to exert maximal force against the 
myometer for a period of 3-5 seconds (Bohannon, 1986). 
7.2.3 Range of motion 
Several methods have been employed by therapists to quantify joint range of 
motion. Joint ROM can be measured using the universal goniometer (full circle), 
computerised pendulum orthoranger, fluid based goniometer, parallelogram 
goniometer, or the inclinometer. 
The universal goniometer was found to be more accurate than computerised 
orthoranger (Clapper and Wolf, 1988) and more reliable than fluid based goniometer 
(Chiarello and Savidge, 1993; Rheault et al, 1988). The reliability of a goniometer 
readings is accepted to be accurate to within 5° for upper limb movement and 6° for 
lower limb motions (Clapper and Wolf, 1988), however, some have argued that no 
inferences should be made for changes less than 10° (Bovens et al, 1990). 
Goniometeric reliability can differ according to several factors such as the 
starting position, joint measured, interference of therapists fingers with the placement 
of the goniometer, goniometric placement and pressure applied (Somers et al, 1997; 
Bovens et al, 1990; Clapper and Wolf, 1988). 
Despite the limitations and the variable range of reliability associated with the 
use of the goniometer, standardising the testing positions and establishing the 
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researchers reliability prior to conducting any trial can aid in reducing errors in 
measurements and increasing the reliability range (Rome and Cawiesn, 1996). 
7.2.4 Visual analogue scale (VAS) 
VAS is a widely used self-report method of measuring almost any symptoms or 
behaviour. VAS has been used for years to assess changes in pain level and monitor its 
severity. Conventionally, patients are presented with a 100 mm line and are asked to 
place a mark that would correspond to their symptom. The line is anchored on both 
ends with words or numbers that represent the extreme to the variable studied such as 
no pain -worst pain. 
Essentially, pain is of a multi-dimensional construct, consisting of sensory, 
affective, evaluative, cognitive and behavioural elements. Despite having a face 
validity (Sim and Arnell, 1993), VAS can only measure the intensity component of the 
sensory dimension of pain (Sim and Waterfield, 1997). Although this may suggest low 
content validity, limiting interferences with regard to other scales, VAS was highly 
correlated to other measures used to assess pain such as McGill questionnaire 
(Scrimshaw and Maher, 2001) and computerised VAS (Jamison et al, 2002). 
VAS has been shown to be sensitive to the increase and decrease in pain than 
the fixed interval scales (Bolton and Wilkinson, 1998) or McGill questionnaire 
(Scrimshaw and Maher, 2001). It was shown to be a valid measure when evaluated for 
both chronic and experimental pain (Price et al, 1983), and the young and old 
population (Tiplady et al, 1998). Consistency of VAS was found to increase by 
increasing the number of assessments made, and by assessing pain over several days 
(Jensen and McFarland, 1993), possibly because of a learning effect. 
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Reliability with VAS depends on the ability of the subject to place a mark 
where they intend to put it. Babul (1994) evaluated the memory of pain in 77 subjects 
undergoing orthopaedic surgery. Hourly pain rating, and post surgery ratings, were 
obtained for 48 hours and compared it to retrospective pain memory. Retrospective 
pain rating was found to be highly correlated (r = 0.89) with hourly reports, providing 
support for the reliability and the accuracy of subjects when recalling the rate of pain. 
However, observers cannot accurately assess the subjective experience of another 
person. Apparent discrepancies in self reported pain might be seen in the mismatch 
between the score assigned to pain when patients, health care workers and caregivers 
were compared. It was reported that health professionals and caregivers always rate 
pain lower than that actually experienced by the patient (Clark et al, 2003; Miaskowski 
et al, 1997; Eu et al, 1994). These observations can be attributed to several factors. 
Caregivers tend to think that patients overreact when expressing their pain because of 
the anxiety (Bisseret, 1981), physicians on the other hand evaluate pain in terms of the 
worst pain they have experienced when treating patients (Estrada et al, 1997). 
VAS can be administered either in a vertical or in a horizontal format (Price et 
al, 2003; Gift, 1989) both of which were highly correlated. VAS can also be 
administered using numerical or verbal values. However, no method was found to be 
superior as both were strongly correlated and can be used interchangeably depending 
on the purpose of the study (Bijur et al, 2003, Mantyselka et al, 2001). It was found 
that the failure rate with VAS ranges between 7%-11% in terms of reproducibility 
(Ogon et al, 1996; McGuire, 1984). The failure, is influenced by the way the question 
is asked or the explanation made rather than the orientation or the wording of the scale 
(Ogon et al, 1996). 
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According to Gallagher et al (2001) and Todd et al (1996) a difference of 13 
mm or 1.3 cm on VAS represents the minimum clinical significant difference although 
other have accepted 9 mm to be the minimum acceptable difference (Deloach et al, 
1998). 
7.3 CONCLUSION 
This chapter have described the various methods available for measuring BVol, Skin 
and core temperature, NCV, body fat, muscle strength, ROM and pain level. It was 
undertaken to decide on the best approach to measure the primary and the secondary 
measures with sufficient reliability to ensure the validity of the data collected. Based on 
the review it was decided to use PPG to measure BVol, tympanic thermometer to 
measure CorT, skin calliper and Jackson and Pollock equations for men and women to 
measure body fat, hand held myometer to measure muscle strength, classic goniometer 
to measure ROM, and horizontal VAS to measure pain level. 
The next chapter will discuss issues related to reliability, validation of the acquisition 
system in a series of pilot laboratory experimentation. 
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CHAPTER 8 
PILOT LABORATORY EXPERIMENTS 
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8.0 INTRODUCTION 
In chapters five and six a work was reported that explored the nature of 
PSWT use in outpatient clinics. This chapter provides validation of the acquisition 
system, examination of the recorded signal, and pilot experiments aiming at 
developing the experimental protocol that will be used for the subsequent trials. Two 
trials will be conducted to measure the changes in BVo1, SkT and NCV as a result of 
irradiating the knee joint with PSWT. The intended plan of the experiments was to 
take the measurements from both limbs simultaneously. Measurements will also be 
taken before, during and after PSWT administration. As such it was crucial that the 
interaction between the EMF and the measuring instrument, the quality of the signal 
recorded be studied beforehand. 
The pilot study was also conducted to check the accuracy of the parameters used as 
outcome measures, explore the feasibility, practicality of the experiment protocol 
and the reliability of the measuring device. 
8.1 THE PILOT AIMS 
1. To calibrate the gain of the biopotential amplifiers 
2. To examine the effect of distance between the data acquisition system and 
the PSWT (Megapulse) machine on the measured signal. 
3. To examine the ability of the electrodes to detect changes in the 
physiological signal when under the effect of PSWT 
4. To examine the time taken by various electrodes to return to baseline reading 
after being subjected to PSWT 
5. To examine the effect of the distance between the PSWT (Megapulse) 
treatment head and a phantom on the measured signal. 
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6. To examine the effect of different external noises on the recorded signal. 
7. To examine the nature of pulse signal derived from PPG 
8. To compare the magnitude and the nature of interference between two 
PSWT machines (Megapulse, and Phyaction Performa+) on the acquisition 
system 
9. To examine the developed experimental protocol for practicality on a small 
group of subjects 
The work was undertaken in four parts: 
Part 1 deals with calibrating the acquisition system (aim 1). 
Part 2 deals with validation of the acquisition system, and examination of the 
variables affecting the signal quality in general such as the distance between the 
acquisition system and the PSWT machine, and the stability of electrodes under 
PSWT (aim 2-8). 
Part 3 deals with comparing the nature of interference from two PSWT machines on 
the data acquisition system (aim 8). 
Part 4 deals with the experimental pilot work and recommendations to improve the 
quality of data collected in the next two trials (aim 9). 
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PART 1: EQUIPMENT CALIBRATION 
The signal was recorded using an MP100 (Biopac Systems, Santa Barbara, 
CA, USA). It is an acquisition system that collects, analyses, stores, and retrieves 
data. It has 16 input/ output channels and a sampling rate of up to 7000 
samples/second. Details of the specification are in Appendix (D. 2). 
Calibrating the gain of the amplifiers used in the study is essential prior to the start of 
data collection. Description of the calibration of biopotentials is found in Appendix D. I. 
The current study will be employing EMG amplifier, PPG amplifier, and SkT amplifier, 
nerve stimulator (specifications of all amplifiers can be found in Appendix D. 2), and 
PSWT. All of these units were checked regularly for accuracy and when necessary were 
calibrated to maintain the quality of the recorded signal. 
Both the stimulator and the PSWT machine were calibrated by the manufacturer 
prior to data collection. Although some of the pilot work was undertaken prior to the 
calibration of PSWT, this did not raise any concerns as according to the technician, 
no major problems were detected in the unit and as a result no major modifications 
were made that altered the output accuracy. 
8.2 CONCLUSION 
The work reported in this section revealed inaccuracy in the EMG and PPG 
outputs. Calibration was done across the whole range of the gain setting with EMG 
and on the gain that would be used for collecting data with PPG. This was done 
because PPG was more sensitive than EMG to the change in the gain setting. 
Changing the gain alters the zero point of the signal with PGG, and as such it was 
decided to only calibrate the gain that would be used for acquiring the signal. 
197 
Chapter 8 Pilot laboratory experiments 
All calibrations were done following the manufacturer's instructions. Thereupon and 
throughout the conduct of the rest of the pilot experimentation, the amplifiers were 
checked weekly by the researcher and recalibrated when necessary. 
The next section will involve validation of the acquisition system, examination of 
the nature and the accuracy of the recorded signal. This was considered essential 
prior to data collection to ensure the validity of data collected and reported. 
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PART 2: VALIDATION OF THE ACQUISITION SYSTEM 
The administration of PSWT is associated with the emission of both E and H 
fields (Section 2.2). This field is known to extend several meters from the applicator 
(Shields, 2003; Tzima and Martin, 1994; Coppell, 1988). Thus it was crucial to explore 
whether the field surrounding PSWT equipment was strong enough to interfere with the 
function of the data acquisition system. Such work was seen fundamental in order to 
determine the safe working distance for both pieces of equipment. The effect of EMR 
was also examined on the nature and accuracy of the recorded signal and methods of 
improving the quality of the data collected are discussed. 
Ethical approval for the pilot was obtained from Ethical Committee of Radiography 
and Physiotherapy in University of Hertfordshire (Appendix D. 3). 
8.3 EQUIPMENT 
8.3.1 PSWT machine 
Experimentation was done using a Megapulse Senior machine (Electro-Medical 
Supplies, Greenham, Ltd; UK). 
Megapulse is a therapeutic machine that can deliver both continuous and pulsed SW. In 
the pulsed mode it can deliver short pulses, which are adjustable in duration (20 - 
400µsec) and PRR (50-800 Hz) enabling the operator to vary the output. The peak 
output however, is fixed at 150 watts, while the mean output varies depending on the 
parameters selected. The pulses can be delivered either continuously (3: 3), two thirds of 
the time (2: 3) or one third of the time (1: 3). The applicator houses the silver-plated 
copper coil and has 4 turns and an outside diameter of approximately 140 mm. The 
electric field is suppressed by a faradic screen adjusted in front of the coil (personal 
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communication with manufacturer). As the coil is wrapped around the extremity, the 
magnetic field is restricted to the inside circumference of the applicator (Figure 8.1) 
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Figure (8.1) EMF penetration with drum electrode (adapted from Hand, 1990) 
8.3.2 Phantom 
There was a need to use a phantom to complete the circuit and ensure that 
the PSWT machine was working under a suitable load. Although the use of subjects 
would provide better representation of the expected response, subjecting volunteers 
to PSWT repeatedly in order to plan the experimental protocol was unjustified. 
The phantom used was a saline bag. Saline phantoms were previously employed by 
other investigators to study EMR around SW machines (Martin et at, 1991; 
McDowell and Lunt, 1991; Martin et al 1990; Skotte, 1986). The conductivity of 
saline used was 0.9% NaCl which is similar to muscle conductivity of . 84-1.08 
(Ward, 1980). 
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Although the majority of testing was conducted on a phantom, some of the testing was 
conducted on subjects (ethics form can be found in Appendix D. 3). 
8.4 THE EFFECT OF DISTANCE BETWEEN PSWT AND MP 100 
ON THE INPUT SIGNAL 
In order to determine where to position PSWT machine in relation to the 
acquisition system both the size and the shape of interference were examined from three 
locations (Figure 8.2). PPG* electrodes were attached to the phantom and the signal was 
recorded from Dl (lm), D2 (3m) and D3 (4 m). These distances were chosen as 4m 
represented the maximum available distance to work around in the laboratory, lm 
represented the safe distance recommended by the CSP which the therapists can work 
around. The 3m reading was taken as an intermediate value between the two readings to 
complete the overall picture on how the field would vary with distance. The same was 
repeated with SkT** probes and EMG*** electrodes attached to the phantom. The 
Megapulse head was placed in close proximity to the phantom. During measurement the 
recording system is left in place while the PSWT device was moved to the above 
mentioned distances. 
An interference band was observed (Figure 8.3 a-b) that was superimposed on the input 
signal recorded by MP100. This interference band was picked up as soon as the PSWT 
machine was turned on. The field was extensive such that it was picked up even with a 
distance of 4m between the two pieces of equipment (the maximum laboratory setting is 
4m). 
*The unit has an infrared light source (860 nm ± 90 nm), and a detector (a photo diode), positioned in reflection or transmission 
mode). Specification of PPG in Appendix D. 2 
**TSD 102D rapid response thermistor, sensitivity <83 µ°C, specification of SkT amplifier in Appendix D. 2 
*** Ag-AgCl pre-gelled paired (dual) electrodes (41 nun x 82 mm x 1.5 thick foam), The ground electrode is a 35 mm diameter 
general purpose pre-gelled electrode Ag-AgCI., specification of EMG amplifier in Appendix D. 2 
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Figure (8.2) Laboratory arrangement for testing EMR 
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Figure (8.3a) Changes in the recorded signal as a result of turning PSWT on 
The shape of the interference band was not affected by the distance or the type of 
electrodes used to record it. The band was consistent in appearance and was reflecting 
the pulsed output of the SW machine. The pulses were rectangular in shape with a pulse 
period of 9.8±0.2 sec and an interpulse interval of 16.2±0.2 sec. These measurements 
were consistent regardless of the pulsing mode (1: 3 - 2: 3 -3: 3) or the dose. This band 
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was named electronic interference band (EIB) to distinguish the interference pulses from 
those of the PSWT output. 
The nature of the signal and the factors affecting its quality were further examined in the 
subsequent sections. 
8.5 THE EFFECT OF THE DISTANCE BETWEEN THE PSWT 
(MEGAPULSE) APPLICATOR AND THE PHANTOM ON THE 
INPUT SIGNAL 
Specifying the distance between the treatment head and the area treated was 
seen crucial as it could affect the amount of temperature increase and possibly the 
changes recorded in BVol. Electrotherapy literature, whether those found in text 
books or manufacturers' manuals do not give a distinct answer for this query " the 
treatment head needs to be placed in close proximity from the part treated", 
deciding on the best placement is however left to the operator. As such it was seen 
necessary that this distance should be determined to ensure both standardization and 
repeatability of the protocol. Six different conditions were used to examine the 
effect of the distance between the PSWT applicator and the phantom on the 
magnitude of temperature increase recorded to determine the optimum placement of 
the applicator in relation to the treated site. All experiments were conducted using 
the temperature probe, which was attached using adhesive tape to the phantom. The 
temperature of the phantom was checked between conditions and was allowed to 
return to baseline before another reading was taken. The baseline temperature 
reading for the phantom was 18.4°C. The room temperature was 21°C with all the 
conditions. Two treatment doses were chosen to represent high and low output. 
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Condition 1: the treatment head was placed in contact with the phantom, Megapulse 
setting was PD 1001isec, PRR 200 Hz, MP 3W, irradiation time 15 minutes. 
Condition 2: the treatment head was 1 inch away from the phantom, Megapulse 
setting was PD 100µsec, PRR 200 Hz, MP 3W, irradiation time 15 minutes. 
Condition 3: the treatment head was 1.5 inch from the phantom, Megapulse setting 
was PD 100µsec, PRR 200 Hz, MP 3W, irradiation time 15 minutes. 
Condition 4: the treatment head was in contact with the phantom, Megapulse setting 
was PD 400µsec, PRR 800 Hz, MP 48 W, irradiation time 15 minutes. 
Condition 5: the treatment head was 1 inch away from the phantom, Megapulse 
setting was PD 400µsec, PRR 800 Hz, MP 48W, irradiation time 15 minutes. 
Condition 6: the treatment head was 1.5inch away from the phantom, Megapulse 
setting was PD 400µsec, PRR 800 Hz, MP 48W, irradiation time 15 minutes. 
Findings of the 6 conditions are summarised in Table (8.1). Trials were repeated 10 times 
for each condition, the value reported represents the mean. 
Condition PSWT setting T in temperature of 
phantom ('C±SD) 
Treatment head in close contact with the phantom 1001is, 200Hz, MP 3W, 0.85 ± 0.11° C 
15 min 
Treatment head 1" away from the phantom 100µs, 200Hz, MP 3W 0.52 ± 0.09° C 
15 min 
Treatment head 1.5" away from the phantom 100µs, 200Hz, MP 3W 0.08 ± 0.11° C 
15 min 
Treatment head in close contact with the phantom 200µs, 800Hz, MP 24W, 4.42 ± 0.39° C 
15 min 
Treatment head 1" away from the phantom 200µs, 800Hz, MP 24 W, 3.15 ± 0.57° C 
15 min 
Treatment head 1.5" away from The phantom 200µs, 800Hz, MP 24W, 2.37 ± 0.37° C 
15 min 
-raufe (a. i) uonaiaons empioyea to test the relation between treatment head and increase in temperature 
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Figure (8.4) Change in temperature following two treatment protocols (each column represents the 
mean of 10 repetitions ±SD) 
It can be seen from Table (8.1) and Figure (8.4) that there was an inverse 
relationship between the distance between the phantom and the applicator and the 
increase in temperature. Therefore to ensure repeatability and consistency of the 
experimental protocol and standardisation of the experimental setting a cardboard 
innovated by the author was used (23 cm long, 20 cm wide and 15 mm thick). This 
board will be used in the experimental trials conducted in the laboratory and in the 
hospital. 
From the findings above, it was not clear though whether the increase in the 
temperature was caused by the heating of the temperature probe or warming up of 
the fluid inside the saline bag. For safety reasons this issue warranted further 
investigation before any experimentation is conducted on subjects. The experiments 
were conducted on temperature probes, as it was possible to follow changes in 
temperature as a result of PSWT irradiation unlike the PPG and EMG, which were 
resistant to change in temperature. 
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8.6 POST IRRADIATION EFFECTS ON THE ELECTRODES 
Prior to collecting any data, the effect of EMF emitted from PSWT was examined 
on the electrodes. It was crucial that no dysfunction is detected in the ability of the 
electrodes to return to baseline reading once the PSWT machine is turned off ensuring that 
the tracing recorded after treatment is a reflection of the change in the physiological 
function and not of a disturbed signal. 
The effect of EMF on the electrodes was examined in 6 conditions, conditions 1 and 4 
were done using PPG electrodes, conditions 2 and 5 were done using SkT probes, and 
conditions 3, and 6 were done using EMG electrodes. 
Condition 1: PPG electrodes were attached to the phantom using adhesive tape, 
recording of the signal was commenced for 15 minutes (5 minutes baseline, 5 minutes 
treatment, and 5 minutes post treatment period). PSWT was set on the maximum dose 
(MP 48W, PRR 800, PD 400 gsec) to represent the worst case scenario. Changes in the 
recorded signal were observed and remarks made. 
Condition 2: SkT probes were attached to the phantom using adhesive tape, recording of 
the signal was commenced for 15 minutes (5 minutes baseline, 5 minutes treatment, and 
5 minutes post treatment period). PSWT was set on the maximum dose (MP 48W, PRR 
800, PD 400 µsec) to represent the worst case scenario. Changes in the recorded signal 
were observed and remarks made. 
Condition 3: Ag-AgCI EMG electrodes were attached to the phantom using adhesive 
collars, recording of the signal was commenced for 15 minutes (5 minutes baseline, 5 
minutes treatment, and 5 minutes post treatment period). PSWT was set on the 
maximum dose (MP 48W, PRR 800, PD 400 µsec) to represent the worst case scenario. 
Changes in the recorded signal were observed and remarks made. 
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Condition 4: Same as condition 1 but instead of attaching the electrodes to the phantom 
they were attached to the knee of a volunteer using non-allergic adhesive tape. PPG 
electrodes were attached to the base of the patella on the anterior knee while the subject 
is lying on the plinth. 
Condition 5: Same as condition 2 but instead of attaching the electrodes to the phantom 
they were attached to the knee of a volunteer using non-allergic adhesive tape. SkT 
probes were attached to the base of the patella on the anterior of the knee while the 
subject is lying on the plinth. 
Condition 6: Same as condition 3 but instead of attaching the electrodes to the phantom 
they were attached to the knee of a volunteer using adhesive collars. EMG electrodes 
were attached to the base of the patella on anterior knee while the subject is lying on the 
plinth. 
With both PPG and EMG electrodes the input signal returned to a baseline 
reading immediately after the PSWT was turned off. This happened regardless of 
whether the electrodes were attached to a phantom or to a subject. However with the 
temperature probes there was an instant increase in the temperature (picked up in the 
first 10-13 sec subsequent to turning PSWT machine on). It continued to mount 
throughout the time of irradiation and only started to decline after the cessation of 
PSWT. These findings are in agreement with the previous section. No speculation 
can be made as to the cause of temperature increase recorded. It was not clear 
whether the increase in temperature recorded was a measure of heating up of the 
temperature probe or heating of the fluid inside the saline bag, this issue was 
investigated further in the following section. 
The ability of the PPG and EMG electrodes to return to baseline readings means that 
the measurements taken from the subjects at the recovery period (after treatment 
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time) can be analysed as a representation of the subjects' physiological reactions to 
PSWT treatment. However, this cannot be said for the changes recorded post 
treatment using temperature probes until further exploration of the increase in 
temperature is commenced. 
8.7 EXAMINING THE NATURE OF THE TEMPERATURE 
INCREASE IN TEMPERATURE PROBES 
To further analyse the nature of temperature increase, it was vital to distinguish 
between temperature increase as a result of warming up of the electrodes or warming up 
of the liquid inside the phantom. In order to examine this, 6 experimental conditions were 
used with 3 different output powers. The whole experimental session was 30 minutes, 10 
minutes baseline, 10 minutes PSWT, and 10 minutes recovery post treatment. To avoid 
any build up of heat that may interfere with the analysis, enough time was left between 
sessions to allow the temperature to return to baseline before any data were collected. The 
dose was either 200µsec-400 pps- MP 12W-10 minutes, or 400 µsec- 400 pps-MP 24 W- 
10 minutes, or 400µsec -800 pps -MP 48W- 10 minutes. Temperature probes were 
attached to the phantom using adhesive tape. They were either left recording while being 
exposed to PSWT, or were removed before the PSWT machine was turned on, and then 
returned to record the post treatment period. The distance between the phantom and the 
treatment head was standardised using the cardboard described earlier (Section 8.10). 
Each condition was repeated 5 times and the mean was used for analysis. 
Figure (8.5) shows the schematic representation of the experiments and the time taken for 
analysis. It was decided to use the 5 minutes because of the difficulty in using one minute 
to one minute analysis, the period before treatment was stable while the period post 
treatment was changing as a result of cooling of the phantom. As such it was decided to 
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use the mean of points for better representation. The change in temperature pre and post 
treatment was noted and compared. Summary of the results is shown in Table (8.2). 
Bodine Treatment Time Post Uzt period 
10 min 10 min 10 min 
Analysis period Analysis Period 
Pro-aatment Post-trefft 
5 mm 5 min 
Figure (8.5) Schematic representation on the period taken for analysis 
200 sec-4 s (12W) 400 sec-4 s (24 400 sec-8 s (48W) 
Electrodes Electrodes Electrodes Electrodes Electrodes Electrodes 
removed in place removed in place removed In place 
0.785 0.985 0.830 1.615 0.925 2.712 Mean increase in temperature 
oc 
Table (8.2) Increase in temperature following 3 testing protocols 
*The mean was calculated for the last 5 minute in baseline and first 5 minutes recovery time 
The value reported in the table is the mean of the 5 repetitions. 
From the table above it could be seen that the temperature increase recorded 
was proportional to the MP applied. A higher dose resulted in a higher increase in 
temperature. Furthermore, the amount of increase was higher when the probes were left 
in place compared to when they were removed prior to irradiation. The fmdings suggest 
that the increase was the result of 2 components: heating of the metal inside the 
temperature probe and the fluid inside the phantom. 
These findings have implications for the interpretation of the results. In order to avoid 
misleading conclusions and for safety reasons, it was decided that the temperature 
probes be removed at the time of exposing subjects to PSWT and be returned for 
measurement at the recovery period. The site of recording would be marked to ensure 
consistency and reproducibility. 
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8.8 THE ABILITY OF PPG ELECTRODES TO CONVEY 
CHANGES IN BVol WHEN UNDER PSWT EFFECTS 
BVol will be measured at three periods: before treatment, during treatment and 
post treatment. As such it was crucial to examine the ability of the electrodes to measure 
and reflect changes in the physiological signal. This was accomplished by attaching 
PPG to the knee of a subject. PSWT was set to 200 µsec, 800 pps, MP 24W, 10 minutes. 
The recording session was 15 minutes (5 minutes pre treatment, 5 minutes treatment and 
5 minutes post treatment). 
Figure (8.6 a, b) shows the signal and a magnified portion of the signal. It could be seen 
that despite the superimposing EIB, the shape and the changes in the PPG signal could 
still be seen in the off pulse period. 
Figure (8.6 a) Changes in PPG when under PSWT effect. With the PPG placed on the knee, the changes 
in underlying signal as a result of isometric contraction could still be seen even with the superimposed 
EIB. 
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8.9 EFFECTS OF DIFFERENT EXTERNAL NOISES ON THE 
INPUT SIGNAL 
The sensitivity of the recording electrodes was examined in relation to external 
noise. It was crucial that the effect of noise on the quality of the recorded signal be 
examined in order to quantify the size of the noise and the extent of its interference with 
the recorded signal. Several conditions were created to account for the natural noises 
that may occur during the course of the experiment. These conditions were repeated 
with PPG and EMG electrodes and the SkT probes. The data will enable the researcher 
to distinguish between genuine changes demonstrated by the subjects and any other 
unrelated noise. Electrodes were attached to the phantom using either adhesive tape for 
PPG electrodes and temperature probes and adhesive collars for EMG electrodes. 
The electrodes were attached to the phantom, and the variation in the recorded signal 
was observed as a result of generating artificial sounds. These sounds included the 
sounds of moving pieces of furniture such as chairs, slamming doors and drawers, the 
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Figure (8.6 b) Magnified section of Figure (8.6-part in square) of PPG signal when under the effect of 
PSWT. It could be seen that even with the superimposing EIB the pulsating nature of blood signal can 
still be detected 
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field around the mobile phone when switching it on and off, sending and receiving text 
messages, or making and receiving calls. All these noises were attempted to account for 
all the noises that may occur during the course of data collection. 
EMG and SkT electrodes were resistant to noise and the signal was clean with no 
artefacts noticed. Unlike the other electrodes the PPG electrodes demonstrated the most 
disturbances to the signal (Figure 8.7). Moreover, high level of noise in the PPG signal 
was observed when the leads connecting the electrodes to the recording device were 
touching. 
These findings necessitate that careful monitoring and recording to any unexpected or 
unwanted event during the course of acquisition is paramount to avoid misleading or 
faulty interpretations of findings. 
213 
Figure (8.7) The effect of noise on the input signal 
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8.10 COMPARISON BETWEEN THE NATURE OF THE PulsR 
WHEN MEASURED FROM DIFFERENT ANATOMICAL SITES 
PPG will be used in this study to record changes in BVo1 and measure PulsR 
from the knee. According to the manufacturer, PPG probes (or transducers) are expected 
to measure the blood signal from any tissue bearing blood. However, PPG probes are 
known to convey best results when they are attached to the pads of the toes or fingers, 
being areas rich in arteriovenous anastomosis. PPG probes reliability in measuring 
PulsR from other body parts was not examined. Thus it was crucial that the nature of the 
signal and the PulsR derived be of sufficient quality before using it as an outcome 
measure. 
The above notion was examined on a volunteer (the experimental condition was 
repeated 4 times the same day over 3 days and every time the same outcome was 
obtained). The PPG electrodes were attached to different sites around the knee (big toe, 
the medial side, lateral side, medial knee while the knee was extended, and medial knee 
while the knee was flexed). The PulsR was also measured from the index finger (a 
standard site for measuring pulse) and the reading was used for comparison with the 
other readings. The PulsR was recorded from each site for 5 minutes and the mean was 
compared across sites (Table 8.3). 
Findings have shown that the PulsR derived from the PPG when it was attached to the 
knee was higher in rate compared to the measurement from the finger, which was 
considered the normal value (Marieb, 2002). This could be caused by the amount of 
noise or possibly the displacement of the electrodes when they were attached to the 
knee, which may have disturbed the signal. 
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Big toe Medial Knee 
(knee flexed) 
Medial Knee 
(knee extended) 
Lateral knee Index finger 
BPM BPM BPM BPM BPM 
Test 1 147.92 148.12 145.6 147.17 74.38 
Test 2 143.98 147.95 148.5 148.59 72.27 
Test 3 145.60 144.13 146.5 144.51 74.97 
Test 4 147.190 143.12 144.8 144.41 76.98 
Test 5 145.24 148.63 146.8 148.92 77.54 
Mean 145.98±0.89 145.39±1.72 146.44±0.70 146.72±1.29 75.22±1.16 
Table (8.3) PulsR values obtained from different sites, shaded area resembles normal values. The 
reported values are the mean ± SD (the value reported is the mean of 1 minute interval over 5 minutes) 
Hitherto, it was decided to use PPG to reflect changes in BVol in the knee, and to use 
another device to record the PulsR. 
8.11 COMPARISON BETWEEN PulsR READING USING TWO 
DIFFERENT DEVICES 
The previous section has raised issues about the accuracy of the pulse signal 
measured by MP100 when the PPG was placed around the knee joint. As such there was 
a need to compare the pulse value obtained by MP100 to another validated device. 
It was decided to use Tunturi (TPM-400, Japan), which was validated by Watson 
(1994). Using a volunteer the Tunturi probe was attached to the ear lobe using a clip and 
was set to display the continuous fluctuation in the PulsR. Measurements were recorded 
by the researcher minute by minute for ten minutes. 
With the Biopac MP 100 the PulsR was measured by attaching the PPG to the index 
finger using a Velcro strap. MP100 recorded continuous real time PulsR for 10 minutes. 
The mean of 60 seconds was taken to be compared for minute by minute with the 
Tunturi Table (8.4). 
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PulsR measured using Tunturi PulsR derived from PPG signal 
Min 1 86.2 86.2 
Min 2 78.9 78.7 
Min 3 77.3 76.8 
Min 4 77.9 77.5 
Min 5 77.4 76.9 
Min 6 84.3 82.4 
Min 7 84.5 84.9 
Min 8 75.3 74.1 
Min 9 77.3 76.6 
Min 10 78.6 78.1 
Table (8.4) The mean YuisK readings taken by the two devices, each raw with MP 100 is the mean of 60 
seconds. 
... rT, 
Table (8.4) suggested a strong resemblance between the PulsR reading when measured 
using the MP 100 or Tunturi. Pearson correlation coefficient revealed r=0.98, the 
correlation was significant at p=0.01. Both readings were plotted as a scatter graph 
(Figure 8.8) that further confirmed the strong correlation between the two sets of 
readings. 
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Figure (8.8) Scatter graph of the PulsR measured using Biopac MP100 and Tunturi 
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Given this it was decided to use Tunturi to measure PulseR and use PPG to monitor 
BVo1 from the knee during the experiment. 
8.12 SAMPLING RATE 
In order to decide the most appropriate sampling rate to use for collecting the 
data, there was a need to find the frequency of the input signal. The Biopac MP 100 
allows for one sampling rate regardless of the source of the input signal or the number of 
channels used. It was decided to use PPG signal for analysis. The blood signal was 
analysed using Fast Fourier Transform (FFT). It is a method of computing the frequency 
component of the input signal (Zonst, 2000; Chu and George, 1999). Figure (8.9) shows 
the frequency component of the BVo1 signal. 
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Figure (8.9) A trace of PPG signal using FFT. FFT was used to reveal the frequency component. Same 
graph was obtained whether the signal was sampled on 200 samples/second or 500 samples/second 
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The graph shows the frequency response up to 50 Hz. According to the literature 
it is enough to set the sampling rate to twice the frequency of the variable studied 
(Zonst, 2000; Chu and George, 1999). According to the manufacturer's recommendation 
the sampling rate should be set at 3-4 times the frequency of interest. This means that a 
sampling rate of 200 Hz will be enough to capture the characteristics of the signal. From 
the literature it was found that the majority of studies that have examined the 
hemodynamics characteristics of the blood signal using PPG have employed a sampling 
rate of 500 Hz. 
Given this both sampling rates (200 samples/second-500 samples /second) were 
compared and no difference was noticed in the nature of the signal measured. Therefore 
it was decided that a sampling rate of 200 samples /second will be used in the laboratory 
and clinical trials. 
8.13 PPG PROBE ATTACHMENT 
The PPG electrodes supplied with Biopac MP 100 are provided with a 
Velcro strap for ease of attachment to the fingers or toes. In this study PPG 
transducer will be attached to the knee. There was a need to search for the best way 
to attach the electrodes to the skin. To achieve this different types of non-irritating 
adhesive tapes were used and they were examined in terms of ease of application 
and removal and their ability to keep the electrodes in close contact with the skin. 
None of the tapes used resulted in a clear trace of the signal (Figure 8.10 a). They 
were replaced with a velcro strap, which was found to give the closet reflection of 
the signal as the one recorded from the fingers (Figure 8.10 b). 
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The strap will be wrapped around the knee to secure the PPG in place during the 
experiment. 
It is acknowledged that the skin is not homogeneous and the measured value is greatly 
dependent on the location of the probe (Swain and Grant, 1989) as such all attempts 
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Figure (8.10 a) 't'he shape of the PFU signal when using an adhesive tape 
Figure (8.10 b) The shape of the PPG signal when using a velcro 
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were made to ensure the repeatability of the electrode placement and to ensure 
consistent pressure by the Velcro. 
8.14 CONCLUSION 
Part two of the pilot examined the nature and quality of the signal recorded 
by PPG, EMG, and SkT electrodes. Findings have revealed that the temperature 
probes heat up when irradiated with PSWT as such will be removed during the 
treatment and replaced post treatment. PPG electrodes were found to be sensitive to 
motion artefacts as such extra care need to be taken during data acquisition to 
instruct subjects not to move during the experiment and to ensure that leads are not 
touching. Pilot experimentation has also shown that PulsR derived from PPG when 
it was applied to the knee was not reliable and as such the PPG will be used to 
convey changes in BVo1 while a Tunturi with the electrode attached to the ear lobe 
to measure pulse. All these findings were crucial in planning the experimental 
protocol and ensuring better data quality. 
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PART 3: COMPARING THE NATURE OF INTERFERENCE 
BETWEEN TWO PSWT MACHINES 
8.15 INTRODUCTION 
Examining the effect of Megapulse on the recorded signal (Section 8.9), it 
was thought that the use of an alternative PSWT machine might be associated with 
lower levels of EMF, lesser EIB and a cleaner recorded signal. The Phyaction 
Performa (PP+) was the only PSWT machine that could mimic all the outputs of 
Megapulse hence it offered an attractive device that can be used instead. However, 
before employing PP+ in the study it was necessary to examine its effect on the 
recorded signal with the MP 100. 
Almost all commercial PSWT machines utilise a carrying frequency of 27.12 MHz, 
and work on the same basic physical manufacturing principles, it is not known 
however, if they can be used interchangeably. Different machines are built to 
employ different peak outputs, different combinations of PD and PRR (Table 8.5). 
Some authors have treated different makes of PSWT as one (Svarcova et al, 1988) 
while others have suggested that they are dissimilar (Forster and Palastanga, 1985). 
The work by Pasila et al (1987) comparing the effects of a Diapulse to a Curapuls 
has confirmed that PSWT machines are different. Table (8.5) shows different 
manufacturing characteristics of some PSWT machines. 
Model Pulse Pulse Peak Manufacturer 
width Frequency power 
sec) (Hz) (W) 
Curapuls 400 15-200 1000 Enraf-Nonius 
Ultratherm 400 20-180 400 Siemens 
Megapulse 20-400 50-800 150 Electro 
Senior Medical 
Supplies 
Phyaction 65-400 25-1125 200 Gymna 
Performa + Uniphy 
Therapulse 65-400 12.5-400 Chattanooga 
Group Ltd 
Table (8.5) Specifications of some of FSWI machines (although other makes of PSWT machines are 
available, the ones mentioned here are those reported by the surveyed sample in Chapter 6). 
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All of this necessitates, that the PP+ be compared to the Megapulse and the effect of 
both machines on the recorded signal be examined before deciding on which unit to 
be used for the study. 
8.16 AIMS 
" To examine whether Megapulse machine can be used interchangeably with 
PP+ and which machine will result in a better quality signal. 
Both the Megapulse senior and PP+, were compared in terms of 
" The effect of interaction between EMF and the MP 100 on the recorded signal 
" The shape of EIB as recorded by MP 100 
" The duration of the pulse as recorded from EIB 
" The duration of the inter-pulse period as recorded 
from EIB 
" The thermal component with the two machines 
measured from a phantom 
Figure (8.11) Phyaction Performa 
machine 
(Gymna Uniphy, Australia) 
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8.17 EQUIPMENT 
PP+ (Figure 8.11) is a PSWT machine that utilises 27.12MHz frequency, and 
a main voltage of 230V±15% at 50/60 Hz (the equipment could be used in both the 
thermal and athenmal modes of treatments). It can deliver the energy via the 14 cm 
thermoplode, which can be used with one or two channels. It has a PP of 200W(it 
could vary depending on whether one electrode or two electrodes are used). The 
PRR ranges between 25-1125 Hz if one channel is used or 25-800 Hz if the two 
channels are in use. 
The PD ranges between 65-400µs. In addition, the time allowed for treatment 
ranges between 0-60 minutes. The PP per arm is 90 W if one channel is used and 64 
W if the two channels are in use. Superior to other PSWT equipments it has an 
indication mode where the clinicians can choose from a wide range of pathologies 
and their preset treatment programmes. 
As mentioned earlier Megapulse (Figure 8.12) is a machine that can deliver both 
CSWD and PSWT. In the pulsed mode it can deliver short pulses, which are 
adjustable in duration (20-4001. ts) and PRR (50-800Hz) enabling the operator to vary 
the output. The peak output is fixed at 150 W, while the mean output is dependent 
on the treatment parameters selected. The pulses can be delivered either 
continuously (3: 3), two third of the time (2: 3) or one third of the time (1: 3). 
The characteristics of the two machines are displayed in Table (8.6). 
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Figure (8.12) Megapulse Senior 
(Electro-Medical Supplies, Greenham, 
Ltd; UK). 
Description Megapulse S PP+ 
PD (sec) 20-400 65-400 
Treatment time (minutes) 0-29 0-60 
PP (fir) 150 200 
PIER (Hz) 50-800 25-1125 (if one channel is used) 
25-800 (if two channels are used) 
Electrode Circu lode Thermo lode 
Mode Continuous /pulsed Continuous / pulsed 
Table (8.6) Companson between nnegapuise ana rr-t- 
The PP+ was utilised because it was the only PSWT machine that could mimic the 
settings of Megapulse hence providing a basis for comparison. In all the conditions 
examined both PSWT machines were set to 400µsec-800Hz, MP 48 W (the maximum 
setting for Megapulse) to provoke the worst case scenario. 
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8.18 THE EFFECT OF INTERACTION BETWEEN PSWT 
MACHINES AND MP100 
As was shown from the previous pilot experimentation that both PPG and EMG 
behave the same under the influence of EMF and neither electrodes heat up. It was 
decided to use PPG electrodes to examine the nature of interaction between MP100 and 
both PSWT machines. 
The above notion was examined in 2 conditions: 
Condition 1: The PPG electrodes were attached to the phantom using adhesive tape, the 
recording session was 30 minutes (10 minutes baseline, 10 minutes PSWT and 10 
minutes recovery post treatment), PP+ was set to 400µsec-800 Hz, MP 48 W. 
Condition 2: The PPG electrodes were attached to the phantom using adhesive tape, the 
recording session was 30 minutes (10 minutes baseline, 10 minutes PSWT and 10 
minutes recovery post treatment), Megapulse was set to 400µsec-800 Hz, MP 48 W. 
In both conditions the distance between the treatment applicator and the phantom was 
standardised using the template. The conditions were repeated 5 times and the outcome 
was the same. 
Both PSWT devices generated different signal shapes and both had affected MP 100 
differently. The EIB disappeared once the PSWT (whether it was PP+ or Megapulse) 
machine was turned off and the signal went back to baseline reading (Figure 8.13-8.15). 
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Figure (8.13) The shape of EIB with Megapulse and PP+. It could be seen that due to the massive size of 
EIB from PP+, it was not possible to fit the two signals to the same scale 
Figure (8.14) The shape of EIB with Phyaction performa + (amplified from Figure 8.13) 
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The Figures above demonstrate the difference in appearance in the EIB pulse 
between the two machines. The pulses with PP+ were more of trapezoid shape unlike 
Megapulse, which had rectangular pulses and were consistent in appearance. It could be 
seen from the Figures that the scale was different reflecting the large size of EIB with 
PP+ compared to Megapulse. In order to be able to see the shape of the pulse clearly 
with PP+ the signal was magnified to the order of seconds unlike with Megapulse where 
the pulses were obvious without the need for magnification. 
Although the underpinning reasons for such differences are not known it could be 
related to the differences in the composition of the circuits inside the PSWT unit. 
However, it is not known how would such differences affect the general therapeutic 
effects of each machine. 
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Figure (8.15) The shape of EIB with Megapulse (amplified from Figure 8.13) 
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8.19 CHARACTERISTICS OF EIB 
The above signal was used to analyse the duration of the pulse and the interpulse 
period as recorded from EIB. This was examined in 6 conditions using 3 treatment 
combinations. 
Conditions 1: using PP+, the dose was set on 200 Asec- 400 Hz-MP 12W 
Condition 2: using Megapulse the dose was set on 200 µsec- 400 Hz-MP 12W 
Condition 3: using PP+, the dose was set on 400 µ sec - 400 Hz - MP 24W 
Condition 4: using Megapulse the dose was set on 400 it sec - 400 Hz - MP 24W 
Condition 5: using PP+, the dose was set on 400 µsec, 800 Hz, MP 48W 
Condition 6: using Megapulse, the dose was set on 400 µsec, 800 Hz, MP 48W 
Each condition was repeated 10 times with both machines. The mean value for each 
setting was analysed separately. It was found regardless of the dose, the duration of the 
pulse was the same. Table (8.7) shows the mean and SD for PD and inter-pulse period, 
Megapulse PP + 
PD 9.77 ± 0.2µsec 22.50±2.7 µsec 
Duration of inter-pulse 16.21±0.2 µsec 21.25±2.3 sec 
Table (8.7) EIS for both the Megapulse and Yhyaction Yertorma +, values reported represent mean ± SD 
When comparing the two PSWT machines, there was a difference in the on/off ratio. The 
on: off period with Megapulse was 1: 1.8 while the on: off period with PP+ is 1: 1. Such 
differences although they may seem small, their cumulative effect on tissues may not be 
trivial. 
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8.20 THE THERMAL COMPONENT WITH THE MEGAPULSE 
AND PHYACTION PERFORMA 
The effect of EIB was also tested on the temperature probes. Section (8.11, 
8.12) examined the effect of PSWT on heat build up with the temperature probes, 
this section examines the effect of irradiation and post irradiation effects on 
temperature probes using both PP+ and Megapulse. 
Both PSWT machines were set to 400µsec and 800 Hz, MP 48 Hz for 10 minutes. 
The electrodes were attached to a phantom using adhesive tape. The recording was 
repeated 3 times and each time it gave similar results. The effect of EMF on the 
temperature probes with both machines is shown in Figure (8.16). 
Figure (8.16) The effect of turning on Phyaction performa + and Megapulse on temperature signal 
The shape of the pulses of the EIB can still be seen with the Megapulse however, 
with PP+ it was shown as a thick block. The graph also demonstrates that the 
amount of temperature increase with PP+ being higher than the Megapulse. 
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To further examine the effect of increase in temperature on the post treatment period, 
the same conditions as the above were repeated however, this time MP 100 was left to 
record the post irradiation period for 40 minutes in order to monitor the rate of decline 
in the temperature after turning PSWT machine off. Electrodes were left in place during 
irradiation. 
Table (8.8) displays the temperature increase with the two machines during and post 
PSWT irradiation. Temperature has increased by 1.69 °C with the Megapulse while the 
increase was 14.15 °C with PP+ after 10 minutes of irradiation. 
At 40 minutes post treatment, the temperature was still 6.38°C above baseline reading for 
PP+ while it declined to 0.38°C above baseline for the Megapulse. Figure (8.17) 
demonstrates the rate of temperature decay with the two machines. 
Megapulse 
Senior 
°C 
Difference in 
temperature °C 
Phyaction 
Performa + 
°C 
Difference in 
temperature °C 
Pre-administration (TO) 23.87 0 23.44 0 
End of treatment (TI) 25.56 1.69 37.59 14.15 
5 min post treatment (T2) 24.81 0.94 35.38 11.94 
10 min post treatment (T3) 24.64 0.77 33.87 10.43 
15 min post treatment (T4) 24.52 0.65 32.78 9.34 
20 min post treatment (T5) 24.43 0.56 31.90 8.46 
25 min post treatment (T6) 24.36 0.49 31.23 7.79 
30 min post treatment (T7) 24.30 0.43 30.64 7.2 
35 min post treatment (T8) 24.27 0.40 30.20 6.76 
40 min post treatment (T9) 24.25 0.38 29.82 6.38 
Mean ±SD 24.50±31.68 31.68±2.38 
Table (ä. S) 'l emperature aecay wan the iviegapuise senior ana rnyacuon rerrorma + over a perioa or '+v 
minutes. This example is typical of all the trials performed. Difference in temperature is the value of the 
temperature at point Tn - temperature at TO 
230 
Chapter 8 Pilot laboratory experiments 
40 
35 PP + 
30 
= 25 
LB 20 
E 15 
Megapulse 
10 
5 
0 
Pre cad min 5 rain 10 min15 min 20 min25 min3O min35 min4O 
Rx Rx 
Figure (8.17) The rate of temperature decay with two machines. (Horizontal scale resembles the time post 
irradiation shown in 5 minutes period, the graph shows a typical response. Rx: treatment) 
8.21 IMPLICATION OF THE FINDINGS 
The above comparisons were not meant to cover all aspect of differences between 
the two machines. It is however to examine whether Megapulse and PP+ could be used 
interchangeably during the experiment. 
PSWT machines are different though they utilise the same carrying frequency. Findings 
in this part have shown that both PP+ and Megapulse machines can be set on the same 
parameters however the stimulating pulse as measured from EIB and its characteristics 
are different. The differences observed could be related to the shape of the coil inside the 
applicator which could be helmhlotz, or cylindrical. The difference in outcome could 
also be related to the diameter of the encapsulated coil within the treatment head (Hand, 
1990). 
Theses results are in agreement with Foley-Nolan (1990) and Hayne (1984) who argued 
that although identical settings could be achieved with two PSWT machines of a 
different make, the resultant outcome might not be the same. As such, their therapeutic 
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effects may differ. Support to these findings were found in the study by Pasila et al 
(1978). Their work has compared the effects of Curapuls and Diapulse on ankle sprain, 
they reported that Curapuls had better effects on pain while Diapulse improved the 
walking ability for patients with recent ankle sprains, though the authors failed to 
mention whether both machines were set on the same parameters or not. They only 
reported that the MP was different which means that different levels of energy were 
delivered to both groups of patients hence the difference in outcome. 
Therapists need to be aware that each manufacturer uses their own system and methods 
of characterising their product, making comparison between different models difficult. 
The findings of this work highlight the importance of efficient documentation of 
treatment parameters. The audit work conducted by the author has revealed that 
therapists fail to assign units (µsec or Hz) to the numbers they use to describe their 
treatment with PSWT, making it hard to distinguish between PD or PRR. Moreover, only 
in isolated occasions the machine name was noted in the file. The problem is made worse 
if the department has more than one type of PSWT machine. This creates confusion in 
understanding the treatment and may result in discontinuity in whatever beneficial effect 
obtained by the treatment. As a result affecting the overall outcome of the treatment and 
therapist's satisfaction with this equipment. 
8.22 CONCLUSION 
The work conducted in this section was not intended to examine all the 
differences between PP+ and Megapulse machine, and although it needs to be validated 
with more equipment it has highlighted two main issues. Firstly: the evidence provided 
by some reports on the efficacy or lack of efficacy with some brands of PSWT machines 
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is not necessarily transferable to all PSWT makes. As such care should be taken when 
extrapolating research findings. 
Secondly: the current work highlights the importance of documenting PSWT 
specification when reporting outcome in published articles or describing a treatment in 
patient file. 
In the experimental work the author had the option of using either Megapulse or PP+. 
However, following the pilot work it was apparent that Megapulse was the best option 
and this was based on comparing the mode by which PSWT affected the acquisition 
system, shape of the pulse, duration of on/off ratio and some of the factors contributing 
to the thermal component with the two machines. 
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PART 4: DEVELOPING THE EXPERIMENTAL PROTOCOL 
8.23 INTRODUCTION 
The previous sections of the pilot work were devoted to the validation of the 
acquisition system, examination of the nature and the characteristic of the signal picked up 
by the electrodes and calibration of the various units employed for collecting the data. This 
section includes a description and examination of the validity and practicality of the 
protocol developed for both the laboratory and the clinical trials and as such, is considered 
a pilot study for both trials. The amendments made to the protocol are discussed at the end 
of the section, prior to its application in the main experimental phases. No reporting of 
findings will be included in this section as results are reported and analysed following the 
actual experimental studies. 
8.24 METHODOLOGY 
The study protocol was approved by the ethical committee of Radiography and 
Physiotherapy (Appendix D. 3). 
All experiments were conducted in the Physiotherapy Research Laboratory at the 
University of Hertfordshire by the same investigator. 
8.24.1 Subjects allocation to experimental groups 
Ten healthy subjects were recruited from University of Hertfordshire students and staff. 
The sample included 2 males and 8 females with an age range between 19-47 years 
(36.5±11.2 years-mean ±SD). 
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The study was a same subject single blinded trial, which means that all the 10 subjects 
were blinded to the nature of the treatment given to them. They had to attend for 3 times to 
take part in the 3 experimental conditions. 
On the first visit, each subject selected a sequence paper at random that determined the 
order of the 3 experimental sessions. Subjects were randomly assigned to one of three 
groups, two treatments (high or low dose PSWT) and one control (Figure 8.18). Condition 
1 had a 10 minutes treatment with PP 150W, PD 200µsec, PRR 800 Hz, which gave a 
mean power of 24 W. Condition 2 had 10 minutes treatment with PP 150W, PD 100µsec, 
PRR 200 Hz, and MP of 3W. All treatments were applied using Megapulse Senior (Section 
8.8.1). The dose used for the experiment is based on proposed treatment plans suggested 
by physiotherapists (Section 6.5.4). Condition 3 was the control condition where subjects 
had to lie on the plinth for 10 minutes and measurements were taken with no treatment 
applied. Treatment was delivered using a drum electrode applied to the front of the knee. 
Condition 1 Treatment (200 'sec, 800 Hz, 10 min, MP 
(high dose) 24W) 
1 group of 10 
subjects Condition 2 Treatment (100 µsec, 200 Hz, 10 min, MP 
(low dose) 3W) 
10 Condition 3 no treatment, 10 min 
(control) 
Figure (8.18) Schematic representation of the different experimental groups 
There were six possibilities for randomisation (Table 8.9) The sequence paper was 
returned to the container once the order of the sessions was written down by the researcher 
so that all subject had the same number of options each time they withdraw the order of 
their sessions. 
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Session 1 Session 2 Session 3 
1 2 3 
1 3 2 
2 1 3 
2 3 1 
3 1 2 
3 2 1 
Table (8.9) Table for randomisation 
1 (24 W), 2 (3W), 3 (control) 
8.24.2 Procedure 
Subjects were asked to attend for three appointments with at least 2 days in between the 
sessions to allow for the effect of previous treatment to recede hence washing out any 
latent effect of the PSWT treatment (Cleary, 1996). Subjects were asked to attend at the 
same time for the three sessions to minimise the effect of CorT variation on the outcome 
(Guyton and Hull, 2000; Houdas and Ring, 1982). Furthermore, all subjects were asked to 
refrain from smoking, drinking coffee and exercise at least one hour before the trial to 
minimise their effect on circulatory system as a result of the changes in metabolism (Drust 
et al, 2003). They were asked not to exercise because of the possibility that fluid may shift 
between tissues and eventually increase SFM reading (Jackson and Pollock, 1987). 
On the day of the trial, subjects were presented with an information sheet (Appendix D. 4) 
and were asked to read it, this was followed by a briefing on the procedure and time to 
enquire about any issues of concern. Contra indications were checked (Appendix D. 5), and 
a consent form (Appendix D. 6) was signed by all the subjects. Subjects were excluded 
from the study if their SFM was above 40 mm for two main reasons. Firstly: because of the 
possible effects that a thick layer of adipose fat may have on PSWT penetration (Hand, 
1990; Ward, 1980) and consequently the physiological effects gained from the treatment. 
Secondly: body fat calculation for subjects above 40 mm have been found to be unreliable 
(Kwok et al, 2001; Jackson and Pollock, 1987) and that reliability decreases with obesity 
(Scherf et al, 1986). 
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Subjects were asked to wear shorts for ease of measurements. Skinfold (Appendix 
D. 7), height, and weight were measured for all subjects. Height and weight were taken 
using an electronic kit (Marsden Weighing Machine Group Ltd, BMB-620, Tanita 
Corporation, Japan)(Figure 8.21). All information that could reveal the subject's identity 
was kept in a secure place where only the investigator could gain access. 
All the testing procedures were conducted in the physiotherapy research laboratory 
with a room temperature between 23°C and 26°C. The window in the laboratory was kept 
shut during the experiment to prevent significant fluctuation of the air temperature. In order 
to prevent unnecessary distraction, and to minimize the effect it may have on subjects' 
comfort, the laboratory door was kept closed throughout the experiment with a sign to limit 
access. Both the room humidity and temperature were monitored and recorded before and 
after each experimental session (Thermo Hygro-RS 212-124-China). 
Subjects were asked to lie supine on a plinth throughout the experiment. They were 
allowed 15 minutes before the start of the experiment to acclimatise to laboratory 
temperature and to allow the vital signs to stabilise. This period was also used to attach 
electrodes to the subject's knees after cleaning the skin with alcohol wipes and abrading it 
with fine sand paper. Subjects were instructed to remain still throughout the experiment as 
this may alter blood flow in the limb and disturb the recorded signal (Section 8.14). All 
measurements were taken from subjects' right knee to ensure consistency. The procedure 
for conducting the trial started with 10 minutes baseline measurements, followed by NCV 
measurement, and was followed by 10 minutes of PSWT treatment (as shown in Figure 
20). At the end of the treatment session, NCV was taken again and this was followed by 
another 10 minutes for post treatment measurements. The plan of the experiment is further 
explained in Figure (8.20). The experimental setting is shown in Figure (8.19,8.21). 
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Figure (8.19) Placement of the Megapulse treatment head during the trial 
Nerve conduction measurement Nerve conduction nwasurement 
(before treatrnent) (after treabnent) 
Pre-treatment phase During treatment phase Post treatment Phase 
(10 min) (10 min) (10 min) 
BVoI & SkT m urements 
BVoI & SkT measurement 
BVol during treatment 
2 Measurement of CorT Mean rent of PulsR icy t 
Figure (8.20) Schematic representation of the plan of the experiment. The plan is preceded by 15 minutes 
stabilisation time, which is not shown in the drawing 
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Height/ weight kit 
Mima 
Biopac MP 100 
Physiological 
aQr - recording 
equipment 
Figure (8.21) The 
8.25 DATA COLLECTION 
The data (BVol, SkT, and NCV) were collected using MP 100 (Biopac Systems, Santa 
Barbara, CA, USA). Sampling rate for this experiment was set to 200 samples/second 
based on the pilot work (Section 8.17). 
8.25.1 Recording of blood volume 
BVo1 was measured using TSD 100B PPG transducer. The unit is interfaced with a 
computer that has a processor unit. The processor converts the blood flow related 
photocurrent signal to direct current level, which is related to the volume of blood in the 
tissues under investigation. As such PPG provides real time continuous estimate of the 
BVol in the superficial microvasculature. The unit also has an infrared light source (860 
nm ± 90 nm), and a detector (a photo diode, positioned in reflection or transmission mode). 
The PPG probe was placed 2 cm medial to the tibial tubrosity along the knee joint line 
(Figure 8.24). The probe was secured in place using a Velcro strap. BVo1 was monitored 
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continuously the whole time of the experiment (pre, during and post treatment). There was 
no danger of heating of PPG electrodes as was demonstrated in Section (8.11). 
8.25.2 Recording of skin temperature 
AT was measured using SKT 100B amplifier module (sensitivity <83 µ°C) 
connected to TSD 102D rapid response thermistor. The temperature probe was attached 2 
cm lateral to the tibial tubrosity along the knee joint line (Figure 8.24). The probe was 
secured in place using a non-allergic tape. Real time continuous SkT was measured pre and 
post treatment for 10 minutes. During the treatment the temperature probe was removed 
because of the heating of the metal element within the probe (Section 8.11 and 8.12). 
8.25.3 Recording of NCV 
In this study, motor NCV of the deep branch of the common peroneal nerve was measured 
antidromically. First attempts were made to measure NCV in the femoral nerve. The 
femoral nerve was chosen as it supplies the quadriceps muscle, which lies under the direct 
effect of PSWT treatment head. The femoral nerve was rejected for two main reasons. 
Firstly: because the femoral nerve becomes superficial in the groin area (Oh, 1996). It was 
difficult to locate the exact site of the nerve at this sensitive area, which could jeopardise 
reliability of the test. Secondly: the recommended points for measuring the nerve lie 
outside the treatment area (the two points for stimulation and recording are in the groin 
area and 10 cm below that). All of this necessitated the search for another alternative, 
which was the common peroneal nerve. 
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8.25.3.1 Anatomy of common peroneal nerve 
The common peroneal nerve (Figure 8.22) emerges from lumbar 4,5 sacral 1, then travels 
in through the lumbosacral plexus into the sciatic nerve alongside the tibial nerve. In the 
thigh it innervates the short head of the biceps femoris muscle. Above the popliteal fossa it 
gives off the lateral cutaneous nerve of the calf, which innervates the lateral upper leg, the 
nerve then travels laterally around the neck of the fibula. It then divides into superficial and 
deep branches. The superficial branch supplies the ankle evertors (peroneus longus and 
brevis), sensation of the lower lateral aspect of the leg and ankle. The deep branch supplies 
the dorsiflexers (tibialis anterior, extensor digitorum longus and brevis, extensor hallucis 
longus and peroneus tertius) of the foot and toes, sensation between the first and the second 
toe (Mendell et al, 2001). 
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Figure (8.22) The course of the common peroneal nerve (from Mendell et al, 2001) 
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8.253.2 Instrument 
The unit used to record NCV interfaced with MP 100 and consisted of a stimulator (STM 
1000- Figure 8.23) module and EMG 100B unit. The stimulator allowed for 20V 
maximum peak to peak output. 
Both the stimulator and the EMG module were set according to the manufacturer's 
recommendation. The stimulus consisted of square pulse of 0.2 ms duration. The sampling 
rate was set to 10000 samples /second. The stimulus was increased gradually until a visible 
contraction was detected and a clear response was recorded by the MP 100 (Section 8.31.2). 
The stimulating and recording electrodes consisted of Ag-AgCI pre-gelled paired (dual) 
electrodes (41 mm x 82 mm x 1.5 thick foam), which were 41 mm apart centre to centre. 
The ground electrode was a 35 mm diameter general purpose pre-gelled electrode Ag- 
AgC1. 
STM IOOC 
UlM 1000 
STIMSOC 
Dual recording 
electrode 
Ground electrode 
Dual stimulating 
clccUodc low 
Figure (8.23) Biopac stimulation and recording unit 
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Both legs were prepared by wiping them with alcohol to remove skin oils or sweat. The 
skin was then abraded with fine sand paper to remove scaly skin, reduce skin resistance to 
the applied current and to enhance skin conductivity (Oh, 1996; Dong and Liveson, 1983). 
Electrodes were placed following the methodology adopted by Campagnolo et al (2000) 
and Devi et al (cited in Oh, 1996). A stimulating electrode was used to identify the course 
of the nerve and to determine the best sites for recording and for stimulation. The 
stimulation electrodes were placed inside the lateral border of the popliteal fossa, in line 
with the patella. The recording electrode was placed on the motor point of tibialis anterior 
muscle at the junction of the upper 1/3 and lower 2/3. The ground electrode was placed 
between the stimulating and recording electrodes (on the lateral tibial condyle) (Figure 
8.24). All recordings were done antidromically where the nerve fibres were stimulated 
proximally and the response was recorded distally (Oh, 1996). 
Temperature probe PPG transducer 
Ar'-ý 
0 
TT! 
T 
Stimulating electrodes 
Ground electrode 
äor 14 
Recording electrodes 
Figure (8.24) Electrodes placement 
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Because the electrodes were to be removed during treatment and replaced after PSWT 
administration, the electrodes sites were marked for reproducibility. Nerve conduction was 
measured at minute 10 after the baseline measurement and at minute 20 immediately after 
the treatment (Figure 8.20). 
8.25.4 Recording of pulse rate and core temperature 
The pulse rate was recorded from the right ear lobe using a Tunturi unit (TPM-400, Japan) 
(Figure 8.25) every 2 minutes. The mean of the PulsR readings for each phase (pre-during 
treatment and post treatment) was used for analysis. 
The CorT was recoded using Tympanic Thermometer (Figure 8.26) (Ivac Medical 
Systems, Model 2090, San Diego, California). The CorT was measured from the left ear 
twice during the recording period, that is every 5 minutes, as the CorT is not expected to 
vary significantly (Guyton and Hall, 2000) in a 10 minute period, which is time for each 
experimental phase. The mean for the 2 readings was calculated and used for analysis. 
PulsR and CorT were recorded using a special grid (Appendix D. 9). 
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Figure (8.25) Tunturi unit 
T 
'l 
i 
Figure (8.26) Tympanic Thermometer 
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8.25.5 Measurement of body fat 
The calliper used in the study was the Lafayette model 01127 (Bissell Healthcare 
Company, UK). It was employed for the trial as it was designed with the assistance of Dr. 
Andrew S. Jackson, co-author of the Jackson-Pollock skinfold equations employed for the 
current study. 
Subjects stood in a relaxed posture while measurements from the right side were taken. 
The three sites for skinfold were marked according to guidelines from Jackson and Pollock 
(1987) and anthropometric standardization reference manual (Lehmann et al, 1988). 
Measurements were taken from triceps, abdominal and iliac area for women and from 
triceps, subscapular, and chest for men (Appendix D. 7). The measurements were taken by 
the same researcher 3 times and the mean was used for analysis. The researcher reliability 
using Lafayette was calculated with Pearson Correlation Coefficient r and was found to be 
between 0.957-0.991, p =0.01. Full description of the findings could be found in Appendix 
(D. 8). 
8.25.6 PSWT unit 
All treatments were administered using Megapulse Senior treatment unit, which was fully 
serviced and calibrated by the manufacturer prior to the start of the trial. The parameters 
for PSWT were selected based on therapist's answers to the theoretical case studies in 
section 2 of the questionnaire (Section 6.5.4). 
Although the Megapulse unit allows the adjustment of the pulses for one third, two 
third or all the time it was seen appropriate to choose 3: 3 mode as not all the PSWT 
machines will have the advantage of controlling the pulse delivery mode. By doing 
this, it is expected that the MP chosen will be representative of the majority of the 
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PSWT equipment available in the clinical environment. Moreover, choosing 1: 3 or 2: 3 
means that the power will be delivered to the subjects either 1/3 or 2/3 of the time. 
In order to prevent subjects from observing the setting and predicting their 
experimental group, the Megapulse console was fitted with a cover that measured 21 
cm high. The indictor light on the treatment head was also covered as this could give 
subjects some indication as of whether the treatment was on or off Figure (8.27). This 
was done in order to minimise its effects on subject's biofeedback (Low and Reed, 
2000). 
A drum electrode was used to deliver the treatment and was applied to the anterior of the 
knee. To standardise the distance between the treatment head and knee, the template (23 
cm long, 20 cm wide, 15 mm thick) was used. All treatments were delivered using drum 
electrode placed at the front of the knee. 
The indicator 
light was 
covered 
The 
shortwave 
console was 
covered with 
a board to 
prevent 
subjects from 
guessing the 
delivered 
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The equipment was warmed up before the actual use on subjects to allow it to come to 
room temperature (Docker et al, 1994). Inspection of the mains lead and casing for 
faults was completed before each application. 
Room temperature and humidity were recorded each session before and after data 
collection. 
8.26 MAIN OBSERVATIONS AND AMENDMENTS MADE TO 
THE PILOT PROTOCOL 
This section will not report the findings of the study, as it was only a pilot to examine 
the feasibility of the experimental protocol. Emphasis however will be made on the 
alternations made to the improve the quality of the methodology used for data 
collection. 
8.26.1 Stabilisation of temperature probes 
The effect of removing the probes during the treatment and re-attaching them post 
treatment resulted in the effects seen in Figure (8.28). It could be seen from the graph 
that the temperature electrodes take some time to stabilize, although the manufacturer 
has stated in the manual that they were quick response electrodes. The duration of this 
acclimatisation could vary from one subject to the other, however, with most subjects it 
lasted for the whole period of recording which was 10 minutes. 
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Figure (8.28) Time needed for temperature probes to stabilise 
This was found to occur because during the irradiation periods the electrodes were left 
exposed to the environment temperature. To overcome the above problem the 
temperature probes were attached to subjects' ankle when removed from the knee, in 
this way they will maintain the subject temperature and reduce the time needed to 
recover when re-attached. Additionally, the placement of the electrodes at the ankle 
provided sufficient distance from the treatment applicator in terms of the probe heating 
and subject safety. 
8.26.2 Stabilisation of nerve conduction electrodes 
Having identified the time it took temperature probes to acclimatise to skin 
temperature, there was a need to examine the time it took nerve conduction electrodes 
to stabilise after being re-attached. The same protocol was adopted for attaching 
electrodes and applying the treatment, the electrodes were then removed for treatment 
and re-attached for post treatment recording. The NCV reading was repeated 5 times 
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during the first 5 minutes with the readings being taken every minute post irradiation. 
No difference in nerve conduction velocity was noticed, and following discussion it 
was decided that it was not a reliability/ stability issue. 
One disadvantage with using the Stim 1000 was that the dial for increasing the 
strength of the stimulus was not marked. Although the author developed a marking system 
that was attached to the dial, it was hard to maintain the exact strength of the stimulus each 
time. The strength of the stimulus given to subjects was dependent on the subject's 
reporting of its strength and as such it varied from session to session and from subject to 
subject. Therefore, it was decided to avoid reporting all the variables that relates to 
amplitude such as negative and positive peak amplitude and only to report the onset 
latency, and response duration. Amplitude refers to the number and the synchrony of the 
fibres being tested (Dong and Liveson, 1983). It is not a reliable (Oh, 1996; Delisa, 1994; 
Dong and Liveson, 1983) characteristic of the nerve and could vary up to 43% (Raynor et 
al, 1997) and sometimes up to 70% if the electrode were misplaced (Bromberg and 
Spiegelberg, 1998). Figure (8.29) shows the characteristics of the motor nerve signal when 
measured with Biopac MP 100. 
Stimulus artefact 
7 
Negative peal` latency 
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Figure (8.29) Component of the motor nerve signal measured by MP 1 00 
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8.26.3 Time to re-attach the nerve conduction electrodes 
The procedure adopted for the study necessitated that the temperature and nerve 
electrodes be removed before irradiation with PSWT. The reason for removing the 
temperature electrodes was explained in Section (8.11-8.12). Nerve electrodes were 
removed because they have a metal component, which is considered a contra-indication 
for applying PSWT. 
This procedure however resulted in loss of the data in the first 3-4 minutes after PSWT 
treatment because this was the time needed to reattach the electrodes to the skin. This 
time was seen very long in comparison to the period used for recording and could cause 
the loss of valuable information about the patient's response. 
In an attempt to reduce the total time lost, it was decided to leave the electrodes on the non- 
treated side as they did not constitute a real threat to safety, not being in the immediate 
field of irradiation. By leaving the electrodes in place there is a need to acknowledge that 
skin underneath the electrodes in the non-treated area may not undergo the same reaction to 
removing and reattaching adhesive electrodes as the other leg and this may have its 
implication on the findings. However, this is a confounding variable that needed to be 
accepted at this level. 
As for the treatment area, both of the temperature probes, the stimulating and the recording 
electrodes were removed and re-attached immediately following PSWT application. With 
practice the researcher was able to re-attach the electrodes in under a minute. 
To ensure reproducibility when reattaching the electrodes the orientation of the electrodes 
need to be exactly the same each time. The leg was marked using reproducible technique to 
ensure consistency in electrode placement during and in between sessions hence improving 
investigator reliability. To achieve that the placement of the electrodes was measured in 
relation to the lateral malleolus and the base of patella (Figure 8.30). 
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Distance between mid 
electrode 
Recording electrode 
once between mid dccfto e and 
of patella 
x between mid electrode and lateral 
Figure (8.30) Measurements taken to ensure orientation of the electrode 
With the control group the nerve electrodes were left in place the whole time of the 
experiment. 
8.26.4 Eliminating the EIB contamination from the recorded signal 
It has been shown in the pilot Section (8.9) that the recorded BVol signal was 
contaminated with EIB, and this contamination was picked up even from a distance of 
4 m, which is the maximum distance available in the research laboratory. Although it 
was hard to eliminate the effect of EIB on the physiological signal, it was possible to 
quantify its effects and judge the extent of its interference with the nature of the 
recorded signal. The effect of the two modes of treatments that will be used in the 
succeeding experiments on the shape of the signal is shown in Figure (8.31). 
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The shape of the signal with The shape of the signal with 
I00ps, 200Hz 200µs, 800Hz 
1.561 
1.408 
The measured 
signal at baseline 
0.520 Vom 
0.000 
Figure (8.31) The effect of PSWT on the shape of the blood volume signal, it could be seen that the inter-pulse 
period remained at baseline reading regardless of the superimposing EIB 
The work that had been conducted to date either examined the pre/post effect of 
PSWT (Garret et al, 2000; Oosterveld et al, 1992) or has interrupted the treatment time 
for measurements of the variables (Draper et al, 1999). The attempts to include the 
"during treatment" period in the analysis is a unique feature of this study and may help 
explain further part of the mechanism of PSWT action. 
Due to the scarcity of the work in this field there was a need to identify a novel 
method to overcome the effect of EIB interference with the data collected. 
The first attempt was to filter the interference from the physiological signal. Different 
filters with different settings were tried, however these attempts were not successful as 
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the input signal was also filtered out at the time of the on pulse period. Personal 
communication with Biopac manufacturer did not contribute much to the solution. 
There was another way of taking out or cutting the on pulses period (Figure 8.32) from 
the acquisition and compensating for this period by multiplying with a factor that will 
replace the lost treatment time. Although the reading obtained will not be the actual 
reading, it would provide the closest representation to the response observed without 
interference. This method was rejected as this had left uneven recording times and 
because comparisons between different conditions will be done using the area under 
the curve, it was shown that adopting this method for analysis might result in 
misleading findings, as the area in between different conditions would vary. 
It was decided later to use a function in the software called "connect ends" (was also 
recommend by manufacturer in UK following personal communication). This function has 
left the recorded time unchanged, which made comparing the area under the curve for both 
modes of therapy plausible. In this function the last point in the recorded signal was joined 
by a line with the first point in the following signal superimposing the PPG signal. The 
mean value for this period was always found to be zero. Given that there was 11 periods of 
EIB with the high dose, 7 periods of EIB with the low dose, and 6 EID pulses with the 
placebo dose, this meant that there was 3.84 minutes lost when high dose was applied, 1.13 
minutes when low dose was applied, and 0.83 minutes when placebo PSWT was applied. 
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Figure (8.32) The graph shows the shape of the original signal (line I-red), the shape of the signal after using 
the connect end function (line 2-blue), the shape of the signal after cutting the pulses (line 3-green) 
8.26.5 Sample size 
One of the essential features in conducting good trials is planning the sample size at 
the design stage. Power analysis and sample calculation minimises the number of patients 
required to answer the research question. Conducting too small a study wastes resources on 
a trial that may end up with inconclusive findings. Conducting too large studies on the 
other hand, could deny potential treatment benefits from patients randomized to placebo or 
a previous standard treatment (Bailey et al, 1994). 
The number of the sample is usually based on several factors such as minimum expected 
difference between the different groups (also known as effect size or treatment size), 
estimated measurement variability, statistical power, significance criterion and whether a 
one tail or a two tail hypothesis will be used. Although the golden rule is that the larger the 
sample size the less chance there will be in reporting type I or type II errors. (Eng, 2003; 
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Karlsson et al, 2003), ethical considerations prevent basing decisions on just this 
assumption. Type I (or (x) is a false positive that occurs when the findings are accepted and 
the treatment is considered effective when actually it is not. Type II error (or ß) is a false 
negative, rejecting the findings when there is a real difference between the experimental 
groups (Eng, 2003). 
One of the aims of conducting this pilot study was to use the results to calculate the sample 
size required for the main laboratory study. Unfortunately, this could not be done as some 
changes were made to the methodology, which could have an effect on these calculations. 
The next attempt was to collate findings from previous studies that examined MP 3W and 
24W. By knowing the mean and SD and using specialised equations the number needed for 
the current study can be determined (as discussed with the department statistician). 
Regrettably, these efforts were unproductive, as the published studies did not report enough 
statistical information, and none has considered sample size calculation. Moreover, only 
one study was done using 3.25 W but because it was an abstract from a conference and 
insufficient data could be obtained from it (personal communication with the institute that 
conducted this study revealed that it was an undergraduate student project). 
Table (8.10) summarises the studies from the literature in terms of quality and the 
amount of information reported. 
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Study Author Topic Sample Mean power Mean and Treatment 
& Year size of PSWT SD of outcome 
variance 
Erdman, 1960 Blood flow 20 16 No Indirect irradiation 
T peripheral blood 
flow 
Abramson et al, Motor nerve conduction 42 No Mean but not SD T Conduction speed 
1966 
Morrissey, 1966 Blood now 26 40 Yes Blood flow T after 
direct muscle 
irradiation 
Wessman & Kottke, Blood flow, temperature, 10 No No T Blood flow 
1967 pulse 
Currier and Nelson, Motor nerve conduction 10 No Yes T Conduction speed 
1968 
Oosterveld et al, Core & intra-articular 42 180 W Yes PSWT T both skin 
1992 temperature & intra-articular 
temp 
Draper et al, 1999 Muscle temperature 20 48 Yes Tintra-muscular 
temperature 
Garrett et al, 2000 Muscle temperature 16 48 Yes PSWT heats large 
areas better than US 
f Burden and Blood flow 19 3.25 No T blood flow 
Mitchell, 2000 
Table (8.10) The quality of the studies conducted on PSWT 
f Abstract from conference proceedings 
Therefore, it was decided to use retrospective power analysis (Eng, 2003; Karlsson et al, 
2003) where the data from the laboratory study are used to calculate the number of subjects 
needed. 
8.27 CONCLUSION 
This chapter has presented the laboratory work that identified the confounding 
factors, which may interfere adversely with the course of the succeeding experiments. 
The work has shown that although the temperature probes were fast response they took 
up to 10 minutes to acclimatise to subject's body temperature after being removed 
during PSWT application, and this was observed with the majority of subjects. To 
overcome that and to allow temperature probes to maintain body temperature it was 
decided not to leave them exposed to environmental temperature during PSWT 
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irradiation but instead to attach them to the subject's ankle. Stabilisation of the 
electrodes was not a reliability issue with NCV electrodes. 
Another important issue that has emerged from the pilot experiment was that it takes 
around 3-4 minutes to re-attach NCV electrodes to the subject's knee after being 
removed for PSWT application. To reduce this time the electrodes will be left attached 
on the non-treated side and only be removed from the treated side. This has reduced the 
lost time to less than a minute. 
Furthermore, the findings have shown that it was difficult to eliminate the effect of EIB 
on the recorded signal, however, it was possible to quantify its effects by adopting a 
function in the software that still allowed for comparison of the area under the curve in 
all the experimental conditions. Although the use of this function led to the loss of 
around 3 minutes from the recording in the high dose it was the closest representations 
to the changes that could be seen during PSWT application. However, given that very 
limited number of studies examined the effects of PSWT during irradiation, the current 
work remains to be of great importance even with this confounding variables. 
The fact that with all the studies conducted on the physiological effects of PSWT, it was 
not possible to use them to calculate a sample size highlights the importance of improving 
the quality of the trials conducted and increasing the amount of information reported for the 
reports to be of value. 
The next phase of this research will examine the physiological effects of PSWT on healthy 
subjects using the improved protocol developed in the current pilot work. 
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CHAPTER 9 
THE PHYSIOLOGICAL EFFECTS OF PSWT 
ON HEALTHY SUBJECTS 
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9.0 INTRODUCTION 
Recent surveys in UK have shown that PSWT is one of the most commonly 
used electrotherapy modalities among physiotherapists (Shields, 2003, Kitchen and 
Partridge, 1996; Pope et al, 1995). The literature review (Chapter 4) has demonstrated 
that the evidence supporting PSWT use in different pathological conditions is lacking, 
nevertheless PSWT has been accepted clinically to be useful in conditions such as soft 
tissue injuries (traumatic, operative), arthropathies (RA, OA), nerve regeneration and 
pain reduction. 
It is thought that PSWT works by increasing blood flow, decreasing joint pain 
and stiffness, reducing inflammation, accelerating wound healing and aiding the faster 
resolution of oedema (Kloth and Ziskin, 1996). These effects have only been examined 
in a limited number of studies most of which are of low methodological quality. The 
PSWT mechanism of action has stirred long debates with some arguing that temperature 
change is the main factor responsible for all the reactions observed, and that PSWT 
achieves its physiological actions through heating the tissues and increasing the blood 
supply to the heated area (Lehmann and DeLateur, 1990; Ward, 1980). On the other 
hand, there were those who expounded the non-thermal effects of PSWT through 
restoration of cells' membrane potentials, an interaction that is believed to occur at both 
molecular and ionic levels (Cleary, 1996; Adey, 1988; Hayne, 1984). 
With the mechanism of action being an area of dispute, many trials have focused 
on PSWT effectiveness and its possible physiological effects. The downfall with the 
majority of these trials was that they focused on the maximum output of PSWT 
machines and neglected other ranges. Maximum output is associated with a definite 
increase in SkT (Garrett et al, 2000, Murray and Kitchen, 2000; Bricknell and Watson, 
1995), and an output that is rarely used in clinics (based on researcher's own 
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investigations (Chapter 5) and communication with therapists). Moreover, 
physiotherapists prefer to use the minimum level of energy possible to achieve the 
desired physiological responses, as it is associated with minimal side effects (Low and 
Reed, 2000). Given the above, it is unlikely that therapists will be employing the 
maximum setting of PSWT in the clinics. Though these studies are informative, they are 
of limited value to physiotherapists in informing their clinical decisions. The limited 
trials on the non-thermal mode warrant further research. 
With the current status of the literature, PSWT effects on BVo1 and SkT remain 
inconclusive, and the area of PSWT effects on peripheral nerves remains under 
researched, all of this necessitates the conduction of further investigations. 
Given this, the current study was set to examine the effects of low dose and high 
dose PSWT on BVo1, SkT and nerve conduction in treated and non-treated limbs. One 
of the objectives of this trial was to investigate both the thermal and the non-thermal 
effects produced by PSWT via a single blinded trial on healthy subjects. Using a high 
dose (MP 24W) and a low dose (MP 3W), the physiological effects were compared to a 
placebo dose (0.05W) and a control group. 
9.1 STUDY HYPOTHESIS 
Hol: Irradiating the knee for 10 minutes with MP of 24 W will not result in a change in 
BVol, SkT and NCV in the treated side. 
Hoe: Irradiating the knee for 10 minutes with MP of 3W will not result in a change in 
BVol, SkT and NCV in the treated area. 
Ho3: Irradiating the knee for 10 minutes with MP of 24 W will not result in a change in 
BVol, SkT and NCV in the non-treated area. 
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Ho4: Irradiating the knee for 10 minutes with MP of 3W will not result in a change in 
BVo1, SkT and NCV in the non-treated area. 
Hoy: Irradiating the knee for 10 minutes with MP of 24 W will not result in a change in 
CorT and PulsR. 
Hob: Irradiating the knee for 10 minutes with MP 3W will not result in a change in 
CorT and PulsR. 
9.2 METHODOLOGY 
9.2.1 Sample recruitment and allocation to experimental groups 
The study design was approved by the ethical committee of Radiography and 
Physiotherapy in University of Hertfordshire (Appendix E. 1). Thirty one healthy 
subjects were employed in a within subjects design as such each subject acted as its 
own control. The sample had 7 males and 24 females recruited from University of 
Hertfordshire students and staff. 
Subjects were assigned randomly to experimental groups. The randomisation was 
accomplished using Table (9.1) and following the same procedure in the pilot for 
collecting the data (Section 8.25). 
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Session 1 Session 2 Session 3 Session 4 
1 2 3 4 
2 4 3 
1 3 2 4 
1 3 4 2 
1 4 2 3 
1 4 3 2 
2 3 4 
2 4 3 
2 3 4 
2 3 1 4 
2 4 1 3 
2 4 3 
3 1 2 4 
3 1 4 2 
3 2 1 4 
3 2 4 
3 4 1 2 
3 4 2 
4 1 2 3 
4 1 3 2 
4 2 1 3 
4 2 3 
4 3 1 2 
4 3 2 
Table (9.1) Sequences for randomisation, 1 (24 W), 2 (3W), 3 (placebo), 4 (control) 
All 31 subjects attended for 3 sessions, which represented high, low and 
placebo. Those who were able to attend for a fourth session (n=14) took part in the 
control group. The high dose was administered using PP 150 W, MP 24W, PD 200µsec, 
PRR 800 Hz, for 10min. The low dose was applied on PP 150 W, MP 3W, PD 100µsec, 
PRR 200 Hz for 10min. The placebo PSWT was accomplished with PP 150 W, PD 
20µsec, PRR 50 Hz for 10 minutes. These parameters resembled the lowest output for 
the Megapulse and resulted in a MP of 0.05W. The subjects in the control group were 
required to lie on the plinth for 10 minutes where measurements are taken and no 
treatment was administered. Further clarification of group distribution is explained in 
Figure (9.1). 
263 
Chapter 9 The physiological effects of PSWT on healthy subjects 
Condition I 
10 n=31 High PSWT (200 µsec, 800Hz,, MP 24 W, 10 
min) 
31 healthy 
Subjects Condition 2 Low PSWT (100 µsec, 200Hz, MP 3W, 10 min) 
n=31 
Condition 3 
n=31 
No 
F 
lacebo PSWT (20µsec, 50Hz, MP 0.05W, 10 
in) 
10 Condition 41 Control (no treatment, 10 min) 
n=14 
Figure (9.1) Schematic representation of the different experimental groups 
Measurements to BVo1, SkT and NCV, PulsR, and CorT were taken in three 
periods; a baseline (measurement taken before turning PSWT on for a period of 10 
minutes), treatment (during the administration of PSWT for a period of 10 minutes), 
and recovery (post treatment for 10 minutes). At the beginning of each session subjects 
were asked about the nature of their activities in the last 2 hours prior to attending to the 
experiment (Appendix E. 2) to note any activities that may affect the data collected. At 
the end of each session subjects were asked few questions about their thermal sensation 
with the treatment, and how well they could guess their treatment (Appendix E. 3). 
Room humidity and temperature were monitored and measured before and after data 
collection. The protocol of treatment and the data was collected following the 
methodology outlined in the pilot study (Section 8.24) 
9.2.2 Data analysis 
All data were analysed using repeated measure analysis of variance (ANOVA), a 
test designed to compare group results for differences (Hicks, 1999). With every 
variable and before applying the ANOVA, normality and homogeneity of variance were 
examined. It was crucial that these two assumptions are met before considering using 
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ANOVA as any violation to these assumption will result in erroneous significant level 
and a false F value (Field, 2002). 
Normality was examined using Kolmogorov-Smimov and Shapiro-Wilk tests. These 
tests compare the data to a normally distributed set of scores. Non-significant results 
means that the data are not significantly different from the pre programmed set of data 
hence it can be accepted to be normally distributed. Whilst some argue that this 
assumption need to be met before ANOVA is used (Field, 2002), others (Bland, 1995; 
Winer et al, 1991) debate that parametric tests such as ANOVA can still be used and 
demonstrate robustness even if the data have been occasionally not following the 
normal distribution. 
The homogeneity of the variance was examined using Manuchley's Test for 
Sphericity. This analysis basically tests that the variance between all variables are 
roughly the same (Winer et al, 1991). If this value is significant then the assumption is 
violated. SPSS provides corrected values for sphericity with adjustment made to the 
degrees of freedom. For the purpose of this analysis and the clinical trial in Chapter 10 
the corrected values in Greenhouse-Geisser will be reported whenever F value needed 
correction. 
Significant F value indicates that at least two conditions are likely to represent a real 
relationship and that the dependant variable varies with the levels of the factor. 
However, it does not determine which means are different from which other means 
unless the factor examined had two levels. 
Within subjects contrasts were performed to examine the existence of differences in the 
levels of the variable. A post hoc comparison (Bonferroni) was conducted to compare 
all possible pairs of conditions. It was done on all statistically significant findings to 
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determine which experimental group was significantly different from the rest of the 
groups and under what conditions (Fields, 2002). 
Correlation between BVol, SkT, NCV, PulsR, CorT and the anthropometric data 
(age, height, weight, and % of body fat) was achieved using Pearson-Product Moment 
Correlation Coefficient in order to examine whether there was a relationship between 
any of the anthropometric variables and the results (Hicks, 1999). Environmental 
conditions were analysed using one way ANOVA. 
The factors used with ANOVA analysis were condition, which had 4 levels (high dose, 
low dose, placebo PSWT and control), phase, which had 3 levels (baseline, treatment, 
and recovery or post treatment period), and side, which had two levels (treated and non- 
treated). With each variable, a different level of each factor was analysed depending on 
the period when the data were collected. 
9.2.3 Sample size calculation 
Determining the sample size prior to conducting any experimental trial is crucial 
as it determines the power by which a test is able to detect a statistical difference 
between the experimental groups when a real difference exists (Eng, 2003). As such 
conducting a pilot study is crucial to determine the size of the anticipated difference 
between the groups (Bailey et al, 1994). 
One of the aims of conducting the pilot study in part four (Section 8.24) was to 
decide on the size of the difference between the experimental groups. However, the 
changes made to improve the methodology prevented that. Therefore, it was decided to 
use a retrospective sample size calculation. In this type of calculation the sample is 
calculated based on the results obtained after a certain amount of data has been 
collected. Very little is mentioned in the literature on the optimal amount of data that 
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need to be gathered before this sort of analysis is conducted, and it seems that it is the 
researcher's responsibility to decide on what best suits their objectives. 
In the current study after collecting 17 full sets of data, the information was used to 
calculate the number of subjects needed using a specialised software 
(www. calculators. stat. ulca. edu/powercalc)*. Based on SD, effect size, significance 
level a< 0.05 and a power of 0.8, the number of subjects needed was determined (Table 
9.2). Twenty six subjects were needed in the BVo1 group, 31 subjects were needed in 
SkT group and 37 subjects were needed in NCV group. The literature usually provides 
information on how to calculate sample size when one variable is studied, however, 
when more than one variable is examined like in the current study the information was 
scarce. It was agreed to include 31 subjects given the difficulty encountered in 
recruiting the subjects, time limitation and financial constraints. 
Variable a Power of the test Number needed 
Blood volume 0.05 0.8 26 
Skin temperature 0.05 0.8 31 
NCV 0.05 0.8 37 
Table (9.2) Findings of sample calculation (based on n=17 subjects) 
9.2.4 Body fat equations 
The choice of equations for calculating body density (BD) was based on the 
ability of the equation to accommodate large variation in age and percentage of body 
fat, without inflating the estimation error. Two different equations were employed for 
men and women because of the inherent difference in fat distribution in both genders; 
with men having more fat in the chest and women having most fat at the abdomen and 
waist (Jackson and Pollock, 1987; Jackson and Pollock, 1985). Moreover, using two 
Software was developed by Barry W Brown, Department of Biomathematics, USA, Houston, based on a book by Thompson 
S (1992) Sampling, New York, Wely. (Chapter 4) 
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equations accounts for the variation in age and percentage of body fat that may be 
encountered in the laboratory and clinical trials. 
The equations used to calculate BD (Jackson and Pollock, 1987; Jackson and Pollock 
1985; Jackson et al, 1980) were: 
Equation (9.1) for men BD=1.109380- 0.0008267 (X2) + 0.0000016 (X2)2 - 0.0002574 
(X3) 
(X2 sum of triceps, chest and subscapular skinfold, X3 age in years) 
Equation (9.2) for women BD= 1.0994921-0.0009929 (X3) + 0.0000023 (X3)2- 
0.0001392 (X4) 
(X3=sum of triceps, abdominal and suprailium skinfold, X4 is the age in years) 
The percentage of body fat was calculated using the widely used Siri equation (1961) 
Equation (9.3) %F= [(4.95/ BD) - 4.5] / 100 
9.3 RESULTS 
Thirty one subjects were recruited for the study. Subjects ranged in age between 19-48 
years. Summary of the demographic data is presented in Table (9.3). More analysis can 
be found in Appendix (E. 4). Raw data is presented on a floppy disk at the back of the 
thesis. 
N= Age 
(years) 
Sex Height 
(cm) 
Weight 
(kg) 
Fat% Dominant side 
Male Female Right Left 
31 26±7.22 7 25 167.8±8.98 70.15±12.35 23.67±7.08 27 5 
Table (9.3) Demographic data of the subjects 
Subjects' randomisation is presented in Table (9.4). 
Sessi on 1 Sessi on 2 Sessi on 3 Sessi on 4 
Treatment Frequency Treatment Frequency Treatment Frequency Treatment Frequency 
24 W 7 24 W 11 24 W 12 24 W 9 
3W 11 3W 10 3W 5 3W 7 
Placebo 9 Placebo 7 Placebo 9 Placebo 13 
Control 4 Control 3 Control 5 Control 2 
n =31 n =31 n =31 n =31 
Table (9.4) The sequence of treatments 
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9.3.1 Blood volume results 
A 4*3*2 (condition, time, side) repeated measure ANOVA was used to examine the 
main effects and interaction between factors. The experimental conditions had 4 levels 
(control, placebo, high dose and low dose), time had 3 levels (before, during, and after 
treatment) and side had 2 levels (treated and non-treated). 
Running the ANOVA, it was found that the value for condition was significant for 
sphericity (p = 0.002), the interaction between condition/ phase (p=0.000), and 
condition/ phase/ side (p=0.000). 
The Kolmogrov-Smirnov test for normality have shown occasional data, which are not 
significant however, it was not considered a threat to the outcome. 
Results show that there was a significant main effect for condition (F(1.860,22.316)=18.949, 
p=0.000), a significant main effect for phase (F(2,24)=61.428, p=0.000), a significant 
interactive effect between condition/ phase (F(2.250,26.998)=26.533, p=0.000), and a 
significant interactive effect between condition/phase/side (F(I. 902,22.828)=2.448, p= 
0.000). There was no main effect for side (F(1,12)=4.287, p=0.061) and no interactive 
effect for condition/side (F(3,36)=1.239, p=0.310), no interactive effect for phase/side 
(F(2,24)=1.622, p=0.218). 
Using contrast to compare the levels of the independent variables, there was significant 
effect of different levels of conditions (high/control - low/control - placebo/control). 
There was a significant effect between "before treatment" to "during treatment" and 
"during treatment" results to "after treatment", and there was a significant effect 
between treated and non-treated side. Findings are displayed in Table (9.5). 
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Source Condition Phase Side Signifi cance 
Condition High vs control . 000 s Low vs control . 000 S 
Placebo vs control . 
042 S 
Phase Before vs after . 051 NS Before vs during . 000 S 
Side Treated vs non treated . 061 NS 
Condition vs 
phase 
High vs control Before vs after . 009 
S 
Before vs during . 
000 S 
Low vs control Before vs after . 
064 NS 
Before vs during . 
009 S 
Placebo vs control Before vs after . 099 NS Before vs during . 006 S 
Condition vs side High vs control Treated vs non treated . 
133 NS 
Low vs control Treated vs non treated . 
110 NS 
Placebo vs control Treated vs non treated . 
530 NS 
Phase vs side Before vs after Treated vs non treated . 682 NS 
During vs after Treated vs non treated . 
049 S 
Condition vs 
phase vs side 
High vs control Before vs after Treated vs non treated . 
102 NS 
During vs after Treated vs non treated . 033 S Low vs control Before vs after Treated vs non treated . 619 NS 
During vs after Treated vs non treated . 
042 S 
Placebo vs control Before vs after Treated vs non treated . 
952 NS 
During vs after Treated vs non treated . 227 NS 
Table (9.5) Main effects and contrast analysis of BVol (significant results are highlighted in red). S: 
significant, NS: non significant 
To examine whether the difference, was statistically significant a post hoc test 
(Bonferroni) was used. Results show that there was significant difference between all 
phases of condition except between placebo and low, and for before to during treatment 
and before and after treatment. Findings of post hoc test are displayed in Table (9.6). 
Source Condition Si nificance 
Condition High vs low . 
001 S 
High vs placebo . 
032 S 
High vs control . 
000 S 
Low vs Control . 
002 S 
Placebo vs Control . 253 NS Low vs placebo 1.000 NS 
Phase Before vs after . 153 NS Before vs during S 
Table (9. b) tost noc results or rs v oº isigntncant results are highlighted in red), S: significant, NS: non 
significant 
These results mean that there was a statistically significant increase in BVo1 with the 
high dose, low dose, and placebo condition. This extent of increase was higher with the 
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24W compared to low dose and placebo . There was no statistical difference between 
changes recoded with the low dose and the placebo dose in BVo1. The non-treated side 
(Figure 9.3) displayed changes that mirrored the treated side (Figure 9.2) but with lesser 
degree. 
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Figure (9.2) The changes in the four experimental conditions in the treated side 
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Figure (9.3) The changes in the four experimental conditions in the non-treated side 
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Mean changes in BVol across the four experimental conditions is presented in Table 
(9.7) for the treated side and in Table (9.8) for the non-treated side. More analysis can 
be found in Appendix (E. 4). 
Condition Treated 
Before During After 
High dose 30.709±11.985 134.223±71.309 74.937±56.316 
Low dose 20.210±9.894 74.566±50.238 38.852±24.169 
Placebo dose 27.107±19.005 63.327±38.745 37.652±31.434 
Control 26.469±10.489 26.879±16.035 22.965±9.176 
Table (9.7) Mean changes in BVo1 across the experimental conditions ±SD in the treated side (values are 
reported in arbitrary unit) 
Condition Non-treated 
Before During After 
High dose 24.944±10.424 115.993±49.094 23.121±12.821 
Low dose 24.127±9.710 36.300±13.450 27.954±14.142 
Placebo dose 25.457±15.510 68.734±41.914 31.395±18.712 
Control 23.416±10.248 26.102±13.425 24.074±16.160 
Table (9.8) Mean changes in BVol across the experimental conditions ±SD in the non-treated side 
(values are reported in arbitrary unit) 
9.3.2 Skin temperature results 
A 4*2*2 (condition, time, side) repeated measure ANOVA was used to analyse SkT 
data. The condition consisted of 4 levels (control, placebo, high dose, and low dose), 
the time consisted of 2 levels (before and after treatment), and the side consisted of 2 
levels (treated and non-treated). Skin temperature was not recorded in the "during 
treatment" phase. 
The Kolmogrov-Smirnov test for normality have shown occasional data, which are not 
significant however, this was not considered a threat to the results. Sphericity was 
significant for condition/ phase (p=0.021). 
There were a significant main effects for phase (F(I, 12)=11.828, p=0.005), a main effect 
for side (F(1,12)=18.636, p=0.001). There was no main effect for condition (p=0.277). All 
interactions were significant condition/phase (F(2054,24642)=11.606, p=0.000), 
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condition/side (F(3,3)=6.888, p=0.001), phase/side (FI, 12)= 33.959, X0.000), 
condition/phase/side (F(3,36)=21.056, p=0.000). 
Contrast analysis has showed that there was a significant effect of phase between before 
and after treatment (p=0.005), in the side between treated/non treated (p=0.001). There 
was a significant interactive effect between the high dose and the control in the treated 
and non-treated limb (p=0.006). There was an interactive effect in the before and after 
treatment in the treated and non-treated side (p=0.000). There was a significant 
interactive effect between the high dose and the control in the before and after treatment 
in the treated and non-treated (p=0.000). Using post hoc (Bonferroni) none of the above 
difference were significant. 
The results mean that although high dose, low dose and placebo conditions increased 
SkT and the extent of that increase was more with the high dose, the amount of that 
increase was not large enough to reach statistical significance. Results of contrast 
analysis are shown in Table (9.9). Further analysis can be found in Appendix (E. 4). 
Source Condition Phase Side Sig. 
Condition High vs control . 
846 NS 
Low vs control . 
416 NS 
Placebo vs control . 
096 NS 
Phase Before vs after . ()()S 
S 
Side Treated vs non treated . 
001 S 
Condition vs 
phase 
High vs control Before vs after . 002 
S 
Low vs control Before vs after . 220 
NS 
Placebo vs control Before vs after . 
587 NS 
Condition vs 
side 
High vs control Treated vs non treated . 006 
S 
Low vs control Treated vs non treated . 
282 NS 
Placebo vs control Treated vs non treated . 
750 NS 
Phase vs side Before vs after Treated vs non treated . 000 S Condition vs 
base vs side 
High vs control Before vs after Treated vs non treated . 000 S 
Low vs control Before vs after Treated vs non treated . 
067 NS 
Placebo vs control Before vs after Treated vs non treated . 
356 NS 
Table (9.9) Contrast anaiysis of main errects ana interactions (significant results are highlighted in red) 
S: significant, NS: non-significance 
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Mean changes in SkT across the four experimental conditions are displayed in Table 
(9.10). Changes in SkT in the treated side and non treated side are shown in Figure 
(9.4). 
SkT before 
treatment 
SkT after 
treatment ° 
High Dose Treated 26.758±1.372 28.710±1.143 
Non treated 27.155±1.365 27.601±. 990 
Low dose Treated 27.495±1.233 27.830±1.176 
Non treated 28.135±1.366 28.009±1.134 
Placebo Treated 27.647±1.236 27.626±1.310 
Non treated 28.448±1.233 28.498±1.257 
Control Treated 26.883±1.158 26.994±1.486 
Non treated 27.527±1.467 27.750±1.585 
Table (9.10) Summary of mean changes in SkT across the experimental conditions ±SD 
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Figure (9.4) Changes in SkT in the treated side before and after treatment across the experimental 
conditions, B: before treatment, A: after treatment 
9.3.3 Nerve stimulation results 
A 4*2*2 (condition, phase, side) repeated measure ANOVA was used to analyse the 
data collected from the peroneal nerve. Condition had 4 levels (control, placebo, high 
dose and low dose), phase had 2 levels (before and aller treatment), and side had 2 
levels (treated and non-treated). 
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The data collected on the nerve stimulation was analysed using the onset latency 
(measured from the end of the stimulus to the negative peak), duration of the response 
was measured from the negative peak to the next negative peak (Figure 9.5) and the 
NCV was calculated by dividing the distance by the onset latency. Distance was 
measured as the length between the centres of the recording and the stimulating 
electrodes using a tape measure (Oh, 1996; Delisa, 1994; Dong and Liveson, 1983, 
personal communication with the manufacturer). 
Duration of the response will also be reported as it reflects the number and the 
synchrony of the fibres contributing to the response (Dong and Liveson, 1983). 
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Figure (9.5) Characteristics of the nerve response that are used for analysis as measured from Biopac 
MP 100 
9.3.3.1 Nerve conduction velocity 
Sphericity was not assumed with the interaction between condition/phase, and the 
interaction between condition/phase/side. The Kolmogrov-Smirnov test for normality 
has shown occasional data, which are not normally distributed. 
There was no main effect of condition (F(3,36)=0.612, p=0.612), no main effect of side 
(F(i, 12)=0.076, p=0.787), but a main effect of phase (F(112)=10.561, p=0.007). The 
majority of the interactions were non significant, condition/phase (F(I 437, ». 246)=4.674, 
p0.033), condition /side (F(3,36) = 0.172, p=0.915), phase/side (F(1,12)=1.176, p=0.299), 
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condition/phase/side (F(3,36) 0.749, fir=0.530). Using contrast analysis there was no 
significant differences between condition levels: high/control (p=0.097), low/control 
(p=0.322), placebo/control (p=0.401). More analysis can be found in Appendix (E. 4). 
The changes in NCV across the four experimental conditions is shown in Figure (9.6) 
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Figure (9.6) Changes in nerve velocity across the experimental conditions in the treated side 
The mean change in NCV across the experimental conditions is presented in Table 
(9.11). 
NCV before m/sec NCV after m/sec 
High Dose Treated 51.828±2.838 49.278±3.135 
Non treated 51.668±2.859 50.581.407 
Low dose Treated 52.076±2.949 51.309±2.891 
Non treated 51.893±2.938 51.770±3.226 
Placebo Treated 51.755±3.161 52.317±3.695 
Non treated 51.666±2.963 51.738±2.974 
Control Treated 52.813±3.434 52.893±3.857 
Non treated 52.724±3.780 52.617±3.759 
Table (9.11) Mean changes in NCV across the experimental conditions f SD in the treated and non- 
treated side 
Results show that there was a decrease in NCV in the treated side. Low dose and 
placebo condition displayed a very small change in NCV, which were not significant. 
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9.3.3.2 Nerve onset latency 
Sphericity was significant for condition (p=0.048), the interaction between 
condition/phase (p=0.000), condition/side (p=0.001), and condition/phase/side 
(p=0.000). There was a main effect of phase (p=0.035), no main effects of condition 
(p=0.228), or side (p=0.428). No interactive effects were found between 
condition/phase (p=0.218), condition/side (p=0.330), phase/side (p=0.189) 
condition/phase/side (p=0.235). More analysis can be found in Appendix (E. 4). 
As almost all main effects and interactive effects were found non significant, there was 
no need to pursue further analysis (Field, 2002). 
9.3.3.3 Duration of the response 
Although sphericity was assumed with condition/side, condition/phase/side and no 
correction was needed for the F value, correction was still needed for condition, the 
interaction between condition/phase where sphericity was violated. 
Examining the main effects and interactions for differences, there was not a difference 
in duration between all experimental conditions (F(I. 577,22.522)=2.124, p=0.114). Phase 
was significant (F(1,12)=9.515, p=0.009), this significance was between high and control 
in the before and after treatment (p=0.029). Side was not significant (F(1,12)=0.244, 
p=0.630). The following interactions were significant: condition /phase (F(1.571,18.853)= 
3.795, p=0.018), phase/side (F(1,12)=15.003, p =0.002). The interaction between 
duration/side and duration/phase/side were not significant (p=0.072, p=0.302 
respectively). 
Post hoc tests revealed that none of the above relationships reached statistical 
significance. More analysis can be found in Appendix (E. 4). 
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These findings reveal that although the treatment conditions did not alter the outcome 
when viewed separately, when examined in relation to the results of before and after 
treatment or the treated and the non-treated side the results show significance. Although 
the duration of the response has changed with the treatment, none of the doses applied 
seemed to have profound effect on the outcome. 
9.3.4 Pulse rate results 
A 4*3 (condition, time) two way ANOVA was used to examine the difference between 
the experimental groups. Condition had 4 levels (control, placebo, high dose and low 
dose); time had 3 levels (before, during and after treatment). 
Using ANOVA, there was no main effect detected in condition (F(3,36)=1.214, p=0.318), 
or in phase (F(2,24)=0.217, p=0.807). Interaction between phase and condition was not 
significant (F(6,72)=1.603, p=0.159). 
The mean change in PulsR values ± SD across the four experimental conditions is 
displayed in Table (9.12). More analysis can be found in Appendix (E. 4). 
Condition PulsR before 
treatment (b m) 
PulsR during 
treatment (b pm) 
Pu1sR after 
treatment bm 
High Dose 69.216±11.699 68.900±11.429 68.940±10.75 
Low dose 68.372±13.937 69.203±13.426 69.226±13.201 
Placebo 68.230±13.696 68.193±14.086 69.183±14.204 
Control 73.187±9.644 72.557±9.569 71.757±9.414 
Table (9.12) Mean changes in FulsK across the experimental conditions ± SD. bpm: beat per minute 
The findings above demonstrate that the different experimental conditions did not have 
an effect on the PulsR. 
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9.3.5 Core temperature results 
A 4*3 (condition, time) two ways ANOVA was used to examine the difference between 
the experimental groups. Condition had 4 levels (control, placebo, high dose and low 
dose), time had 3 levels (before, during and after treatment). 
The sphericity assumption was met for the phase (p =0.414), condition (p= . 35 1) and the 
interaction between condition/ phase (p = 0.333), and hence the no correction to F is 
needed. 
There was a main effect of condition (F(3,36)=3.928, p=0.016) which was significant 
with the high dose (p=0.045). There was a main effect in phase (F(2,24)= 6.015, p=0.008) 
which was significant with before and after treatment (p=0.024). There was no 
interaction effect between condition and phase (F(6,72)=0.1.209, p=0.311). 
Results show that the high dose has led to increase in CorT when compared to other 
conditions. 
The mean change in CorT before, during and after treatment is summarised in Table 
(9.13). More analysis can be found in Appendix (E. 4). 
Condition CorT before treatment 
'C 
CorT during treatment 
ýC 
CorT after treatment 
ýC 
High Dose 34.763±0.514 34.761±0.396 34.795±0.433 
Low dose 34.810±0.346 34.918±0.294 35.002±0.386 
Placebo 34.862±0.336 34.951±0.354 34.948±0.338 
Control 34.830±0.433 34.975±0.423 34.925±0.399 
Table (9.13) Mean changes in CorT across the experimental conditions ± SD 
9.3.6 Ambient temperature 
Using repeated measure ANOVA sphericity was only violated for condition. There was 
a main effect of condition (F(2.471,29.66)=3.369, p=0.029), and a main effect on phase 
(F(1,12)=6.943, p=0.022). The difference was not statistically significant when the post 
hoc test for all the levels of the condition were examined and compared. 
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This means that there was a change in room temperature before and after the data 
collection, however, this did not alter the outcome obtained with various variables 
examined during the experimental conditions as confirmed by the post hoc test. More 
analysis can be found in Appendix (E. 4). 
The mean change in room temperature before and after the experiment in the four 
experimental conditions is presented in Table (9.14). 
Condition Room tem erature before °C Room temperature after °C 
High Dose 23.933±1.257 24.133±1.166 
Low dose 24.166±0.949 24.200±0.924 
Placebo 24.066±1.172 24.200±1.156 
Control 24.000±0.784 24.000±0.784 
Table (9.14) Mean changes in room temperature across the experimental condition ± SD 
9.3.7 Ambient humidity 
Sphericity was met with all the factors. There was no main effect of condition 
(F(3,36)=2.119, p=0.115), no main effect of phase (F(I, 12)=0.000, p=1), no interactive 
effect between condition/ phase (F(3,36)=2.215, p=0.103). 
This means that there was no significant change in room humidity that could have 
affected the outcomes of the various variables examined. 
The mean change in room humidity before and after the experiment in the four 
experimental conditions is presented in Table (9.15). More analysis can be found in 
Appendix (E. 4). 
Condition Room humidity before %) Room humidity after (%) 
High Dose 31.200±2.455 31.433±2.192 
Low dose 29.666±3.994 29.400±3.926 
Placebo 30.300±3.611 30.233±3.682 
Control 32.785±1.188 32.642±1.336 
Table (9.15) Mean changes in room humidity across the experimental condition ± SD 
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To summarise all the above, there was a significant change in BVo1 with the high dose 
(24W) and low dose (3W) in the during and post treatment periods when the results 
were compared to the control group. This difference was statistically significant 
between baseline readings and "during treatment" readings but not between the baseline 
and recovery "post treatment" period. Although the placebo group displayed a change in 
BVol in the during treatment period, this change did not reach a statistical significance. 
There was a measured increase in SkT with high dose of 24W (mean increase 
1.9±1.119°C), low dose (0.335±0.668 °C) and no change with placebo dose 
(-0.020±0.438°C). The change recorded with the high dose and low dose did not reach 
statistical significance. 
There was a measured reduction in NCV with high dose (-2.550±2.014 m/sec), low dose 
(-1.433±3.769 m/sec), and placebo (0.562±2.451 m/sec). This change did not reach a 
statistical significance. 
Both PulsR and CorT did not change significantly in response to the interventions. 
Although it was difficult to control the temperature in the laboratory, the change in 
room temperature and humidity between before and after treatment did not have an 
effect on the outcome. 
9.3.8 Correlation between anthropometric data and experimental 
conditions 
Using Pearson-Product Moment Correlation Coefficient, there was a correlation at 
p<0.05 between PulsR and age, BVol and height. There was a correlation between 
PulsR and fat % at p<0.01. Summary of the results can be found in Table (9.16). 
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BVol SkT NCV Pulse rate CorT 
Age NS NS NS S <0.05 NS 
Height S <0.05 NS NS NS NS 
Weight NS NS NS NS NS 
Fat % NS NS NS S <0.01 NS 
-lame (9., a) summary or coneianons between anthropometric data and the primary variables recorded 
during the experiment (significant results are highlighted in red). S; significant, NS: non-significant 
9.3.9 Results of the blinding questionnaire 
All the subjects in the trial were asked a few questions at the end of each session to 
judge the effectiveness of the blinding used in the study. Subjects were asked whether 
they thought that the PSWT machine was on or off. Fifteen subjects in the high dose 
have given correct answers, and they justify their answer with the heat they felt under 
the treatment head. The number of subjects decreased to 8 with the low dose and to 2 
subjects in placebo; however, when subjects were asked, "how sure were they that the 
PSWT machine was on? " except for the high dose when subjects reported thermal 
sensation, the answers were only a guess (Table 9.17). 
High dose Low dose Placebo 
Yes 15 8 2 
No 5 8 12 
Not sure 10 13 16 
Did not attend 1 2 1 
Table (9.17) Description of the answers to the question: "Do you think that PSWT machine was 
working during the session? " 
When subjects were asked whether they thought that the session was a treatment or not, 
14 in the high dose group, 7 in the low dose group, 1 in the placebo, and 5 in the control 
were able to guess correctly. The same as with the previous question the answers were 
guesses except for the high dose when thermal sensation was reported (Table 9.18). 
High dose Low dose Placebo 
Correct answer 14 7 1 
Wrong answer 16 22 29 
Did not attend 1 2 1 
Table (9.18) Description of the answers to the question: "Do you think your session was a treatment, 
placebo or a control session? 
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Subjects were also asked about the thermal sensation under the treatment head, 11 have 
felt heat with high dose, 1 subject has felt heat with low dose, and none have felt 
anything with the placebo dose (Table 9.19). 
High dose Low dose Placebo 
Yes 11 1 - 
No 17 27 27 
Not sure 2 1 3 
Did not attend 1 2 1 
Table (9.19) Description of the answers to the question: "Did you feel any heat under the treatment 
head? " 
9.4 DISCUSSION 
The effects of PSWT on SkT and BVol have been studied before, however, the 
majority of the studies have focused on the maximum dose with MP of 48W. Moreover, 
although there were other studies that examined lower PSWT outputs, the limited 
reporting of substantial information needed for judging the quality of the studies and the 
absence of reporting of full treatment parameters, the diverse methodologies, and the 
arbitrary choice of dosage limit their clinical value. No published reports have been 
found that employed MP of 3W or 24 W to be used for comparison with the current 
study. 
The study employed 5 dependent and 2 independent variables. The dependent variables 
were the change in SkT, change in BVo1 and change in NCV, PulsR, and CorT. The 
independent variables were the treatment dose and the side (treated or non-treated 
knee). 
9.4.1 Blood volume 
It is argued that PSWT serves no physiological action other than heating the 
tissues and increasing the blood supply through the treated area (Wilson, 1974). This 
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study has provided evidence that there could be an increase in the circulating blood even 
with very minimal increase in SkT as was seen with the 3W and the placebo dose, 
which could possibly be attributed to the athenmal effects. 
Though PSWT at 3W did not elicit a significant increase in BVol post treatment, 
it did produce a considerable rise in BVo1 during the treatment. The increased recording 
of PPG output provides an estimate of the change in BVo1 in the treated area. This 
increase in the recorded signal could be explained by the joint result of the increase in 
haematocrit, and the expansion of intravascular volume (Jespersen and Pedersen, 1986) 
as a result of a decrease in arterial system compliance (Babchenko et al, 2001). 
Moreover, given that the change in BVo1 in the vessels corresponds to the change in 
vessel diameter (Lindberg, 1991) it is expected that the increase in BVol noticed in both 
treatment conditions (high, low) is associated with vasodilatation. 
Morrissey (1966) reported that there was no statistical change in peripheral 
blood flow after irradiating the calf with PSWT at MP of 40W for a period of 15 
minutes. The findings of the current study challenge this, and demonstrate that there 
was a significant increase in BVol with 24W, 3W and with placebo condition during 
treatment. This difference was not significant for the increase in BVo1 for post treatment 
period. Although the current study employed lower MP, the increase in BVo1 could be 
attributed to the difference in methodology and sensitivity of the measuring device 
employed. 
There was a 2.5 fold measured increase in BVol with 24W, these findings carry clinical 
implications. In cases where swelling or haematoma are present, this dose should not be 
used as it may exacerbate the symptoms by dilating blood vessels and increasing the 
amount of interstitial fluid. 
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Lack of statistical significance between the outcome of 3W and placebo conditions 
means that energies as low as 3W could be no better than placebo as the amount of 
energy is very small to achieve therapeutic results. However, it is of interest to mention 
that no published work has identified whether findings from trials conducted on healthy 
subjects are transferable to patient population. 
9.4.2 Skin temperature 
It has been argued that pulsing the output of PSWT could eliminate the thermal 
effects associated with its application. Bricknell and Watson (1995) have demonstrated 
a definite heat perception that was felt after 7minutes of exposure with MP of 10.8W. 
Murray and Kitchen (2000) have shown that definite thermal sensation can be 
experienced if the MP was 21.19 ± 8.27W. The distance between the treatment head 
and the treated area was 4 mm in Bricknell and Watson, but it was not mentioned in the 
Murray and Kitcken study. 
The current study has examined the effect of MP 3W and MP 24 on SkT. 
Findings demonstrated that there was a mean increase of 1.9±1.119°C in SkT post high 
dose and a mean increase of 0.335±0.688°C with the low dose. The number of subjects 
however, who reported a thermal sensation was 11 (42.3%) with the high dose and 1 
subject (0.3%) with the low dose. This difference in findings could be attributed to 
several reasons. The distance between the treatment head and the treatment area 
(Lehmann et al, 1969) which could either increase or decrease the amount of circulating 
air underneath the treatment head and as such change the perception of thermal 
sensation. Another factor could be the dose employed which was the maximum setting 
of the PSWT with Bricknell and Watson. A third factor could be the difference in the 
equipment employed (Diapulse in Murray and Kitchen and Curapuls in Bricknell and 
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Watson) in comparison to Megapulse. Each of these machines has a different PP (975W 
with Diapulse, 200W with Curapuls 403 and 150W with Megapulse Senior). Previous 
pilot work by the author has showed that different PSWT machines do not behave the 
same (Section 8.15-8.20). Moreover, it could be added that the thermal sensation 
reported in the above studies have shown different results probably because different 
body parts have different temperature sensitivity to heat and this could be affected by 
the difference in somatosensory representation or the difference in vascularisation in 
different body parts (Odia and Aligogun, 1988), hence the time needed to feel the heat 
on the front of the thigh could be different from the front the knee. The implication of 
these findings is that the skin is not always a reliable source for detecting changes in 
thermal build up. 
In dispute with the literature that have shown a definite thermal sensation with 
MP as low as 10.8W, Morrissey (1966) has demonstrated that with an MP of 40W, 
there was no statistical significant increase in SkT. The findings of the current study 
have also shown statistical non-significant increase in SkT with 24W, despite the 
measured temperature increase that reached 2°C. However, this increase although not 
statistically significant could have detrimental effects on treatment outcome with 
conditions such as RA or OA or soft tissue inflammation, where slight increase in 
temperature may exacerbate the symptoms (Hosie and Dickson, 2000). 
Temperature increase in the current study was around 2°C for the high dose and 
below 1°C with both the low dose and the placebo application. This increase in 
temperature was found to go back to baseline or slightly above baseline after 
termination of PSWT only when the MP was 3W or 0.05W in placebo. These findings 
are in agreement with Tenforde (1996) who stated that with athermal exposure or when 
the increase in tissue temperature does not exceed 1°C, the effects were found to be 
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reversible upon termination of the exposure. These findings imply that if the thermal 
effect was the aim of the treatment the dose needs to either be increased or the time of 
exposure needs to be increased to allow the delivery of higher outputs of energy to the 
tissues. 
The increase in temperature associated with PSWT use is expected to increase 
metabolism and speed up chemical reactions (Ward, 1980). It is expected that for each 
1°C increase in tissue temperature, there could be 13% increase in the rate of metabolic 
reaction (Kitchen, 2002). Research has shown that the intramuscular temperature needs 
to increase to at least 39°C and some say to 41°C in order to gain therapeutic effects 
(Noonan et al, 1993). The application of 24W was associated with 1.9±1.119°C increase 
in SkT as such could be expected to increase metabolism and speed up chemical 
reactions, consequently be of therapeutic value. 
Findings with the high dose have shown an increase in SkT of around 2°C 
above baseline reading. Although intramuscular temperature was not measured, it is 
expected that with energy delivered at MP 24W and irradiation time of 10 minutes 
therapeutic effects may be obtained. Lehmann et al (1983) have demonstrated on 
human tissue substitute substances that the SAR ratio of muscle to fat heating with 
inductive electrodes could reach up to 2.67 times higher. This could mean that the deep 
tissue temperature may have increased to a possible 4°C degree. In an efficient 
circulatory system it is expected that no build up of heat will develop due to the 
dissipation of heat by the circulating blood. These findings are of major concern in 
cases with incompetent thermoregulatory system where areas of hot spots may develop. 
Although the authors did not use a Megapulse machine with the eight units examined 
they were able to demonstrate that this ratio could vary between equipments. As such 
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no definite conclusion can be drawn unless such findings were validated with 
Megapulse. 
Findings also suggest that the increase in SkT could be measured when the 
subject does not report thermal sensation. These results may have safety issues 
signifying that the skin is not always a reliable source for judging the thermal 
component of the treatment. Further work is warranted in this area to examine this 
supposition. 
9.4.3 Nerve conduction velocity 
Unlike other electrotherapy modalities, NCV have been examined in modalities 
such as laser, transcutaneous electrical nerve stimulation and IFC (Cramp et at, 2000a; 
Cramp et al, 2000b; Walsh et at, 2000), PSWT on the other hand has received almost no 
attention. A limited number of studies that are outdated have examined the effect of 
PSWT on NCV (Currier and Nelson 1969; Abramson et al, 1966). It is a commonly 
accepted belief that increasing tissue temperature increases NCV and a decrease in 
tissue temperature decreases NCV (Rutkove, 2001; Delisa, 1994). Contrary to what 
was expected, a slowing of nerve velocity was recorded in the current study. PSWT 
does not have the ability to stimulate sensory or motor nerves, because pulses need to 
be at least 0.1 ms long to have excitatory effect on muscle or nerve. The usual pulse 
time with PSWT is around 1 over 50`h of a gs as such the time of pulse is too short to 
stimulate nerves (Low and Reed, 2000). 
The results obtained in this experiment could be explained by the change in 
temperature around the measured nerve. In the majority of NCV studies, the segment of 
the nerve studied is usually under the direct application of cold or heat. In the current 
study, while the front of the knee was irradiated with PSWT, the common peroneal 
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nerve was stimulated from the posterior aspect of the knee. This site was chosen for 
stimulation as the nerve was most superficial at this point. With the increase in SkT at 
the front of the knee, there might have been redistribution of BVol as a result of the 
vasodilatation occurring anteriorily and vasoconstriction occurring elsewhere (Marieb, 
2002). This could have decreased the temperature of the tissues around the nerve and 
might have resulted in a decrease in NCV. Unfortunately as no measurement to SkT or 
BVo1 was undertaken at that area no firm conclusion could be drawn. A possible 
method of avoiding this for future studies would be by studying NCV in the femoral 
nerve as this nerve supplies the quadriceps, which is a muscle in the direct area of the 
treatment or possibly measuring from a different body part. 
Additionally as the near nerve temperature adjusts slowly to changes in temperature 
when the source is applied externally (Halar et al, 1980), it could be speculated that the 
treatment time applied may have not been long enough to cause warming of the area 
around the nerve. This mechanism could be responsible for pain reduction experienced 
by patients as stimulation to the afferent nerve fibres (being mediated by the morphine 
receptors in the brain) makes them work as a counter irritant, closing the gate control 
(Low and Reed, 2000). Though no direct conclusions could be drawn with regard to the 
effects of increase in SkT on the change of temperature around the nerve, pervious work 
has demonstrated that the near nerve temperature could differ by 1.7°C in response to 
changes in SkT (De Jesus et al, 1973; Behse and Buchthal, 1971) though this may vary 
between individuals (Rutkove, 2001). 
Another interpretation to the current findings could be that the decrease in NCV 
detected is a possible mechanism by which PSWT works. However, since very few 
studies have been found on the effect of PSWT on nerve conduction, and they cannot 
be compared to the current study due to difference in equipment used and methodology 
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employed, further studies in the field need to be conducted to gain further insight into 
PSWT mechanism of action. 
The application of PSWT is associated with a decrease in pain level. The 
mechanism of this decrease is not fully understood. Further work in the area of 
interaction between nerve conduction and PSWT application is warranted, as it needs to 
be explored whether the nerve velocity plays a role in pain reduction as reported by 
patients. 
The duration of the response is a measure of the number of fibres contributing to 
the response. A change in either the shape or an increase in duration could mean 
asynchrony in the number of fibres responding to a stimulus (Dong and Liveson, 1983). 
The current study did not demonstrate a significant change in the duration of the 
contraction although there was a recorded increase with both 3W and 24W, an issue 
that need to be investigated further. 
During the experiment, NCV electrodes were left on the non-treated side to 
reduce post irradiation delay (Section 8.27.3). By leaving the electrodes in place there is 
a need to acknowledge that the skin underneath the electrodes in the non-treated area 
may not undergo the same reaction to removing and reattaching adhesive electrodes as 
the treated leg and this may have its implication on the findings. However, this is a 
confounding variable that needed to be accepted at this level. 
An inherent difficulty with nerve conduction studies is reliability. Even with 
extreme standardising procedure the percentage of error for the measured value could 
vary between 4-5% (Dong and Liveson, 1983). This problem may have been improved 
by the extensive piloting procedures conducted by the researcher before conducting the 
laboratory and clinical trials. 
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Change in body part temperature is known to alter NCV (Rutkove, 2001). It is 
advisable to warm the part in cases where the limb is cold. This was not accomplished 
in this study as warming up the part could alter the response obtained by the variables 
studied. Despite that the room temperature ranged from 23-26°C during the course of 
the study, it did not vary more than 1°C during any one treatment period as such is not 
expected that it affected the values recorded. 
Although comparable readings were obtained bilaterally within individuals, side to side 
differences were detected. This may be related to the nature of the measuring device. 
Such differences were not alarming as it was reported previously in the literature 
(Morita et al, 2002; Bromberg and Jaros, 1998). This could be caused by the difference 
in nerve diameter, the strength of the stimulus which determines the number and the 
size of the activated nerves. This issue was taken into consideration and the amount of 
normal variability was calculated to be 1.6m/second. This means that all changes above 
this value are considered real changes and not fluctuation in recording due to 
methodological issues. 
9.4.4 Others 
The findings of the current study have shown that the application of PSWT is 
associated with a placebo effect and this is in accordance with many of the findings 
reported in the literature (Klaber-Moffett et al. 1996; Foley-Nolan et al, 1992,1990; 
Reed et al, 1987). The study has also shown that the use of a low dose application, 
culminates in similar findings to placebo PSWT. Such findings may have their 
implication on the choice of parameters and time of exposure as these findings implies 
that lower power outputs could be no better than placebo in relation to the physiological 
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parameters investigated. However, the use of very low power outputs needs to be 
examined in the patient population before they are discarded clinically. 
In all conditions it was found that the increase in the variable studied whether it 
was BVo1, SkT or NCV was directly proportional to the amount of energy applied. The 
fact that the response obtained during the treatment and was lost for the post treatment 
period (3 W) or was not statistically significant (24W) could indicate that higher 
energies need to be applied to preserve the treatment effects. The conclusions that could 
be drawn from the above findings were that the increase in SkT is associated with an 
increase in BVol and a decrease in NCV. 
The measurements were taken from both sides because the work on other 
frequencies of EMF has shown a "cross talk" effect between treated and non-treated 
side (Tabrah et al, 1990). Findings of this study concurs with Tabrah et al (1990) 
findings as the response seen in the non-treated side was found to mirror the treated side 
but with smaller magnitude. 
Although there was significant correlation between height and BVo1, and 
between PulsR, and age and PulsR and fat%, with the absence of a trend among other 
variable it is doubtful that these resemble important findings. 
One of the drawbacks of laboratory testing is that experiments are done on 
young healthy subjects, the majority of whom are university students. In the current 
study, subjects with a wide age range were included in the study to enable better 
generalisation on a wider age range of patients. 
The findings of the current study may have implications with regard to the decisions 
that therapists need to consider when deciding on efficacy of different treatment 
parameters. 
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In summary the findings of this experiment support the null hypothesis with 
regard to effects of high dose on SkT and NCV and reject the null hypothesis with 
regard to effects of high dose on BVo1. The findings also support the null hypothesis 
with regard to the effects of low dose on BVol/ SkT/ NCV, the effects of high dose on 
CorT and PulsR, the effect of low dose on CorT and PulsR, and the effect of both low 
dose and high dose on the non-treated side. 
9.5 CONCLUSION 
The effect of applying PSWT at two different treatment doses was examined in 
thirty one healthy subjects. The results demonstrated a significant increase in BVo1 
with both 24W and 3W during treatment. It was demonstrated that the post treatment 
effects of the treatment was not significant possibly because of the amount of energy 
delivered to the tissues. This could be overcome by increasing the time of exposure or 
using higher energy output. Such issues may have their implication in the clinical 
decision process by physiotherapists. 
Subjects with a wide age range were included in the current study; however this does 
not facilitate extrapolation to patient population as patient may react differently to the 
same stimulus. 
In the next phase of the thesis the same study will be replicated with osteoarthritic 
patients in order to explore the effect of PSWT on SkT, BVo1 and NCV on the clinical 
picture of OA patients. 
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10.0 INTRODUCTION 
PSWT is one of the electrotherapeutic modalities that have been used by 
physiotherapists in UK for decades; nonetheless, the knowledge about its clinical use and 
rationale for dosage selection is scant (Kitchen, 1995b). The literature reviewed (Chapter 4) 
has demonstrated that evidence from clinical trials is controversial and that published 
reports have failed to describe their treatment protocols thoroughly, making it hard for 
therapists to reach consensus on the appropriate dosage to administer with various 
conditions (Murray and Kitchen, 2000). 
It has been argued that the diseased tissues react differently from healthy tissues when 
exposed to exogenous energy (Bricknell and Watson, 1995) suggesting direct extrapolation 
of research findings between healthy and patient population is unwise. Although this 
assumption has been accepted for some time, it has not been validated by experimental 
work. The majority of research papers have examined the physiological effects of PSWT on 
healthy subjects with little attention paid to patients' physiological response to 
electrotherapeutic modalities. This highlights the importance of further research in this area 
(Murray and Kitchen, 2000). 
The audit conducted (Chapter 5) has shown OA to be one of the most common conditions 
seen in physiotherapy outpatient clinics. Between 34%-42% of the sample comprised from 
86 therapists in one of England health authorities reported that PSWT is the treatment of 
choice for acute, and for moderate and severe OA (Green, 1991). A survey by Shields 
(2003) has revealed that one of the reasons for considering the purchase of new PSWT 
units was the belief that it was effective with arthritic conditions. The volume of literature 
on PSWT use for OA is limited in number and of controversial outcomes (Section 4.1). A 
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literature review on OA and the use of PSWT has shown that the majority of the published 
studies have examined the effect of a course of treatment with PSWT in comparison to 
other forms of treatments and those who compared more than one mode of PSWT to each 
other failed to provide sufficient details on the dosage. 
Given the above, this study aimed to examine the effects of high and low doses of PSWT 
on OA patients. Three modes of PSWT treatments were administered (24W, 3W, and 
placebo) and their effects on SkT, BVo1, and NCV were compared to a control group. This 
study is unique in that the variables examined with OA patients will be compared to healthy 
subjects using the same experimental protocol and equipment. Findings of this study are 
expected to help substantiate the effect of some modes of treatments that have not been 
validated before by clinical trials. 
10.1 METHODOLOGY 
The study was conducted in the Physiotherapy Department in Lister hospital. Before 
commencing the trial ethical approval was granted from East & North Hertfordshire 
Hospitals Local Research Ethics Committee (Appendix F. 1) and approval of the 
Physiotherapy Manager was obtained (Appendix F. 2). 
10.1.1 Patient recruitment 
Patients in the waiting list of the department who were diagnosed as OA knee were 
treated as potential candidates for the trial. Patients were contacted by phone and were 
questioned using the American College of Rheumatology list (Table 10.1). In cases where 
the patients agreed to participate, they were given an appointment to visit the department 
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and an information package was sent to them by mail. The package contained an 
explanatory letter about who is conducting the trial, the underpinning aims for the study, 
and the course of the experiment. The package also contained a contra indication form 
(Appendix D. 5), a consent form (Appendix D. 6) and an information sheet (Appendix D. 4). 
Twenty six subjects participated in a same subject design which meant that each subject 
had to attend for 4 sessions to take part in high dose, low dose, placebo and control session. 
1 2 3 4 
Clinical and 
laboratory 
Clinical and 
radiographic 
Clin öra I (1) Clinical (2) 
Knee ' Knee ' Knee m Knee m 
Must have at least 
5of9: 
Must have at least 
1of3: 
Must have at least 
3of6: 
Must have at least 
4of6: 
Age > 50 years Age > 50 years Age > 50 years Age > 50 years 
Stiffness < 30 minutes Stiffness < 30 minutes Stiffness < 30 minutes Stiffness < 30 minutes 
Crepitus Crepitus Crepitus Crepitus 
Bony Tenderness Osteophytes Bony Tenderness Bony Tenderness 
Bony enlargement Bony enlargement Bony enlargement 
No palpable warmth No palpable warmth No palpable warmth 
ESR <40 mm/hour 
RF <1: 40 
SF OA 
Table (10.1) OA ciassilication accorWng to me American c; ouege of xneumawiogy taaaptea tram Altman, 
1991, Altman et al, 1990; Altman et al, 1986). 
ESR = erythrocyte sedimentation rate; RF = rheumatoid factor, SF OA = synovial fluid signs of OA (clear, 
viscous, or white blood cell count Q, 000/mm3). 
The study was conducted following the same protocol used with healthy subjects (Section 
8.24). 
On arrival on the first day, the contra-indications were checked again. A brief patient 
history was taken using the form in Appendix (F. 3). Muscle strength, ROM, pain level, 
height, weight, and SFM were taken. 
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Perform it b CONAM *Mir The perk residing was recorded. The test was 
mpeoW 3 tiý Ord is noes aw wed for analysis. A five second rest was allowed 
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between tests to avoid fatigue (Phillips et al, 2000) longer periods of rest were given when 
seen necessary. 
10.1.3 ROM measurement 
The universal goniometer was used to measure ROM. The axis of the goniometer 
was aligned with the knee joint; the stationary arm was aligned along the femur pointing 
towards the greater trochanter. The movable arm was aligned parallel to the fibula pointing 
towards the lateral malleolus. The movement was shown to the patients and they were 
allowed to practice the movement a couple of times before recording the actual 
measurement. All measurements were taken by the same investigator to improve reliability 
(Brosseau et al, 2001). The error margin for the researcher was found to be ±3° (Appendix 
F. 4). 
10.1.4 Pain level measurements 
Pain was measured using VAS. Pain is a major reason for OA patients to seek 
physiotherapy interventions. Evaluation of pain in OA is necessary to assess the 
effectiveness of any intervention (Wessel, 1995) 
Patients were presented with a line that measured 100 mm. The line was anchored at the 
extremes with "no pain" at one end and the "worst pain imaginable" at the other end 
(Figure 10.2). 
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Patients were asked to mark their pain pre and post each session to represent the severity 
of their pain. Patients were presented with a different sheet of paper every time to ensure 
that they were blinded from their previous marking (Tiplady et al, 1998; Hagino et al, 
1996). 
No pain Worst pain 
imaginable 
Figure (10.2) Visual analogue scale 
A ruler was then used to assign a numerical value to the mark; the value was used 
for 
analysis. 
All patients were encouraged to continue to use any type of medication they were taking 
prior to the entry in the trial. 
At the end of all the sessions subjects were asked to answer few questions to evaluate the 
efficacy of the treatment in general (Appendix F. 5). 
10.2 INCLUSION CRITERIA 
All patients classified by the author as having OA following the American College of 
Rheumatology Classification for clinical 1 and clinical 2 (Table 10.1) were included in the 
tri al. 
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10.3 EXCLUSION CRITERIA 
" Patients having any of the contra-indication listed in Appendix (D. 5) 
" Patients receiving physiotherapy 
" Patients having OA as secondary to other conditions 
" Patients having OA Hip 
" Patients who had intra-articular injection in the knee joint within the last month 
" Obese patients (fat % more than 40 mm). Obese patients were excluded as the 
application of a high dose of 24W may be associated with increase in temperature 
and although patients may not report heat, this does not mean that heat is not 
developing in deeper tissues. Moreover, fatty layer has the tendency to develop hot 
spots as a result of heat accumulating in the tissues (Ward, 1980). 
10.4 DATA ANALYSIS 
Measurement of BVo1, CorT, PulsR was taken before, during and after intervention. 
Measurement of NCV and SkT were taken before and after the intervention (NCV 
electrodes has metal component hence contra-indication to PSWT, and the SkT probes 
heats with PSWT). Measurements of secondary measures were taken pre and post PSWT 
administration to provide a baseline data and information about the rate of change and 
intervention efficacy. 
Data were analysed following the same methodology in Section 9.2.2. All statistical 
data was computed using SPSS software (version 11). Differences between groups was 
determined using ANOVA and significant results were examined for statistical significance 
using Bonferroni Post Hoc. Pearson's Correlation Product Coefficients was used to 
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correlate age, gender, height, weight, and SFM, with measurements taken on BVol, SkT, 
NCV, PulsR and CorT. Data were also checked for normality and homogeneity of the 
variance before the start of any analysis. In cases where sphericity was not assumed the 
corrected F value from Greenhouse- Geisser was reported. 
Functional improvement was assessed following a small scale questionnaire (Appendix 
F. 5) that was developed by the investigator based on the general symptoms of OA. 
Findings were reported in terms of frequencies. 
10.5 RESULTS 
Fifty two patients were approached by the researcher for the study. Table (10.2) displays 
the numbers of patients recruited and those who completed the trial. Out of the 26 patients 
entered the study, 24 completed the sessions and 2 attended two sessions only. Subjects 
were asked to attend for 5 sessions although there were 4 experimental settings because 
patients were measured prior to each experimental session. Baseline measurement was 
taken before the first session, first measurement for changes in pain, muscle strength and 
ROM was taken prior to the second session, third measurement was taken before the 
second session and so on. The mean age of participants was 55.07 years (ranging between 
32-80 years), of whom 53.8% (n=14) were women and 46.2% (n=12) were men. 
Description No of patients 
Number of patients approached by the researcher 52 
Patients refused 15 
*Patients excluded before starting 8 
Patients withdrawn: 
a- Withdrawn before starting the trial 3 
b- Did not complete the sessions (one patient attended all but placebo 
session, one patient attended all but control and placebo) 
2 
Total completing all the experimental sessions of the study 24 
Table (10.2) Profile for patient recruited for the study 
*: This category contains patients found to fall into exclusion criteria after initial assessment 
a: This category contains patients who were given appointments but did not attend. 
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The sample profile is shown in Table (10.3) and more information can be found in 
Appendix (F. 6). Raw data is presented on a floppy disk at the back of the thesis. 
Description Range Meant SD 
Age 32-80 years 55.076±11.976 
Height 150-190 cm 167.911±10.141 
Weight 47.78-109.85 Kg 26.400 ± 6.480 
Duration of OA 2 month -20 years 4.66±4.87 
Fable (10.3) Characteristic of the study sample 
Patients were randomised into treatments using the same table from chapter 9 (Section 
9.2.1). The result of randomisation is shown in Table (10.4). 
Sessi 
Treatment 
on 1 
Frequency 
Sessi 
Treatment 
on 2 
Frequency 
Sessi 
Treatment 
on 3 
Frequency 
Sessi 
Treatment 
on 4 
Frequency 
24 W 5 24 W 3 24 W 4 24 W 6 
3W 8 3W 8 3W 6 3W 6 
Placebo 6 Placebo 8 Placebo 9 Placebo 6 
Control 7 Control 7 Control 7 Control 8 
n=26 n=26 N=26 =26 
I able (10.4) Patient randomisation 
10.5.1 Blood volume results 
Manuchley's test of sphericity was significant for condition, the interaction between 
condition/side, condition/phase and the interaction between condition/phase/side, with these 
variables the corrected F value (Greenhouse-Geisser) will be reported. ANOVA analysis 
has shown a main effect (Table 10.5) for the four experimental conditions (F(2.379,54.719) 
=32.400). The difference was significant at all levels between high/control (p=0.000), 
low/control (p=0.001), and placebo/control (p=0.000). There was a main effect for phase 
(F(2,46)=526.731), which was significant between before/after (p=0.000) and between 
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during/after at (p=0.000). There was a main effect of side between right and left 
(F(l, 23)=66.015, p=0.000). 
There was a significant interaction effect between condition/phase (F(2.205,50.726)=79.514 
P=0.000), a significant interactive effect between condition/side (F(2168,49.867)=14.529, 
P=0.000), a significant interaction between phase/side (F(2,46)=73.214, p=0.000), and a 
significant interactive effect between condition/phase/side (F(,. 938,44.579)=33.957, p=0.000) at 
all levels. Using Bonferroni as post hoc all the above differences were statistically 
significant. 
Source Condition PHASE SIDE S' 
Condition High vs control . 000 S 
Low vs control . 001 S 
Placebo vs control . 000 
S 
Phase Before vs after . 
000 S 
Before vs during . 
000 S 
Side Treated vs non treated . 000 S Condition * 
base 
High vs control Before vs during . 000 S 
Before vs after . 000 
S 
Low vs control Before vs during . 000 S 
Before vs after . 000 S 
Placebo vs control Before vs during . 000 5 
Before vs after . 
000 S 
Condition * 
side 
High vs control Treated vs non treated . 000 S 
Low vs control Treated vs non treated . 030 
S 
Placebo vs control Treated vs non treated . 
084 NS 
Phase * side Before vs after Treated vs non treated . 000 S 
Before vs during Treated vs non treated . 000 S Condition * 
Phase * side 
High vs control Before vs during Treated vs non treated . 
000 S 
Before vs after Treated vs non treated . 007 S Low vs control Before vs during Treated vs non treated . 000 S 
Before vs after Treated vs non treated . 002 S 
Placebo vs control Before vs during Treated vs non treated . 029 S 
Before vs after Treated vs non treated . 003 5 cable (1U. 5) Contrast analysis for blood volume (significant findings are highlighted in red). S: significant, 
NS: non significant 
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Changes in BVol across the experimental conditions are shown in Figure (10.3). The Figure 
shows that the highest level of increase in BVol was recorded with the high dose, followed 
by the low dose, then placebo. The increase measured during treatment was higher than that 
measured for the period post treatment and this was evident with high, low, and placebo. 
Though this increase declined post treatment, it remained above the baseline level. A 
summary of the descriptive changes in BVol across the experimental conditions is shown in 
Appendix (F. 6). 
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Figure (103) Changes in BVoI across the experimental conditions in the treated side 
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Summary of the findings can be found in Table (10.6) 
Condition Side Treatment phase Mean ±Std. Deviation 
High Treated Before 27.742±17.653 
During 220.743±68.750 
After 71.171±39.868 
Non treated Before 23.303±13.895 
During 69.252±43.607 
After 43.161±33.087 
Low Treated Before 24.590±20.083 
During 108.469±55.444 
After 57.218±32.993 
Non treated Before 24.683±17.802 
During 55.107±26.249 
After 37.916±22.500 
Placebo Treated Before 30.142±17.806 
During 76.895±29.303 
After 56.702±25.624 
Non treated Before 23.016±11.856 
During 54.040±22.738 
After 32.627±15.553 
Control Treated Before 34.336±18.673 
During 33.455±17.464 
After 33.872±18.957 
Non treated Before 29.694±13.371 
During 29.152±14.929 
After 29.170±16.468 
tame Uiu. o) summary or cnanges in cs voi across experimental conditions 
10.5.2 Skin temperature results 
With SkT, sphericity was assumed and there was no need for correction. There was a main 
effect of experimental conditions (F(3,69) 5.400, p=0.002), this difference was only 
significant between high/control (p=0.012). There was a main effect of phase, which was 
significant in the difference between before/after (F(1,23)=76.704, p=0.000). There was no 
main effect for side (F(1,23)=0.517, p=0.480). There was an interaction effect between 
condition/ phase (F(3,69)=30.119, p=0.000), an interaction between condition/side 
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(F(3,69)=7.317, pß. 000), and an interaction between phase/side (F(I, 23F50.020, pß. 000), 
and there was aP level interaction between condition/phase/side (F(3,69 =21.830, pß. 000), 
there was significant interaction between high/control for the before/after measurement in 
the treated/non treated side (Table 10.7). 
However, when post hoc test was used, none of these relationships reached statistical 
significance. 
Source Condition Phase Side S! L. 
Condition High vs control . 012 
1S 
Low vs control . 461 NS Placebo vs control . 832 NS Phase Before vs after . 000 S Condition * base High vs control Before vs after . 000 5 Low vs control Before vs after . 611 NS 
Placebo vs control Before vs after . 
148 NS 
Condition * side High vs control Treated vs non treated . 000 S Low vs control Treated vs non treated . 464 NS Placebo vs control Treated vs non treated . 750 NS Phase *side Before vs after Treated vs non treated . 000 S Condition *phase * 
side 
High vs control Before vs after Treated vs non treated . 
000 S 
Low vs control Before vs after Treated vs non treated . 396 NS Placebo vs control Before vs after Treated vs non treated . 385 NS 
lame tiu. i) t. onuast analysis of sKm mmperauue (significant tindings are highlighted in red), S: significant, 
NS: non-significant 
Condition Side Treatment phase Mean±Std. Deviation 
High Treated Before 28.974±1.743 
After 31.048±1.667 
Non treated Before 28.931±1.689 
After 29.281±1.737 
Low Treated Before 27.955±1.432 
After 28.369±1.471 
Non treated Before 28.397±1.541 
After 28.492+1.582 
Placebo Treated Before 28.444±1.410 
After 28.414±1.391 
Non treated Before 28.623±1.159 
After 28.599±1.212 
Control Treated Before 28.300±1.192 
After 28.554±1.139 
Non treated Before 28.439±1.401 
After 28.546±1.265 
Table (1U. 5) unanges in sKm temperature across the experimental conditions 
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Table (10.8) provides a summary of the changes in skin temperature across the 
experimental conditions. Figure (10.4) is a box plot showing the increase in SkT in the four 
experimental conditions. The graph shows that there was a minimal change in the 
experimental conditions for placebo and low conditions in the before and after PSWT 
administration. The increase in high dose was the greatest as could be seen from the shift in 
the position of the box plot for the high after condition. 
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Figure (10.4) Changes in skin temperature across the experimental conditions in the treated side 
This means that only the high dose have increased skin temperature significantly. 
.. 
308 
Chanter 10 Physiological effects of PSWT on osteoarthritic patients 
10.5.3 Nerve stimulation results 
10.53.1 Nerve conduction velocity 
Manuchley's test of sphericity was non-significant for all variables except for the 3`' level 
interaction between condition/ phase/ side where the corrected F value (Greenhouse 
Geisser) will be reported. There was a main effect for condition (F(3,69)=6.070 p=0.00I ), the 
difference was between high/control (p 0.000), low /control (p 0.002), placebo/control 
(p=0.03 1). There was a main effect for phase in the before and after treatment 
(F(J, 23F39.841 p=0.000). There was a main effect for side between the treated and non- 
treated knee (F(l, 23)=8.772 p0.007). There was an interaction effect between 
condition/phase (F(3,69) 12.748 p=0.000), and an interaction effect between phase/side 
(F(3,69)=7.44G9 Pß"012). Post hoc tests (Bonferroni) revealed a statistical significance 
between high/control (x-0.000), and low/control (p=0.014). Further description to main 
effects and interactions following contrast analysis is shown in Table (10.9). Figure (10.5) 
shows the changes in NCV recorded for the before and after PSWT administration across 
the experimental conditions in the treated side. 
Source Condition Phase Side S' nificance 
Condition High vs control . 000 s Low vs control . 002 S Placebo vs control . 031 S 
Phase Before vs after . 
000 S 
Condition * 
pbase 
High vs control Before vs after . 
000 S 
Low vs control Before vs after . 000 s Placebo vs control Before vs after . 
207 NS 
Condition *side High vs control Treated vs non treated . 
339 NS 
Low vs control Treated vs non treated . 295 NS Placebo vs control Treated vs non treated . 165 NS Phase * side Before vs after Treated vs non treated . 01 ' S 
onditioe *pbase 
* side 
High vs control Before vs after Treated vs non treated . 521 NS 
Low vs control Before vs after Treated vs non treated . 237 NS Placebo vs control Before vs after Treated vs non treated . 
255 NS 
Table (10.9) Contrast analysis of NCV, (significant findings are highlighted in red), S: significant, NS: non- 
significant 
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Ferro (10.5) Line plot of the changes in NCV across the experimental conditions in the treated side 
Condition Side Treatment phase Mean±Std. Deviation 
High Treated Before 53.659±1.876 
After 50.227±4.147 
Non treated Before 54.159±1.763 
After 51.847±2.760 
Low Treated Before 53.885±2.140 
After 50.848±4.122 
Non treated Before 53.922.073 
After 52.017.920 
Placebo Treated Before 53.433±1.969 
After 52.024±4.740 
Non treated Before 53.968±2.036 
After 54.093±2.169 
Control Treated Before 54.586±1.798 
After 54.601±1.972 
Non treated Before 54.464.116 
After 54.458±2.167 
Table (10.10) Summary of changes in NUV across experimental conditions 
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Summary of the experimental conditions is presented in Table (10.10). Figure (10.5) shows 
the decrease in NCV with the high dose, low dose and placebo. Both high and low dose 
displayed a reduction in NCV, which is greater than was recorded with the placebo group. 
It is interesting that the NCV decrease recorded with the low dose closely resembled that of 
the high dose. A finding that was not seen with BVo1 or SkT because usually the high dose 
demonstrates the largest change. 
10.5.3.2 Nerve onset latency 
Sphericity was only significant for condition/phase/side (p=0.000). There was a main effect 
of condition (F(3,69)=4.619) between high/control (p=0.001), low/control (p=0.002), but not 
placebo/control (p=0.306). 
There was a main effect of phase (F(l, 23)=55.323, p=0.000). There was a main effect of side 
(F=(I, 23)=14.520, p=0.001). There was no interactive effect between condition/side 
(F(3,69)=1.395, p=0.252). There was no interactive effect between phase/side (F(1,23)=2.322, 
p=0.141), no interactive effect between condition/phase/side (F(1.865,42.98o)=0.446, p=0.629). 
Post Hoc test revealed a statistical significant difference between high/control (p=0.004) 
and low/control (p=0.009). 
This means that both the high and the low dose have affected nerve onset latency 
significantly. 
10.5.3.3 Duration of the response 
Sphericity was violated for condition/phase and condition/phase/side. There was no main 
effect of condition (F(3,69)=1.429, p=0.242), no main effect of phase (F(1,23)=1.895, 
p=0.182), no main effect of side (F(1,23)=1.064, p=0.313). There was no interaction between 
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condition/phase (F(1.446,33.248)=1.971, p=0.126), condition/side (F(3,69)=1.874, p=0.142), 
phase/side (F(l, 23)=2.639, pß. 118), or between condition/phase/side (F(l. 723,39.619)=1.625, 
p=0.191). More analysis can be found in Appendix F. 6. This means that none of the 
experimental conditions have affected nerve response duration. 
10.5.4 Pulse rate results 
Using two way ANOVA there was no main effect of condition (F(3,69)=0.148, p=0.930), 
There was a main effect of phase (F(2,46)=5.381, p=0.008) in the before and after conditions 
which was lost when phase was viewed in relation to the experimental conditions No 
interactive effect between condition and phase (F(6,13s)=. 812, p=0.562). More analysis can 
be found in Appendix F. 6. Summary of pulse rate is found in Table (10.11). 
This means that none of the experimental conditions had an effect on PulsR. 
Condition Mean±Std. Deviation 
24W-mean pulse before 66.807±13.070 
Mean pulse during 68.034±13.163 
Mean pulse after 67.753±12.436 
3W-mean pulse before 66.313±10.911 
Mean pulse during 66.138±10.856 
Mean pulse after 65.707±10.357 
Placebo-mean pulse before 65.339±12.684 
Mean pulse during 66.612±13.251 
Mean pulse after 66.544±12.560 
Control-mean pulse before 63.589±9.338 
Mean pulse during 64.425±11.489 
Mean pulse after 64.858±10.790 
Table (11.11) Summary of change in pulse rate in the experimental conditions 
10.5.5 Core temperature results 
Using two way ANOVA, there was no main effect of condition (F(3,69)=1.461, p=0.233), 
there was a main effect of phase (F(l. 604,36.893)=3.736, p=0.042) between before and after 
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which was lost when phase was viewed in relation to the experimental conditions. No 
interactive effect between condition/ phase (F(3.917,90.082)=0.. 937, p=0.445). Summary of 
core temperature is found in Table (10.12). 
This means that although there was a change in CorT, none of the experimental conditions 
resulted in significant increase. 
Condition Mean±Std. Deviation 
24W- mean core temp before 34.942±. 524 
Mean core temp during 34.900±. 423 
Mean core temp after 34.943±. 491 
3W- mean core temp before 34.711±. 318 
Mean core temp during 34.819±. 250 
Mean core temp after 34.832±. 374 
Placebo mean core temp before 34.867±. 265 
Mean core temp during 34.976±. 257 
Mean core temp after 34.980±. 253 
Control mean core temp before 34.920±. 520 
Mean core temp during 35.018±. 314 
Mean core temp after 35.052±. 350 
Table (10.12) Summary of core temperature in the experimental conditions 
10.5.6 Ambient temperature 
Using one way ANOVA there was no main effect of condition (F(3,69)=0.225, p=0.879), no 
main effect of phase (F(1,23)=1, p=0.328), there was no interactive effect between condition/ 
phase (F(3,69)= I, p=0.398). 
This means that ambient temperature did not affect the outcome in any of the experimental 
conditions. 
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10.5.7 Ambient humidity 
Using one way ANOVA there was no main effect of condition (F(3,69)=0.733, p=0.536), no 
main effect of phase (F(1,23)=2.902, p=0.102), no interactive effect (F(3,69)=0.799, p=0.499). 
This means that ambient humidity did not affect the outcome obtained with the four 
experimental conditions. 
10.5.8 Correlations with anthropometric data 
Using Pearson Correlation Coefficient, no significant correlation was found between BVol, 
SkT, NCV, PuIsR, CorT and the anthropometric data except for SkT and weight (p<0.05). 
More detail is can be found in Table (10.13). 
Age Height Weight Fat percentage 
Bvol Pearson Correlation -. 245 . 148 . 282 -. 226 
Sig. (2-tailed) . 227 . 470 . 162 . 268 
SkT Pearson Correlation -. 030 -. 102 . 390 . 279 Sig. (2-tailed) . 883 . 621 . 049 . 167 
NCV Pearson Correlation . 035 . 319 . 021 . 076 
Sig. (2-tailed) . 867 . 112 . 920 . 711 
PulsR Pearson Correlation . 066 -. 241 -. 291 . 242 Sig. (2-tailed) . 750 . 236 . 149 . 234 
CorT Pearson Correlation . 055 . 206 . 085 . 138 
Sig. (2-tailed) . 789 . 313 . 678 . 500 
Table (10.13) Summary of correlations, (significant tinamgs are hignughted in red), i: significant, Ivß: non - 
significant 
10.5.9 Visual analogue scale results 
Sphericity was violated for condition hence the corrected F values will be reported. Using 
one way ANOVA there was a main effect of condition (F(3.153,72.527)=10.303, p=0.000). This 
difference was found significant between high/ baseline (p=0.000), low/baseline (p=0.000), 
placebo/baseline (p=0.000), and control/baseline (p=0.011). Post Hoc test revealed a 
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statistical significant difference between all the above mentioned conditions (Table 10.14). 
Post hoc results can be found in Appendix (F. 6) 
Source Condition Sim . 
VAS Hi vs baseline . 000 S 
Low vs baseline . 038 S Placebo vs baseline . 
010 S 
Control vs baseline . 000 S 
Table (10.14) Changes in VAS across experimental conditions, (significant results are highlighted with red), 
S: significant, 
10.5.10 Muscle strength results 
Using a one way ANOVA, there was a main effect for muscle strength (F(2.445 23o»=7.592, 
pr0.001). A significant difference was found between baseline and high dose (pß. 005). 
Post hoc test revealed a marginal statistical significance between baseline/ high dose 
(p=0.051). Further findings can be found in Table (10.15). More results are presented in 
Appendix (F. 6). 
Son Condition Si t. 
Muscle High vs baseline . 05 I S 
Low vs baseline . 
238 NS 
Placebo vs baseline . 725 NS 
Control vs baseline . 517 NS 
Table (10.15) Changes in muscle strength across experimental conditions, (significant results are highlighted 
in red), S: significant, NS: non-significant 
10.5.11 Range of motion results 
Using a one way ANOVA, changes in ROM between baseline and other experimental 
conditions were significant between high and baseline only (-0.02). Further findings can 
be seen in Table (10.16). Complete data profile can be found in Appendix (F. 6). 
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Source Condition Si . 
ROM High vs Baseline . 
02 S 
Low vs Baseline . 
264 NS 
Placebo vs Baseline . 442 NS 
Control vs Baseline . 146 NS 
Table (10.16) Changes in ROM across experimental conditions, (significant results are highlighted in red), S: 
significant, NS: non-significant 
Table (10.17) summarises treatment outcome with the different conditions. In Figure (10.6) 
it could be seen that when PSWT was administered for 10 minutes there was improvement 
in 77% of the patients with 24W, 61.5% with 3 W, and an interesting 39% improvement 
with placebo. These findings are based on patient reporting, and outcome of VAS (the 
percentage was calculated by dividing the number of subject improved by the total number 
of subjects). 
Treatment Improved Stayed the same Deteriorated 
Hi (24W) 20 (76.9%) 5 (19.2%) 1 (3.84%) 
Low 3 16 61.5% 9(34.6%) 1(3.840/o) 
Placebo (0.05W) 11(38.5%) 14 (53.8%) 0 
Control 3 (11.5%) 21 (84.6%) 0 
Table (10.17) Summary of treatment outcome with the expenmentat conarnon 
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Figure (10.6) Treatment outcomes with experimental conditions 
10.5.12 Functional status 
0% 
Following the small scale questionnaire, it was found that 87.5% (n=21) of patients 
experienced lower levels of pain, 83.3% (n=20) of patients felt better in their general status 
compared to when they started the treatment. 75% (n=18) of patients felt that the treatment 
reduced their pain when ascending the stairs, while 45.8% (n=11) felt that PSWT helped 
them with their pain when descending the stairs. More results can be found in Appendix 
(F. 6). 
10.6 DISCUSSION 
The literature reviewed in Chapter 3 has showed that the evidence in favour of the 
use of PSWT with OA knees is still inconclusive with some reporting positive outcomes 
317 
Chanter 10 Physiological effects of PSWT on osteoarthritic patients 
and others reporting negative outcomes and this is because of the nature and the poor 
quality of the majority of the published studies. In a controlled, placebo single blinded trial, 
the current study has compared the effects of a high (24W) and a low (3W) dose of PSWT 
on BVo1, SkT, NCV, PulsR and CorT. Twenty six patients participated in the study and 
they were randomly allocated to experimental groups. 
Studying OA has always been associated with many difficulties due to the lack of clear 
definition of the condition, lack of agreed diagnostic criteria, poor correlation between X- 
ray and the patient clinical picture (Doherty, 1994). This problem has been overcome in this 
study by using the American College of Rheumatology Classification (Altman, 1991, 
Altman et al, 1986). This classification system takes into account the clinical picture, 
laboratory and X-ray findings and as such is considered to be one of the comprehensive 
systems of classifying OA besides being a widely cited source in the literature. 
There was a need to establish a diagnostic criterion as many patients were referred to the 
physiotherapy department in Lister Hospital, where this study was conducted, diagnosed as 
knee pain. Having a classifying system allowed for enrolling patients with similar 
symptoms and closer baseline point. 
At the planning stage of this trial and in the laboratory trial, there was a need to take 
a decision regarding how to space out the sessions. The decision at that time was taken to 
space them by a minimum of 2 days based on the available literature. The reference was 
electrotherapy textbooks along with manufacturers' manual (Wadsworth and Chanmugam, 
1983). The results of the current work suggests that PSWT at the dose given in this 
experiment has a latent or a carry over effect that lasts for a day and symptoms return to 
pre-treatment status the following day. This could mean that none of the findings reported 
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is the result of a build up of energy or a consequence of the latent treatment effects. 
Furthermore, given that improvement reverts to pre-treatment status after a relatively short 
period could suggest that the energy delivered is not sufficient to maintain therapeutic 
effects over time, and hence need to be increased either by administering daily treatment or 
by increasing treatment duration. However, such notions need to be validated in further 
experimentation before they are accepted clinically. 
Following the collection of 20 sets of data, a reverse sample size calculation was 
performed using the same software in Section 9.2.3. The mean values for change in BVol, 
SkT, NCV were used to calculate the number of subjects needed for the trial. Based on SD, 
effect size, and significance level ct< 0.05 and a power of 0.8, the number of subjects 
needed was determined to be 13 when BVo1 results were analysed, 11 when nerve 
conduction results were analysed and 10 when SkT were analysed. However, it was 
decided to go for the twenty six patients recruited at the initial stage of this study for two 
main reasons. Firstly: unlike other studies when it is not ethical to recruit large number of 
patients and being denied treatment, the current study is a same subject design and all 
patient will have the advantage of getting treatment while still waiting for their turn in the 
waiting list. 
Secondly: appointments have already been given and patients were expecting to get 
treatment and it would be unprofessional to cancel them. 
10.6.1 Blood volume 
According to Hand (1990) with inductive PSWT, the heating is expected to be 80% 
more in deeper tissues compared to superficial. There was almost 10 times increase in BVo1 
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during the treatment in 11 out of 26 patients with the high dose and 4 out of 26 in the low 
dose. These readings declined to 2 out of 26 with the high dose and none in the low dose 
group when baseline readings were compared to post treatment period. As mentioned in the 
pervious chapter, no speculation can be made about muscle temperature, however such an 
increase in BVo1 could be associated with an increase in the internal temperature, and 
increase in metabolic activity in the muscles (Kitchen 2002) hence better treatment 
outcomes as was demonstrated in the findings. However, this remains speculative and 
would need to be confirmed experimentally. 
The majority of the patients in this study reported that the relief of symptoms was 
felt within 1 or 2 hours after the treatment. This aspect of PSWT mechanism has not been 
explored before in the literature and needs further experimentation in order to find out 
whether this phenomenon is specific to the doses used in this trial or is it a mechanism by 
which PSWT works. It is also interesting to see whether this observation does occur with 
the continuous mode of SW. 
10.6.2 Skin temperature 
There was a significant increase in AT recorded with the high dose. This increase 
was around 2°C, which is similar to that recorded in the laboratory study (Chapter 9). The 
increase with the low dose was less than 0.4°C. The fact that minimal increase in SkT was 
recorded (was not statistically significant) with the low dose suggests that the changes seen 
in BVoI could be a possible micro-thermal reaction. Similar amount of increase was 
recorded by both Erdman (1960) and Bricknell and Watson (1995). 
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It was observed that the increase in temperature with the high and low dose did not 
reach a plateau which could mean that further increase in SkT could occur if the treatment 
duration was extended. It could also mean that although the examined dose has altered SkT, 
BVol, and NCV, it may not be the optimum treatment duration, thus other durations need to 
be examined as it may lead to better treatment outcomes. 
10.6.3 Nerve conduction velocity 
It has long been accepted that the high frequency current delivered by PSWT does 
not have any direct effect on motor and sensory nerves as the duration of the impulse 
required to stimulate a nerve should be more than 0.01 ms (Oh, 1996). High frequency 
currents have a pulse duration of 0.001 ms which is shorter than the pulse required to 
stimulate a nerve (Kitchen 2002; Forster and Palastanga, 1985). Findings from the 
laboratory experimentation in Chapter (9) have demonstrated that the application of PSWT 
is associated with a decrease in NCV. Administering PSWT on OA patients has also 
demonstrated a significant reduction in NCV with both treatment and placebo groups. This 
reduction was with the high dose in the laboratory trial, and with the high and the low dose 
in the current study. Interestingly, the decrease in NCV in the low dose was similar to the 
high dose. Such a reaction was not seen with the amount of increase in BVo1 or increase in 
SkT as a higher increase was consistently associated with high dose and smaller amounts of 
increase were associated with low dose but in no experimental condition have the two doses 
displayed similar findings. The current study has demonstrated that, contrary to previous 
reports (Currier and Nelson, 1969; Abramson et al 1966), the increase in temperature is not 
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always associated with increase in NCV. Although the underpinning reasons are not very 
clear, possible interpretations of the findings have been presented in Section (9.4.3). 
It was noticed when performing the NCV studies that patients needed between 60- 
90% of the stimulus strength to stimulate their motor points and result in visible 
contraction, while healthy subjects in the laboratory trial considered 50% of the stimulus 
strength very painful. Muscle contraction with healthy subjects was also seen around 40% 
of stimulus strength with the majority of the subjects. The reason underpinning this 
observation is not known however, it could be speculated that with the long history of pain, 
there might have been an increase in patients threshold to noxious stimulus. Other reasons 
could be changes in nerve conduction characteristics in association with the disease 
process, an area that warrants further research. 
10.6.4 Secondary outcome measures 
Outcomes measures such as muscle strength, ROM and pain level were included in 
the study to provide data that will help link changes in physiological parameters measured 
with the improvement or deterioration in function reported or objectively measured. Pain 
was assessed being one of the prime symptoms in OA (Peat et al, 2001). Although ROM 
and muscle strength are not expected to improve dramatically as a result of applying 
PSWT, apparent changes in muscle strength are expected to result from the decrease in pain 
level. 
The intention was to measure pain, muscle strength, and ROM before and immediately 
after treatment, however, after taking the measurement with 7 patients it was found that no 
patient have reported a change in the level of pain, ROM or muscle strength immediately 
322 
Chapter 10 Physiological effects of PSWT on osteoarthritic patients 
after the treatment. Therefore, it was decided that there was no benefit to continue taking 
these measurements immediately post treatment and to continue taking them prior the start 
of each treatment session only before the application of PSWT. 
10.6.4.1 Visual analogue scale 
VAS was employed in the study in order to reflect changes in pain level as a result 
of the applied treatment. VAS has been criticized of being unidimensional because it only 
resembles the sensory side and fails to reflect the multi-dimensional construct of pain 
namely the affective, evaluative, cognitive and behavioural elements (Sim and Waterfield, 
1997). Despite that it was employed because it was easy to use by patients and requires 
almost no reading or verbal skills (Collins et al, 1997). Furthermore, as, the study involves 
ongoing assessment of pain, it is important that the scale used be short, rapid, reliable and a 
valid measure. 
Reduction of pain could be the resultant of counterirritant effect which is mediated by the 
effect of morphine receptors in central nervous system and the possibility of pain 
moderation caused by enkephalins and endorphins (Field and Basbaum, 1999; Lehmannn 
and DeLateur, 1990). 
According to Gallagher et al (2001) and Todd et al (1996) a difference of 13 mm or 
1.3 cm on VAS represents the minimum clinical significant difference while others have 
accepted 9 mm to be the minimum acceptable difference in pain level for a clinical change 
in patient's pain level (Deloach et al, 1998). In this study 16 patients (61.5%) showed 
clinical improvement according to these criteria (13 mm) with the high dose. There was a 
42.3% improvement with the low dose, 23% improvement with placebo and an interesting 
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19.2% improvement with the controlled condition where no treatment was applied. All of 
this highlights the role that placebo effect plays in patient response to the delivered (or not) 
treatment. 
Two patients reported an increase of pain (one after high dose and one after low 
dose), both patients reported the pain after the first session and this may be caused by the 
testing procedure which demanded greater effort from the knee muscles in order to achieve 
the maximum isometric strength. This also places the joint in ranges, which the patient 
usually tries to avoid in order to avoid pain 
10.6.4.2 Muscle strength 
Unlike the findings of Chastain (1978) who demonstrated that subjects 
demonstrated an increase in their isometric strength following a 20 minutes of SW 
application, the findings of the current study did not find any difference between the pre 
and immediately post treatments periods. There are several factors that could be responsible 
for those observations. It could be the duration of the treatment, which was 20 minutes in 
the Chastain study and 10 minutes in the current study. Moreover, the mode of application 
was different it was continuous in Chastain trial and it was pulsed in this study. The current 
findings were in agreement with Quirk et al (1985) and Pasila et al (1978), who 
demonstrated that using PSWT with OA patients does not result in an increase in muscle 
strength. The findings provide evidence to the faulty belief of therapists that PSWT could 
increase muscle strength. A belief that have appeared repeatedly in the literature and was 
one of the findings of the survey conducted in Chapter 6. 
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Although it was not directly related to the objective of this trial, this finding was 
worth reporting. Initial examination has revealed that almost all patients had muscle spasm 
around the knee, which is expected to limit the ability of the muscle to exert its maximum 
effort. Although the PSWT dose applied is not expected to alter the state of the spasm 
dramatically, a certain degree of relief is expected to occur as a result of the increase in 
blood supply and the reduction of pain. This is expected to be one of the reasons for the 
significant apparent increase in muscle strength and ROM recorded with the high dose 
intervention. 
10.6.4.3 Joint stiffness 
The functional scale developed by the researcher for the purpose of the current study to 
follow changes in functional status with patients has revealed interesting findings. It was 
found that almost all patients have reported a decrease in joint stiffness and a smoother 
movement after PSWT treatment. Patients have also reported that less time is needed to 
overcome the stiffness in the joint after periods of immobility. Unfortunately, no 
quantitative measurements were taken to measure the degree of stiffness. These effects are 
expected to occur as a result of decrease viscosity of synovial fluid and reduce the 
resistance to joint movement (Scott, 2002). Effects of PSWT on stiffness was documented 
in the literature (Yung et al, 1986), however, this study used the continuous mode of SW. 
No other work has been identified that examined the same topic, therefore it warrants 
further exploration. 
To state that a treatment is effective, it must produce a change in function and not 
just a change in outcome detected by the researcher. The current study has demonstrated 
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that applying PSWT at either 3W or 24W is associated with subjective reporting of 
improvement that was validated by objective measurements. 
In partial disagreement with Pasila et al (1978) who reported that applying PSWT 
on MP 40W does not alter ROM, the current study has showed a significant improvement 
in ROM with 24W but not 3W or placebo. 
10.6.5 Placebo effect 
The placebo group was employed in the current study to mask the treatment 
allocation hence eliminate the subjective effects of the treatment which could bias the 
results (Wall, 1992). 
Although it was expected that patients will only report improvement after actual treatments 
(3W or 24W), it was interesting to have 39% of the sample reporting improvement after a 
placebo treatment. There was one patient who even felt heat with placebo application. This 
confirms the strong placebo role in the clinical improvement of patients and demonstrated 
its associated role with the use of PSWT. This also reinforces the need to include a placebo 
group in future experiments with PSWT to quantify its effects and judge the genuine effect 
of PSWT before any generalisations on the results are made. 
In disagreement with Klaber-Moffett et al (1996) who demonstrated that there was a 
difference between the outcome of active and placebo group on OA knees and hips, the 
current study has shown 39% of the patients in the placebo group felt better. This 
improvement was shown in the level of pain and function and was confirmed by 
physiological measurements. Additionally, in any medical intervention the placebo effect 
accounts for 30-40% of symptom relief (Gifford, 1998). Previous experimental work 
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conducted on healthy subjects has demonstrated that the effect of a placebo treatment on 
the treated side gives a response that is similar to 3W MP. 
More interestingly, is the 19.2% improvement seen with the control condition where 
no treatment was applied. It seems that by attending sessions and being in hospital where 
patient's complaints are heard and cared for has an impact on how patients' bodies react to 
no actual treatment. This is possibly an effect mediated by higher centre in the brain. All of 
this highlights the role that placebo effect plays in patient improvement. 
In all experimental conditions, similar to the laboratory trial, the non-treated side 
has demonstrated changes that mirrored the changes in the treated side with effects that are 
smaller in effect and are lost once the PSWT machine is turned off. 
Based on the findings of this work, the null hypothesis of the high dose was rejected, the 
null hypothesis of the low dose was rejected, the null hypothesis of the effect of treatment 
on the non-treated side was rejected and only the null hypothesis on CorT and PulsR were 
supported. 
10.7 CONCLUSION 
The clinical study examined the effect of applying PSWT at 3W and 24W MP to 
patients with OA knees. The effect of PSWT was examined in single blinded placebo 
controlled trial. It was found that both power levels led to an improvement in the measured 
variables (BVol, SkT, and NCV). The high dose led to improvement in the general status of 
the patients (decrease in the pain level, increase in muscle strength and increase in ROM). 
The placebo group demonstrated changes that were similar to the low dose outcome. 
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Findings provide support to the positive effects associated with applying PSWT to patients 
with OA knee. Further detailed evaluation to the longer term effects of the measured 
variables needs to be undertaken. Future trials need to relate the duration of the disease and 
the severity of the symptoms with the response to the treatment. 
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CHAPTER 11 
GENERAL DISCUSSION AND CONCLUSION 
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11.0 INTRODUCTION 
PSWT is one of the most commonly used electrotherapy modalities among 
physiotherapists. Recent surveys have shown it to be one of the top three electro- 
physical modalities employed in outpatients clinics in England and Ireland (Foster et al, 
1999). It has been used for decades to manage a myriad of conditions such as wound 
healing, arthropathies, and nerve regeneration (Low and Reed, 2000). Despite the 
relatively long history of PSWT use, very little is known about its bio-effects and 
mechanism of action. It is argued that the increase in tissue temperature is the main 
factor responsible for the biological reactions observed such as the increase in blood 
flow, dilatation of blood vessels, increase in metabolism rate. 
Another area that continues to stir long debates is the unresolved issue about 
PSWT dosage. Considerable confusion exists between clinicians with respect to the 
application of PSWT due to the wide range and the variety of methods available for 
setting the treatment parameters. Literature, contributed very little to resolve this dispute 
with the majority of the studies failing to report the full profile of the dosage used and 
the rationale behind it. 
The current project was set to explore some of the possible mechanisms of 
interaction between PSWT and biological systems. Although several attempts to 
examine the physiological effects of PSWT on SkT and BVo1 had preceded the current 
work, two downfalls could be found in the previous work. Firstly: a large number of 
experiments had focussed on the maximum setting of PSWT machine, a setting that 
was proved to be thermal, and very few attempts were undertaken to explore other 
ranges of PSWT dose. Secondly: the majority of the work conducted to-date was based 
on investigator's intuition and arbitrary choices of dosage with no rational given for the 
choice of the experimental protocol. 
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With therapists increasingly moving towards applying lower levels of energy 
and preferring athermal to thermal modes of treatments (Watson, 2000; Kitchen, 
1995b), PSWT has become a widely used modality being employed clinically more than 
CSWD (Shields, 2003; Kitchen, 1995b). Surveys have confirmed it to be one of the top 
three electrotherapy modalities used in physiotherapy after US and IFC (Foster et al, 
1999; Pope et al, 1995). Despite this popularity, PSWT remains an under-explored 
therapeutic modality (Pope et al, 1995) and the one with least paid attention in terms of 
researching its efficacy (Kitchen, 1995a). 
The literature reviewed (Chapter 3 and Chapter 4) has demonstrated that the 
majority of laboratory and clinical studies on PSWT were of poor quality, lacking 
crucial information on treatment parameters, sufficient information on the inclusion/ 
exclusion criteria, blinding and statistical analysis making them of limited clinical 
value. Furthermore, almost all the studies have employed treatment doses that were 
chosen arbitrary without any justification given for their choice. 
This research program was planned with PSWT efficacy being the main focus. In order 
to examine this, a series of experimental protocols were developed and executed. The 
program started with an audit (Chapter 5) that gave an overview on the nature of use, 
the documented evidence on PSWT efficacy as could be ascertained from therapists' 
notes, and the quality of the therapists' documentary skills with regard to PSWT. The 
audit was used to define areas in clinical practice that needed further exploration. It was 
also used to define the content of the questions that were later used in the survey 
(Chapter 6). The nationwide survey involved a wider sample and a broader base of 
information such as techniques employed by therapists when using PSWT, their 
general use, treatment progression and termination. The questionnaire also contained 
case studies on OA for therapists to construct treatment plans. These proposed plans 
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were the basis of choice of the treatment parameters that were later employed in the 
controlled randomised laboratory trial (Chapter 9). The evolution of experimentation 
from laboratories to clinical settings is expected to move the research to a new and 
better status in terms of the nature of evidence, hence enriching practice and improving 
the nature of patient care. Given this, a controlled randomised trial was conducted on 
patients with OA (Chapter 10) following the same protocol used in the laboratory 
experiment. 
This chapter will summarise the previous chapters; it will bring the main findings of 
different chapters together and present the wider picture of the research, its clinical 
implication and areas for future research. 
11.1 AUDIT 
Published reports have examined therapist documentation in general however, 
no work have been identified to date that examined the quality of therapists' 
documentations in outpatient clinics with regards to PSWT, hence the importance of the 
current audit. A number of interesting findings have emerged from this audit. The audit 
was conducted in 8 randomly chosen hospitals that were selected to represent the 
clinical practice in all the health regions in England. The audit (Chapter 5) has identified 
the poor written standards of patient's notes as a priority area that needs to be addressed. 
It was surprising that from the entire sample of files examined (n=192), none had a 
complete profile that described treatment according to CSP standards. It has also shown 
that the amount of documentation is neither complete nor comprehensive and does not 
convey the nature of care delivered to patients. The standard of the files was not in 
accordance with CSP recommendation in that they lack crucial information necessary 
for treatment replication, the problem list, and the time for achieving treatment goals. 
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Feedback on patient improvement was lacking and progress notes were not always 
updated with changes in treatment parameters. In the majority of the files examined, it 
was not clear though why the pre-treatment status of the patients is mentioned in full 
and very little is reported on the patients after cessation of the treatment with PSWT. In 
cases when therapists alter the treatment plan, no rationale was given. The arbitrary 
recording of power levels of a treatment is inadequate in an environment that demands 
therapist to justify their treatments and rationalise their choices. All of this puts 
therapists at a disadvantage when it comes to protecting their rights against litigation 
and providing quality patient care. 
Another issue that emerged from the audit was in relation to treatment 
progression. Three major approaches appear to have been adopted by therapists to 
progress a treatment plan (therapists either increase, decrease, or leave the dose the 
same). The majority opted for increasing the dosimetry either by increasing the time or 
any other parameter on the machine console. Best results were obtained by either 
increasing the dose or by leaving it the same; the worst results however, were obtained 
when the dose was decreased (Section 5.5.3). 
From the audit it was found that OA was the most common condition seen in outpatient 
clinics in England, as such it was employed for the paper-based case studies in the 
survey. 
11.2 NATIONWIDE SURVEY 
Chapter 6 was a nationwide survey that examined the nature of PSWT usage on 
a wider sample of physiotherapists (n=247) in 90 randomly selected outpatient clinics 
across England. Results have shown that pain relief was the main goal for using PSWT, 
despite the lack of clear documented evidence on PSWT mechanism of action with 
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pain. It was expected that reduction of bruising, inflammation, oedema or healing of 
soft tissue to be at the top of the list given the amount of literature that has investigated 
these conditions. 
Another important finding was that a large number of therapists (40%) use 
PSWT for a duration of 10 minutes while 22% use it for 8 minutes. Experimentation on 
the other hand, employs treatment of longer durations (15 or sometimes 20 minutes). 
This mismatch between practice and research findings could be the reason for 
therapists describing research as alienated and that research findings may not be 
transferable to clinical setting. 
The majority of therapists surveyed (70%) reported that they were satisfied with 
the outcome of PSWT with their patients, this may have been responsible for the 
continued use of this modality clinically despite the inconclusive evidence provided by 
the experimental work in the area. 
Combining modalities and interventions have been reported in the literature 
before (Kitchen, 1995 a, b; Gray et al, 1994). The findings of this work confirmed the 
belief that using more than one modality will boost the treatment outcome. Such 
supposition needs to be examined in laboratory and clinical setting to justify its use 
clinically and mechanism of action. Interestingly, a state of confusion has been detected 
in the way therapists progress their treatment plan. It is interesting that 57% choose to 
change all parameters in the same session and only 3% prefer to change PRR, and 2.5% 
prefer to change PD. The effect of changing one or more parameters has not been 
discussed sufficiently in the literature and needs to be explored experimentally. The 
findings have also revealed a mismatch between short and long term goals of treatment 
with PSWT being believed to restore ROM and improve function. 
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It is expected that therapists rely on experience to make clinical decisions. In 
this survey, attempts were made to separate the years since qualification from years 
therapists spent working in outpatient with electrotherapy in order to identify the 
effects of experience in the field of electrotherapy on the process of decision making. It 
is interesting that the years of experience as a whole determines the frequency of 
applying a modality, treatment progression and termination while the experience in the 
field of electrotherapy has its impact on the choice of treatment duration and whether to 
combine modalities or not. These findings are an important part in the clinical decision 
making process and it is crucial that these issues are explored further as it may shed 
some light on the reason behind both the poor and the excellent treatment outcomes 
obtained by therapists when using PSWT. 
The theoretical case studies employed in the last section of the questionnaire 
revealed that both acute and sub-acute conditions are perceived the same hence treated 
with the same MP. Interestingly, it was found that regardless of the severity of the 
condition, it would still be treated twice a week, which raises the question of whether 
this was judged by experience or it was related to patient load and departmental policy. 
When the findings from the proposed plans were divided in terms of good and 
bad outcomes (as reported by therapists) it was interesting to find out that those who 
reported a good outcome opted to use low dosage with less time for acute and sub-acute 
conditions. Therapists also tended to increase the dosage and the time for chronic 
conditions. In contrast, those who reported poor outcome appeared to make no 
distinction in their choices with different stages of the disease, suggesting that they were 
not selective in their dosage. This approach to treatment has been discussed earlier in 
the literature and is bound to occur when clinicians are not sure on the dosage to apply 
(Kitchen, 1995b). 
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Based on the most commonly reported responses, it was decided to use PD of 100 µsec, 
PRR of 200 Hz, MP 3W, and PD of 200 µsec, PRR of 800 Hz, MP 24W as the two 
treatment protocols for the experimental groups. 
It is of interest to mention that with both the audit and the survey, it was found 
that best outcomes were obtained when the dose was increased to progress the 
treatment or left the same and the worst results were obtained when the dose was 
decreased during the sessions. Although electrotherapy textbooks have provided a 
vague explanation, it is expected that by increasing the dose other levels of the tissues 
and possibly other structures with different thresholds are overcome hence better 
results are obtained. However when the dose is left the same the tissues may reach a 
state of plateau after which no other change can be seen. This may be related to the 
cumulative effect of the dosage in the tissue that may override tissue thresholds and 
hence produce improvement (Cleary, 1996). 
11.3 LABORATORY TRIAL 
The current thesis was undertaken to provide some explanation on the 
mechanism of action of PSWT. This modality has been accused of being no better than 
placebo; nevertheless it is still being employed clinically. This raises the question of 
whether the majority of these trials have missed out on the beneficial effects of PSWT 
due to the way they have been executed. Almost all studies conducted on PSWT 
examined modes of treatment and have chosen dosage arbitrarily without justifying the 
reason underpinning their choices. In an attempt to overcome that, this study derived the 
dosage from theoretical case studies presented to physiotherapists. OA was chosen as 
the focus of the case studies being the most commonly seen condition in outpatient 
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clinics as revealed from the audit. Hence it could be argued that the dose selection in 
this experimentation was dictated by practice and as such is expected to better inform it. 
The pilot experiments undertaken prior to the completion of the laboratory 
experiments compared two PSWT machines. Although it was not one of the main 
remits of this thesis to examine differences and similarities between PSWT makes and 
models, it was a complementary part of the pilot experimental work to conduct a limited 
comparison between two PSWT makes (Megapulse and Phyaction Performa +). The 
findings provided evidence that even when two PSWT are set on the same parameters 
they may exhibit different characteristics. Although these findings need to be elucidated 
further, their importance is in two areas. Firstly: it is crucial that researchers report the 
make of the equipment they use in their experimentation as each model and make has its 
own manufacturing features that may govern its effects. Secondly: it is not wise to use 
research findings interchangeably as the amount of energy delivered which is one of the 
main factors in the outcome obtained varies with the machine used. 
The laboratory trial has shown that using a MP of 24 W increased BVo1 in the 
treated area, raised the temperature of the treated part (2°C) and reduced NCV but not to 
a statistical significant level when applied for 10 minutes. Low intensity PSWT (3W) on 
the other hand, was found to increase the amount blood circulating the treated area, 
resulted in an non-significant increase in SkT (less than 1°C) and did not reduce NCV 
significantly. Placebo treatment was found to have the same effect as low dose PSWT. 
The change in BVo1 in low and placebo conditions were found to go back to 
baseline after the PSWT is turned off suggesting that higher levels of energy need to be 
applied or possibly longer treatment duration in order to allow enough time for the 
tissues to preserve treatment effects. While none of the above conditions had a 
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significant effect on CorT or PulsR, the high dose has increased CorT in post treatment 
period. 
One of the aims of this laboratory work was to examine the mechanism of pain 
reduction associated with the use of PSWT. Unlike other electrotherapy modalities such 
as TENS, and IFC, PSWT does not stimulate Aß afferent fibres (Low and Reed, 2000). 
It was long thought that heat can decrease pain, however the exact mechanism is not yet 
known. It is believed that heat can stimulate afferent nerve fibres closing down the pain 
gate (Low and Reed, 2000). It is also believed that heat influences muscle spindles, 
nerve endings and golgi tendon organs leading to a decrease in gamma afferent activity 
and a decrease in muscle tone. The increase in BVol means that pain provoking 
metabolites such as prostaglandins and bradykinins are removed from the tissues hence 
less pain is experienced (Lehmann and DeLateur, 1990). 
An important issue that needs to be standardised with PSWT application is the 
distance between the treatment head and the treated part. This factor is one of the 
reasons underpinning different findings when it comes to thermal sensation and other 
physiological effects. Although the distance between the treatment head and the part 
treated is very important in treatment outcomes, not enough attention was paid to it. It is 
not enough to state that the treatment head is held in close proximity to the part treated. 
There should be guidelines to the distance, should the applicator be touching the part 
treated or should it not and if not how far should it be. This is an area that urges 
immediate definition in the literature to ensure safe use and treatment repeatability. 
Although laboratory trials on healthy subjects are accused of presenting findings 
that do not represent patient population and are alienated from the real world, the 
findings of this work are still important in that they have examined parameters that were 
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not previously considered in the literature, hence they have provided normative data on 
physiological reactions. 
11.4 CLINICAL TRIAL ON OA PATIENTS 
Twenty six patients with OA knees were recruited for the study. In a within 
subject design each subject was exposed to 4 experimental conditions (high dose, low 
dose, placebo PSWT, and control) in a random sequence. Both the protocol and the 
treatment dose were identical to that employed in the laboratory trial. Results have 
shown that high dose was associated with significant increase in BVo1, SkT and a 
significant reduction in NCV. 
Low dose was associated with significant increase in BVo1 and a significant reduction 
in NCV but the increase in SkT did not reach statistical significance. 
The placebo condition was associated with a significant increase in BVo1, a significant 
decrease in NCV and an increase in SkT which did not reach statistical significance. 
The control group although have displayed small fluctuations in the values of the 
variables examined none though reached statistical significance. 
These results were associated with significant decrease in pain levels in all the 
experimental conditions. Only the high dose was associated with a significant increase 
in apparent muscle strength and ROM. Though not directly related, the improvement in 
ROM is expected to be secondary to the reduction in pain levels (mean VAS value on 
baseline 5.438±1.661 mm, mean VAS value with the high dose 3.446±1.755 mm, mean 
VAS value with the low dose 3.711±2.271 mm). The changes in physiological 
parameters were associated with an improvement in functional status which was 
reflected in easier movements and an improvement in the general patient condition 
compared to when patient first started the sessions. Although the reduction in pain 
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recorded in this study may have several explanations as explained in the previous 
section, it may be one of the effects of PSWT that needs further exploration. 
Interestingly the non-treated side exhibited reactions that mirrored the treated side but to 
a lesser extent. 
PSWT has been accepted to reduce joint stiffness by reducing synovial fluid 
viscosity (Scott, 2002; Yung et al, 1986) despite the lack of the experimental evidence 
that supports these claims. The reporting by patients on reduction in joint stiffness and 
smoother movement experienced after treatment could provide some evidence for the 
above theories, though experimentation is still needed to validate that. 
11.5 PLACEBO EFFECT 
Despite the well-established role of placebo in medicine (Biller-Anrorono, 2004; 
Fuente-Fernandez and Stoessl, 2004), only few controlled clinical trials in 
physiotherapy have compared various modes of PSWT treatment, evaluated and 
quantified the size of placebo associated with them. This could be one of the reasons for 
accepting many of PSWT effects as being only a placebo response (Svarcova et al, 
1988). Although the placebo effect was first quantified by Beecher to be 53% (Kienle 
and Kiene, 2001), this percentage no longer stands, as more recent experimentations 
have reported the placebo effect to be as high as 70% in some cases (Vase et al, 2002; 
Gifford, 1998). Kienle and Kiene (2001) refute the above claims and argue that such 
results lacks evidence of therapeutic effects and studies findings can easily be attributed 
to methodological flaws. The current study has demonstrated that these non-specific 
effects (placebo) are measurable change in physiological reactions and symptom 
behaviour that the author was able to quantify with both placebo and the control group. 
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The placebo effect is an integral part of treatment with electrotherapy modalities. 
Over the years therapists were found to use it to increase patient co-operation and 
satisfaction (Kitchen, 1995b). The survey conducted by the author has also 
demonstrated that some therapists use PSWT as a placebo modality. With placebo 
treatment PSWT resulting in 39% improvement (as found in the current study) its 
impact on the outcome cannot be ignored. 
It is interesting that low intensity PSWT was no better than placebo when 
applied to healthy subjects however when patients were involved, low intensity was 
shown to result in a significant change in many of the variables examined. Although the 
reason is unclear it could be because that lower thresholds increased sensitivity of 
patient's systems making their tissues more sensitive to exogenous energy compared to 
healthy subjects (Bricknell and Watson, 1995). Another reason could be the long history 
of pain makes patients believe in whatever modality applied to them and believe in its 
efficacy. 
11.6 COMPARISON BETWEEN HEALTHY AND PATIENT 
POPULATION RESPONSE TO TREATMENT 
Several studies have shown that PSWT is no better than placebo (Klaber- 
Moffett et al 1996; Quirk et al, 1985) and others have shown that it resulted in 
outcomes that are better than placebo (Gray et al, 1994; Comorosan et al, 1993; 
McGill, 1988; Barker et al, 1985; Wilson, 1972). The current study concurs with all of 
those studies in that it is the amount of energy delivered to the tissues and the type of 
tissue treated are two determining factors for the outcome. PSWT could result in 
outcomes that are similar to placebo if the dose was insufficient to trigger a 
physiological reaction; however when this threshold is overcome the outcome was 
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found to be significantly superior to placebo. All of this provides evidence on the 
existence of a window effect. The work conducted in this research program 
demonstrates that the MP is one of the factors affecting outcome. The treatment time is 
another important factor as it could increase or decrease the net energy delivered to the 
tissues. 
Comparison of the outcome from the laboratory and clinical trials is presented in Tables 
(11.1-11.4). From the tables and the data presented in Chapter 9 and 10 it could be seen 
that in the laboratory trial there was a significant increase in the high dose in BVo1 for 
"before treatment" vs "during treatment" (p=0.033), and an associated increase in SkT 
(p=0.000). With the low dose there was a significant increase in BVo1 in the "before 
treatment" vs "during treatment" (p=0.042). 
In the clinical trial, with the high dose there was an increase in BVo1 in the "before 
treatment" vs "after treatment" (p=0.000) and "before treatment" vs "during treatment" 
(p=0.007), there was an associated increase in SkT (p=0.000), and a reduction in NCV 
(p=0.000). The low dose has increased BVo1 in the "before treatment" vs "after 
treatment" (p=0.000) and "before treatment" vs "during treatment" (p=0.002), 
decreased NCV (p=0.000). The placebo PSWT has only increased BVol in the "before 
treatment" vs "after treatment" (p=0.024) and "before treatment" vs "during treatment" 
(p=0.003) and did not affect other parameters. 
By employing a same subject design, subjects acted as their own controls hence 
minimized individual variations between groups. Treatments were also randomised to 
overcome the effect of order on the outcome (Hicks, 1999). 
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Chanter 11 General discussion and conclusion 
It is expected that with the increase in tissue temperature which reached 2°C with the 
high dose in both the healthy and patient population, there might have been a production 
of a histamine like substance, stimulation of sensory cutaneous nerve endings and the 
release of mediators by both axon reflex and local spinal cord reflex, all of which results 
in vasodilatation. Heat is also expected to increase metabolic rate, enhance cellular 
activity and increase chemical reactions as such result in efficient muscle contractions 
(Lehmann and DeLateur, 1990). 
Results from both trials have demonstrated that the greatest increase in blood 
flow was observed during the treatment. However, due to the warming up of the 
temperature thermistor during PSWT and for safety issues, it was decided to measure 
change in SkT post treatment only. It is expected that the changes in SkT would be the 
highest during treatment and to decline post treatment as was shown with BVo1 
measurements. 
Similar to other studies (Cramp et al, 2001; Kurvers et al, 1997), the current 
study has shown that a significant increase in BVol is not always associated with a 
significant increase in SkT which could suggest that thermal build up and dilatation of 
blood vessels are not the only mechanism of PSWT action. It is of interest that the 
magnitude of the reaction measured is proportional to the amount of energy delivered as 
such greater responses are recorded with high dose followed by the low dose. 
The results from both trials where further analysed to examine whether the 
difference was statistically significant using unrelated t-test. The findings were analysed 
in terms of the during and after treatment data and the magnitude of change for the 
during (during-before values), and after (after-before values) treatment periods. 
Findings show that the change in the during period was significant with the high, and 
low dose with blood volume data. The after results were significant with low dose and 
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the placebo condition. The magnitude of change for the during-before period however, 
was significant with the high, and low dose. 
Skin temperature data were significant for the period after treatment with the 
high, low and placebo, however the magnitude of change was not significant. 
With NCV results the magnitude of change after treatment was significant with 
low dose only. Findings are displayed in Tables (11.5-11.7). 
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Chapter 11 General discussion and conclusion 
11.7 WINDOWS OF EFFECTIVENESS 
The concept of windows of effectiveness has been discussed previously in the 
literature (Section 2.4.1). According to this concept the different carrying frequencies of 
EMF if applied at certain intensities could affect different target tissues (Trock, 2000). It 
is expected that outside these frequencies (intensities) the energy delivered will lack 
effects to trigger physiological reactions (Watson, 2000) because it is believed that cells 
can only absorb energy in narrow windows (Charman, 1990). Windows have been 
discussed in terms of time, intensity, amplitude, and energy (Trock, 2000; Cleary, 
1996). Transferring this concept to PSWT, some have argued the existence of an 
amplitude window that requires pulses of certain shapes and frequencies (Low, 1995). It 
could be also argued that as the carrying frequency of therapeutic PSWT is fixed at 
27.12 MHz (though not the only frequency for PSWT, but the widely used), there could 
exist a time and an amplitude window. The time window means that positive reactions 
to treatment could occur at certain durations of exposure while the amplitude window is 
dependent on how high or how low the pulse frequency and duration are being set. Both 
time and amplitude contribute to the total energy delivered to the tissues, therefore it 
could be debated that it is a window of energy with PSWT rather than multiple of 
windows (Figure 11.1). 
Unpublished work by Watson and Evans (www. electrotherapy. org), and 
Wagstaff et al (1986) have demonstrated that manipulating the treatment parameters 
while stabilising MP have resulted in same outcomes. This was also confirmed by 
laboratory experiments by Hill et al (2001) on human fibroblasts. Though it needs 
further validation, it could be debated that it is the MP rather than individual parameters 
that could alter outcome. 
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However, the problem with such concept is that it is not yet clear whether the 
MP delivered from PSWT that have PP of 150W would be interchangeable with MP 
with PSWT machine with PP of 1000W for example. This area still lacks exploration 
and intensive investigation as to whether MP between PSWT of different makes can be 
used interchangeably. Finding the answer to such notions would save a lot of 
researchers' time and unify their efforts instead of working in tangents with little 
benefit. 
PD 
OO 
PRR 
Time 
Figure (11.1) The concept of windows with PSWT 
It was suggested in the literature that increasing numbers of therapists are 
moving towards using low doses of energy to achieve therapeutic effects (Watson, 
2000) possibly because of the belief that lower levels of energy are expected to trigger 
physiological reactions with minimal side effects (Low and Reed, 2000). These were 
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only assumptions mostly based on individual observations with minimal investigations 
Interesting findings have emerged from reviewing the literature along with the 
findings from this research program. All the work that has been conducted on MP 
ranging between 23-29W has been shown to be beneficial clinically (Figure 11.2). Mean 
powers outside these ranges were either ineffective or no better than placebo treatments. 
Low (1995) has also attempted to collate studies' findings to find out common trends in 
outcome and dosage. It was found that energies as high as 38W could also be effective. 
However, the calculation reported by Low was based on predictions or assumptions 
about the missing (not reported) treatment parameters. Figure (11.2) has only included 
studies that have reported their MP (n=5), hence more factual, thus the difference in the 
outcome. These frequencies need to be validated further as this could mean a 
breakthrough in the windows concept. 
Wound healing Ineffective mean 5.6W, 38W, 40W, 30.8W 
powers 
OA Wound Healing Pain 
23W 25.3 W 23.3W 
24W, 3W 29.5W 23.4W 
0 10 20 30 40 50 60 70 80 90 Mean power 
Effective mean powers 
MP 
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The point to consider is that only the studies that have been conducted on 
pathological conditions or have mentioned their MP are included in the above Figure. 
There are other studies that were not included due to absence of full reporting. Studies 
that have been conducted on physiological parameters and have demonstrated positive 
outcomes were not included as it was unwise to extrapolate that they would be of 
therapeutic value just because they were able to increase the amount of circulating 
blood or increase tissue temperature. 
As argued by Watson (2000) the window effect is dependent on the sensitivity 
of the tissues. Acute tissues are more sensitive than chronic tissues, which are more 
sensitive than healthy tissues. This is an assumption that has never been examined 
experimentally before. The current study was one of the first attempts to demonstrate by 
delivering the same amount of energy to healthy and patient population that diseased 
tissues are indeed more sensitive to energy. 
All of the above suggest that power needs to be specific to provoke particular 
cell response, it remain to be theoretical with minimal evidence, and although this 
concept is starting to be the driving thought for many investigations, attempts need to be 
both at cell and pathological condition level. 
11.8 CLINICAL IMPLICATION 
In order for research to be informative, it needs to be focused and derived from 
practice as with the work at hand. The current work has revealed crucial information 
about the nature of clinical practice with PSWT. Issues such as documentation were one 
of the main areas that needed urgent attention. 
Additionally, in a nation that is partly dependent on electrotherapy (Murphy, 
1993) it becomes crucial that various modes of application be validated for efficacy. 
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Although the use of both 3W and 24W was employed clinically, the current work is one 
of the few if not the only one that has attempted to validate these modes with both 
healthy and patient populations. 
The findings of the experimental work have demonstrated that similar amounts of 
energy could result in different outcomes when applied to healthy and patients' 
population. The findings provide evidence for the claim that healthy subjects and 
patients do not respond similarly to interventions. The findings of the current study 
clearly indicate that the non-significant results reported by the majority of the studies 
could be caused by the nature of the sample. Healthy tissues could have higher 
thresholds hence require higher levels and possibly greater intensities to achieve 
statistically significant results. Similar findings to the present work have been 
demonstrated by Ek et al (1985) although was done on the effects of massage, their 
findings concur with the current study that patients react differently to healthy subjects. 
Hitherto, given that PSWT was intended to be used with patient populations, its 
physiological and therapeutic effects should be examined on the intended population to 
facilitate extrapolation of results. 
Half the sample in the clinical trial has demonstrated a 10 fold measured 
increase in BVol with 24W, these findings could carry clinical implication. In cases 
where swelling or haematoma are present, this dose should not be used as it may 
exacerbate the symptoms by dilating blood vessels and increasing the amount of 
interstitial fluid. The significant increase in BVol demonstrated in the radiated area 
could mean that PSWT can be used in musculoskeletal treatment and wound healing to 
aid the removal of toxins and exudates from the injured site. 
The mechanism of the increase in BVol was seen to be mediated by the increase 
in heat with the high dose. It is not clear though how the increase in BVol was achieved 
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when the increase in temperature was only 0.5°C (low dose). Such findings may suggest 
a microthermal mechanism that warrants further research. 
With a measured increase of 2°C, the high dose is considered a thermal mode of 
PSWT. Care should be taken when using it with patients due to the detrimental effect it 
may have on treatment outcome when used with conditions such as RA or OA or soft 
tissue inflammation, where slight increase in temperature may exacerbate the symptoms 
(Hosie and Dickson, 2000). 
Prentice and Draper (2001) argue that an increase of around 1°C is useful for 
mild inflammation, and an increase between 2-3°C is helpful in reducing pain and 
muscle spasm whereas an increase of 3-4°C is necessary to cause tissue extensibility. If 
these assumptions are based on experimentation, this could mean that the use of 24W 
for 10 minutes could be useful in reducing pain and the use of 3W is useful in reducing 
inflammation. These notions remain to be theories until validated. 
Given that different combinations of PSWT result in same findings if the MP 
was kept the same (Hill et al, 2001; Wagstaff et al 1986) it could be argued that the 
findings of the current work can be extrapolated to all combination of Megapulse that 
result in either 3 or 24W. The next step is to examine whether MP from different PSWT 
makes can be used interchangeably as this will help reduce the confusion in the 
literature. 
The fact that patients experienced symptom relief that lasted for a day and 
returned the following day has implications for planning follow up sessions. Based on 
these findings sessions should be given either daily or every other day for best results. 
The reporting that PSWT helps relieve stiffness is crucial in helping therapists decide 
the proper modality to use when faced with such complaint. Hence the results of the 
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current work are crucial in helping therapists reach a clinical decision when it comes to 
PSWT efficacy. 
It is surprising that both the audit (Chapter 5) and the questionnaire (Chapter 6) 
have shown that only a small proportion of physiotherapists use PSWT for 20 minutes 
and the majority use it for 10 minutes or 15 minutes. The experimental literature 
however is conducting the majority of research with 20 minutes. Furthermore, based on 
the survey findings, only 4.7% applied PSWT 3 times a week, while the majority of the 
studies administer and examine the effect of PSWT treatments when applied 3 times a 
week. These are areas of mismatch and where the research does not reflect the clinical 
needs and hence not necessarily informs practice. This gap between theory and practice 
need to be reduced and one of the ways forward is a collaborative approach between 
academics (with their research experience) and clinicians (facing the clinical problems) 
to identify both the literature and the clinical gaps. Instead of working in isolation and 
adding more to the state of literature confusion. Working together could improve the 
state and the nature of the evidence. 
Based on the outcome of this research program, some key guidelines can be put forward 
that could improve the quality of the care delivered to patients: 
9 Files need to be comprehensive in terms of the amount of information 
documented. All files need to contain information on the type of equipment 
used, MP, PP, PD, PRR, patient position, patient consent, type of electrode, and 
treatment time to facilitate reproducibility of treatment. 
9 Patients files need to be updated regularly with changes in treatment plan with 
rationale for any change undertaken. 
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" Progression of treatment dose should involve change of one parameter in order 
to know which variable had brought about the improvement or the deterioration 
" MP of 3W and MP of 24W were found to be effective with OA patients in terms 
of increasing blood volume, increasing skin temperature and reducing NCV. The 
recorded changes observed in the physiological parameters have manifested 
themselves in the reduction of pain felt in the knee joint, and the reported 
smoothness of movement felt by the patients when ascending and descending 
the stairs. 
" The application of 24W was associated with 2°C increase in skin temperature as 
such is expected to exacerbate symptoms when diseases such as RA or OA are 
in the active stage and the inflammation is in progress. PSWT application in 
these circumstances should therefore be avoided. 
" Based on patients reporting it was found that PSWT was an effective 
electrophysiological modality in reducing joint stiffness. 
" The dose delivered in the clinical trial (100µsec, 200 Hz, 10 min, 3W and 
200µsec, 800 Hz, 10 min, 24W) resulted in a decrease in patients' symptoms 
that lasted for a day. This could mean that treatments need to be delivered either 
daily or every other day to maintain the accumulative effect of the treatment. 
11.9 CONCLUSION 
Throughout this experimental programme the question of PSWT efficacy was 
the focal point. All the experiments conducted contributed to the understanding of the 
nature of the clinical use of PSWT and its mechanism of action, as such have fulfilled 
the main aims. 
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Novelty in this project could be seen in employing a qualitative approach to explore 
practice and derive the experimentation protocol. This was done, as it is expected that 
there are many treatments that have been developed by physiotherapists (either by 
experience or by trial and error) throughout the years that lack evidence of 
effectiveness. Hence by developing protocols based on clinical practice the findings are 
expected to be more informative, instead of experimenting on arbitrary doses and 
imposing findings upon clinicians. As such the current work has subjected clinical 
practice to validation. 
The project conveyed the nature of practice and use with therapists' common 
beliefs on PSWT. It has examined and compared the outcome of high and low doses of 
PSWT in a controlled blinded study. Another unique feature of the current experimental 
work was the examination of NCV, an area that has hardly received any attention with 
PSWT. Moreover, by replicating the same experimental protocol with patients in the 
clinical setting, this project is a step forward in the direction of a comprehensive 
understanding to the interaction between EMF at the frequency of 27.12 MHz with both 
healthy and diseased tissue. Moreover, this study is one of the very few if not the only 
one, which quantified the effect of placebo, associated with PSWT application and 
confirmed it with physiological measurements. 
The findings of the current work, whether presented positive or negative 
outcomes, have presented some kind of evidence on the window effect. The work 
conducted on the frequency of 27.12 MHz and the current work suggested that this 
frequency holds promises for therapeutic efficacy. Although the ongoing challenge is to 
establish the precise dosimetry capable of initiating the healing process, the findings of 
the current work has shown that both low intensity (3W) and high intensity (24W) 
PSWT are effective in altering physiological responses in healthy and OA population. 
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Additionally, by basing the laboratory experiment on the findings of a 
nationwide survey it is expected that the findings will be of value to a wide sector of 
clinicians in the process of clinical decision-making. Moreover, by replicating the 
laboratory experiment in the clinical setting, it is expected that the current work have 
bridged the divide between theory, laboratory, and clinical environment and with this 
research tackling areas that were not examined thoroughly the findings of the present 
research extends the existing knowledge and contributes significantly to the literature on 
PS WT. 
11.10 LIMITATION OF THE STUDY 
9 Although it is acknowledged that blinding the investigator when collecting the 
data reduces bias, this was difficult to achieve in both the laboratory and the 
clinical trial due to the nature and the complexity of the data acquisition system. 
However, given the time it would take to train another investigator and the 
limited resources, blinding of the investigator was accepted as a limitation to the 
current study. 
" Due to the warming up of the temperature sensors the decision was made to take 
measurement post treatment only. There might have been a significant increase 
in SkT during PSWT application as was measured with BVol, and this may have 
been missed as result of that. This problem can be avoided in the future by using 
heat resistant thermocouples. 
" Although PPG electrodes can be used on any tissue bearing blood (according to 
the manufacturer), its ability to function maximally is dictated by the area 
sampled. The beds of fingers and toes are known to have areas rich in 
arteriovenous anastomsis (Lindberg and Oberg, 1991) hence are the best places 
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for measuring BVo1. However, because toes were not shown to display a similar 
reaction to treatment as the area under the treatment head it was decided to 
measure from anterior knee and bear in mind its limitation. 
9 The environment where the experiments were conducted (whether it was the 
laboratory or the hospital) was not thermostatically controlled. Nevertheless 
attempts were taken to limit the effect of temperature fluctuation on the 
outcome. This point needs to be taken into consideration when conducting or 
comparing laboratory trials to clinical trials. 
" The values obtained with PPG are dependent on the pressure of the probe 
against the skin as this could increase or decrease the amount of light reflected 
and absorbed by the probe. Although all attempts were made to standardise that, 
it is necessary to acknowledge that there could be slight differences between 
individuals, which might have affected the results. 
11.11 AREAS FOR FUTURE INVESTIGATIONS 
Future research will be presented in two sections; those that emerged from reviewing 
the literature and those that stemmed from the direct results of the current investigations 
Future research based on the literature reviewed 
" Whilst much experimentation has been done on OA knees, a very limited 
number of trials have examined the role of various electrotherapy modalities on 
OA hip. 
" Literature has shown promising results with the use of portable EMF equipment 
in treatment of oedema, wound healing and fracture, these types of equipment 
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are rarely used in physiotherapy. Further exploration to the possibility of using 
them could save therapist time, as they do not require that the patient attend as 
frequently to the hospital. 
" Hepatic applications have been shown to result in beneficial effects on PSWT 
outcomes. This area warrants further exploration whether clinically or in the 
laboratory setting. 
" There is a need to develop an instrument that could be worn by therapists and is 
capable of measuring the duration and the extent of exposure to EMR. With 
such device it is possible to limit unwanted exposure and quantify the actual risk 
associated with the use PSWT. 
Future research based on the current research program 
" The literature reviewed has discussed the possibility of the latent effects of RF at 
a frequency of 27.12 MHz to last up to 4 days, the patients in this trial reported 
that the symptom relief lasted for a day. This observation warrants further 
investigation. Such findings could be of great importance to clinicians for better 
planning of follow up treatments. 
" The issue of written against oral consent need to be explored further with regard 
to electrotherapy and possibly link that with actual incidents to investigate 
whether there is a real need for a written consent or is it enough to obtain an oral 
consent. A retrospective study that looks into the cases of litigation against 
therapists would be interesting and of vital importance. 
" Exploration to the optimal approach to progress treatment plans need to be 
undertaken. The current work has shown that increasing the dose results in better 
outcomes when compared to reducing it. The work should also explore what 
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parameters need to be manipulated to obtain the best results. Although this issue 
has been discussed in the literature, claims were not based on experimentation. 
" More research needs to be conducted to explore whether MP value is 
interchangeable between PSWT machines of different makes. This aspect of 
research is very important to reduce the state of confusion and unify researchers' 
efforts. 
" The current work has shown that PSWT reduces pain, the mechanism 
underlying these observations need to be examined in further experimentations. 
" PSWT was shown to decrease stiffness and according to patients' reports it 
helped them move easier. There is no identified work that examined the effect of 
PSWT on stiffness, an area that warrants further experimentation. 
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APPENDICES 
APPENDIX A. 1 
LETTER TO PHYSIOTHERAPY DEPARTMENT MANAGERS 
Dear 
Date 
My name is Maryam Almandil, and I am a physiotherapy PhD student from University 
of Hertfordshire. I am undertaking a research program on the effectiveness of Pulsed 
Short Wave Therapy. 
As part of my structured research program I am evaluating therapists documentation 
with regard to Pulsed Short Wave Therapy. Eight hospitals have been chosen randomly 
to represent the clinical practice in the eight health regions. The protocol of the 
investigation has been approved by the Ethical Committee of Radiology and 
Physiotherapy in University of Hertfordshire. 
The study will involve a visit from me to your premises, where I will look through the 
files and examine them in terms of quality and content. It is expected that my presence 
will not cause any disturbance to the course of the work in your department. 
The information collected will be treated with strict confidentiality. No information will 
be reported that would disclose the hospital, therapists or patient identity. 
This letter is to inform you that your hospital is one of those chosen to be in my 
investigation. If you have no objection on the purpose of the study I would be very 
grateful if you could decide on a date when I can visit your department. However, if you 
think that my visit is not possible in the time being, please accept my apology for the 
inconvenience and thank you for your time. 
For further information please do not hesitate to contact me on the address below. 
Yours truly, 
Maryam Almandil 
University of Hertfordshire 
Department of Physiotherapy 
Hatfield campus 
College Lane 
Hatfield Herts 
AL10 9AB 
Or call at 01707 284000 Ext 2054 
e-mail: almary22@hotmail. com 
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APPENDIX A. 3 
ETHICAL APPROVAL FOR AUDIT 
ETHICS COMIVUTTEE OF THE DEPARTMENTS 
OF RADIOGRAPHY AND PHYSIOTHERAPY 
Radiography/Physiol 
(delete as necessary) 
Protocol Number: 
Name of Investigator: 
Name of Supervisor: 
Title of Study: 
herapy 
RPEC. 100.2.01 
Maryam Almandil 
Tim Watson 
An Audit to Investigate Physiotherapy Practice with Pulsed 
Short Wave Diathermy (PSWD). 
Dates of Study: Academic Year 2000/01 
No. of Subjects: N/A 
1) 1 support the approval of the study without pre conditions. YES I 
2) I support the approval of the study, subject to the following: 
a) essential pre conditions which will affect the granting of approval: 
b) general recommendations and comments which will not affect approval: 
3) I do NOT support approval of the study for the following reasons: 
Signature 
'rtt... 
1Lt 11Ytý Date: 2.2joL1p 
Chair of Ethics Committee 
RC. (oo. 2. oi 
(JDN. 2D. 2.01) 
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APPENDIX A. 4 
CONSENT FORM FOR PHYSIOTHERAPY MANAGERS 
I .......................................................................................... 
(Name) 
.......................................................................................... 
(Position) 
Health Region: ........................................................................ 
Health authority: ...................................................................... 
Acknowledge the work carried out by Miss Maryam Almandil as part of her PhD project. I 
am aware that she will be examining patients' files to gather information on how 
physiotherapists record their practice with Pulsed Short Wave Therapy. I also acknowledge 
that confidentiality will be maintained and no hospital, patient or therapist name will be 
included in the reporting of the final results. 
I appreciate that contributing to such a study will enrich physiotherapy knowledge base and 
hopefully result in better patient service. 
I hereby give my signature as consent 
Signature: ...................................... 
Stamp of the department: 
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APPENDIX B. 1 
Please use this form to add in any comments or suggestions regarding: 
Clarity of questions (wording): 
......................................................................................................... 
......................................................................................................... 
......................................................................................................... 
...................................................... 
Sequence and ordering of questions: 
......................................................................................................... 
......................................................................................................... 
......................................................................................................... 
...................................................... 
Layout and presentation: 
......................................................................................................... 
......................................................................................................... 
......................................................................................................... 
...................................................... 
Length of the questionnaire: 
......................................................................................................... 
......................................................................................................... 
......................................................................................................... 
...................................................... 
What other questions do you think need to be added to the questionnaire to throw more 
light on the nature of the clinical use of Pulsed Short Wave Diathermy in outpatient 
clinics? 
......................................................................................................... 
......................................................................................................... 
......................................................................................................... 
...................................................... 
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APPENDIX B. 2 
QUESTIONNAIRE 
1- What is your clinical grade? ....................... 
2- When did you qualify? ............................. 
3- How long have you been working in the outpatient clinic as a whole (whether in this hospital or in 
other hospitals)? .............................. 
4-How long is your usual treatment time with Pulsed Short Wave Diathermy? ..................... 
5- What type of Pulsed Short Wave Diathermy equipment do you use? (Please specify the model and the 
manufacturer) 
6- What best describes your preferred approach to the frequency of use with patients when using Pulsed 
Short Wave Diathermy? 
Tick the most appropriate answer 
Q Daily 
Q3 times a week 
Q Twice a week 
Q Once a week 
Q Less than once a week 
7- For what conditions would you use Pulsed Short Wave Diathermy (give the S most common 
conditions, arrange according to priority) 
8- List the parameters that you need to record in patient's notes to describe your treatment plan with 
Pulsed Short Wave Diathermy? 
9- What determines your choice to treatment dosage? 
Rank your answers in order of priority from 1-8, with 1 being the most important 
Q Site of lesion 
Q Equipment manual 
Q Discussion with colleagues 
Q Personal experience 
Q Knowledge gained through undergraduate training 
Q The published literature (books, journals) 
Q The stage of the disease (acute, sub-acute, or chronic) 
Q Patient general symptoms (pain, swelling, etc) 
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10- Rank the reasons that determine your choice to apply Pulsed Short Wave Diathermy in preference to 
other electrotherapy modalities. 
Rank your answers in order of priority from 1- 5, with 1 being the most important 
Q Patient's signs and symptoms 
Q Previous experience 
Q Recommendation by the physician or senior physiotherapist 
Q Familiarity with the machine 
Q Availability of the machine 
11- List the outcomes (aims) that you are trying to achieve when choosing Pulsed Short Wave Diathermy 
as a treatment modality 
Your answer should be ranked according to priority 
12 -Do you usually combine the application of 
Pulsed Short Wave Diathermy with other electrotherapy 
modalities? 
Tick the appropriate box 
Q Yes 
Q No 
If No proceed to Question 13 
If your answer is YES proceed to questions 12a/ 12b 
12- a- Specify the modality (ultrasound, laser, interferential etc) that you would usually combine with 
Pulsed Short Wave Diathermy 
12- b- What is your aim of combing the two modalities? 
....................................................................... 
....................................................................... 
13- How would you rate your treatment outcome with Pulsed Short Wave Diathermy? Tick the 
appropriate box 
Q Excellent Q Good Q Poor Q Indifference 
14- After how many sessions do you stop using Pulsed Short Wave Diathermy if there is no reported 
improvement? 
IS- If your patient is improving with Pulsed Short Wave Diathermy administration, what parameters 
would you change to progress your treatment? 
16- Do you think that the existing literature on Pulsed Short Wave Diathermy helps informs your 
decisions (as a clinician) on treatment parameters? 
Q Yes 
Q No 
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If yes proceed to question 17, if no proceed to question 16-a 
16-a If No, row could this be improved? 
17- What dosage would you select for the following patients (al patients have no contraindication to using 
Pulsed Short Wave Diathermy) 
These case studies are meant to be answered with regard to Pulsed Short Wave Diathermy, therefore Do not 
advocate other types of treatment 
17- a- 43 years old female complains of osteoarthritis of the knee (right) for less than a year; she suffers 
dull aching pain that is present all the time. Most of her pain is after activity (especially if the activity 
involves standing or walking), she has trouble standing up after sitting. 
Please specify your parameters 
Pulse width (psec) ................ 
Pulse rate (pps) .................. 
Mean power (W) .................... 
Time (min) ..................... 
Frequency of administering the treatment per week .................... 
17- b- 62 male patient complains of osteoarthritis in right knee since 5 years. Main symptom were 
morning pain and stiffness, pain going down the stairs, occasional swelling. Patient suffered a recent 
exacerbation of symptoms, was on anti-inflammatory drugs for 3 weeks with little benefit. 
Please specify your parameters 
Pulse width (psec) ................ 
Pulse rate (pps) .................. 
Mean power (W)........... 
Time (min) ........................ 
Frequency of administering the treatment per week ....................... 
17 - c- 71 female complains of osteoarthritis of both knees (more than 10 years) with reduced range of 
motion, crepitus on movement and dull pain present all the time. Pain increases when using stairs or 
when walking on uneven ground. Her knees are swollen most of the time. 
Please specify your parameters 
Pulse width (µsec) ................ 
Pulse rate (pps) .................. 
Mean power (W) .................. 
Time (min) ........................ 
Frequency of administering the treatment per week ......................... 
Thank you for completing this questionnaire 
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ETHICAL APPROVAL FOR THE QUESTIONNAIRE 
ETHICS COMN T17EE OF THE DEPARTMENTS 
OF RADIOGRAPHY AND PHYSIOTHERAPY 
izediogr6pb3i /Physiotherapy 
(delete as necessary) 
Protocol Number. 
Name of Investigator. 
Name of Supervisor. 
Title of Study: 
Dates of Study 
No. of Subjects 
RPEC. 100(part2)3.01 
Maryam Almandil 
Tim Watson 
A Survey to Examine the use of Pulsed Short Wave in 
Outpatient Clinics in Britain. 
Academic Year 2000/01 
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1) 1 support the approval of the above study without pre-conditions. YES 10 
2) I support the approval of the study, subject to the following: 
a) essential pre-conditions which will affect the granting of approval: 
b) general recommendations and comments which will not affect approval: 
3) 1 do NOT support approval of the study for the following reasons: 
Signature tlý ,, wOoý 
Chair of Ethics 
IIizin I 
Date: 2-113101 
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APPENDIX B. 4 
LETTER TO THE MANAGER OF PHYSIOTHERAPY 
DEPARTMENT 
Dear 
Date // 
My name is Maryam Almandil, a PhD student from University of Hertfordshire. 
Originally, I am a physiotherapist and currently I am conducting a series of 
investigations as part of my structured program for a PhD in electrotherapy. At the 
moment I am involved in carrying out a nationwide questionnaire focused on the 
effectiveness of Pulsed Short Wave Therapy (PSWT). The questionnaire examines the 
rationale and the factors affecting therapists' choices with this modality. The ultimate 
aim of this study is to help therapist challenge their beliefs and current use to PSWT. 
The results of this study are also expected to help therapists in the process of clinical 
decision-making. However, the goals of this study can only be made possible by your 
co-operation. 
Your hospital has been chosen randomly among the other hospitals within your health 
authority to be part of this survey. As the manager of the department I am seeking your 
help in identifying those working in the outpatient department and using PSWT with 
their patients. Enclosed are 4 questionnaires to give to whom you think will be suitable 
candidates for this study. 
I appreciate all the help you could offer 
For further inquiries do not hesitate to contact me on the following address 
University of Hertfordshire 
Department of Physiotherapy 
Hatfield campus 
College Lane 
Hatfield Herts 
AL10 9AB 
Or call at 01707 284000 Ext 2054 
Thank you 
Yours truly, 
Maryam Almandil 
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APPENDIX B. 5 
LETTER TO PHYSIOTHERAPISTS (survey) 
Dear Colleague; 
My name is Maryam Almandil, a PhD student from the Physiotherapy Department in 
University of Hertfordshire. As part of my PhD I am conducting a nationwide survey. 
This questionnaire is part of a series of investigations I am conducting on the 
effectiveness of Pulsed Short Wave Therapy. Having worked as a physiotherapist in the 
outpatient clinic for many years I think that deep understanding of electrotherapy 
modalities is one of the key issues to a successful treatment. Equipment such as Pulsed 
Short Wave Therapy demand greater attention as literature presents conflicting evidence 
on their efficacy. This questionnaire is structured to examine your preference, choices, 
and understanding of the theory behind Pulsed Short Wave Therapy. I strongly believe 
that practitioners are better qualified to address their clinical problems; hence sharing 
your experiences and opinions becomes a strong informative tool to this project. 
Your hospital has been chosen randomly among the other hospitals within your health 
authority. The manger of your department, helped identify the therapists working with 
Pulsed Short Wave Therapy, hence, those identified are not known to me. 
All envelopes are coded with numbers. These numbers are meant to act as indicator of 
the response rate (in case a follow up letter is needed). Therefore, it plays no role in 
identifying the individuals. Confidentiality will be maintained throughout the study, and 
the published results will not uncover the identity of the respondents or their hospital. 
Dear colleague, if you decided to participate in this survey, after receiving your copy of 
the questionnaire, please take few minutes to answer the questions. All the questions are 
there for a reason therefore, I would be most grateful if you could answer them all. The 
last section of the questionnaire deals with cases on osteoarthritis (OA). OA was chosen 
following an exploratory auditing investigation in the area. 
After answering all the questions, use the self- addressed envelope provided to post the 
questionnaire back to me 
Your co-operation is deeply appreciated. 
To obtain a copy of the results, get in touch with me on the following address 
University of Hertfordshire 
Department of Physiotherapy 
Hatfield campus, College Lane 
Hatfield, Herts 
AL10 9AB 
Or call at 01707 284000 Ext 2054 
Thank you, 
Yours truly, 
Maryam Almandil 
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APPENDIX B. 6 
OSTEOARTHRITIS 
OA which is also known as hypertophic arthritis or degenerative joint disease is 
the most common non-inflammatory arthropathy seen in adults (Nguyen and Marks, 
2002). In a population of 100,000,3000 will be complaining of OA (Clarke, 1999) with 
the bulk being OA of the lower limb (Green, 1991) and the knee joint being the most 
frequent (Peat et al, 2001). 
OA accounts for 30% of disability in women over 80 years (Clarke, 1999). It is 
known to cause destruction of the articular cartilage and subchondral bones (Cicuttini 
et al, 2001). The cartilage serves to provide smooth articular surface and to distribute 
the biomechanical forces across the bone surface. The ongoing changes in the 
biomechanical environment of the joint as a result of the disease can lead to 
remodelling in the subchondral and trabecular bone, which is characterised by loss of 
water content, proteoglycan, and collagen along with a decrease in the number of 
chondrocytes. These changes besides the fissuring and ulceration soften the cartilage 
making it more prone to damage. This alters joint biomechanical behaviour even 
further, and the degeneration of more cartilage initiates a cycle that may end up in 
additional loss of the articular cartilage and permanent 
joint loss (Bailey and Mansell, 
1997; Wu et al, 1990). Advanced conditions may show subchondral bony cysts, and the 
formation of spurs or osteophytes. The inception and progression of OA can be 
aggravated by factors such as knee alignment, injury and biomechanical insults to the 
joint (Sharma, 2001). 
Jones et al (2004) demonstrated in a sample of 372 subjects, that heavier older 
subjects tend to show more radiographic changes. Joint space narrowing was associated 
with cartilage volume loss. Even with very minor OA degeneration there was 11-13% 
cartilage loss. This magnitude of loss was similar in men and women. 
Lindsey et al (2004) in a group of patients complaining from OA knee (21 controls, 21 
mild OA, 32 severe OA) demonstrated by using MRI that there was an increase in bone 
density in the medial compartment with thickening of the trabacular bone and these 
changes were correlated with the severity of the disease (chronic cases show more 
changes). They also demonstrated that bone loss with arthritis occurs not only on the 
diseased side but also on the opposite compartment. 
OA is associated with deep, diffuse, and dull pain, which is usually worse as the 
day progresses. Pain increases with activity and decreases with rest and could be 
associated with stiffness after immobility that lasts for few minutes. Symptoms usually 
affect daily life and change the patient's daily routine making accomplishing simple 
tasks very demanding (Nguyen and Marks, 2002). The mechanisms that lead to pain 
remain unclear (Creamer et al, 1996). Pain fibers are present in several structures that 
are often affected by the pathologic processes in OA knee, including the joint capsule, 
ligaments in and around the knee joint, the outer third of the meniscus, possibly the 
synovium, the periosteum and the bone marrow (Heppelmann, 1997). Cartilage loss and 
alterations in patella volume on arthroscopy appears to show substantial correlation with 
pain and disability (Hunter et al, 2003). 
The clinical metrology of OA is complex because of the changing clinical 
presentation. OA may be symptomatic or not, and may be associated with normal or 
abnormal radiographs, may have symptoms that are also common in RA or ankylosing 
spondylitis. That is why it is hard to find a satisfactory classification criterion. OA 
severity has been classified for years according to the radiographic appearance. X-ray 
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has been the traditional method of diagnosing OA pathological processes. Features such 
as joint space narrowing, subchondral sclerosis and osteophyte formation can be used to 
judge the severity of the condition (Spector and Hart, 1992). This method however, has 
been criticized of being insensitive to change due to the possibility of measurement 
error and the radiographic grading system being semi-quantitative. Normal X-ray also 
lacks the ability to detect changes in cartilage and even if they do it is very hard to relate 
the changes to the disease stage. Moreover, less than 50% of people with evidence of 
OA on plain radiographs do not have symptoms related to their clinical findings 
(Spector and Hart, 1992), as such poor relationships have been reported between the 
severity of the reported knee pain and the degree of radiographic change (Cicuttini et al, 
1996). 
OA can also be classified as being primary or secondary. It is considered 
primary if the cause was idiopathic. However it is classified secondary if the cause was 
mechanical, congenital or systemic. Mechanical causes could be trauma, previous 
inflammatory arthritis, and hyperlaxity while congenital causes could include hip 
dysplasia, slipped epiphysis, and Legg-Perthe's disease. Systemic causes could include 
anything from acromegaly, hypothyroidism, haemochromatosis, haemoglobinopathies 
to neuropathies (Dequeker and Dieppe, 1998). 
Another system of classification that is widely used is the classification of the 
American College of Rheumatology, which utilises symptoms, laboratory findings and 
X-ray manifestations. The system allows for the choice between categorising patients 
according to clinical and laboratory symptoms, clinical and radiographic symptoms, 
clinical 1 or clinical 2 (all were found to be over 90% sensitive to the symptoms) 
(Altman, 1991, Altman et al, 1990; Altman et al, 1986). 
Due to the pathogenesis being inconclusive, management of OA is largely 
dependent on conservative measures (Nguyen and Marks, 2002). The management of 
OA ranges from pharmacological, non-pharmacological to surgical corrections. Patients 
with varying degrees of OA are often referred to physiotherapy outpatient clinics where 
various modalities such as short wave (pulsed and continuous), US, IFC, electrical 
stimulation, Ex, mobilisations, hot and cold packs and hydrotherapy may be used. There 
is a lack of consensus on the best methods to approach this condition among therapists 
(Nguyen and Marks, 2002; Green, 1991) and this may be caused by the difficulty in 
determining the structure causing the pain. Other non-pharmacological interventions 
include patient education, weight management, orthosis or assistive devices (Pendleton 
et al, 2001; Hochberg et al, 1997), and wedged foot insole (Pham, 2004). None of the 
interventions above have enough evidence to support its efficacy possibly because of 
the small number of studies that examined these interventions or the methodological 
flaws in the published reports (Harley and Walsh, 2001). 
PSWT is one of the modalities employed by physiotherapists to manage the symptoms 
associated with OA (Nguyen and Marks, 2002). It has been used for mild, moderate and 
severe OA and was found to be favoured by therapists after exercise, and mobilisation 
(Green, 1991). It is used with the aim of minimising symptoms such as pain, swelling, 
muscle weakness and loss of function (Nguyen and Marks, 2002). However, there is not 
enough evidence to support the above aims. Interestingly, despite the lack of evidence 
that PSWT could have a direct effect on the muscle spasm or weakness, it has been 
widely accepted by physiotherapists that it does increase muscle strength and relieve 
spasm. 
In general, trials conducted on OA and PSWT were in favour of positive 
outcomes with the majority of these trials reporting improvement in function and 
reduction in pain (Ganguly et al 1996; Klaber-Moffett et al 1996; Leclaire and 
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Bourgouin, 1991; Jan and Lai, 1991; Quirk et al, 1985). In studies where PSWT was 
compared to other treatments or other interventions it was found to be more effective 
than placebo (Quirk et al, 1985; Klaber-Moffett et al 1996) and no better than other 
active groups such as US, IFC, Ex, and stretching (Quirk et al, 1985; Svarcova et al 
1988; Jan and Lai 1991; Leclaire and Bourgouin 1991; Ganguly et al 1996). 
Despite the number of studies that examined the efficacy of PSWT with OA, the 
findings of these studies needs to be viewed with caution as these reports lack 
significant information about treatment dose, methodology, and statistical analysis that 
are needed to judge the quality of the outcome. Such an issue justifies the conduction of 
more trials that investigate the therapeutic effects of PSWT on OA. 
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APPENDIX C. 1 
ACTION POTENTIAL 
Basis Of The Action Potential (AP) 
(Marieb, 2001, Oh, 1996) 
Normal cell membrane exhibits different permeabilities to ions such as Na' and K. At 
rest it is most permeable to K+ while it is relatively impermeable Na'. Although each 
ion has some tendency to move across the membrane, ion pumps are used to maintain 
the ion gradients, this creates a resting membrane potential of -70 mV. The selectivity 
of the channels results from the diameter of the channel and the charge arrangements of 
amino acids lining the channel. Ions do not pass through a channel by themselves, each 
individual ion has highly structured water molecules surrounding it. This covering of 
water is called a hydration sphere, and it is the diameter of the sphere surrounding the 
ion which determines the functional diameter of the ion. 
AP is a transient depolarization of the membrane where the inside of the neuron 
becomes less negative, this usually lasts for 1-2 milliseconds. With depolarization there 
is a change in membrane potential (from -70 mV to - +30 mV). 
The depolarization phase of the AP is triggered by the opening of voltage-sensitive 
sodium channels, which are normally closed at rest. This causes a sudden increase in 
sodium permeability making the inside of the neuron more positive with respect to the 
extracellular fluid. 
There are also specific voltage-sensitive channels for potassium which open during AP. 
These channels begin to open at the same time as the sodium channels, but the increase 
in permeability for potassium proceeds more slowly than the sodium channels. They are 
different from Na+ channels in that they have only a single activation gate which opens 
when threshold is reached. The increase in potassium permeability is maintained until 
this activation gate closes. The increase in potassium permeability lasts longer during 
the AP than does the increase in sodium permeability because there is no inactivation 
gate to close the channel prematurely. This activation gate closes when the membrane 
potential has sufficiently repolarized. 
In the resting state, the activation gate is closed and the inactivation gate is open. 
Sodium ions can pass through the channel only when both gates are open. 
Stimulating the neuron directly by using an electrical stimulus can increase the 
membrane potential above threshold (threshold is the membrane potential at which the 
activation gate opens) and generate AP. If the nerve is stimulated in the middle, the AP 
moves in two directions: orthodromic, towards the axon terminal and antidromic, 
toward the dendrites. The increased positive charge content inside the neuron causes a 
change in the activation gate portion of the sodium channel, opening them. The rapid 
depolarization causes a second voltage-sensitive change in the channel: the inactivation 
gate closes, and sodium permeability falls back to normal, even though the activation 
gate is still open. The activation gate then closes slowly while the inactivation gate is 
closed. 
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It is impossible to generate a second AP during the time that the inactivation gate is 
closed. This period occurs from the peak of AP until repolarization dips below the 
threshold and it is called the absolute refractory period. It is the period when no AP can 
be produced no matter how strong the stimulus. This period is followed by another 
period called the relative refractory period where stimulus of sufficient strength could 
result in AP. 
Conduction of action potential 
The AP generated in the axon travels along the axon and, eventually, on to other 
neurons or excitable cells, such as muscles. Thus, AP move a little way down the 
membrane. As this positive charge moves, two things happen: some of the charge is 
short-circuited, lost to the extracellular fluid. Secondly: the charge remaining inside the 
neuron depolarizes the area which it enters and opens the voltage-sensitive sodium 
channels. This causes fresh positive charge to enter the neuron in the new location, 
replenishing the AP by replacing the positive charge which was short-circuited. The 
rejuvenated AP then proceeds to move further along the axon, opening new sodium 
channels as it proceed the length of the axon. 
Conduction is faster with myelinated fibres. The AP travels through salutatory 
conduction where the impulse jumps from one Node of Ranvier to the other being the 
sites where voltage-sensitive sodium and potassium channels are concentrated, unlike 
non-myelinated fibres where the conduction is slow. Axons are not insulated with 
myelin hence this decreases the rate of loss of positive charge as it moves along the 
membrane, which means that the AP has to move longer distance along the membrane 
before it regenerated. 
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CalbratinE the gain of the PPG biopotential amplifiers 
Examination of the gain of both PPG biopotential amplifiers was done by 
starting the acquisition and observing the starting point signal. The first channel read 
0.3V while the second channel read 0.2 V above baseline (Figure1), both channels 
needed calibration. 
The baseline signal was resealed following the manufacturer' instructions and by using 
the zero adjusts screw at the top of the front face of the module. Setting all dials 
according to the manual, the MP 100 was turned on to acquire the electrical noise which 
was shown on the screen as spiked wave form. The screen was adjusted to show 
amplitude between ±10 V (the maximum amplitude that can be collected on the 
recording window of the monitor). Using a small screwdriver, the zero adjust was 
turned until the baseline of the signal read 0.000 V. Figure (2) shows the amplified 
signal with the noise reduced to the minimum. This procedure was done at a gain of 
100, the same gain that would be used to collect data. It was not appropriate to calibrate 
the signal at other gain setting as different gains change the zero starting point of the 
signal. 
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Figure (2) PPG signal after calibration 
Calibrating the gain of the EMG biopotential amplifiers 
The gain of both EMG biopotential amplifiers was tested by turning on the 
acquisition system and observing the signal. Both channels read an excess of 0.3V from 
the baseline, which meant that both channels needed calibration. 
Calibrating the channels was done following the instruction provided by the 
manufacturer, which involves using a known stimulus signal. A special output cable 
(CBLCAL) was used to attenuate the recorded signal and re-route it back into the 
amplifier where it is amplified by the selected gain setting. 
A 5V sinusoidal signal with a frequency of 10Hz was delivered via the UIM100A 
stimulator. Data were collected and peak-peak amplitude was measured using a 
specialised function in the software. The voltage was measured using the following 
formula: 
Equation (1): Measured Voltage = (Stimulator Input Voltage) * (1/1,000) 
(Biopotential Amplifier Gain Setting). 
Since the amplifier gain was set to 1,000, the CBLCAL attenuation (1/1,000) will be 
cancelled and as result, the measured voltage will equal the stimulator input voltage, 
which is 5V (Figure 3). Checking the accuracy of the calibration was done by using the 
peak detection mode. 
The EMG was calibrated on all the possible gain setting 500,1000,2000, and 5000, 
then it was set to 2000 the gain that would be used in the study and was calibrated 
again. 
Calibrating the gain of the temperature biopotential amplifiers 
The temperature probes used were small (1.7 mm in diameter- 5 mm long), 
fast response (0.6 sec) thermistors and can be attached to any part of the body by 
securing it in place by an adhesive tape. The SKT 1000 can be calibrated to record 
temperature in either °C or T. According to the manufacturer (personal 
communication) once these setting are chosen the module will not require further 
calibration and the front panel controls of the amplifier can be used to display 
absolute or relative temperature measurements (all reported temperatures in this 
study are in absolute °C readings) 
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Figure (3) The gain of EMG amplifier with a stimulus of ±5 Volts (after calibration) 
APPENDIX D. 2 
BIOPAC SPECIFICATION 
EMG SPECIFICATIONS 
Gain 500,1000,2000,5000 
Low Pass Filter 500,5000 Hz 
High Pass Filter 1,10,100 Hz 
Input voltage range ±10 V 
Output voltage range ±10 V 
Gain 
500 
1000 
2000 
5000 
+20 mV 
+10 mV 
±5 mV 
±2 MV 
Noise voltage (10-500 Hz) 0.2 v 
UMI 100C SPECIFICATIONS 
Weight 520g 
Dimensions 7cm wide, 11cm deep, 19cm high 
Analog 1/0 access 16 channels with 3.5 mm front panel 
hone jacks 
D/A outputs 2 channels with 3.5 mm front panel 
hone jacks 
Digital UO access 16 channels screw terminal (back panel) 
External trigger access 1 channel screw terminal (back panel) 
Isolated power access ±12V, +5V @ 100 mA screw terminal 
(back access) 
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STIMULATOR 100C SPECIFICATIONS 
Stimulus output voltage 20V peak-peak maximum value 
Minimum pulse width 10 sec 
Input sources DaO, DA1, pulse (I/O 15) CH16 
_ Polarity control Manual or digital control 
(Digital 1/0 7, H-POS, L-NEG 
Attenuation control Manual or digital control 
Attenuation control range 128dB (digital UO, 0-6, LSB MSB) 
Attenuation resolution 1dB 
Indicators Pulse, current limit 
Uniphasic pulse width 10 sec 
Biphasic pulse resolution 25 sec 
Biphasic pulse width 50 sec 
Arbitrary wave resolution 25 sec 
STIMISOC SPECIFICATIONS 
Weiht 190g 
Dimention 10 cm wide, 5 cm deep, 4.5 wide 
Output via 3.5mm mono phone jack 
_ Bipolar voltage stimulation 2 setting (1: 5), (1: 10) 
1: 5 maximum output voltage is 100V 
peak to peak, 1: 10 of stimulation voltage 
1: 10 mode maximum voltage output is 
200 peak to peak, 1: 20 of stimulation 
voltage 
Current setting 0.01,0.02,0.05,0.1,0.2,0.5,1,2,5, 
10,20,50 mA 
Pulse width range 50 sec -2 msec 
Maximum pulse energy 160 mJ 
Sine wave frequency range 100 Hz, 5000 Isolation capacitance 120pf 
Hz Isolation voltage 1500VDC 
PPG 100C SPECIFICATIONS 
Gain 10,20,50,100 
Low pass Filter 3 Hz, 10 Hz 
High Pass filter DC, 0.05 Hz, 0.5 Hz 
Noise voltage 0.5 V 
Output range ± lo v 
Input signal source TSD 200 
Excitation 6V 
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SKT 100C SPECIFICATION 
Gain 5,2,1,0.5 °F/V 
also can be calibrated in °C 
Low pass filter 1 Hz, 10 Hz 
High pass filter DC, 0.05 Hz, 0.5 Hz 
Sensitivity 180 . t°F 
100 °C 
Output range ± lo v 
Gain Range OF Range °C 
5 40-140 5-60 
2 70-110 22-43 
1 80-100 27-37 
0.5 85-95 30-35 
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APPENDIX D. 3 
ETHICAL APPROVAL OF THE PILOT 
ETHICS COMMITTEE OF THE DEPARTMENTS 
OF RADIOGRAPHY AND PHYSIOTHERAPY 
Radiograpby/Physiotherapy 
(delete as necessary) 
Protocol Number: RPEC/100(Part 3)/06/01 
Name of Investigator: Maryam Almandil 
Name of Supervisor: Dr Tim Watson 
Title of Study: A study to examine the physiological changes that 
accompany pulsed short wave administration (pilot study) 
Dates of Study: 
No. of Subjects: 
Subject information sheet: 
Academic Year 2000/01 
16 
I 
1) 1 support the approval of the study without pre conditions. 
2) I support the'approval of the study, subject to the following: '/ 
a) essential pre conditions which will affect the granting of approval: 
Rewrite some questions so that they are more sensitive 
b) general recommendations and comments which will not affect approval: 
Review use of phraseology in subject information sheet, suggest that you 
discuss this with your supervisor. 
3) 1 do NOT support approval of the study for the following reasons: 
Signature 
fa,, 
* j& L Date: tLl (, fo1 
Chair of Ethics Committee- 
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APPENDIX D. 4 
INFORMATION SHEET 
Pulsed Short Wave Therapy is a popular modality among therapists, it has been used for 
many years to treat a variety of musculoskeletal conditions. Despite this wide use, its 
mechanism of action is not yet understood. The current study is conducted with the aim 
of having a better and a deeper understanding into the physiological effects of this 
modality. The study will involve examining the effects of applying pulsed 
electromagnetic energy to the knee joint and measurements to the accompanying 
reactions in terms of blood volume, skin temperature and nerve conduction velocity. 
The procedure of the study will be as follows: 
" On arrival, you will be briefed about the study protocol (do not hesitate to ask about 
any issue of concern). 
" Next you will be given a form to fill in to exclude any contraindication (this is to 
ascertain that you do not have a problem that might react adversely with the 
treatment modality applied). 
" Then you will be given a consent form to sign. 
" You should bring with you comfortable clothes (shorts) to wear, as this will facilitate 
ease of movement and of measurements. 
" Next measurements to your height, weight, and body fat will follow. 
" You will lie on a plinth, and inspection to the area to be treated will be done by me to 
exclude further contra-indications. 
" Skin test to the area to be treated will be undertaken to ensure that you have a normal 
skin reaction. 
" The area around the knee will be wiped with alcohol to clean it and to remove signs 
of dirt, or sweat. 
"A fine type of sand paper will be used to reduce skin resistance to the applied 
current. 
" Leads will be connected to your knees on both sides, to measure changes in skin 
temperature, blood volume, and nerve conduction velocity. 
" After attaching the leads, measurements will be taken for 10 minutes. 
" The treatment head will then be placed in close contact to your knee and the 
treatment will start. 
"I will remain with you in the room for the whole time of the experiment; therefore do 
not hesitate to report any unpleasant feeling or discomfort. 
" When the treatment time has elapsed, you will hear the sound of a timer, I will then 
remove the treatment head and the measurements will continue for another 10 
minutes. 
" The treatment time will be 10 minutes, however, the overall time that you need to be 
in the laboratory varies between 50 - 60 minutes for the first session and 45-50 
minutes for the following sessions. 
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Please remember NOT to 
eat or 
1 hour prior to the experiment 
Thank you for being part in this study 
For further inquiries do not hesitate to contact me either by 
e-mail me on almary22! ü hotmail. com 
or visit me in room 2F 381 
Researcher: 
Maryam Al-Mandil 
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1' 
APPENDIX D. 5 
CONTRA INDICATION LIST 
Please fill in the appropriate circle 
Do you use a hearing aid? 
Do you complain from ear infection? 
Do you complain from hypersensitivity to heat? 
Do you have high fever? 
Do you have any skin problems that may be exacerbated by heat? 
Do you complain from blood pressure abnormalities? 
Do you have any cardiac disorder? 
Do you have a metal implanted in any part of your body? 
Do you wear a pacemaker? 
Have you sustained an injury to your knees within the last three 
month? 
Have you sustained an injury to your back in the last month? 
Have you ever complained from venous thrombosis or phlebitis? 
Have you ever complained from any arterial disease in your legs? 
Have you ever complained from Tuberculosis? 
Have you ever complained from any malignant diseases (cancer)? 
Are you currently receiving any treatment or medication? 
If yes please print down your medication 
........................................... 
........................................... 
........................................... 
Participant name Participant signature 
YES NO 
00 
00 
00 
00 
00 
00 
00 
00 
00 
00 
00 
00 
00 
00 
00 
00 
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APPENDIX D. 6 
SUBJECTS CONSENT FORM 
Title of the research project: A study into the effectiveness of Pulsed Short Wave Therapy 
YES NO 
The purpose of this study has been explained to me QQ 
I have been informed of the details of my involvement in the QQ 
study 
My questions regarding this study have been answered to 
my satisfaction 
13 
I understand that I am not obliged to take part in this study 
and may withdraw at any time without the need to justify my 
decision and without affecting my care in any way QQ 
I understand that any personal information obtained as a 
results of my participation in this study will be treated as 
confidential and will not be made publicly available QQ 
I, the undersigned, agree to take part in this study 
Signature of the subject 
Name of subject 
(Please print) 
Signature of the investigator: 
Name of the investigator: Maryam Almandil 
Status of investigator: PhD student Date: 
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APPENDIX D. 7 
PROCEDURE FOR MEASURING SKINFOLD 
Reference (Jackson and Pollock, 1985, Lehman et al, 1988) 
Sites for measuring skinfold in women 
Triceps: over the triceps midway between acromion and the olecranon process. The site 
is determined by a tape measure with the elbow flexed 90°. Test is done with the subject 
standing and the investigator behind the subject. The calliper is placed perpendicular to 
the skinfold. 
Suprailium: an oblique (45 from horizontal), the skin is grasped posterior to the 
midaxillary line, immediately above the iliac crest. The test is done with the subject 
standing. 
Abdomen: vertical fold taken at a distance of 2 cm from the umbilicus 
Sites for measuring skinfold in men: 
Chest or pectoral: a skinfold is picked up on the anterior axillary fold in a line directed 
to the nipple. Measurements are taken while the subject is standing. 
Triceps: over the triceps midway between acromion and the olecranon process. The site 
is determined by a tape measure with the elbow flexed 90°. Test is done with the subject 
standing and the investigator behind the subject. The calliper is placed perpendicular to 
the skinfold. 
Subscapular: the fold is taken along the diagonal line connecting the vertebral border 
of the scapula to 1-2 cm below the inferior angle of the scapula. 
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APPENDIX D. 8 
RELIABILITY WITH SFM 
Intertester reliability with skin fold measurements: 
Skinfold measurements (SKF) are known to be affected largely by the operators skill 
(Heyward and Stolarczyk, 1996; Lohman, 1992). As the SFM will be taken on the first 
visit only and it will not be repeated between days it was seen crucial to establish the 
researcher test re-test reliability for the same day. 
The trials were conducted in the same day with a minimum of 30 minutes in between 
trials to avoid having any skin marks guiding the researcher when placing the caliper. 
The reliability was established by measuring the abdominal skinfold in 5 subjects (4 
female and I male). 
Summary of the findings is shown in the table. 
Same da measurements 
Readin I mm Readin 2(mm) 
1 31 31 
2 33 32 
3 35 35 
4 32 31 
5 34 34 
Fat measurement of the abdominal area taken in the same day 
Using Pearson Correlation Coefficient test the r values have shown highly related sets 
of data with r =0.957, p 0.01 
Error margin for the researcher was found to be ±1mm 
40 
39 
£ 38 
37 
av36 
35 
34 
33 
32 
Go 
31 
30 
SFM (reading 2) mm 
Scatter graph of SFM 
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APPENDIX D. 9 
Subject 
TEMPERATURE/ PULSE SHEET 
Order of sessions: 
H' (24 NV) Low (3 Pla cebo Con trol 
Time to 
stabilise 
Pu R CorT PuisR Coil PulsR CorT PulsR Coil 
min 0 
min 2 
min 4 
min 5 
min 6 
min 8 
min 10 
min 12 
min 14 
min 15 
min 16 
min 18 
min 20 
min 22 
min 24 
min 25 
min 26 
min 28 
min 30 
Before After Before After Before After Before After 
Temperature 
Humidity 
ýr Ir 
Inter-electrode distance (mid recording electrode to mid stimulating electrode) 
Distance between mid recording electrode to apex of pattela 
Distance between mid recording electrode to lateral malleolus 
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APPENDIX E. 1 
ETHICAL APPROVAL FOR LABORATORY STUDY 
U University of Hertfordshire 
Hatfield Campus 
College Lane 
Hatfield Hems 
AL 10 9AB 
Switchboard (01707) 284000 
Minicom (01707284000 
Fax (01707) 284115 
Vice-Chancellor 
Prokasor Neil K Buxton 
April 1" 2004 
To whom it may concern 
Maryam Almandil received approval from the Radiography and Physiotherapy Ethics Committee 
for her pilot study on June 12th 2001 (protocol number RPEG100(part3)/06/01). The study had 
two elements, a laboratory experiment and a questionnaire. Her request for to extend the size of 
her sample for the laboratory experiment was discussed and approved at the committee meeting 
held on 16'" April 2002. 
Janet High (Mrs. ) 
Chair of the Radiography and Physiotherapy Ethics Committee 
Department of Allied Health Professions 
Faculty of Health and Human Sciences 
Direct line (01707) 284963 
Fax(01707)284977 
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APPENDIX E. 2 Subject 
CHECK LIST FOR 2nd, 3rd 4th SESSIONS 
2° session 3 session 4h session 
Yes No Yes No Yes No 
Do you have any comments from the 
last session? 
Did you sustain an injury since the last 
time I saw you? 
Have you eaten in the last 2 hours? 
Did you do strenuous sports in the last 
2 hours? 
Did you drink coffee, alcohol in the last 
2 hours 
Did you smoke in the last 2 hours? 
Are you menstruating? 
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Subject 
APPENDIX E. 3 
BLINDING QUESTIONNAIRE 
BEFORE TREATMENT 
1. Have you experienced PSWT before? 
1 Yes D No 
2. How long ago was that? 
3. For what reason? 
4. What do you think you would feel during PSWT treatment? 
AFTER TREATMENT 
(24W) 
1. Do you think that PSWT machine was working during the session? 
Q Yes Q No QI don't know 
2. How sure are you? 
Q Very sure QI think I am sure 
QI am not sure 
3. Do you think your session was a? 
Q Treatment Q Placebo Q Control QI don't know 
4. Did you feel any heat under the treatment head during the treatment? 
Q Yes Q No Q1 am not sure 
(3W) 
1. Do you think that PSWT machine was working during the session? 
Q Yes Q No QI don't know 
2. How sure are you? 
Q Very sure QI think I am sure QI am not sure 
3. Do you think your session was a? 
Q Treatment Q Placebo Q Control QI don't know 
4. Did you feel any heat under the treatment head during the treatment? 
Q Yes Q No Q1 am not sure 
(Placebo) 
1. Do you think that PSWT machine was working during the session? 
Q Yes Q No QI don't know 
2. How sure are you? 
Q Very sure QI think I am sure QI am not sure 
3. Do you think your session was a? 
Q Treatment Q Placebo Q Control QI don't know 
4. Did you feel any heat under the treatment head during the treatment? 
Q Yes Q No Q1 am not sure 
(Control) 
1. Do you think that your session was? 
Q Treatment Q Placebo Q Control QI don't know 
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APPENDIX E. 4 
RESULTS FROM LABORATORY EXPERIMENT 
Age Sex Height (cm) Weight k Fat% Dominant side 
1 21 female 162 50.86 19.65 LT 
2 21 female 159 52.8 18.9 RT 
3 23 female 169 57.36 19.58 RT 
4 23 female 158.3 93.74 30.06 RT 
5 19 female 165 86 30.62 RT 
6 29 male 171 82.06 14.84 RT 
7 22 female 162.5 86.48 33.55 RT 
8 20 female 163 55 19.29 RT 
9 26 male 172.8 68.76 14.49 RT 
10 20 female 196.4 61.22 28.12 LT 
11 29 female 168.9 59.2 21.43 RT 
12 33 male 173 78 16.78 LT 
13 25 female 152 44.56 23.84 RT 
14 22 female 171.8 75.5 22.7 RT 
15 30 female 172.5 60.72 17.25 RT 
16 23 female 171.5 82 39.47 RT 
17 29 male 182 79.8 11.62 RT 
18 20 male 173.5 65 13.7 RT 
19 33 female 166.8 88.12 30.12 RT 
20 20 female 172.92 77.92 31.51 RT 
21 19 female 170.5 73.78 25.03 RT 
22 23 female 171.8 73.8 25.21 RT 
23 23 female 172 70.88 25.02 RT 
24 23 female 154.5 74.42 26.21 RT 
25 32 female 158.81 61.81 31.62 LT 
26 19 female 162 49.9 19.72 LT 
27 38 female 171.2 70.34 25.01 RT 
28 48 female 152.6 64.9 35.93 RT 
29 44 male 166 82.01 25.83 RT 
30 21 male 169 78.2 11.34 RT 
31 23 female 179 72 21.66 RT 
Summary of demographic profiie of the subjects 
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SUMMARY OF BLOOD VOLUME DATA 
Tests of Within-Subjects Effects 
flA*IIDC I 
Type III Sum 
Source of Squares df Mean Square F Sig 
condition Sphericity Assumed 64407.827 3 21469.276 18.949 . 000 
Greenhouse-Gelsser 64407.827 1.860 34634.122 18.949 . 000 
Huynh-Feldt 64407.827 2.187 29452.014 18.949 . 000 Lower-bound 64407.827 1.000 64407.827 18.949 
. 001 
Error(COND) Sphericity Assumed 40787.762 36 1132.993 
Greenhouse-Geisser 40787.762 22.316 1827.739 
Huynh-Feldt 40787.762 26.242 1554.265 
Lower-bound 40787.762 12.000 3398.980 
phase Sphericity Assumed 88240 069 2 44120.034 61.428 . 000 
Greenhouse-Geisser 88240.069 1.980 44560.074 61.428 . 000 
Huynh-Feldt 88240.069 2.000 44120.034 61.428 . 000 
Lower-bound 88240.069 1.000 88240.069 61.428 . 000 
Error(PHASE) Sphericity Assumed 17237.877 24 718.245 
Greenhouse-Gefsser 17237.877 23.763 725.408 
Huynh-Feldt 17237.877 24.000 718.245 
Lower-bound 17237.877 12.000 1436.490 
side Sphericity Assumed 5169.747 1 5169.747 
4.287 . 061 
Greenhouse-Geisser 5169.747 1.000 5169.747 4.287 . 
061 
Huynh-Feldt 5169.747 1.000 5169.747 4.287 . 081 
Lower-bound 5169.747 1.000 5169.747 4.287 . 061 
Error(SIDE) Sphericity Assumed 14471.088 12 1205.924 
Gtr 14471.088 12.000 1205.924 
Huynh-Feldt 14471.088 12.000 1205.924 
Lower-bound 14471.088 12.000 1205.924 
condition " phase Sphericity Assumed 80083.553 6 13347.259 26.533 . 000 Greenhouse-Gaisser 80083.553 2.250 35595.403 26.533 
. 000 Huynh-Feldt 80083.553 2.795 28656.597 26.533 . 000 
Lower-bound 80083.553 1.000 80083.553 26 533 . 000 
Error(COND'PHASE) Sphericity Assumed 36219.041 72 503.042 
Gtr 36219.041 26.998 1341.548 
Huynh-Feldt 36219.041 33.535 1080.033 
Lower-bound 38219.041 12.000 3018.253 
Condition " $kis Sphericity Assumed 3752.970 3 1250.990 1.239 . 310 
Greernhouse-Geiser 3752.970 2.007 1870.288 1.239 . 307 
Huynh-Feldt 3752.970 2.410 1557.112 1.239 . 309 
Lower-bound 3752.970 1.000 3752.970 1.239 . 287 
Error(COND"SIDE) Sphericity Assumed 36336.990 36 1009.361 
Greenhouse-Geisser 36396.990 24.080 1509.041 
Huynh-Feldt 36336.990 28.923 1256.355 
Lower-bound 36336.990 12.000 3028.083 
Phase" side Sphericity Assumed 1829.177 2 914.589 1.622 . 218 
Greenhouse-Geisser 1829.177 1.531 1194.722 1.622 
. 225 Huynh-Feldt 1829.177 1.710 1069.592 1.622 
. 223 Lower-bound 1829.177 1.000 1829.177 1.622 227 
Error(PHASE'SIDE) Sphericity Assumed 13532.979 24 563.874 
Greenhouse-Gelsser 13532.979 18.373 736.586 
Huynh-Feldt 13532.979 20.522 659.439 
Lower-bound 13532.979 12.000 1127.748 
condition " phase " Sphericity Assumed 6669.907 6 1111.651 2.448 . 033 
side Greenhouse-Geisw 6669.907 1.902 3506.099 2.446 , 111 Huynh-Feldt 6669.907 2.251 2962.945 2.446 
. 100 Lower-bound 6669 907 1.000 6669.907 2.446 
. 144 
Error(COND"PHASE"S Sphericity Assumed 32728.034 72 454.556 
IDE) Greenhouse-Gelsser 32728.034 22.828 1433.650 
Huynh-Feldt 32728.034 27.013 1211.553 
Lower-bound 32728.034 12.000 2727336 
Summary of within subjects effects for blood volume 
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IMauchq's Isst of Sphsricit f 
Umslum MEASURE I 
Epsilon' 
Approx. Greenhous 
Within Subjects Effect Ma sW Chi-Square df Sig. e-Geisser Hu h-Feldt Lower-bound 
condition . 171 
18.919 5 . 002 . 
620 . 729 . 333 
phase . 990 
110 2 . 
946 . 990 
1.000 
. 
500 
side 1.000 . 000 0 1.000 1.000 1.000 
condition " phase . 005 52.128 
20 . 000 . 375 . 466 . 167 
condition " side . 397 9903 5 . 079 . 669 . 
803 
. 333 
phase " side . 694 4.023 2 . 134 . 766 . 855 . 500 
condition " phase " 
. 001 
73.982 20 
. 000 . 317 . 375 . 167 side 
Summary of Sphericity values for factors In blood volume analysis 
Pirwi» Comparisons 
UrAQI Ing: I 
n M 95% Confidence 
Interval for 
ea Diff s Difference erence 
COND J COND IJ Std. Error Lower Bound Upper Bound 
High ow 29.307' 5.342 . 001 12.465 46.149 
Placebo 25.569' 7.537 . 032 1.807 49.331 
Control 38.846' 4.570 . 000 24.439 53.253 
Low High -29.307' 5.342 . 001 -46.149 -12.465 
Placebo -3.738 5.520 1.000 -21.141 13.664 
Control 9.539* 1.874 . 002 3.630 15.448 
Placebo High -25.569' 7.537 . 032 -49.331 -1.807 
Low 3.738 5.520 1.000 -13.664 21.141 
Control 13.277 5.839 . 253 -5.131 31.686 
Control High -38.846* 4.570 . 000 -53.253 -24.439 
Low -9.539* 1.874 . 002 -15.448 -3.630 
Placebo -13.277 5.839 . 
253 -31.686 5.131 
Based on estimated marginal means 
'. The mean difference is significant at the . 05 level. 
a. Adjustment for multiple comparisons: Bonferroni" 
Summary of Post hoc test for blood volume 
P. irwiss Comparisons 
IAnaciim MFASURE I 
mean 95% Confidence Interval for 
Difference Diff erence' 
PHASE (J) PHASE W Std. Error Si q. * Lower Bound Upper Bound 
Before During -38.877' 3.830 . 000 -49.523 -28.231 
After -7.643 3.528 . 153 -17.450 2.163 
During Before 38.877* 3.830 . 000 28.231 49.523 
After 31.234' 3.784 . 
000 20.716 41.752 
After Before 7.643 3.528 . 
153 -2.163 17.450 
During -31.234' 3.784 . 000 -41.752 -20.716 
Based on estimated marginal means 
'" The mean difference is significant at the . 05 level. 
a. Adjustment for multiple comparisons: Bonferroni. 
Summary of Post hoc test for blood volume (experimental phase) 
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SKIN TEMPERATURE DATA 
Tub of WI hki-Aubjects Efbcb 
Type III Sum 
Source of Squares df Mean Square F Sig. 
condition herfaty Assumed 14.999 3 5.000 1.340 . 277 
Greenhouse-Geisssr 14.999 2.692 5.571 1.340 . 279 
Huynh-FNdt 14.999 3.000 5.000 1.340 . 277 
Lower-bound 14.999 1.000 14.999 1.340 . 270 
Erra(COND) Sphericity Assumed 134.303 36 3.731 
Greenhouse-Gsiseer 134.303 32.307 4.157 
Huynh-Feldt 134.303 36.000 3.731 
Lower-bound 134.303 12.000 11.192 
phase Sphericity Assumed 8.266 1 8.266 11.828 . 005 
Greenhouse-Geisser 8.266 1.000 8.266 11.828 . 005 
Huynh-Fellift 8.266 1.000 8.266 11.828 . 005 
Lower-bound 8 266 1.000 8.266 11.828 . 005 
Error(PHASE) Sphericity Assumed 8.386 12 . 699 
Greenhouse-Geisser 8.386 12.000 . 699 
Huynh-Feldt 8.386 12.000 . 699 
Lower-bound 8.386 12.000 . 699 
side Sphericity Assumed 9.898 1 9.898 18.636 . 001 
Greenhouse-Geisser 9.898 1.000 9.898 18.636 . 001 
Huynh-Feldt 9.898 1.000 9.898 18.638 . 001 
Lower-bound 9.898 1.000 9.898 18.636 . 001 
Error(SIDE) Sphericity Assumed 6.373 12 . 531 
Greenhouse-Gaisser 6.373 12.000 . 531 
Huynh-Feldt 6.373 12.000 . 531 
Lover-bound 6.373 12.000 . 531 
condition ' phase Sphericity Assumed 15.224 3 5.075 11.606 . 000 Greenhouse-Geisser 15.224 2.054 7.414 11.606 
. 
000 
Huynh-Feldt 15.224 2.483 6.132 11.606 . 000 Lower-bound 15.224 1.000 15.224 11.606 . 005 
Error(COND'PHASE) Sphericity Assumed 15.742 36 . 437 
Greenhouse-Geisser 15.742 24.642 . 639 
Huynh-FSldt 15.742 29.794 . 528 
Lower-bound 15.742 12.000 1.312 
condition ' sift Sphericity Assumed 8.612 3 2.871 6.888 . 001 
Greenhouse-Geister 8.612 2.639 3.263 8.888 . 002 
Huynh-Feldt 8.612 3.000 2.871 6.888 . 001 
Lower-bound 8.612 1.000 8.812 6.888 . 022 
Error(COND'SIDE) Spheric "Assumed 15.003 36 . 417 
Greenhouse-Geisser 15.003 31.668 . 474 
Huynh-Feldt 15.003 36.000 . 417 
Lower-bound 15.003 12.000 1.250 
phase- side Sphericity Assumed 4.017 1 4.017 33.959 . 000 
Greenhouse-Gsisser 4.017 1.000 4.017 33.959 . 000 
Huynh-Feldt 4.017 1.000 4.017 33.959 . 000 
Lower-bound 4.017 1.000 4.017 33.959 . 000 
Error(PHASE'SIDE) Sphericity Assumed 1.419 12 . 118 
Greenhouse-Gsisser 1.419 12.000 
. 118 
Huynh-Feld[ 1.419 12.000 . 118 
Lower-bound 1.419 12 000 . 118 
condition " phase " Sphericity Assumed 7.706 3 2.568 21.056 . 
000 
side Greenhouse-Geisser 7.705 2.268 3.398 21.056 
. 000 Huynh-Feldt 7.705 2.823 2.729 21.056 
. 000 Lower-bound 7.705 1.000 7.705 21.056 
. 001 
Error(COND'PHASE'S Sphericity Assumed 4.391 36 . 122 
IDE) Greenhouse-Geiseer 4.391 27.211 . 161 
Huynh-Fedt 4.391 33.880 . 130 
Lower-bound 4.391 12.000 . 366 
Summary of within subjects effects of skin temperature 
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. ýY..., ý. LAN--e4 hoc 4 
Mean 95% Confidence Interval for 
Difference a (AbrenCe 
COND J COND Std. Error Sig ° Lower Bound Upper Bound 
high low -. 304 . 
364 1.000 -1.451 . 
843 
placebo -. 600 . 340 . 617 -1.672 . 472 
control 7.84SE-02 . 395 1.000 -1.168 1.325 
l high . 304 . 364 1.000 -. 843 1.451 
placebo -. 296 . 331 1.000 -1.340 . 748 
control . 
383 . 
454 1.000 -1.049 1.814 
placebo high . 600 . 
340 . 617 -. 472 1.672 
low 296 . 331 1.000 -. 748 1.340 
control . 
679 
. 
375 
. 
574 -. 504 1.862 
Domrot high -7.845E-02 . 395 1.000 -1.325 1.168 
low -. 383 . 454 
1.000 -1.814 1.049 
placebo -. 679 . 375 . 574 -1.862 . 504 
Based on estimeMd mar final mean 
a. /4dijatrnent for ffx*iple compare ns: Bonfenor i. 
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DATA FOR NERVE CONDUCTION VELOCITY 
Taft of Wi hin4ubject. Effects 
U... IAFACt )RF I 
Type III Sum 
source of Squares df Mean Square F Sig. 
condition Sphericity Assumed 60.531 3 20.177 . 612 . 612 Greenhouse-GMISSr 60.531 1.728 35.036 
. 
612 
. 
529 
4uynh-F. 60.531 1.992 30.391 
. 612 . 550 Lower-bound 60.531 1.000 60.531 
. 612 . 449 Error(COND) Sphericity Assumed 1186.509 36 32.959 
Grwnhouss-Geissen 1186.509 20.732 57.231 
Huynh-Fs4dt 1186.509 23.901 49.643 
Lower-bound 1186.509 12.000 98 876 
phase Sphericity Assumed 18.993 1 18.993 10.561 . 007 Greenhouse-Gsisssr 18.993 1.000 18.993 10.561 . 007 Huynh-Feldt 18.993 1.000 18.993 10.561 
. 007 Lower-bound 18.993 1.000 18.993 10.561 
. 007 
Error(PHASE) Sphericity Assumed 21.582 12 1.798 
GreenhouseGsisser 21.582 12.000 1.798 
Huynh-Feldt 21.582 12.000 1.798 
Lower-bound 21.582 12.000 1.798 
s Sphericity Assumed . 252 
1 . 252 . 076 . 767 
Gre. nhouse-Giisser . 252 
1.000 . 252 . 076 . 787 
Huynh-Fe1dt . 252 1.000 . 252 . 
076 . 787 
Lower-bound . 252 1.000 . 252 . 076 . 
787 
Error(SIDE) Sphericity Assumed 39.721 12 3.310 
Greenhouse-Gsisser 39.721 12.000 3.310 
HuyTM-FNdt 39.721 12.000 3.310 
Lower-bound 39.721 12.000 3.310 
condihon'pha" Sphericity Assumed 30.788 3 10.263 4.674 
. 
007 
GrMnhous -GMsser 30.788 1.437 21.423 4.674 . 033 Huynh-Feldt 30.788 1.579 19.494 4.674 
. 
029 
Lower-bound 30.788 1.000 30 788 4.674 
. 052 
Ena(COND'PHASE) Sphericity Assumed 79.038 36 2.196 
GreenhoussGsiwr 79.038 17.246 4,583 
Huynh-Feldt 79.038 18.953 4.170 
Lower-bound 79.038 12.000 6.587 
corA*W'slft Sphericity Assumed 1.917 3 . 639 . 172 . 915 Grnanhouse-Gshser 1.917 2.198 
. 872 . 172 . 862 Huynh-Feld[ 1.917 2.711 
. 707 . 172 . 899 
Lower-bound 1.917 1.000 1.917 . 172 . 686 
Error(COND'SIDE) Sphericity Assumed 134.140 36 3.726 
Greenhouse-GNsssr 134.140 26.379 5.085 
Huynh-FNdt 134.140 32.537 4.123 
Lower-bound 134.140 12.000 11.178 
phase-side Sphericity Assumed 2.677 1 2.677 1.176 . 
299 
Greenhouse-Gelsser 2.677 1.000 2.877 1.176 . 299 Huynh-FNdt 2.677 1.000 2.677 1.176 . 299 Lower-bound 2.677 1.000 2.677 1.176 
. 299 Error(PHASESIDE) Sphericity Assumed 27.312 12 2.276 
Greenhouse-Gsisser 27.312 12.000 2.276 
Huynh-Feldt 27.312 12.000 2.276 
Lower-bound 27.312 12.000 2.276 
condition"phasa'slds Sphericity Assumed 4.874 3 1.558 . 749 . 530 Greenhouse-G. isser 4.674 2.081 2.245 
. 749 . 488 Huynh-F" 4.674 2.526 1.850 
. 
749 
. 510 Lower-bound 4.574 1.000 4.674 
. 749 . 404 Error(COND'PHASE'S Sphericity Assumed 74.642 36 2.079 
IDE) Greenhouse-Gsissei 74.842 24.977 2.996 
Huynh-Fsidt 74.842 30.317 2.469 
Lower-bound 74.842 12.000 6.237 
Summary of between subjects effects for NCV 
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TOsts of Within-Subjects Contrast. 
L cnrQ" UFARI IRF I 
Type III Sum 
Source Condition Phase Side of S uares df Mean Square F Sig. 
Condition High vs control 27.808 1 27.808 3.245 . 097 
Low vs control 11.342 1 11.342 1.067 . 322 
Placebo vs control 15.672 1 15.672 . 757 . 401 
Error(COND) High vs control 102.826 12 8.569 
Low vs control 127.604 12 10.634 
Placebo vs control 248.321 12 20.693 
Phase Before vs after 4.748 1 4.748 10.561 . 007 
Error(PHASE) Before vs after 5.395 12 . 450 
Side Treated vs non 
treated 6.306E-02 1 6.306E-02 . 076 . 787 
Error(SIDE) Treated vs non 
treated 9.930 12 . 828 
Condition vs phase High vs control Before vs after 50.433 1 50.433 6.329 . 027 
Low vs control Before vs after 3.932 1 3.932 4.013 . 068 
Placebo vs control Before vs after 
. 545 1 . 545 . 314 . 586 
Error(COND'PHASE) High vs control Before vs after 95.618 12 7.968 
Low vs control Before vs after 11.757 12 . 980 
Placebo vs control Before vs after 20.829 12 1.736 
Condition vs side High vs control Treated vs non 
treated 3.002 1 3.002 . 718 . 413 
Low vs control Treated vs non 
. 381 1 . 381 . 
047 . 832 treated 
Placebo vs control Treated vs non 
treated 2.221 1 2.221 . 542 . 476 
Error(COND'SIDE) High ve control Treated vs non 
treated ri0.189 12 4.182 
Low vs control Treated vs non 
treated 97.812 12 8.151 
Placebo vs control Treated vs non 
treated 49.145 12 4.095 
Phase vs side Before vs after Treated vs non 
treated 2.677 1 2 677 1.176 299 
Error(PHASE'SIDE) Before vs after Treated vs non 
treated 27.312 12 2.276 
Condition vs phase vs High vs control Before vs after Treated vs non 
side treated 
18.326 1 18.326 1.014 . 334 
Low vs control Before vs after Treated vs non 
treated 22.468 1 22.468 1.579 . 233 
Placebo vs control Before vs after Treated vs non 
treated . 175 1 . 175 . 024 . 881 
Error(COND'PHASE*S High vs control Before vs after Treated vs non 
IDE) treated 
216.940 12 18.078 
Low vs control Before vs after Treated vs non 
treated 170.727 12 14.227 
Placebo vs control Before vs after Treated vs non 
treated 89.260 12 7.438 
Summary of within subjects contrasts for nerve conduction velocity 
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Mauchly's Test of Sphericit# 
Measure: MEASURE 
_I 
E sllon' 
Approx. Greenhous 
Within Subjects Effect Mauchl sW Chi-Square df Si q. e-Geisser Hu h-Feldt Lower-bound 
condition . 
272 13.968 5 . 016 . 576 . 
664 
. 
333 
Phase 1.000 . 000 0 1.000 1.000 1.000 
side 1.000 000 0 1.000 1.000 1.000 
conditon'phase 135 21.490 5 . 
001 
. 479 . 526 . 333 
condition'side . 584 5.759 5 . 332 . 733 . 904 . 333 
phase'side 1.000 . 000 0 1.000 1.000 1.000 
condiion'phase'side . 502 7382 5 . 195 . 694 . 842 . 333 
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is proportional 
to an identity matrix. 
a. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed In the 
Tests of Within-Subjects Effects table. 
Design. Intercept 
Within Subjects Design: COND+PHASE+SIDE+COND*PHASE+COND*SIDE+PHASE*SIDE+COND*PHASE'SIDE 
Pairwiss Comparisons 
Measure: MEASURE-1 
Mean 95% Confidence Interval for 
Difference Difference 
(I) COND J COND I-J Std. Error Sig., Lower Bound Upper Bound 
high ow -. 529 . 546 . 352 -1.719 . 662 
placebo -. 365 1.363 . 794 -3.334 2.605 
control -1.463 . 
812 
. 097 "3.231 . 306 
low high . 
529 . 546 . 
352 -. 662 1.719 
placebo . 164 1.543 . 917 -3.198 3.526 
control -. 934 . 904 . 322 -2.905 1.037 
placebo high . 365 1.363 . 794 -2.605 3.334 
low -. 164 1.543 . 917 -3.526 3.198 
control -1.098 1.262 . 401 -3.847 1.651 
control high 1.463 . 812 . 097 -. 306 3.231 
low . 934 . 
904 . 322 -1.037 2.905 
placebo 1.098 1.262 . 401 -1.651 
3.847 
Based on estimated marginal means 
a. Adjustment for multiple comparisons: Least Significant Difference (equivalent to no 
adjustments). 
Summary of Post hoc test of nerve conduction velocity 
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NERVE ONSET LATENCY DATA 
Tests of Within-Subjects Contrasts 
Source condition phase side 
Type III Sum 
of Squares df Mean Square F SIG. 
condition high vs control 4.235E-07 1 4.235E-07 1.6 . 
229 
low vs control 4.561 E-08 1 4.561 E-08 . 166 . 
691 
placebo vs control 1.405E-06 1 1.405E-06 2.7 . 
127 
Error(COND) high vs control 3.162E-06 12 2.635E-07 
low vs control 3.301 E-06 12 2.751 E-07 
placebo vs control 6.263E-06 12 5.219E-07 
phase before vs after 1.031E-07 1.031E-07 5.6 . 035 
Error(PHASE) before vs after 2.190E-07 12 1.825E-08 
side treated vs non treated 1 406E-08 1.406E-08 . 
673 . 
428 
Error(SIDE) treated vs non treated 2.506E-07 12 2.088E-08 
condition' phase high vs control before vs after 4.043E-07 1 4.043E-07 6.0 . 031 
low vs control before vs after 4.284E-07 1 4 284E-07 1.6 . 225 
placebo vs control before vs after 1.674E-09 1 1.674E-09 . 133 . 721 
Error(COND'PHASE) high vs control before vs after 8.140E-07 12 6.783E-08 
low vs control before vs after 3.142E-06 12 2.818E-07 
placebo vs control before vs after 1.507E-07 12 1.256E-08 
condition * side high vs control treated vs non treated 7.039E-09 1 7.039E-09 184 . 
676 
low vs control treated vs non treated 2.356E-07 1 2.356E-07 1.2 . 296 
placebo vs control treated vs non treated 9.289E-09 1 9.289E-09 . 364 . 557 
Error(COND'SIDE) high vs control treated vs non treated 4.597E-07 12 3.831 E-08 
low vs control treated vs non treated 2.371 E-06 12 1.976E-07 
placebo vs control treated vs non treated 3.061 E-07 12 2.551E-08 
phase, side before vs after treated vs non treated 1.412E-07 1.412E-07 1.9 . 189 
Error(PHASE'SIDE) before vs after treated vs non treated 
condition' phase high vs control before vs after treated ve non treated 
8.749E-07 
7.769E-08 
12 7.291 E-08 
7.769E-08 493 . 496 
side low vs control before vs after treated vs non treated 1.877E-06 1.877E-06 1.9 . 190 
placebo vs control before vs after treated vs non treated 
Error(COND*PHASE*S high vs control before vs after treated vs non treated 
8.481E-10 
1.891E-06 12 
8.481 E-10 
1.576E-07 
. 016 . 901 
IDE) low vs control before vs after treated vs non treated 
placebo vs control before vs after treated vs non treated 
1.167E-05 
6.268E-07 
12 
12 
9.728E-07 
5.224E-08 
Summary of within subjects contrast for nerve onset latency 
435 
Ü 
O 
b 
C 
s 4 
C O 
C 0 
0 
z O 
C 
experimental conddion 
Q b810f@ 
after 
Changes in nerve onset latency across the experimental conditions in the treated side 
Ü 
O 
C 
CO 
C 
CC 0 
9 
Q before 
after 
Changes in nerve onset latency across the experimental conditions in the non-treated 
side 
436 
high dose low doss gaoaeo wird 
high dose low dose placebo contra 
NERVE DURATION DATA 
Tests of Within-Subjects Effects 
IW our - LWA I IRF I 
Type III Sum 
Source of Squares df Mean Square F Si . condition Sphericity Assumed 22396 3 7465 2.124 . 114 
Greenhouse-Geisser 22.396 1.877 11.933 2.124 . 145 Huynh-Feldt 22.396 2.213 10.122 2.124 
. 135 Lower-bound 22 396 1.000 22.396 2.124 
. 171 Error(COND) Sphericity Assumed 126.502 36 3.514 
Greenhouse-Geisser 126.502 22.522 5.617 
Huynh-Feldt 126.502 26.551 4.764 
Lower-bound 126.502 12.000 10.542 
phase Sphericity Assumed 1.791 1 1.791 9.515 
. 009 Greenhouse-Geisser 1 791 1.000 1.791 9.515 
. 009 
Huynh-Fe4dt 1.791 1.000 1.791 9.515 
. 009 
Lower-bound 1.791 1.000 1.791 9.515 
. 009 
Error(PHASE) Sphericity Assumed 2.259 12 
. 188 
Greenhouse-Geisser 2.259 12.000 
. 
188 
Huynh-Feldt 2.259 12.000 
. 
188 
Lower-bound 2.259 12.000 
. 188 
side Sphericity Assumed . 
592 1 . 592 . 
244 
. 
630 
Greenhouse-Geisser . 592 1.000 . 592 . 
244 . 630 
Huynh-Feldt . 592 1.000 . 592 . 244 . 630 
Lower-bound . 592 1.000 . 
592 . 
244 
. 
630 
Error(SIDE) Sphericity Assumed 29.125 12 2.427 
Greenhouse-Geisser 29.125 12.000 2.427 
Huynh-Feldt 29.125 12.000 2.427 
Lower-bound 29.125 12.000 2.427 
condition ' phase Sphericity Assumed 1.650 3 
. 550 3.795 . 018 Greenhouse-Geisser 1 650 1.571 1.050 3.795 
. 050 Huynh-Feldt 1.650 1.767 
. 934 3.795 . 044 Lower-bound 1.650 1.000 1.650 3.795 
. 075 Error(COND'PHASE) Sphericity Assumed 5.218 36 
. 145 
Greenhouse-Geisser 5.218 18.853 . 277 
Huynh-Feldt 5.218 21.199 
. 
246 
Lower-bound 5.218 12.000 
. 435 
condition ' side Sphericity Assumed 5.252 3 1.751 2.632 . 072 Greenhouse-Geisser 5.252 2.219 2367 2.532 . 094 Huynh-Feldt 5.252 2.744 1.914 2.532 
. 079 
Lower-bound 5.252 1.000 5 252 2.532 
. 138 
Error(COND*SIDE) Sphericity Assumed 24.889 36 . 691 
Greenhouse-Geisser 24.889 26.626 . 935 
Huynh-Feldt 24.889 32.934 . 
756 
Lower-bound 24.889 12.000 2.074 
phase' side Sphericity Assumed . 929 1 . 929 15.003 . 002 Greenhouse-Geisser 
. 929 1.000 . 929 15.003 . 002 Huynh-Feldt 
. 929 1.000 . 929 15.003 . 002 Lower-bound 
. 929 1.000 . 929 15.003 . 
002 
DE) Sphericity Assumed Error(PHASE SI 
. 743 12 6.192E-02 
Greenhouse-Geisser 
. 743 12.000 6.192E-02 
Huynh-Feldt 
. 743 12.000 6.192E-02 
Lower-bound 
. 743 12.000 6.192E-02 
condition' phase ' Sphericity Assumed . 511 3 . 170 1.262 . 302 side Greenhouse-Geissen 
. 511 1.826 . 280 1.262 . 300 Huynh-Feldt 
. 
511 2.136 
. 
239 1.262 
. 302 Lower-bound 
. 511 1.000 . 511 1.262 . 283 Error(COND*PHASE*S Sphericity Assumed 4.855 36 
. 135 IDE) Greenhouse-Geisser 4.855 21.908 
. 222 
Huynh-Feldt 4.855 25.633 
. 
189 
Lower-bound 4 855 12 000 
. 
405 
Summary of within subjects effects for nerve response duration 
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Tests of Wihin-Subjects Contrasts 
Measure- MEASURE 1 
Source condition se side 
Type III Sum 
of Squares df 
Mean 
Square F S. 
condrtm high vs control . 162 1 . 162 . 114 . 742 
low vs control 1.981 1 1.981 4.719 . 051 
placebo vs control 3.662 1 3.662 1.205 . 294 
Error(COND) high vs control 17.093 12 1.424 
low vs control 5.038 12 . 420 
placebo vs control 36.468 12 1039 
phase before vs after . 448 1 . 448 9.515 . 009 Error(PHASE) before vs after . 565 12 4.7E-02 
side treated vs non treated . 
148 1 
. 148 . 
244 
. 
830 
Error(SIDE) treated vs non treated 7.281 12 
. 
607 
condition " phase high vs control before vs after 3.053 3.053 8.171 
. 
029 
low vs control before vs after . 
500 
. 500 4.147 . 
064 
placebo vs control before vs after . 197 1 . 197 1856 . 198 
Error(COND'PHASE) high vs control before vs after 5.937 12 . 495 
low vs control before vs after 1.447 12 . 121 
placebo vs control before vs after 1.273 12 . 106 
condition " side high vs control treated vs non treated 7.847 7.847 5.334 . 040 
low vs control treated vs non treated . 185 . 185 . 152 . 704 
placebo vs control treated vs non treated 1.231 E-02 1.2E-02 . 013 . 912 
Error(COND'SIDE) high vs control treated vs non treated 17.653 12 1.471 
low vs control treated vs non treated 14.603 12 1.217 
placebo vs control treated vs non treated 11.668 12 . 972 
phase- side before vs after treated vs non treated . 929 1 . 929 15.0 . 002 
Erra(PHASE'SIDE) before vs after treated vs non treated . 743 12 6.2E-02 
oondition" phase " high vs control before vs after treated vs non treated 2.588 2.588 1.651 . 223 
side low vs control before vs after treated vs non treated 2.862 1 2.862 5.230 . 
041 
placebo vs control before vs after treated vs non treated . 
308 1 
. 
308 
. 
504 Ag 
Error(COND'PHASE"S high vs control before vs after treated vs non treated 18.812 12 1.568 
IDE) low vs control before vs after treated vs non treated 6.568 12 . 547 
placebo vs control before vs after treated vs non treated 7.332 12 . 
611 
Summary of within subjects contrast for nerve response duration 
Pairwiss Comparisons 
Measure: MEASURE_t 
Mean 95% Confidence Interval for 
Difference Differencea 
COND (J) COND RI Std. Error Si .a Lower Bound 
Upper Bound 
high low -. 502 . 254 . 428 -1.302 . 
298 
placebo . 419 . 454 
1.000 -1.013 1.851 
control -. 112 . 331 1.000 -1.155 . 932 
low high . 
502 . 254 . 428 -. 298 1.302 
placebo . 921 . 406 . 254 -. 358 2.200 
control . 390 . 180 . 304 -. 176 . 957 
placebo high -. 419 . 454 1.000 -1.851 1.013 
low -. 921 . 
406 . 
254 -2.200 . 
358 
control -. 531 . 483 1.000 -2.055 . 
994 
control high . 112 . 331 1.000 -. 932 1.155 
low -. 390 . 180 . 304 -. 957 . 176 
placebo . 531 . 
483 1.000 -. 994 2.055 
Based on estimated marginal means 
a. Adjustment for multiple comparisons: Bonferroni. 
Summary of post hoc test for nerve response duration 
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DATA FOR PULSE RATE 
Tests of Within-Subjects Effects 
Measure: MEASURE 1 
Type III Sum 
Source of Squares df Mean Square F Si a. 
condition Sphericity Assumed 473.555 3 157.852 1.214 
. 318 Greenhouse-Geisser 473.555 2.429 194.948 1.214 . 317 Huynh-Feldt 473.555 3.000 157.852 1.214 . 318 Lower-bound 473.555 1.000 473.555 1.214 
. 292 
Error(COND) Sphericity Assumed 4679.254 36 129.979 
Greenhouse-Geisser 4679.254 29.150 160.525 
Huynh-Feldt 4679.254 36.000 129.979 
Lower-bound 4679.254 12.000 389.938 
phase Sphericity Assumed 2.851 2 1.425 . 217 . 807 
Greenhouse-Geisser 2.851 1.408 2.025 . 217 . 729 
Huynh-Feldt 2.851 1.539 1.852 . 217 . 750 
Lower-bound 2.851 1.000 2.851 . 217 . 650 
Error(PHASE) Sphericity Assumed 157.702 24 6.571 
Greenhouse-Geisser 157.702 16.897 9.333 
Huynh-Feldt 157.702 18.473 8.537 
Lower-bound 157.702 12.000 13.142 
condition * phase Sphericity Assumed 36.300 6 6.050 1.603 . 159 Greenhouse-Geisser 36.300 4.240 8.562 1.603 
. 185 Huynh-Feldt 36.300 6.000 6.050 1.603 . 159 Lower-bound 36.300 1.000 36.300 1.603 
. 229 
Error(COND'PHASE) Sphericity Assumed 271.714 72 3.774 
Greenhouse-Geisser 271.714 50.877 5.341 
Huynh-Feldt 271.714 72.000 3.774 
Lower-bound 271.714 12.000 22.643 
Summary of within subjects effects for pulse rate 
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DATA FOR CORE TEMPERATURE 
Tests of Within-Subjects Emcts 
Measure- MEASURE_l 
Type III Sum 
Source of uares df Mean Sauare F Si 
condition phencity Assumed 1 548 3 . 516 3.928 . 016 Greenhouse-Geisser 1.548 2.364 
. 655 3.928 . 025 Huynh-Feldt 1.548 2.982 
. 519 3.928 . 016 Lower-bound 1.548 1.000 1.548 3.928 
. 071 Error(COND) Sphericity Assumed 4.728 36 
. 131 Greenhouse-Geisser 4 728 28.373 
. 167 Huynh-Feldt 4.728 35.788 
. 132 Lower-bound 4.728 12.000 
. 394 
phase Sphericity Assumed . 454 2 . 227 6.015 . 008 Greenhouse-Geisser 
. 454 1.742 . 261 6.015 . 011 Huynh-Feldt 
. 454 2.000 . 
227 6.015 
. 008 Lower-bound 
. 454 1.000 . 454 6.015 . 030 Error(PHASE) Sphericity Assumed 
. 906 24 3.774E-02 
Greenhouse-Geisser 
. 906 20.906 4.333E-02 
Huynh-Feldt 
. 
906 24.000 3.774E-02 
Lower-bound 
. 906 12.000 7.549E-02 
condition' phase Sphericity Assumed . 162 
6 2.705E-02 1.209 . 311 
Greenhouse-Geisser 
. 162 3.830 4.237E-02 
1.209 . 320 
Huynh-Feldt 
. 
162 5.849 2.774E-02 1.209 . 
312 
Lower-bound 
. 162 1.000 . 
162 1.209 
. 
293 
Error(COND'PHASE) Sphericity Assumed 1.610 72 2.236E-02 
Greenhouse-Geisser 1.610 45.957 3.503E-02 
Huynh-Feldt 1.610 70.186 2.294E-02 
Lower-bound 1.610 12.000 
. 134 
Summary of within subjects contrast for core temperature 
Palrwise Comparisons 
Measure: MEASURE-1 
Mean 95% Confidence Interval for 
Difference Difference° 
COND (J) COND I-J Std. Error Si .° Lower Bound Upper Bound 
high low -. 232' . 074 . 050 -. 
464 -3.051 E-04 
placebo -. 253 . 094 . 115 -. 548 
4.219E-02 
control -. 180 . 080 . 268 -. 433 7.320E-02 
low high . 232' . 074 . 050 3.051 E-04 . 464 
placebo -2.082E-02 . 076 1.000 -. 260 . 219 
control 5.210E-02 . 059 1.000 -. 134 . 238 
placebo high . 253 . 094 . 115 -4.219E-02 . 548 low 2.082E-02 . 076 1.000 -. 219 . 260 
control 7.292E-02 . 
103 1.000 -. 251 . 397 
control high . 180 . 080 . 268 -7.320E-02 . 433 low -5.210E-02 . 059 1.000 -. 238 . 134 
placebo -7.292E-02 . 103 1.000 -. 397 . 251 
Based on estimated marginal means 
*" The mean difference is significant at the. 05 level. 
a. Adjustment for multiple comparisons: Bonferroni. 
Summary of post hoc test of core temperature 
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DATA FOR ROOM TEMPERATURE 
Mauchlys Test of Sphericit# 
Measure: MEASURE_t 
Epsilon" 
Approx. Greenhous 
Within Subjects Effect Mauchl sW Chi-Square df Sig. e-Geisser Huynh-Feldt Lower-bound 
room temperature . 675 4.210 5 . 521 . 824 1.000 . 333 phase 1.000 . 000 0 1.000 1.000 1.000 
room temperature' 
. 127 22.128 5 . 001 . 483 . 532 . 333 
Summary of Mauchly's test for sphericity for room temperature 
Tats of Within-Subjects Effects 
Measure- MEASURE 1 
Type III Sum 
Source of Squares df Mean Square F Sig 
ROMT Sphericity Assumed 12.029 3 4.010 3.369 . 029 Greenhouse-Geisser 12.029 2.471 4.867 3.369 
. 
039 
Huynh-Feldt 12.029 3.000 4.010 3.369 . 029 Lower-bound 12.029 1.000 12.029 3.369 
. 
091 
Error(ROMT) Sphericity Assumed 42.846 36 1.190 
Greenhouse-Gelsser 42.846 29.656 1.445 
Huynh-Feldt 42.846 36.000 1.190 
Lower-bound 42.846 12.000 3.571 
PHASE Sphericity Assumed . 779 1 . 779 6.943 . 022 Greenhouse-Geisser . 779 1.000 . 779 6.943 . 022 
Huynh-Fe4dt . 779 1.000 . 779 6.943 . 022 
Lower-bound . 779 1.000 . 779 6.943 . 022 
Error(PHASE) Sphericity Assumed 1.346 12 . 112 
Greenhouse-Geissen 1.346 12.000 . 112 
Huynh-Feldt 1.346 12.000 . 112 
Lower-bound 1.346 12.000 . 112 
ROMT " PHASE Sphericity Assumed . 567 3 . 189 
1.788 . 167 
Greenhouse-Geisser 
. 567 1.450 . 391 1.786 . 200 
Huynh-Feldt . 567 1.597 . 365 1.788 . 197 
Lower-bound . 567 1.000 . 567 1.788 . 206 
Error(ROMT'PHASE) Spherioey Assumed 3.808 36 . 106 
Greenhouse-Geisser 3.808 17.401 . 219 
Huynh-Feldt 3.808 19.167 . 199 
Lower-bound 3 808 12.000 
. 317 
Summary of within subjects effects for room temperature 
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Tests of Within-Subjects Contrasts 
Measure: MEASURE t 
Source room temperature phase 
Type III Sum 
of Squares df Mean Square F Sig. 
room temperature high vs control 4.327 4.327 6.553 . 025 
low vs control . 173 . 173 . 148 . 708 
placebo vs control 1.558 1.558 1.230 . 289 Error(ROMT) high vs control 7.923 12 . 660 
low vs control 14.077 12 1.173 
placebo vs control 15.192 12 1.266 
phase before vs after . 389 1 . 389 6.943 . 022 Error(PHASE) before vs after . 673 12 5.609E-02 
room tempeature' high vs control before vs after 1.923 1 1.923 3.261 
. 096 phase low vs control before vs after 7.692E-02 1 7.692E-02 1.000 
. 337 
placebo vs control before vs after 
. 
692 1 
. 692 3.600 . 082 
Error(ROMT'PHASE) high vs control before vs after 7.077 12 . 590 
low vs control before vs after . 
923 12 7.692E-02 
placebo vs control before vs after 2.308 12 . 192 
Summary of within subjects contrasts for ambient temperature 
Pairwise Comparisons 
Measure: MEASURE 1 
Mean 95% Confidence Interval for 
Difference Differences 
ROMT (J) ROMT (I-J) Std. Error Si .° Lower Bound U er Bound 
high low -. 692 . 269 . 146 -1.540 . 155 
placebo -. 923 . 366 . 161 -2.078 . 232 
control -. 577 . 225 . 150 -1.287 . 134 
low high . 692 . 269 . 146 -. 155 1.540 
placebo -. 231 . 323 1.000 -1.250 . 789 
control . 115 . 300 1.000 -. 832 1.062 
placebo high . 923 . 366 . 161 -. 232 2.078 
low . 231 . 323 1.000 -. 789 1.250 
control . 346 . 
312 1.000 -. 638 1.330 
control high . 577 . 
225 . 150 -. 
134 1.287 
low -. 115 . 300 1.000 -1.062 . 
832 
placebo -. 346 . 312 1.000 -1.330 . 638 
Based on estimated marginal means 
a. Adjustment for multiple comparisons: Bonferroni. 
Summary of post hoc test for room temperature 
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DATA FOR ROOM HUMIDITY 
Tests of Within-Subjects Effects 
Measure: MEASURE 
_1 
Type III Sum 
Source of uares df Mean Square F Sig. 
condition Sphericity Assumed 70.346 3 23.449 2.119 . 115 Greenhouse-Geisser 70.346 2.714 25.923 2.119 
. 122 
Huynh-Fe4dt 70.346 3.000 23.449 2.119 
. 115 
Lower-bound 70.346 1.000 70.346 2.119 
. 171 
Error(COND) Sphericity Assumed 398.404 36 11.067 
Greenhouse-Geisser 398.404 32.564 12.235 
Huynh-Feldt 398.404 36.000 11.067 
Lower-bound 398.404 12.000 33.200 
phase Sphericity Assumed . 000 1 . 000 . 
000 1.000 
Greenhouse-Geisser 
. 000 1.000 . 000 . 000 1.000 
Huynh-Fe4dt 
. 000 1.000 . 000 . 000 1.000 
Lower-bound 
. 
000 1.000 . 000 . 
000 1.000 
Error(PHASE) Sphericity Assumed 4.750 12 . 396 
Greenhouse-Geisser 4.750 12.000 . 396 
Huynh-Feldt 4.750 12.000 
. 396 
Lower-bound 4.750 12.000 
. 396 
condition ' phase Sphericity Assumed 3.000 3 1.000 2.215 
. 103 Greenhouse-Geisser 3.000 2.573 1.166 2.215 
. 114 Huynh-Feldt 3.000 3.000 1.000 2.215 
. 103 Lower-bound 3.000 1.000 3.000 2.215 
. 162 
Error(COND'PHASE) Sphericity Assumed 16.250 36 . 451 
Greenhouse-Geisser 16.250 30.878 . 526 
Huynh-Fekit 16.250 36.000 . 451 
Lower-bound 16.250 12.000 1.354 
Summary of within subjects effects for room humidity 
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APPENDIX F. 1 
ETHICAL APPROVAL FOR THE CLINICAL STUDY 
East and North Hertfordshire PUTI 
NHS Trust 
East & North Hertfordshire Hospitals Ambulance Headquarters 
Local Research Ethics Committee Ascots Lane 
Welwyn Garden City 
Chairman: Dr Steve Eckemall Herts 
Administrator: Mrs Jenny Austin AL7 4HL 
Our ref: JCN4.03 
7 May 2003 
Maryam Almandil 
Faculty of Allied Health Professions - Pysiotherapy 
PhD student 
Research Unit, Physiotherapy Unit 
University of Hertfordshire 
Hatfield Campus 
College Lane 
Hatfield 
Herts 
AL10 9AB 
Tel: 01707 365397 or 328111 ext 3607 
Fax: 01707 369010 or ext 3662 
Email: jenny. austin©nhs. net 
aImary22@hotmaiI. com 
Dear Maryam 
Re: ENHLREC/03-04-4/M93 :A study to investigate the physiological effects of 
pulsed short wave therapy on osteoarthritic patients 
The Chairman, on behalf of the Committee, has considered your response to the issues 
raised by the Committee at the first review of your application on 301h April 2003 as set out in 
our letter dated 1" May 2003. The documents considered by the Chairman were as follows: 
" Application Check List Version 2 dated 2.5.03 
" Patient Information Sheet, Version 2 dated 2.5.03 
" Consent Form, Version 2 dated 2.5.03 
" Protocol, Version 2 dated 2.5.03 
The following members were present at this meeting: 
Dr S Eckersall, Consultant Anaesthetist (Chairman) 
Dr Uthayakumar, Consultant GU Medicine (Vice Chair) 
Mr D Grayson, Lay Member 
Professor C Hawley, Consultant Psychiatrist 
Mr D Jackson, Pharmacy Representative 
Dr I King, GP 
Mr D Marcus, Lay Member 
It is a condition of the approval that you send the Committee an annual report and a copy of 
the results of your research when it is completed. Please send these to the administrator at 
the above address. 
Please ensure that you have received approval from the Research & Development 
Department before commencing your research. 
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In any future correspondence please quote our study reference numbers. 
Yours sincerely 
Jenny Austin 
Administrator - East & North Hertfordshire Hospitals LREC 
cc Heather Davies c/o Annabel Thomas, CARD Dept 
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APPENDIX F. 2 
LETTER TO PHYSIOTHERAPY MANAGER 
Dear 
Date // 
I am a PhD student from University of Hertfordshire, Department of Physiotherapy, I 
am conducting a project on The Physiological Effects of Pulsed Short Wave Therapy 
(PSWT) on Osteoarthritic(OA) Patients. As such I am trying to target hospitals serving 
patients with OA of the knee joint. 
This project is a phase of a series of investigations on PSWT. I have finished collecting 
normative data on healthy subjects and my next aim is to compare these observations to 
patients with OA knees. 
The study will involve measuring blood volume, skin temperature and nerve conduction 
velocity in patients complaining from OA knees. Although the study will be conducted 
by myself, I will need your co-operation in directing me to OA patients (possibly from 
OA classes or the department waiting list). 
I will also need a small place to store my equipments, as it would be laborious to carry 
the acquisition unit and its cables around with me. 
I attached a copy of a letter written for me by my supervisor in support of my work. 
Your co-operation is greatly appreciated 
Many thanks 
Yours truly, 
Maryam Almandil 
University of Hertfordshire 
Department of Physiotherapy 
Hatfield campus 
College Lane 
Hatfield Herts 
AL10 9AB 
Or call at 01707 284000 Ext 2054 
e-mail: almary22@hotmail. com 
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APPENDIX F. 3 
GRID FOR PATIENT HISTORY 
Age: 
Occupation: full time/ Part time 
Have you had treatment in physiotherapy department before? 
For what condition? 
How do you rate the outcome? 
For how long have you been complaining from knee problem? 
Do you have RT or LT side knee pain? 
Does your knee swells? 
Do you hear sounds in your knee(s)? 
Is it painful when it clicks? 
Do you feel your knee stiff after periods of immobility (sitting down or lying in bed)? 
How long does the stiffness last? 
Does your knee hurts when you climb the stairs? 
Is it more going up or down stairs? 
Does your pain wakes you up from sleep? 
What eases your pain? 
Are you regular on any kind of sport? 
Do you do any special Ex for your knee? 
Have you had an X-ray done to your knee? 
What did they tell you the problem was? 
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Skinfold measurements 
Measurement 1 Measurement 2 Measurement 3 Mean 
Chest 
Triceps 
Suprailium 
Subscapular 
Abdominal 
Fat% 
Special remarks: 
Height 
Weight 
I1'' " /1A 
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All 
APPENDIX F. 4 
RELIABILITY WITH GONIOMETER 
In both the laboratory and the clinical trial, knee ROM was measured every time the 
subjects attend for the trial. As such it was crucial that the researcher reliability be 
established for the same day and between days. Using 5 volunteers, knee flexion was 
measured twice in the same day with 5 minutes in between the measurement. Subjects 
were also asked to attend the next day for between days reliability. In all the 
measurements, the knee was not marked and the landmarks were only palpated. 
Same day measurements 
(° 
Next day 
measurement(°) 
Reading 1 Reading 2 Reading 3 
1 125 125 124 
2 120 119 120 
3 125 123 124 
4 135 134 135 
5 130 132 131 
Summary of the reading 
Using Pearson Correlation Coefficient, the r was found to be 0.967 at p=0.007 for 
same day measurement and r=0.985, p=0.002 for between days reliability 
The error margin for the researcher was ±3 ° 
150 
ý- 145 
Co 140 
135 
ö 130 
r 125 
ö 120 
115 
Ö 110 
n 105 
100 
A 
118 120 122 124 126 128 130 132 134 136 
Qmkxneter (reading 2) 
Scatter graph of goniometric measurements 
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APPENDIX F. 5 
FUNCTIONAL QUESTIONNAIRE 
Session 2 
Question Yes No Did not have it 
before 
" Did you notice any change in your level of pain since the last time I 
saw you 
Did you notice any change on the way you stand after sitting 
" Did you notice any change on the way you climb up the stairs 
" Did you notice any change on the way you go down the stairs 
" Did you notice any change in the level of pain you feel in the 
evening 
" In general does your knee feels better the same or worse after the 
Treatment 
Session 3 
Question Yes No Did not have it 
before 
" Did you notice any change in your level of pain since the last time I 
saw you 
" Did you notice any change on the way you stand after sitting 
" Did you notice any change on the way you climb up the stairs 
" Did you notice any change on the way you go down the stairs 
" Did you notice any change in the level of pain you feel in the 
evening 
" In general does your knee feels better the same or worse after the 
I saw you 
Session 4 
Question Yes No Did not have it 
before 
" Did you notice any change in your level of pain since the last time I 
saw you 
" Did you notice any change on the way you stand after sitting 
" Did you notice any change on the way you climb up the stairs 
" Did you notice any change on the way you go down the stairs 
" Did you notice any change in the level of pain you feel in the 
evening 
" In general does your knee feels better the same or worse after the 
treatment 
Session 5 
Question Yes No Did not have it 
before 
" Did you notice any change in your level of pain since the last time I 
saw you 
Did you notice any change on the way you stand after sitting 
" Did you notice any change on the way you climb up the stairs 
" Did you notice any change on the way you go down the stairs 
Did you notice any change in the level of pain you feel in the 
evening 
" In general does your knee feels better the same or worse after the 
treatment 
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APPENDIX F. 6 
RESULTS FROM CLINICAL TRIAL 
Age Sex Height (cm) Weight (kg) Fat % 
1 39 male 177 93.22 24.42 
2 56 female 168.5 67.24 33.53 
3 70 male 168.5 76.52 19.7 
4 71 male 174 83.6 33.53 
5 68 female 161.2 92 33.53 
6 50 male 166.5 68.5 33.53 
7 40 female 165 71.76 33.53 
8 32 male 184 91.78 22.13 
9 45 female 165 72 21.5 
10 62 female 190 71.5 29.4 
11 50 female 183 90.32 21.5 
12 51 male 175 95.72 18.98 
13 62 male 169 109.85 32.4 
14 59 female 161 67.54 32.2 
15 73 female 158 84.3 21.9 
16 64 male 167.5 75 15.9 
17 58 female 157 63.12 30.37 
18 65 male 152 64.82 33.99 
19 48 female 165 90 32.97 
20 42 female 157 87.56 29.3 
21 53 female 150 47.78 22.54 
22 52 male 181.5 75.76 15.75 
23 80 female 160 80.28 18.7 
24 48 female 168 90.26 32.84 
25 54 male 163 88.7 19.21 
26 40 male 179 90.7 23.11 
Demographic data of the sample 
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DATA OF BLOOD VOLUME 
Mauchlys Test of Sphericitf 
Measure: MEASURE 1 
E silona 
Approx. Greenhous 
Within Subjects Effect Mauch 's W Chi -Square df Sig. e-Geisser Hu h-Feldt Lower-bound 
condition . 519 14.231 5 . 014 . 793 . 
891 
. 
333 
phase . 919 1.850 2 . 397 . 925 1.000 . 
500 
side 1.000 . 000 0 1.000 1.000 1.000 
condition * phase . 006 105.243 20 . 000 . 368 . 408 . 167 condition 'side . 587 11.569 5 . 041 . 723 . 801 . 333 phase * side . 785 5.338 2 . 069 . 823 . 878 . 500 
condition 'phase 
side . 
003 122.384 20 . 000 . 323 . 352 . 167 
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is proportional 
to an identity matrix. 
a. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in the 
Tests of Within-Subjects Effects table. 
b. 
Design: Intercept 
Within Subjects Design: COND+PHASE+SIDE+COND*PHASE+COND*SIDE+PHASE*SIDE+COND*PHASE"SIDE 
Summary of within subject effects for blood volume 
Pairwise Comparisons 
Measure: MEASURE-1 
Mean 95% Confidence Interval for 
Difference Difference° 
COND (J) COND l-J Std. Error Sig. Lower Bound Upper Bound 
high low 26.097* 5.450 . 000 10.366 41.829 
placebo 32.747* 5.331 . 000 17.359 48.135 
control 46.522* 4.780 . 000 
32.726 60.318 
low high -26.097* 5.450 . 000 -41.829 -10.366 
placebo 6.650 4.254 . 790 -5.629 
18.929 
control 20.425* 5.583 . 008 4.310 36.539 
placebo high -32.747' 5.331 . 000 -48.135 -17.359 
low -6.650 4.254 . 790 -18.929 5.629 
control 13.775* 3.281 . 002 4.306 23.244 
control high -46.522* 4.780 . 000 -60.318 -32.726 
low -20.425* 5.583 . 008 -36.539 -4.310 
placebo -13.775" 3.281 . 002 -23.244 -4.306 
Based on estimated marginal means 
'" The mean difference is significant at the . 05 level. 
a. Adjustment for multiple comparisons: Bonferroni. 
Summary of post hoc test for blood volume across the experimental conditions 
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Line graph of the changes in blood volume across the four conditions in non-treated 
side 
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DATA FOR SKIN TEMPERATURE 
TMh of wwwwaubimu CaMrpts 
Sift ohm 
Type III Sun of 
Squares dl Nest switm F sin. 
- 30.953 30.953 7.378 
. 
012 
= 1.534 1 1.534 . 562 . 
481 =w 
-. 9.075E-02 9.075E-02 
. 018 . 
832 
E Oprp) I- rN word 98.527 23 4.197 
Lowrs--Wof 62.711 27 2.727 
PMosbo vs Conbd 
qý BNw. vs MW 
45.172 
3 717 
23 
1 
1.904 
3.717 76.704 
. 000 
EDAM Before vs of 
Treated va nnn treated side 
1.115 
. 177 
23 4.848E-02 
. 177 . 517 . 480 
std) Treated VS non basted 
CpgBqn "ptrase p116 ve oral Before vs Mier 
LOW VS mot 981de vs at* 
7.890 
23.458 
. 125 
23 
1 
. 343 
23.455 
. 125 
56.502 
. 206 
. 000 
all 
P»omb4 N"wm vs SW 1.043 1 1.043 2.243 
. 148 
Eri,, (C 463 PtI , SE) rich rs coded Before vs after 
9.548 23 . 415 
La. vs colon Beiee vs Mot 10.797 23 AN 
vs ORK 
Cordhorn ' spe Flo vs COWAVl Treated vs non treated 
10.700 
18.885 
23 465 
18.885 23970 
. 000 
Low " wneq Treated vs non treated . 
863 1 
. 
053 
K 
. 
558 
. 44 
pgopepo vs pp* 0t Treated vs non treated . 209 1 . 209 . 104 . 750 
EC . gam High vs cOf" Treated vs non traded 18.097 23 . 
757 
Low vs OOna Treated vs non treated 
35.899 23 1.562 
pyýý y q Treated vs non treated 46.205 
23 2.009 
Phase 'WO Boas vs after Treated vs non treated 8.570 1 8.570 50.020 . 
000 
-9q¬) oaf" vs arw Treated vs nm traded 3.021 23 . 
131 
Cppyp4 pba. " High vs coney Before vs after Treated vs non treated 540924 1 51.924 41.547 . 
000 
Sift Low vs comet Before vs after Treated vs non treated . 
712 1 
. 
712 
. 
749 
. 
398 
Placebo vs oopld Bs/ae vs Mr Treated vs non treated 
. 
163 1 TE3 
. 
784 
. 
70.5 
E, pr(Cp63PKA EIS Mph s control Before va after Treated vs non treated 28.205 23 1.230 
IDE) Low s control Before vs OW Treated va nm treated 
- 
21.878 23 
. 
951 
, Before vs alter Treated vs non treated Placebo rs c; o 22.383 23 
. 
973 
Summary of within subjects contrast for skin temperature 
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Line graph of changes in skin temperature across the experimental condition in the 
non-treated side 
Up-smre" MEASURE 1 
mean 
Difference 
95% Confidence Interval for 
e 
COND (J) COND -J Std. Error Sig. " Lower Bound Upper Bound 
high low 1.389* . 424 . 
020 . 
165 2.612 
placebo 1.074 . 400 . 
079 -7.952E-02 2.228 
control 1.136 . 418 . 074 -7.112E-02 
2.343 
I. high -1.389' . 424 . 020 -2.612 -. 165 
placebo -. 314 . 362 1.000 -1.358 . 730 
control -. 253 . 337 1.000 -1.226 . 720 
placebo high -1.074 . 400 . 079 -2.228 7.952E-02 
low . 314 . 362 1.000 -. 730 1.358 
Control 6.149E-02 . 
286 1.000 -. 764 . 
887 
control high -1.136 . 418 . 074 -2.343 7.112E-02 
low 253 . 337 1.000 -. 720 1.226 
placebo -6.149E-02 . 286 1.000 -. 887 . 764 
estimated marginal means 
mean diference is significant at the . 05 level. 
sbnent for n*Ab le comparisons: Banfenori. 
iary of post hoc test for skin temperature 
0i ýn 
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DATA FOR NERVE CONDUCTION VELOCITY 
Tats of Within-Subjects Effects 
Measure: MEASURE t 
Type III Sum 
Source of Squares df Mean Square F Sig. 
condition Sphericity Assumed 220.194 3 73.398 6.070 
. 001 Gtr 220.194 2.433 90.493 6.070 . 002 Huynh-Feldt 220.194 2.742 80.297 6.070 . 001 Lower-bound 220.194 1.000 220.194 6.070 . 022 Eror(COND) Sphericity Assumed 834.341 69 12.092 
Greenhouse-Geisser 834.341 55.965 14.908 
Huynh-Feldt 834.341 63.071 13.229 
Lower-bound 834.341 23.000 36.276 
phase Sphericity Assumed 201.538 1 201.538 39.841 . 000 
Greenhouse-Geisser 201.538 1.000 201.538 39.841 
. 000 
Huynh-Feldt 201.538 1000 201.538 39.841 . 000 
Lower-bound 201.538 1.000 201.538 39.841 
. 000 
Error(PHASE) Sphericity Assumed 116.348 23 5.059 
Greenhouse-Geisser 116.348 23000 5.059 
Huynh-Feldt 116.348 23.000 5.059 
Lower-bound 116.348 23.000 5.059 
side Sphericity Assumed 38.359 1 38.359 8.772 . 007 
Greenhouse-Geisser 38.359 1.000 38.359 8.772 
. 007 
Huynh-Feldt 38.359 1.000 38.359 8.772 
. 007 
Lower-bound 38.359 1.000 38.359 8.772 
. 007 
Error(SIDE) Sphericity Assumed 100.573 23 4.373 
Greenhouse-Geisser 100.573 23.000 4.373 
Huynh-Feldt 100.573 23.000 4.373 
Lower-bound 100.573 23.000 4.373 
condition " phase Sphericity Assumed 125.616 3 41.872 12.748 
. 000 Greenhouse"Geisser 125.616 2 578 48.734 12.748 
. 
000 
Huynh-Feldt 125.616 2.931 42.854 12.748 
. 000 Lower-bound 125.616 1.000 125.616 12.748 
. 002 Error(COND*PHASE) Sphericity Assumed 226.629 69 3.284 
Greenhouse-Gelsser 226.629 59.285 3.823 
Huynh-Feldt 226.629 67.418 3.362 
Lower-bound 226.629 23.000 9853 
condition ' side Sphericity Assumed 23.078 3 7.693 . 792 . 502 
Greenhouse-Geisser 23.078 2.846 8.109 
. 792 . 497 
Huynh-Feldt 23.078 3.000 7.693 . 792 . 502 
Lower-bound 23.078 1.000 23.078 . 792 . 383 
Error(COND'SIDE) Sphericity Assumed 669.993 69 9.710 
Greenhouse-Geisser 669.993 65.457 10.236 
Huynh-Feldt 669.993 69.000 9.710 
Lower-bound 689.993 23.000 29.130 
phase ' side Sphericity Assumed 15.306 1 15.306 7.446 
. 012 Greenhouse-Geisser 15.306 1.000 15.306 7.446 
. 012 Huynh-Feldt 15.306 1.000 15.306 7.446 
. 012 Lower-bound 15.306 1.000 15.306 7.448 
. 012 Error(PHASE'SIDE) Sphericity Assumed 47.279 23 2.056 
Greenhouse-Gelsser 47.279 23.000 2.056 
Huynh-Feldt 47.279 23.000 2.056 
Lower-bound 47.279 23.000 2.056 
condition ' phase ' Sphericity Assumed 8.598 3 2.866 
. 532 . 662 side Greenhouse-Gelsser 8.598 2.020 4.257 
. 532 . 593 Huynh-Feldt 8.598 2.215 3.882 
. 532 . 609 Lower-bound 8.598 1.000 8.598 
. 532 . 473 Error(COND*PHASE*S Sphericity Assumed 372.020 69 5.392 
IDE) Greenhouse-Gelsser 372.020 46.450 8.009 
Huynh-Feldt 372.020 50.942 7.303 
Lower-bound 372020 23.000 16.175 
Summary of within subject effect for nerve conduction velocity 
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Measure: MEASURE 1 
Mesa' 95% Confidence Interval for 
Difference usareno? 
COND (J) COND FJ Sad. Error Sig. Lower Bound Upper Bound 
high low -4.727E-02 . 493 1.000 -1.471 1.376 
placebo -. 776 . 439 . 
543 -2.042 . 491 
control -1.872' . 388 . 000 -2.993 -. 751 low high 4.727E-02 
. 
493 1.000 -1.376 1.471 
placebo -. 728 . 
643 1.000 -2.584 1.127 
control -1.825` . 
534 
. 
014 -3.365 -. 285 
placebo high . 776 . 439 . 543 -. 491 2.042 
low 
. 728 . 643 1.000 -1.127 2.584 
control -1.097 . 476 . 184 -2.471 . 
277 
Control high 1.872' . 388 . 000 . 751 2.993 low 1.825' . 534 . 014 . 285 3.365 
placebo 1.097 . 476 . 
184 -. 277 2.471 
Based on estirnWed mergI means 
The mean älferenoe is sign IIcant at the . 05 level. 
a- Adjustment for mt* e comparisons: Borferroni- 
Summary of post hoc test for nerve conduction velocity 
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DATA FOR NERVE ONSET LATENCY 
Mauchly's Test of Sphericitf 
Maasura" MFAR11RF I 
E silone 
Approx. Greenhous 
Within Subjects Effect Mauchl 's W Chi-Square df Sig. e-Geisser Huynh-Feldt Lower-bound 
condition . 664 
8.911 5 . 113 . 780 . 874 . 333 
phase 1.000 . 000 
0 1.000 1.000 1.000 
side 1.000 . 000 0 1.000 
1.000 1.000 
condition' phase . 723 
7.031 5 . 219 . 840 . 952 . 
333 
condition * side . 880 2.778 
5 . 734 . 918 1.000 . 
333 
phase ' side 1.000 . 000 0 1.000 1.000 
1.000 
condition * phase ' 282 27.525 5 . 000 . 822 . 674 . 
333 
side . 
Summary of Mauchly's test for sphericity 
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Tests of Within-Subjects Effects 
Measure: MEASURE 1 
Type III Sum 
Source of Squares df Mean S uare F Si a. 
condition Sphericity Assumed 1.491 E-06 3 4.969E-07 4.619 . 005 Greenhouse-Geisser 1.491 E-06 2.341 6.369E-07 4.619 . 010 
Huynh-Feldt 1.491E-06 2.622 5.685E-07 4.619 
. 
008 
Lower-bound 1.491 E-06 1.000 1.491E-06 4.619 . 042 Error(COND) Sphericity Assumed 7.424E-06 69 1.076E-07 
Greenhouse-Geisser 7.424E-06 53.832 1.379E-07 
Huynh-Feldt 7.424E-06 60.309 1.231 E-07 
Lower-bound 7.424E-06 23.000 3.228E-07 
phase Sphericity Assumed 1.905E-06 I 1.905E-06 55.323 . 000 
Greenhouse-Geisser 1 905E-06 1.000 1.905E-06 55.323 . 000 
Huynh-Feldt 1.905E-08 1.000 1.905E-06 55.323 . 000 
Lower-bound 1.905E-06 1.000 1.905E-06 55.323 . 000 Error(PHASE) Sphericity Assumed 7.922E-07 23 3.444E-08 
Greenhouse-Geisser 7.922E-07 23.000 3.444E-08 
Huynh-Feldt 7.922E-07 23.000 3.444E-08 
Lower-bound 7.922E-07 23.000 3.444E-08 
side Sphericity Assumed 4.572E-07 1 4.572E-07 14.520 . 001 
Greenhouse-Geisser 4.572E-07 1.000 4.572E-07 14.520 . 001 
Huynh-Feldt 4.572E-07 1.000 4.572E-07 14.520 . 001 
Lower-bound 4.572E-07 1.000 4.572E-07 14.520 . 001 
Error(SIDE) Sphericity Assumed 7.242E-07 23 3.149E-08 
Greenhouse-Geisser 7.242E-07 23.000 3.149E-08 
Huynh-Feldt 7.242E-07 23.000 3.149E-08 
Lower-bound 7.242E-07 23.000 3.149E-08 
condition * phase Sphericity Assumed 8.565E-07 3 2.855E-07 9.062 . 
000 
Greenhouse-Geisser 8.565E-07 2.521 3.398E-07 9.062 . 000 
Huynh-Feldt 8.565E-07 2.857 2.998E-07 9.062 . 000 
Lower-bound 8.565E-07 1.000 8.565E-07 9.062 . 006 
Error(COND*PHASE) Sphericity Assumed 2.174E-06 69 3.151 E-08 
Greenhouse-Geisser 2.174E-06 57.980 3.749E-08 
Huynh-Feldt 2.174E-06 65.702 3.309E-08 
Lower-bound 2.174E-06 23.000 9.452E-08 
condition *side Sphericity Assumed 3.402E-07 3 1.134E-07 1.395 . 252 
Greenhouse-Geisser 3.402E-07 2.755 1.235E-07 1.395 . 254 
Huynh-Feldt 3.402E-07 3.000 1.134E-07 1.395 . 252 
Lower-bound 3.402E-07 1.000 3.402E-07 1.395 . 
250 
Error(COND'SIDE) Sphericity Assumed 5.611 E-06 69 8.133E-08 
Greenhouse-Geisser 5.611 E-06 63.363 8.856E-08 
Huynh-Feldt 5.611 E-06 69.000 8.133E-08 
Lower-bound 5.611 E-06 23.000 2.440E-07 
phase ' side Sphericity Assumed 7.178E-08 I 7.178E-08 2.322 . 141 
Greenhouse-Gelsser 7.178E-08 1.000 7.178E-08 2.322 . 
141 
Huynh-Feldt 7.178E-08 1.000 7.178E-08 2.322 . 141 
Lower-bound 7.178E-08 1.000 7.178E-08 2.322 . 141 
Error(PHASE*SIDE) Sphericity Assumed 7.109E-07 23 3.091E-08 
Greenhouse-Geisser 7.109E-07 23.000 3.091E-08 
Huynh-Feldt 7.109E-07 23.000 3.091 E-08 
Lower-bound 7.109E-07 23.000 3.091 E-08 
condition *phase * Sphericity Assumed 6.960E-08 3 2.320E-08 . 446 . 721 side Greenhouse-Geisser 6.960E-08 1.865 3.732E-08 . 446 . 629 
Huynh-Feldt 6.960E-08 2.023 3.441 E-08 . 446 . 645 
Lower-bound 6.960E-08 1.000 6.960E-08 . 446 . 511 
Error(COND"PHASE*S Sphericity Assumed 3.586E-06 69 5.197E-08 
IDE) Greenhouse-Geisser 3.586E-06 42.890 8.361 E-08 
Huynh-Feldt 3.586E-06 46.527 7.707E-08 
Lower-bound 3.586E-06 23.000 1.559E-07 
Summary of within subjects effects for nerve onset latency 
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Tests of Within-Subjects Contrasts 
Mwasura" MFAS( IRF I 
Source condition phase side 
Type Ili Sum 
of Squares df Mean Square F SIG. 
condition high vs control 5.251 E-07 1 5.251 E-07 15.841 . 001 
low vs control 5.104E-07 1 5.104E-07 12.960 . 002 
placebo vs control 8.313E-08 1 8.313E-08 1.097 . 
306 
Error(COND) high vs control 7.624E-07 23 3 315E-08 
low vs control 9.058E-07 23 3.938E-08 
placebo vs control 1.743E-06 23 7.577E-08 
PHASE before vs after 4.764E-07 1 4.764E-07 55,323 . 000 
Error(PHASE) before vs after 1.980E-07 23 8.611 E-09 
SIDE treated vs non treated 1.143E-07 1 1.143E-07 14.520 . 001 
Error(SIDE) treated vs non treated 1.811 E-07 23 7.872E-09 
COND' PHASE high vs control before vs after 1.307E-06 I 1.307E-06 25.834 . 000 
low vs control before vs after 1.084E-06 1.084E-06 28.942 . 000 
placebo vs control before vs after 2.063E-07 1 2.063E-07 3.484 . 075 Error(COND'PHASE) high vs control before vs after 1.163E-06 23 6 058E-08 
low vs control before vs after 8.612E-07 23 3.745E-08 
placebo vs control before vs after 1.362E-06 23 5.921 E-08 
COND' SIDE high vs control treated va non treated 1 204E-07 I 1.204E-07 772 . 389 
low vs control treated vs non treated 1.504E-07 1 1 504E-07 1.308 . 264 
placebo vs control treated vs non treated 6.750E-07 1 6.750E-07 4.088 . 
055 
Error(COND'SIDE) high va control treated vs non treated 3.590E-06 23 1.561 E-07 
low vs control treated vs non treated 2.645E-06 23 1.150E-07 
placebo vs control treated vs non treated 3.798E-06 23 1.651E-07 
PHASE' SIDE before vs after treated vs non treated 7.178E-08 1 7.178E-08 2.322 . 141 
Error(PHASE'SIDE) before vs after treated vs non treated 7.109E-07 23 3.091 E-08 
COND' PHASE' SIDE high vs control before vs after treated vs non treated 1.067E-07 1.067E-07 . 898 . 353 
low vs control before vs after treated vs non treated 5.400E-07 5.400E-07 2.545 . 124 
placebo vs control before vs after treated vs non treated 6.510E-08 1 6.510E-08 . 150 . 702 
Error(COND'PHASE"S high vs control before vs after treated vs non treated 2.733E-06 23 1.188E-07 
IDE) low vs control before vs after treated vs non treated 4.880E-06 23 2.122E-07 
placebo vs control before vs after treated vs non treated 9.967E-06 23 4.334E-07 
Summary of within subjects cl 
Patrwise Comparisons 
Measure: MEASURE 1 
Mean 95% Confidence Interval for 
Difference Difference 
COND (J) COND I-J Std. Error Si a Lower Bound upper Bound 
high low 2.083E-06 . 000 1.000 -1.221 
E-04 1.262E-04 
placebo 8.906E-05 . 000 . 
336 -3.870E-05 2.168E-04 
control 1.479E-04" . 000 . 
004 4.065E-05 2.552E-04 
low low -2.083E-06 . 000 1.000 -1.262E-04 1.221 
E-04 
placebo 8.698E-05 . 000 . 
917 -8.279E-05 2.568E-04 
control 1.458E-04" . 000 . 
009 2.891 E-05 2.628E-04 
placebo low -8.906E-05 . 
000 . 336 -2.168E-04 3.870E-05 
low -8.698E-05 . 000 . 
917 -2.568E-04 8.279E-05 
control 5.885E-05 . 000 
1.000 -1.033E-04 2.210E-04 
control low -1.479E-04* . 000 . 
004 -2.552E-04 -4.065E-05 
low -1.458E-04" . 000 . 
009 -2.628E-04 -2.891 E-05 
placebo -5.885E-05 . 000 
1.000 -2,210E-04 1.033E-04 
Based on estimated marginal means 
ý" The mean difference is significant at the . 05 level. 
a. Adjustment for multiple comparisons: Bonferroni. 
Summary of post hoc test for nerve onset latency across the experimental conditions 
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DATA FOR NERVE RESPONSE DURATION 
UmecAlys Tilt at Sph. fkilt 
Meade: MEASURE 1 
Epelona 
Wahn Subjects Effect Mauchlyls W 
APPS 
ChkSquare df Sig- 
Gmmnhots 
e-Geisser elft Lower-bound 
condition . 939 1.356 5 . 929 . 962 1.000 . 333 phase 1.000 . 000 0 1.000 1.000 1.000 
side 1.000 . 000 0 1.000 1.000 1.000 
coiKWm phase . 096 50.972 5 . 000 . 482 . 506 . 333 nm "fine * Side . 871 3.005 5 . 700 . 923 1.000 . 333 phase' side 1.000 . 000 0 1.000 1.000 1.000 
caimiffiot 
side . 120 46.054 5 . 000 . 574 . 616 . 333 
Summary of Mauchley's test of sphericity for nerve response duration 
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Tests of Within-Subjects Effects 
Measure- MEASURE I 
Type III Sum 
Source of Squares df Mean Square F Sig. 
Condition Sphericity Assumed 17.867 3 5.956 1.429 
. 242 Greenhouse-Geisser 17.867 2.885 6.192 1.429 
. 243 Huynh-Feldt 17.867 3.000 5.956 1.429 
. 
242 
Lower-bound 17.867 1.000 17.867 1.429 
. 244 Error(COND) Sphericity Assumed 287.517 69 4.167 
Greenhouse-Geisser 287.517 66.365 4.332 
Huynh-Feldt 287.517 69.000 4.167 
Lower-bound 287.517 23.000 12.501 
phase Sphericity Assumed 
. 834 1 . 834 1.895 . 182 Greenhouse-Geisser 
. 834 1.000 . 834 1.895 . 182 Huynh-Feldt 
. 
834 1.000 
. 834 1.895 . 182 Lower-bound 
. 
834 1.000 
. 834 1.895 . 182 Error(PHASE) Sphericity Assumed 10.126 23 
. 440 Greenhouse-Geisser 10.126 23.000 
. 440 Huynh-Feldt 10.126 23.000 
. 440 
Lower-bound 10.126 23.000 
. 440 
side Sphericity Assumed 4.356 1 4.356 1.064 
. 313 
Greenhouse-Geisser 4.356 1.000 4.356 1.064 . 313 
Huynh-Feldt 4.356 1.000 4.356 1.064 . 313 
Lower-bound 4.356 1.000 4.356 1.064 . 313 Error(SIDE) Sphericity Assumed 94.154 23 4.094 
Greenhouse-Geisser 94.154 23.000 4.094 
Huynh-Feldt 94.154 23.000 4.094 
Lower-bound 94.154 23.000 4.094 
condition ' phase Sphericity Assumed 2.964 3 988 1.971 
. 126 Greenhouse-Geisser 2.964 1.446 2.050 1.971 
. 165 Huynh-Feldt 2.964 1.517 1.954 1.971 
. 163 Lower-bound 2 964 1.000 2.964 1.971 
. 174 Error(COND"PHASE) Sphericity Assumed 34.583 69 
. 501 Greenhouse-Geisser 34.583 33.248 1.040 
Huynh-Feldt 34.583 34.886 
. 991 
Lower-bound 34.583 23.000 1.504 
condition ' side Sphericity Assumed 15.777 3 5.259 1.874 
. 142 Greenhouse-Geisser 15.777 2.770 5.696 1.874 
. 147 Huynh-Feldt 15.777 3.000 5.259 1.874 
. 142 Lower-bound 15.777 1.000 15.777 1.874 
. 184 Error(COND"SIDE) Sphericity Assumed 193.670 69 2.807 
Greenhouse-Geisser 193.670 63.703 3.040 
Huynh-Feldt 193.670 69.000 2.807 
Lower-bound 193.670 23.000 8.420 
phase " side Sphericity Assumed 
. 872 1 . 872 2.639 . 118 Greenhouse-Geisser 
. 872 1.000 . 872 2.639 . 
118 
Huynh-Feldt 
. 872 1.000 . 872 2.639 . 118 Lower-bound 
. 872 1.000 . 872 2.639 . 118 Error(PHASE"SIDE) Sphericity Assumed 7.601 23 
. 
330 
Greenhouse-Geisser 7.601 23.000 
. 330 Huynh-Feldt 7.601 23.000 
. 330 Lower-bound 7.601 23.000 
. 330 condition " phase " Sphericity Assumed 1.615 3 
. 538 1.625 191 side Greenhouse-Geisser 1.615 1.723 
. 938 1.625 
. 
. 212 Huynh-Feldt 1.615 1.849 
. 874 1.625 . 210 Lower-bound 1.615 1.000 1.615 1.625 
. 215 Error(COND'PHASE'S Sphericity Assumed 22.859 69 
. 331 IDE) Greenhouse-Geisser 22.859 39.619 
. 577 Huynh-Feldt 22.859 42.527 
. 538 Lower-bound 22 859 23.000 
. 
994 
Summary of within subject effect for nerve response duration 
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Tests of Within-Subjects Contrasts 
Measure. MEASURE 1 
Source COND PHASE SIDE e III Sum of Sauare df Mean square F Sig. 
condition high vs control 4.084 1 4.084 1.891 . 182 
low vs control 1.063 1 1.063 
. 
458 
. 
505 
placebo vs cont . 
610 1 
. 
610 
. 
355 
. 
557 
Error(COND) high vs control 49.659 23 2.159 
low vs control 53.314 23 2.318 
placebo vs cont 39.550 23 1.720 
PHASE before vs after 
. 209 1 . 209 1.895 . 182 Error(PHASE) before vs after 2.532 23 
. 
110 
SIDE treated vs non treated 1.089 1 1.089 1.064 . 313 Error(SIDE) treated vs non treated 23.539 23 1.023 
COND * PHASE high vs control before vs after 3.375 3.375 1.690 
. 207 low vs control before vs after . 
120 
. 120 . 074 . 788 
placebo vs cont before vs after 9.375E-04 1 9.375E-04 
. 001 . 980 
Error(COND'PHA high vs control before vs after 45.945 23 1 998 
E) low vs control before vs after 37.475 23 1.629 
placebo vs tont before vs after 34.927 23 1.519 
COND' SIDE high vs control treated vs non treated 20.350 1 20.350 3.120 
. 091 
low vs control treated vs non treated 11.620 1 11.620 2.380 . 137 
placebo vs cont treated vs non treated 1.760E-02 1 1.760E-02 . 003 . 956 
Error(COND'SIDE high vs control treated vs non treated 150.010 23 6.522 
low vs control treated vs non treated 112.295 23 4.882 
placebo vs cont treated vs non treated 132.190 23 5.747 
PHASE * SIDE before vs after treated vs non treated . 872 1 . 872 2.639 . 118 
Error(PHASE'SID before vs after treated vs non treated 7.601 23 
. 
330 
COND * PHASE ' high vs control before vs after treated vs non treated 2.282 1 2.282 
. 451 . 508 SIDE low vs control before vs after treated vs non treated 8.402 8.402 2.336 
. 140 
placebo vs tont before vs after treated vs non treated 10.270 1 10.270 2.797 
. 108 Error(COND*PHA high vs control before vs after treated vs non treated 116.238 23 5.054 
'SIDE) low vs control before vs after treated vs non treated 82.738 23 3.597 
placebo vs cont before vs after treated vs non treated 84.440 23 3.671 
Summary of within subjects contrast for nerve response duration 
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DATA FOR PULSE RATE 
Measure: MEASURE 1 
Tests of Wlthln-Subjects Contrasts 
Source condition ohase 
Type III Sum 
of Squares df Mean Square F Sig. 
condition high vs control 112 278 1 112.278 . 394 . 536 low vs control 7.272 1 7.272 
. 
030 
. 
865 
placebo vs control 38.592 1 38.592 
. 119 . 734 Error(COND) high vs control 6546161 23 284.616 
low vs control 5628.219 23 244.705 
placebo vs control 7480 562 23 325.242 
phase during vs before 
after vs before 
17.217 
2.344E-02 
1 
1 
17.217 
2.344E-02 
7.650 
. 012 
. 011 
. 915 Error(PHASE) during vs before 
after vs before 
51.765 
45.789 
23 
23 
2.251 
1.991 
condition " phase high vs control during vs before 
after vs before 
. 103 
3.450 
1 
1 
. 103 
3.450 
. 005 
. 
101 
. 943 
. 753 
low vs control during vs before 
after vs before 
83.004 
24.807 
1 
1 
83.004 
24.807 
2.850 
. 929 
. 105 
. 345 
placebo vs control during vs before 
after vs before 
. 281 
5.134 
1 
1 
. 281 
5.134 
. 011 
. 174 
. 918 
. 680 Error(COND'PHASE) high vs control during vs before 
after vs before 
456.517 
783 460 
23 
23 
19.849 
34.063 
low vs control during vs before 
after vs before 
669.833 
614.153 
23 
23 
29.123 
26.702 
placebo vs control during vs before 
after vs before 
604.618 
677.416 
23 
23 
26 288 
29.453 
Summary of within subjects contrast for pulse rate 
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DATA FOR CORE TEMPERATURE 
Tests of Within-Subjects Contrasts 
Measure: MEASURE 
_I 
Source COND PHASE 
Type III Sum 
of Squares df Mean Square F Sig. 
condition high vs control . 171 1 . 171 . 775 . 388 
low vs control . 940 1 . 
940 3.978 . 058 
placebo vs control . 108 1 . 108 . 464 . 502 
Error(COND) high vs control 5.073 23 . 221 
low vs control 5.438 23 . 236 
placebo vs control 5.347 23 . 232 
phase before vs during 
before vs after 
. 146 
4.690E-03 
1 
1 
. 146 
4.690E-03 
4.769 
. 
396 
. 039 
. 535 
Error(PHASE) before vs during 
before vs after 
. 706 
. 272 
23 
23 
3.071 E-02 
1.185E-02 
condition *phase high vs control before vs during 
before vs after 
. 592 
5.046E-03 
1 
1 
. 592 
5.046E-03 
1.827 
. 050 
. 190 
. 825 
low vs control before vs during 
before vs after 
3.511 E-02 
2.407E-02 
1 
1 
3.511 E-02 
2 407E-02 
. 111 
. 155 
. 743 
. 
698 
placebo vs control before vs during 
before vs after 
7.385E-03 
2.344E-02 
1 
1 
7.385E-03 
2.344E-02 
. 026 
. 
206 
. 872 
. 654 
Error(COND'PHASE) high vs control before vs during 
before vs after 
7.455 
2.317 
23 
23 
. 
324 
. 
101 
low vs control before vs during 
before vs after 
7.305 
3.581 
23 
23 
. 
318 
. 
156 
placebo vs control before vs during 
before vs after 
6.427 
2.619 
23 
23 
. 
279 
. 114 
Summary of within subjects contrast for core temperature 
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DATA FOR ROOM TEMPERATURE AND HUMIDITY 
Tests of Within-Subjects Effects 
Measure: MEASURE 1 
Type III Sum 
Source of S uares df Mean Square F Sig. 
room phericity Assumed 1.516 3 
. 
505 
. 
225 
. 
879 
temperature Greenhouse-Geisser 1.516 2.555 
. 593 . 225 . 849 Huynh-Feldt 1.516 2.902 
. 522 . 225 . 873 Lower-bound 1.516 1.000 1.516 
. 225 . 640 Error(RT) Sphericity Assumed 154.859 69 2.244 
Greenhouse-Geisser 154.859 56.772 2.635 
Huynh-Feldt 154.859 66.742 2.320 
Lower-bound 154.859 23.000 6.733 
phase Sphericity Assumed 5.208E-03 1 5.208E-03 1.000 
. 328 Greenhouse-Geisser 5.208E-03 1.000 5.208E-03 1.000 
. 328 Huynh-Feldt 5.208E-03 1.000 5.208E-03 1.000 
. 328 Lower-bound 5.208E-03 1.000 5.208E-03 1.000 
. 
328 
Error(PHASE) Sphericity Assumed . 120 23 5.208E-03 
Greenhouse-Geisser . 120 23.000 5.208E-03 
Huynh-Feldt 
. 120 23.000 5.208E-03 
Lower-bound 
. 120 23.000 5.208E-03 
room Sphericity Assumed 1.562E-02 3 5.208E-03 1.000 
. 398 temperature* Greenhouse-Geisser 1.562E-02 1.000 1.562E-02 1.000 
. 328 phase Huynh-Feldt 1 562E-02 1.000 1.562E-02 1.000 . 328 Lower-bound 1.562E-02 1.000 1.562E-02 1.000 
. 328 Error(room Sphericity Assumed 
. 359 69 5.208E-03 temperature'PHA Greenhouse-Geisser 
. 359 23 000 1 562E-02 SE) Huynh-Feldt 
. 359 23.000 1.562E-02 
Lower-bound 
. 359 23.000 1562E-02 
Summary of within subject effect for room temperature 
Measure: MEASURE 1 
Source room temperature phase 
Type III Sum 
of Squares df Mean Square F Sin. 
room high vs control 4.167E-02 1 4.167E-02 
. 017 . 896 temperature low vs control 1.260 1 1.260 829 . 372 placebo vs control 4.167E-02 1 4.167E-02 
. 027 . 870 Error(RT) high vs control 54.958 23 2.389 
low vs control 34.990 23 1.521 
placebo vs control 34.958 23 1.520 
phase before vs after 2.604E-03 1 2.604E-03 1.000 
. 328 Error(PHASE) before vs after 5.990E-02 23 2.604E-03 
room high vs control before vs after 
* . 
000 1 . 000 temperature low vs control before vs after 
h 
4.167E-02 1 4.167E-02 1.000 
. 
328 
p ase placebo vs control before vs after 
. 000 1 . 000 , 
Error(RT'PHASE) high vs control before vs after . 000 23 . 000 low vs control before vs after . 958 23 4.167E-02 
placebo vs control before vs after . 000 23 . 000 
Summary of within subject effect for room humidity 
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DATA FOR FUNCTIONAL STATUS 
Better Worse No changes Did not have 
this symptom 
before 
Changes in the 21 - 3 - 
level of pain since 
the last visit 
Changes in 19 - 4 1 
standing after 
sifting 
Changes in 18 - 5 1 
ascending stairs 
Changes in 11 - 10 3 
descending the 
stairs 
Changes in 16 - 5 3 
evening pain 
In general are 20 - 4 - 
you better/ 
worse/ same 
Summary of answers to functional questionnaire 
Moanira" MFASIIRE 1 
Source VAS 
Type III Sum 
of Squares df Mean Square F Si q. 
VAS High vs baseline 106.682 1 106.682 36.965 . 000 
Low vs baseline 66.334 1 66.334 20.214 . 000 
Placebo vs 20.258 1 20.258 19.023 000 baseline . 
Control vs 
baseline 12.615 1 12.615 7.667 . 011 
Error(VAS) High vs baseline 66.378 23 2.886 
Low vs baseline 75.476 23 3.282 
Placebo vs 
baseline 24.494 23 1.065 
Control vs 
baseline 37.845 23 1.645 
Summary of within subjects effects for VAS 
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Pairwise Comparisons 
Measure: MEASURE 1 
mean 95% Confidence Interval for 
Difference Difference 
VAS J VAS I-J Std. Error Si a Lower Bound Upper Bound 
intial high -. 446 . 458 . 000 -1.867 . 976 
low -1.190" . 370 . 038 -2.337 -4.246E-02 
placeb -1.383" . 367 . 010 -2.524 -. 243 
control -2.108' . 347 . 000 -3.185 -1.032 
high intial . 446 . 458 . 000 -. 976 1.867 
low -. 744 . 421 . 907 -2.051 . 564 
placeb -. 938 . 416 . 
339 -2.228 . 353 
control -1.663' . 370 . 
002 -2.810 -. 515 
low intial 1.190' . 370 . 038 
4.246E-02 2.337 
high 
. 744 . 421 . 
907 -. 564 2.051 
placeb -. 194 . 341 
1.000 -1.252 . 864 
control -. 919' . 211 . 
002 -1.573 -. 265 
placeb intial 1.383' . 367 . 
010 . 243 2.524 
high . 938 . 416 . 
339 -. 353 2.228 
low . 194 . 341 
1.000 -. 864 1.252 
control 
-. 725 . 262 . 109 -1.538 
8.775E-02 
control intial 2.108' . 347 . 
000 1.032 3.185 
high 1.663' . 370 . 002 . 515 2.810 
low . 919' . 211 . 002 . 265 1.573 
placeb . 725 . 262 . 109 -8.775E-02 1.538 
Based on estimated marginal means 
The mean difference is significant at the . 05 level. 
a. Adjustment for multiple comparisons: Bonferroni. 
Summary of post hoc for VAS 
Condition Mean change (mm) 
Baseline 5.438±1.661 
High 3.446±1.755 
Low 3.7115±2.271 
Placebo 4.5135±1.623 
Control 4.708±1.837 
Change In pain level across the experimental conditions 
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Measure: MEASURE 
-1 
Source MUSCLE 
Type III Sum 
of Squares df Mean Square F Sig. 
MUSCLE High vs baseline 2.042 1 2.042 9.548 . 005 Low vs baseline . 882 1 . 882 3.220 . 086 Placebo vs 
baseline . 602 1 . 602 2.996 . 097 
Control vs 
baseline 1.170 1 1.170 7.520 . 012 
Error(MUSCLE) High vs baseline 4.918 23 . 214 
Low vs baseline 6.298 23 . 274 Placebo vs 
baseline 4.618 23 . 201 
Control vs 
baseline 3.580 23 . 156 
Summary of within subjects contrasts for muscle strength 
Measure: MEASURE 1 
Mean 95% Confidence Interval for 
Difference Differences 
MUSCLE (J) MUSCLE I-J Std. Error Si a Lower Bound Upper Bound 
intial high . 483 . 156 . 051 -8.877E-04 . 968 
low 
. 450* . 104 . 238 . 129 . 771 
placebo . 513* . 098 . 725 . 208 . 817 
control . 292 . 094 . 517 -1.329E-03 . 585 
high intial -. 483 . 156 . 051 -. 968 8.877E-04 
low -3.333E-02 . 138 1.000 -. 
461 . 394 
placebo 2.917E-02 . 130 1.000 -. 
374 
. 432 
control -. 192 . 107 . 859 -. 523 . 140 
low intial -. 450* . 104 . 238 -. 771 -. 129 
high 3.333E-02 . 138 1.000 -. 394 . 461 
placebo 6.250E-02 . 053 1.000 -. 103 . 
228 
control -. 158 . 091 . 968 -. 442 . 126 
placebo intial -. 513* . 098 . 725 -. 817 -. 208 
high -2.917E-02 . 130 1.000 -. 432 . 374 
low -6.250E-02 . 053 1.000 -. 228 . 103 
control -. 221 . 081 . 116 -. 471 2.913E-02 
control intial -. 292 . 094 . 517 -. 585 1.329E-03 
high 
. 192 . 107 . 859 -. 140 . 523 
low 
. 158 . 091 . 
968 -. 126 . 442 
placebo . 221 . 
081 . 116 -2.913E-02 . 471 
Based on estimated marginal means 
The mean difference is significant at the . 05 level. 
a. Adjustment for multiple comparisons: Bonferroni. 
Summary of post hoc test for muscle strength 
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Measure: MEASURE 1 
Source ROM 
Type III Sum 
of Squares df Mean Square F Sig. 
ROM High vs baseline 459.375 1 459.375 6.971 . 015 
Low vs baseline 4.167 1 4.167 . 060 . 809 
Placebo vs 
basline 9.375 1 9.375 . 223 . 641 
l va 
baseline baseli 234.375 1 234.375 3.616 . 070 
Error(ROM) High vs baseline 1515.625 23 65.897 
Low vs baseline 1595.833 23 69.384 
Placebo vs 
basline 965.625 23 41.984 
Control vs 
baseline 1490.625 23 64.810 
Summary of within subjects contrast for ROM 
Pairwise Comparisons 
lu t,, ra" Iu1FASI JRF I 
Mean 95% Confidence Interval for 
Difference Differencee 
ROM (J) ROM (I-J) Std. Error Si .° Lower Bound Upper Bound 
intial high 4.792 1.915 . 020 -1.152 10.735 
low 5.000 2.107 . 264 -1.539 11.539 
placebo 7.500' 1.831 . 442 1.818 13.182 
control 4.375 1.657 . 146 -. 768 9.518 
high intial -4.792 1.915 . 020 -10.735 1.152 
low . 208 1.915 
1.000 -5.735 6.152 
placebo 2.708 1.728 1.000 -2.657 8.073 
control -. 417 1.700 1.000 -5.694 4.861 
low intial -5.000 2.107 . 264 -11.539 1.539 
high -. 208 1.915 1.000 -6.152 5.735 
placebo 2.500 1.806 1.000 -3.105 8.105 
control -. 625 1.323 1.000 -4.730 3.480 
placeb intial -7.500' 1.831 . 442 -13.182 -1.818 
high -2.708 1.728 1.000 -8.073 
2.657 
low -2.500 1.806 1.000 -8.105 3.105 
control -3.125 1.643 . 698 -8.226 
1.976 
high Intial -4.375 1.657 . 146 -9.518 . 
768 
high . 417 1.700 1.000 -4.861 
5.694 
low . 625 1.323 1.000 -3.480 4.730 
placebo 3.125 1.643 . 698 -1.976 8.226 
Based on estimated marginal means 
'- The mean difference is significant at the . 05 level. 
a. Adjustment for multiple comparisons: Bonferroni. 
Summary of post hoc test of ROM 
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APPENDIX G 
SEARCH STRATEGY FOR LITERATURE REVIEW 
In conducting the literature review in Chapter 3 and 4 several databases were searched. 
A systematic computerised search of CINHAL (Cumulative Index to Nursing and 
Allied Health Literature) was done and this covered literature published from 1982 to 
present. AMED (Allied and Complementary Medicine) covered literature from 1960 to 
2004, PeDRO (Physiotherapy Evidence Database) and PubMed (Medline) using the 
most appropriate Medical Subject Headings (MeSH) were also included in the search. 
The search also included publication in non physiotherapy literature in in Embase 
(Biomedical and Pharmacentical Database) and other physiology and engineering data 
bases. 
The search terms used were short wave, short wave diathermy, electromagnetic field. 
The terms used for initial search were broad due to the limited in number of papers on 
PSWT. 
A general internet search was conducted. Web sites search engines were reviewed to 
identify gray literature relevant to PSWT that was not covered by the above mentioned 
databases. 
A hand search was also undertaken to references and conference abstracts 
The literature identified was later refined to trials that used pulsed and not the 
continuous short wave for the reasons mentioned in Chapter 1. Studies retrieved ranged 
from single to double blinded controlled to non-controlled. 
Summary of papers identified for Chapter 3 is described in Table 1, and papers 
identified for Chapter 4 is described in Table 2. 
PSWT and Temperature PSWT and Blood PSWT and nerve 
(skin and muscle) perfusion conduction 
6 human trials 2 human trials and 2 trials human trials 
1 conference abstract 4 animal studies 
Table (1) Result of literature review on physiological effects of !SW1 
Condition No of papers 
identified 
Rheumatolo 6 
Subdeltoid 2 reports 
Hand injuries 1 
Ankle sprain 5 
Musculoskeletal Laboratory 2 
Post operative wound healing 6 
Skin graft 1 
Skin ulcer 4 
Pressure sore 1 
Others I 
Fractures 2 
Animal studies I 
Pain 5 
Table (2) Results of literature review on the effect of PSWT on the pathological conditions 
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